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ABSTRACT
People with cognitive symptoms often report a long wait to see a specialist in order to begiven a diagnosis of dementia or some other disorder, or be told they are normal. This thesisinvestigates the accuracy of a range of tests potentially suitable for GP use, including GP clinical
judgement, for the diagnosis of two target conditions, dementia and normal.
A systematic review was done in five electronic databases. A diagnostic test accuracy study was
done in 21 GP surgeries in South West England with a total eligible population of 34,956. Qualitative
interviews were done to explore the acceptability of GP diagnosis.
From 12,681 citations, 16 were included, referring to 10 studies, of which seven were included
in a meta-analysis. For dementia, in the studies at lowest risk of bias, the sensitivity of GPs clinical
judgement ranged from 34% (95% CI 18% to 54%) to 91% (95% CI 85% to 96%) and the specificity
ranged from 58% (95% CI 51% to 66%) to 99% (95% CI 97% to 100%).
In 240 people aged 70 years or more without a previous diagnosis of dementia who had presented
to their GP with cognitive symptoms, for dementia using ICD-10 criteria as judged by an expert the
sensitivity of single tests ranged from 23% (95% CI 16% to 31%) for TAC to 100% (95% CI 97% to 100%)
for MOCA; and specificity ranged from 4% (95% CI 1% to 11%) for Sniffin Sticks to 97% (95% CI 92% to
99%) for FAQ. GP judgement had sensitivity 56% (95% CI 47% to 65%) specificity 89% (95% CI 81% to
94%).
In 26 interviews, GP diagnosis of dementia was judged acceptable if the service was adequately
resourced and met the specific needs of patients.
A number of candidate index tests were identified that could be further investigated to help
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his Chapter introduces some important topics in the thesis, specifically dementia, diagnostic
accuracy, and clinical judgement. Presented first is a summary of important literature regard-
ing dementia, including definitions, epidemiology and aetiology, histology, clinical features,
diagnosis, clinical staging, investigations, complications, and prognosis. Section two of this Chapter
reviews the literature relating to diagnosis, diagnostic tests, diagnostic accuracy, and approaches
to combining tests. Section three discusses literature regarding clinical judgement, explaining the
concept and giving illustrative evidence for the accuracy of clinical judgement in different clinical
contexts. The Chapter closes by discussing the scientific rationale for the empirical work in the
context of some existing related literature, and sets out the aims and objectives for this thesis.
1.1 Background
1.1.1 Dementia
1.1.1.1 Definitions of dementia
The term dementia refers to a clinical syndrome of persistent cognitive impairment, from a previ-
ous higher level of functioning, that has a significant deleterious impact on the ability to perform
activities of daily living [1]. Dementia may result from different pathological processes, which are
outlined below in Section 1.1.1.2. Dementia should be distinguished from delirium, a fluctuating
disturbance of attention, awareness and cognition that develops rapidly and is attributable to a
disrupted physiology or multiple aetiologies [2].
Mild Cognitive Impairment (MCI), Section 1.1.1.7), is a clinical syndrome of cognitive decline
that is greater than expected for age and educational attainment, but which is not associated with
significant impact on activities of daily living [3]. The most recent edition of the Diagnostic and
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Statistical Manual of Mental Disorders (5th ed.) (DSM–5) [2] refers to major and minor neurocognitive
disorder in place of dementia and MCI respectively. MCI is discussed further in Section 1.1.1.7. DSM–5
defines major neurocognitive disorder as:
• "A. Evidence of significant cognitive decline from a previous level of performance in one or more
cognitive domains (complex attention, executive function, learning and memory, language,
perceptual-motor, or social cognition) based on:
– Concern of the individual, a knowledgeable informant, or the clinician that there has been
a significant decline in cognitive function; and
– A substantial impairment in cognitive performance, preferably documented by standard-
ized neuropsychological testing or, in its absence, another quantified clinical assessment.
• B. The cognitive deficits interfere with independence in everyday activities (i.e., at a minimum,
requiring assistance with complex instrumental activities of daily living such as paying bills or
managing medications).
• C. The cognitive deficits do not occur exclusively in the context of a delirium
• D. The cognitive deficits are not better explained by another mental disorder (e.g., major depres-
sive disorder, schizophrenia)"
In contrast the Diagnostic and Statistical Manual of Mental Disorders (4th ed., Text Revision)
(DSM-IV-TR) [4], which is used in much of the published literature, offers the following definition:
"The essential feature of a dementia is the development of multiple cognitive deficits that include
memory and at least one of the following: aphasia, apraxia, agnosia, or a disturbance in executive
functioning. The cognitive deficits must be sufficiently severe to cause impairment in occupational or
social functioning and must represent a decline from a previous high level of functioning. A diagnosis of
dementia should not be made if the deficits occur exclusively during the course of delirium." The third
common definition in the literature is The International Classification of Diseases, Tenth Revision
(ICD-10) [5] definition which states that for a diagnosis of dementia "There is evidence of each of the
following:
• G11
– (1). A decline in memory, which is most evident in the learning of new information, al-
though in more severe cases, the recall of previously learned information may also be
affected. The impairment applies to both verbal and non-verbal material. The decline
should be objectively verified by obtaining a reliable history from an informant, supple-
mented, if possible, by neuropsychological tests or quantified cognitive assessments. The
1G1 is one of the criteria
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severity of the decline, with mild impairment as the threshold for diagnosis should be
assessed 2.
– (2). A decline in other cognitive abilities characterized by deterioration in judgement and
thinking, such as planning and organizing, and in the general processing of information.
Evidence for this should be obtained when possible from interviewing an informant, sup-
plemented, if possible, by neuropsychological tests or quantified objective assessments.
Deterioration from a previously higher level of performance should be established. The
severity of the decline, with mild impairment as the threshold for diagnosis, should be
assessed.
• G2. Awareness of the environment is preserved during a period of time sufficiently long to allow
the unequivocal demonstration of the symptoms above.
• G3. There is a decline in emotional control or motivation, or a change in social behaviour
manifest as at least one of the following: emotional lability, irritability, apathy, coarsening of
social behaviour.
• G4. For a confident clinical diagnosis the symptoms in criteria G1 should have been present for
at least six months."
The three definitions outlined above are summarised and compared in Table 1.1. The three defini-
tions are consistent in requiring there to be a decline in cognition from a previous level, highlighting
that dementia may be diagnosed even if an individual performs in the normal range, or even above
average on formal cognitive testing. The most significant differences between the definitions are:
that ICD-10 and DSM-IV-TR require memory impairment in conjunction with impairment in other
domains, whereas DSM–5 only requires impairment in one domain and does not require amne-
sia; that only ICD-10 requires impairment in emotional regulation or social interaction; and that
DSM-IV-TR and ICD-10 require impairment of daily life to be attributable to each of the impaired
cognitive domains. Finally ICD-10 states that for a "confident" diagnosis the symptoms should be
present for at least six months. Two other definitions should be mentioned. Firstly, the Diagnostic
and Statistical Manual of Mental Disorders (3rd ed., Revised) (DSM-III-R) [6] is used in some of
the literature prior to 1995 and defines dementia as "impairment in short- and long-term memory,
associated with impairment in abstract thinking, impaired judgement, other disturbances of higher
cortical function, or personality change. The disturbance is severe enough to interfere significantly with
work or usual social activities or relationships with others. The diagnosis of Dementia is not made
if these symptoms occur. . .in Delirium" [6]. Secondly, The International Classification of Diseases,
Eleventh Revision [7] (ICD-11) is a classification system that was defined in 2018 that aligns to DSM–5
2Mild: a degree of memory loss sufficient to interfere with everyday activities though not so severe as to be incompatible
with independent living... The main function affected is the learning of new material. For example, the individual has
difficulty in registering, storing and recalling elements in daily living, such as where belongings have been put, social
arrangements, or information recently imparted by family members
9
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in using the term neurocognitive disorder in conjunction with dementia, and defines this as "an
acquired brain syndrome characterised by a decline from a previous level of cognitive functioning with
impairment in two or more cognitive domains (such as memory, executive functions, attention, lan-
guage, social cognition and judgement, psychomotor speed, visuo-perceptual or visuo-spatial abilities).
The cognitive impairment is not entirely attributable to normal ageing and significantly interferes
with independence in the person’s performance of activities of daily living. Based on available evidence,
the cognitive impairment is attributed or assumed to be attributable to a neurological or medical
condition that affects the brain, trauma, nutritional deficiency, chronic use of specific substances or
medications, or exposure to heavy metals or other toxins."
10
Table 1.1: Comparison of three definitions of dementia
Domain Definition
DSM–5 DSM-IV-TR ICD-10
Cognition Significant cognitive decline Development of multiple cognitive deficits Decline in multiple cognitive domains
Domains affected One or more of: Memory impairment AND Memory decline AND
complex attention aphasia judgement and thinking
executive function apraxia general processing of information




Evaluation Based on subjective concern AND Not specified Reliable history AND
objective measurement quantitative tests if possible
Activities of Interference with independence Significant impairment in both domains Memory and other cognitive abilities which
daily in daily life sufficient to interfere with social or both interfere with daily living
living occupational functioning to an extent that
is a decline from a previous level
Delirium Not exclusively in delirium Not exclusively in delirium Delirium not present when assessed
Emotions Not specified Not specified Decline in emotional control or change in





Duration Not specified Not specified At least six months
DSM–5 Diagnostic and Statistical Manual of Mental Disorders (5th ed.) DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders (4th
ed., Text Revision) ICD-10 The International Classification of Diseases, Tenth Revision
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Figure 1.1: Prevalence of dementia according to different definitions in five studies

























Figure 1.1 illustrates that studies have reported a lower prevalence of dementia according to
ICD-10, (3% [8] 16% [9] and 3 % [10]) than DSM-III-R (7% [8], 28% [9] and 17% [10]) and DSM-IV-TR
(14%[10]). Critically, while the different definitions have some overlap they classify different people
as having dementia, with ICD-10 identifying people who have more advanced dementia 3 [10]; with
implications for individuals, families, and society. Compared to ICD-10, DSM-III-R and DSM-IV-TR
include more cases with mild dementia and have a trend towards a shorter duration of symptoms [10].
In the identified studies, DSM-III-R typically had higher prevalence than ICD-10 and DSM-IV-TR,
with the exception of one study [11] which had a higher prevalence of DSM-IV-TR dementia. One
study (not plotted) shows that DSM–5 and DSM-IV-TR dementia have similar prevalence [12].
1.1.1.2 Epidemiology and Aetiology
Incidence and Prevalence Figure 1.2 illustrates that dementia is increasingly common with age,
with the prevalence in Western Europe approximately doubling with every fifth birthday over 60
years [14]. Around 1% of the population are estimated to have dementia at ages 60-64 years, based
on meta-analysis of 65 studies, and this rises to around 40% of the population aged 90 years and
over [14]. In some areas, including Western Europe, the prevalence in men is around 15% lower
than that in women (not shown in Figure 1.2). The incidence of dementia, based on 18 studies in a
meta-analysis, also rises with age from 3 per 1000 person-years at ages 60-64 years to 122 per 1000
person-year at ages 90+ year [14].
The prevalence of dementia is similar in other parts of the world, regardless of the extent of
economic development [14], and there is no definite indication of change over the past 30 years
3In [10] dementia was graded as mild, moderate or severe according to DSM-III-R
12
1.1. BACKGROUND


























































[15]. In contrast, there is some evidence that in high income countries, the incidence of dementia
has decreased over the past 30 years [15–17]. However, in Nigeria the incidence is reported to be
stable over time [18] and indeed in China [19] and Japan [20] the incidence has been reported to have
risen, though this is contested [21]. To the extent that incidence of dementia has fallen, there has
been no reduction in the workload for clinicians that is associated with dementia, with recorded
diagnosis of dementia remaining stable with an increasing trend from 1992-2014 in the Netherlands
[22] and increasing in the UK from 2006-2018 [23]. These findings are possibly due to diagnosis at
an earlier stage in the disease [22], a shift towards a milder disease profile with less deterioration
over time [24], or improved life expectancy in late life resulting in larger numbers of older people
compared to previous decades. To the extent that there is a fall in the incidence of dementia, it can
be at least partly attributed to better education of the population and control of hypertension [15]
and vascular risk factors, but there are also concerns that because obesity and diabetes are becoming
more common [16] there could be a reversal of the decline in incidence [25]. Overall, the impact is
that the number of people living with dementia worldwide is anticipated to increase from 50 million
in 2018 to 152 million in 2050 [25] because of increased life expectancy [26].
Aetiology While there are a number of definitions for dementia as a syndrome, there are also a
number of specific aetiologies. Clinical aspects of the different aetiologies are outlined in Section
1.1.1.4. However, attributing a fraction of dementia syndrome in the population to a particular
aetiology is complicated because in older people with dementia, who comprise the majority [27], the
clinical presentation may not correspond to the neuropathology [28–30], with discordance between
the clinical diagnosis and the neuropathology [31, 32]. Indeed, the association between dementia
and Alzheimer’s pathology weakens with age [33] and it is common for people with dementia to have
13
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more than one pathology at the time of death [30]. These findings have led some investigators to
advocate the idea that neuropathology should be regarded together with the clinical and imaging
data, and "trumped" [34] by the clinical presentation in understanding which conditions might have
affected a patient in life [34].
In general, the proportion of dementia attributable to different causes varies by age, with Lewy
body dementias being more common in people aged over 65 years [35] and frontotemporal dementia
occurring more often in people aged younger than 65 years [36], accounting for between 3%-26% of
dementia in this age group [36]. Figure 1.3 shows the prevalence of the different clinical diagnoses of
dementia in a community based sample of 2,170 people aged over 65 years in Spain [37]. Alzheimer’s
disease was the most common clinical diagnosis, which is typical [38], with other diagnoses being
less common, though vascular dementia was unusually rare and more often accounts for around 15%
of cases [39]. A second study of 1085 community-dwelling people in the UK found the prevalence of
dementia was 10%, of whom 31% (95% 95% confidence interval (95% CI), 21%-43%) had probable
Alzheimer’s disease, 22% (95% CI 14%-34%) had vascular dementia, 11% (95% CI 5%-21%) had Lewy
body dementia and 8% (95% CI 3%-17%) had frontotemporal dementia, with overlap between clinical
diagnoses occurring not infrequently. Notwithstanding these studies of the patterns of clinical
dementia by clinical aetiological type [37, 40], reports indicate that the majority of older community-
dwelling people have neuropathological lesions at autopsy, regardless of cognitive status in life, that
clinical dementia is associated with more than one type of neuropathology [41–44] and that in the
oldest-old the extent of clinical cognitive impairment is positively associated with the number of
neuropathologies [45]. Furthermore, as discussed in Section 1.1.1.3, increasing age attenuates the
association between neuropathology and aetiological sub-type and it is uncommon for older people
with dementia to have a single neuropathology.
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Risk factors Risk factors for dementia are considered as conferring a risk of dementia syndrome,
rather than a specific aetiology, because public health is improved by the reduction of dementia
regardless of aetiology [46]. There is some weak evidence that women are more susceptible to
dementia than men [47] but other studies suggest that the risk is similar and that women may
be affected at earlier ages [48, 49]. Some risk factors for dementia, such as genetic profile [48, 50],
have no scope to be modified in the foreseeable future. Others, such as early life experiences and
socioeconomic adversity [51], are difficult to modify without substantial social-political programmes
and investment. Conversely, many risk factors for dementia are potentially modifiable, with the
opportunity for up to one third of cases to be prevented [52] based on observational studies. Based
on observational studies the biggest single factor in reducing preventable cases of dementia may
be in improving crystallised intelligence, lifetime intellectual activity and cultural exposure [46].
Experimental designs investigating the causal effect of improved education on reduced dementia
incidence report mixed findings, with one indicating a 10% (95% CI 4% to 15%) reduction in dementia
risk per year of schooling [53], another finding no evidence of an effect [54], a systematic review
of mendelian randomisation studies reporting no evidence, albeit potentially due to insufficient
power [55], and a two-sample multivariable mendelian randomisation study reporting that with each
standard deviation increase in years of schooling and intelligence, odds of Alzheimer’s dementia were
on average 37% and 35% lower [56]. Table 1.2 presents the population attributable fraction (PAF) for
various risk factors at different stages of the life course and shows that in later life the most important
modifiable risk factors for dementia are smoking, depression, physical inactivity, social isolation, and
diabetes. Because the data in Table 1.2 are based on observational studies it is important to note
that the associations may be (partly) attributable to residual or unmeasured confounding, or (with
depression, inactivity and isolation) reverse causation. In addition to factors that increase risk for
developing dementia, there are also factors which might improve cognitive reserve, "the ability to
optimize or maximize normal performance" [57], which has been proposed as a concept to explain
the individual variation in cognitive decline. In a population based study, a cognitive reserve score
calculated using the formula
(1.1) Cognitive reserve score = 1.7£years of education+1£occupational complexity level
was found to mediate 21% of the variance in Cambridge Cognitive Examination (CAMCOG) scores
that was attributable to four lifestyle factors (physical activity, diet, alcohol, cognitive and social
activity) [58].
Genetics It is unusual for dementia syndrome to be caused by a single gene mutation, as seen in
mendelian inheritance, and single genetic mutations have a low positive predictive value for dementia
[59]. Despite this, family history is often relevant clinically as people with a first degree relative with
non-mendelian Alzheimer’s disease have a lifetime risk that is 2.5x the population risk [59]. A family
history of psychiatric disorders and the age of dementia onset are important in determining the
risk of genetically linked dementia, both Alzheimer’s disease and frontotemporal dementia, with
15
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Table 1.2: Modifiable risk factors for dementia [51]
Risk factor Relative risk for Prevalence PAF §
dementia (95% CI) of risk factor
Early life age < 18 years
Less education 1.6 (1.3-2.0) 40% 20%
(none or primary school only)
Mid life age 45-65 years
Hypertension 1.6 (1.2-2.2) 8.9% 5.1%
Obesity 1.6 (1.3-1.9) 3.4% 2.0%
Hearing loss 1.9 (1.4-2.7) 32% 23%
Later life age >65 years
Smoking 1.6 (1.2-2.2) 27% 14%
Depression 1.9 (1.6-2.3) 13% 10%
Physical inactivity 1.4 (1.2-1.7) 18% 6.5%
Social isolation 1.6 (1.3-22) 11% 5.9%
Diabetes 1.5 (1.3-1.8) 6.4% 3.2%
§ PAF population attributable fraction
the probability that a person has a genetic mutation rising with the number of affected first degree
relatives and the age of onset [59]. Dementia may also be a feature of other neurodegenerative
disorders, notably Huntington’s disease, autosomal dominant Lewy body dementia (which is typically
sporadic) [59], and Parkinson’s disease.
Most Alzheimer’s dementia with an onset over age 65 years is due to sporadic forms of the disease,
with genetic mutations found in only 1% of people who have two or more first degree relatives
with onset at this stage in the life course [59]. Genetic mutations are also rare in people with early
onset Alzheimer’s disease who have no family history. The three most common genetic mutations in
Alzheimer’s disease are PSEN1 on chromosome 14 (60% of mendelian cases), APP on chromosome
21 (15% - 23% of mendelian cases), and PSEN2 on chromosome 1 (which is rare) [59]. Each of these
three mutations has a role in the cellular processing of amyloid-Ø which is a key component of
plaques (Section 1.1.1.3). Other genes contribute to the risk of Alzheimer’s disease in a complex
(i.e. non-mendelian) way. For example, people with ApoE E genotype E2/E2 have a lower risk of
Alzheimer’s disease (0.5x population risk) whereas those with genotypes E3/E4 and E4/E4 have
respectively 3x and 8x the population risk; despite this up to 75% of people with the E4 allele do not
develop Alzheimer’s disease [59].
In contrast to Alzheimer’s disease, 40%-50% of people with frontotemporal dementia have a
relevant family history, and between 10%-30% of them have an autosomal dominant inheritance
pattern [59]. The probability of identifying a genetic mutation in someone with a family history of
frontotemporal dementia is positively associated with younger age at onset and increasing number




There is overlap between the genetics of Lewy body dementia, Parkinsons’s disease, Parkinson’s
disease dementia, and Alzheimer’s disease. Mutations in the SNCA and LRRK2 genes are associated
with a rare form of autosomal dominant inherited Lewy body dementia [35]. There are few studies
investigating the genetics of vascular dementia, and no conclusive evidence of definite genetic
risk factors, other than that a frameshift mutation in the notch gene on chromosome 19 is related



























The hallmark of Alzheimer’s disease pathology is the accumulation of abnormally folded plaques
of amyloid protein comprised of Amyloid-Ø and tau, together with neuronal tangles [38]. However,
in older people with dementia the association with plaques and tangles is weaker, whereas the
association with cerebral atrophy remains [33]. In dementia associated with PSEN1 Amyloid-Ø
accumulates in hydrophobic peptides of increasing length as amyloid precursor protein is cleaved
less efficiently [38]. Neurodegeneration can result from accumulated Tau protein which may act in
parallel or independently of Amyloid-Ø [38]. The medial temporal lobe is preferentially affected by
atrophy in Alzheimer’s disease [38].
In contrast frontotemporal dementia is associated with changes in the frontal lobes, anterior
temporal lobes, and cortex (anterior cingulate and insular), with neurodegeneration manifesting as
gliosis, neuronal loss and microvacular changes [36]. Nearly all frontotemporal lobar degeneration
is attributable to three abnormal proteins. TAR DNA-binding protein with molecular weight 43
kilodaltons (kDa), TDP-43 accounts for almost 50% of cases of frontotemporal lobar degeneration
and has three main subtypes which have characteristic cytoplasmic or intranuclear pathology [36].
Microtubule associated protein tau accounts for 35%-50% of frontotemporal lobar degeneration,
most often manifest as Pick’s disease, corticobasal degeneration, and progressive supranuclear palsy,
each of which accounts for 1/3 of cases of frontotemporal lobar degeneration-tau and is associated
with characteristic histology [36]. Finally fused-in-sarcoma accounts for around 10% of cases of
frontotemporal lobar degeneration and is associated with abundant immunoreactive inclusion
bodies in the dentate gyrus and severe atrophy of the striatum [36].
Lewy body dementias are associated with inclusion bodies of Æ-synuclein and neuronal loss,
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which are proposed to spread from cell to cell, and appear to be synergistic with amyloid-Ø but not
vascular pathologies [35]. Vascular dementia is associated with a variety of neuropathology, including
both macro- and micro-vascular disease in cortical and subcortical regions, as well other vascular
processes such as amyloid angiopathy [39].
Notwithstanding the typical or classic descriptions of neuropathology associated with each
dementia aetiology, older adults with late-onset dementia typically have mixed pathology at death [33,
42]. Furthermore, abnormalities that are classically associated with dementia, such as neurofibrillary
and vascular pathology, are found at death in people both with and without clinical dementia in life
[42]. A greater pathological load is associated with a higher likelihood of clinical dementia [29, 44],
though it is uncertain whether this association may [31], or may not [28], persist in people aged more
than 90 years.
1.1.1.4 Clinical aspects
Table 1.3 presents the clinical features for each dementia aetiology. Often the specific symptoms of
particular dementia aetiologies are more obvious in the initial or early stages of the process, and as
the disease progresses there is often increasing disruption of cognitive function, leading to apathy,
withdrawal, and dependency in activities of daily living. Behavioural and psychological symptoms of
dementia are common with many dementia aetiologies, especially frontotemporal dementia, and
are often particularly distressing for patients and their kin.
Alzheimer’s disease is typically associated with gradually progressive impairment in memory over
months, sometimes years, with early decline in the formation of new memories subsequently leading
to diminishing executive function and difficulties with other cognitive domains [38]. The clinical
features of Alzheimer’s disease are associated with the age at diagnosis, with higher odds of non-
memory symptoms, especially abnormal visuospatial processing, at lower ages of first presentation
[60]. Posterior cortical syndrome (not in table) [61] is a rare presentation (perhaps 5% of cases) often,
but not always, associated with Alzheimer’s disease pathology and may present with symptoms of
anxiety, visual problems (especially with lines of text, judging distances and climbing stairs), and
parietal lobe dysfunction such as dyspraxia, dyscalculia and dyslexia [61]. The standard diagnostic
criteria are based on working groups from the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) [62, 63].
Frontotemporal dementia, in contrast to Alzheimer’s disease, is much less likely to manifest
with memory impairment in the early stages. Frontotemporal dementia is described as having three
presentations, one of which predominantly affects behaviour, and two of which (the progressive
aphasias) are associated with progressive deficits in speech, grammar and word output which are the
exclusive symptoms for the first few years. Firstly, behavioural variant frontotemporal dementia is
associated with early behavioural deficits including apathy, personality changes and disinhibition
[36]. Patients may be hyper-oral with an appetite for sweet food or alcohol, less sympathetic and
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empathetic leading to difficulties in personal relationships and limited insight, socially unruly leading
to public displays of nudity or overtly sexual comments (though often with impaired libido), and
suffer from disrupted motivation resulting in repetitive stereotyped behaviour whilst becoming
increasingly apathetic [36]. Secondly, semantic variant primary progressive aphasia is manifest as
incomprehension and mispronunciation of isolated words, especially those infrequently used by the
patient, but the syntax and fluency of speech is initially maintained so that repetition may not be
impaired [36]. Behavioural symptoms develop as the disease progresses, and are influenced by the
lateralisation of the neuropathology, right and left sided degeneration resulting in respectively verbal
and visual compulsions [36]. Finally, Non-fluent variant primary progressive aphasia is characterised
by awkwardness in the production of speech, with inappropriate additions, deletions or pauses im-
peding the fluency of speech, though understanding and pronunciation of single words is preserved
[36].
Vascular dementia may manifest with a variety of presentations, depending on where the vascular
damage has occurred in the brain, but is classically associated with impaired executive function
and attention with relative preservation of memory [39]. Apathy and depression characterise the
neuropsychiatric symptoms of vascular dementia, but there is considerable overlap with Alzheimer’s
disease and other more unusual symptoms may be present such as delusions and hallucinations
[39]. Vascular dementia may present as part of vascular parkinsonism, a disease of older people
often manifest as gradual onset gait disturbance particularly of the lower body, postural instability,
falls, incontinence, and pseudobulbar effect [64]. The standard diagnostic criteria for much of the
literature is based on a working group from the National Institute of Neurological Disorders and
Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences
(NINDS-AIREN) [65].
Lewy body dementias can be difficult to diagnose. Firstly, dementia with Lewy bodies can present
similarly to Alzheimer’s disease; secondly, the onset of Parkinson’s disease dementia in someone with
Parkinson’s disease can be insidious [35]. Once established, Parkinson’s disease dementia is indistin-
guishable clinically from dementia with Lewy bodies, because the conditions are differentiated on
the basis of the time course: in dementia with Lewy bodies dementia presents before, or within one
year, of spontaneous parkinsonism, whereas Parkinson’s disease dementia presents after Parkinson’s
disease has been present for a number of years. Dementia with Lewy bodies is characterised by a
gradually progressive cognitive impairment, perhaps especially affecting visuospatial skills, which is
seen in 74% of people compared to 45% of those with Alzheimer’s disease [35]. Executive function,
and attention are other commonly affected domains in dementia with Lewy bodies, though these
are likely to be less useful to diagnose the aetiology given the overlap with vascular and Alzheimer’s
dementia. Other features of dementia with Lewy bodies may include: fluctuating severity, well formed
visual hallucinations, rapid eye movement sleep disorder (expressed as a person acting out or vocalis-
ing vivid, often persecutory dreams), spontaneous parkinsonism relatively early in the disease course,
sensitivity to antipsychotics, falls, and autonomic dysfunction [35]. The clinical diagnostic criteria for
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dementia with Lewy bodies identify only 32% of people who meet the neuropathological criteria at
autopsy, with greater concordance associated with florid Æ°synuclein pathology and sparse neuritic
plaques [35]. Investigations can be helpful to refine the diagnosis of dementia with Lewy bodies
from Alzheimer’s disease. Single-photon emission computed tomography (SPECT) demonstrating
low dopamine transporter uptake may be used to distinguish dementia with Lewy bodies from
Alzheimer’s disease, but not from other parkinsonian syndromes [35].
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Table 1.3: Clinical aspects of dementia by aetiology
Aetiology Clinical features Investigations Definitions Treatment
Alzheimer’s disease [38] Impaired memory and CSF McKhann [62, 63] acetylcholinesterase
executive function Amloid Ø42, total-tau & inhibitors
phosphorylated tau (p-tau) Glutamate
Imaging Antagonists
Atypical presentations with medial temporal lobe atrophy
language, visual, practic, or Nuclear imaging
executive function initially FDG pattern temporoparietal
and posterior cingulate
Frontotemporal dementia [36] Three variants , converging over Nuclear imaging Neary [66] Symptomatic
time, gradually developing global FDG pattern anterior, Brun [67]
cognitive impairment & motor asymmetric, or both Boxer [68]
deficits: parkinsonism; motor
neuron disease
Vascular dementia [39] varied imaging demonstrating NINDS-AIREN [65] Symptomatic
subcortical lesions result in changes to account for ADDTC [69] &
inattention, processing & clinical presentation DSM–5 [2]
executive function.
Lewy body dementia [35] Visuospatial defects and CSF McKeith [70, 71] Acetylcholinesterase
RBD common, well formed visual Æ°synuclein may be lower inhibitors





CSF cerebrospinal fluid FDG fluorodeoxyglucose (18F) ADDTC Alzheimer’s Disease Diagnostic and Treatment Centers
NINDS-AIREN National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences
SPECT Single-photon emission computed tomography DSM–5 Diagnostic and Statistical Manual of Mental Disorders (5th ed.)




Dementia usually presents as a gradual onset of progressive cognitive symptoms over months to
years. A history of decline in a cognitive domain from a previous higher level is the hallmark symptom,
which is often (though not always) verified by a person who knows the patient before their symptoms
started. A clinical evaluation of someone with symptoms that could indicate dementia often begins
with understanding who has raised concerns about the possibility of cognitive problems, the patient,
their kin, or a health professional. An understanding of the nature and impact of the perceived
cognitive deficits, onset, fluctuation, progression, trigger to seek help, and other affected domains is
essential. Elicitation of the persons level of education, occupational role(s), family history (including
of psychiatric disease), and exposure to risk factors (e.g. alcohol, smoking, trauma, and toxins) may
also be helpful. Understanding the symptoms in the context of the persons medical, social and
psychological history, as well as their medications, current comorbidities, and wishes for the future
is an important part of providing holistic, responsive care, and may be relevant to the diagnostic
evaluation.
Cognitive testing can be helpful in measuring objective impairment, though the evaluation
should be targeted based on the history, so that there is confidence that the evaluation will test the
cognitive domains where problems have been reported. In some cases a specialist neuropsychological
evaluation is required to ascertain the full range of cognitive deficits. Often the physical examination
of someone with dementia will be normal, but there may be signs of previous vascular insult, such as
hemiplegia, or of a prior neurological disease, such as Parkinson’s disease, and some investigators
have reported clinical signs such as the head turn sign 4, applause sign, 5 or came alone sign 6 [72].
The most important alternative diagnoses to be considered in the evaluation of someone with
possible dementia are delirium (Section 1.1.1.9), MCI (Section 1.1.1.7), and psychiatric conditions
(such as depression). However, the differential diagnosis is broad and may include functional mem-
ory disorder, trauma (causing subdural haematoma), cerebral neoplastic disease (either metastatic
cancer, or more rarely primary cancer), neurodegenerative conditions (such as normal pressure
hydrocephalus), immunologically mediated disease (such as encephalitis or paraneoplastic phe-
nomenon) or auto-immune (multiple sclerosis). Typically these alternative diagnoses are discounted
on the basis that dementia is more in keeping with the clinical history, especially the time course,
and of investigations, especially neuroimaging.
1.1.1.6 Clinical staging
The Clinical Dementia Rating scale (CDR) [73] was designed to stage Alzheimer’s disease but can also
be used to stage other dementias [74]. An interview is used to judge the capacity of an individual in
six domains, memory, orientation, judgement and problem solving, community affairs, home and
4the patient looks to an accompanying person to help support them answering questions
5when asked to clap three times the person claps more than this indicating possible perseveration
6to clinic, supporting a a non-dementia diagnosis
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hobbies, and personal care. The scale can be used to derive a global scale, which is calculated using
an algorithm [75] and typically used for purposes of staging dementia with scores ranging from 0
(normal) through 0.5 (questionable), 1 (mild), 2 (moderate), to 3 (severe). An alternative approach
is to score the sum of boxes, which results in a more detailed quantitative index ranging from 0 to
18 and provides more useful information in mild dementia [76–78]. An alternative clinical staging
system is the global deterioration scale (GDS) which can be used to rate the severity of a primary
neurodegenerative condition [79]. The GDS has seven stages from 0 to 7 (most severe), with stages
1-3 being pre-dementia and stages 4-7 being the stages in dementia. CDR 2 (moderate dementia)
approximately corresponds to GDS 5 (moderate dementia), as both stages describe people at this
stage as continent and being able to recall names but disorientated to time and place; GDS 6 relates
approximately to CDR 3 described as forgetting names, disturbed diurnal rhythm, and dependency in
activities of daily care, with variable incontinence; in contrast GDS 7 (describing generalised rigidity,
incontinence and mutism) corresponds to a yet more advanced stage of disease than CDR 3.
A challenge for patients, clinicians, researchers and policy-makers is that in the hypothetical
model of Alzheimer’s disease pathology the disease develops many years before symptoms are
present [80]. Alzheimer’s disease has a long preclinical phase with pathology accumulating many
years (perhaps decades) before symptoms develop, once the brain has accumulated a substantial
load of Amyloid-Ø [81]. The pathological burden at which the disease manifests is not uniform,
and may be influenced by cognitive reserve (Section 1.1.1.2) and comorbidities. As neuropathology
develops a person may present to health services with subjective cognitive impairment (SCI), which
is deficits in memory but objective cognitive tests scores within the normal range [82]. SCI in the
absence of objective cognitive impairment is reported by around 17% of people in the community
[83], and of this group 19% have dementia and 32% have MCI [84], (Section 1.1.1.7).
People with SCI who do not currently meet criteria for dementia or MCI have an annual risk
of progression to these states which is approximately 2% for dementia and 6% for MCI [83]. At
population level SCI is more likely to be an indicator of affective disorder than an organic cognitive
disorder, and investigators have reported that functional impairment of activities of daily living may
be a helpful way to identify a group of people who are most likely to have an underlying cognitive
disorder [82], though necessarily this would mean that people with cognitive disease that is less
advanced will not be identified. However, in the general practice population a history of depression
and anxiety are also both associated with an increased risk of dementia [85].
One approach to identify people who have the highest risk of developing dementia is to evaluate
the risk of future dementia [86] using a risk score, though many of these scores cannot be based on
routinely collected data [87–89]. One model using routine data may be useful to identify people aged
60-79 years who are at high risk of a diagnosis of dementia within the subsequent five years, but
unfortunately this did not extend to people aged 80+ years [90]. The model to predict risk of dementia
in the subsequent five years in people aged 60-79 years comprised predominantly vascular risk
factors (age, sex, smoking, current anti-hypertensives, body mass index, diabetes, cerebrovascular
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disease, current aspirin use), together with harmful alcohol use, depression and atrial fibrillation [90].
The incidence of dementia in the group aged 60-79 years was 1.9 (95% CI 1.8–1.9) per 1000 person
years at risk compared to 17 (95% CI 16-17) per 1000 person years at risk in the 80+ years age group.
The discrimination and calibration (see Section 1.1.2.5) of the risk algorithm were good for the group
aged 60-79 years: 2.0 (95% CI 1.9 to 2.1) C 0.84 (95% CI 0.81 to 0.87) slope 0.98 (95% CI 0.93 to 1.0)
but were poor in the group aged 80-85 years: D 0.86 (95% CI 0.76 to 0.95) C 0.56 (95% CI 0.55 to 0.58)
slope 1.0 (95% CI 0.89 to 1.2) [90]. Therefore while more of the older-old population develop dementia
annually than than the younger-old, risk prediction is more difficult in the older group. An alternative
model for estimating risk of dementia over a 10-year time frame using information that might be
routinely available in primary care was derived from and validated in a population based cohort
study of 2,170 people aged over 60 years (mean age 71 years) [91]. In this study, age, history of stroke,
subjective memory decline, and need for assistance with finances or medication (which is less likely
to be routinely available in general practice records) had good discrimination for predicting the risk
of dementia with a c-statistic of 0.78 (95% CI 0.75-0.81), though once again the discrimination was
lower in the 465 people aged over 80 years (c statistic 0.57, 95% CI0.49 - 0.63) [91].
People with SCI may derive some benefit from group sessions on education about cognitive
symptoms, or cognitive training, but the evidence for these interventions is weak [92], and there is
no evidence that people who are highest risk of progressing to dementia or MCI are more likely to
benefit.
1.1.1.7 Mild Cognitive Impairment
MCI is a syndrome of cognitive decline where a person has cognitive function that is not normal for
age, with minimal impairment of the activities of daily living to the extent that it is insufficient to meet
criteria for dementia [3, 93–95]. MCI may occur either with memory impairment (amnestic-MCI)
or without (non-amnestic-MCI), with more restrictive definitions unsurprisingly being reported to
have a lower prevalence in the population [96]. Similarly to dementia, additional years of education
reduce the risk of MCI, there is no clear evidence that sex is a risk factor [96], and the prevalence
increases with age. MCI is identified in 6.7% (95% CI 3.4% - 13%) of people at ages 60-64, rising to
8.5% (95% CI 5.2% - 13%) at 65-69 years, 10% (95% CI 7.5% - 14%) at ages 70-74 years, 15% (95% CI 10%
- 21%) at ages 75-79 years and 25% (95% CI 17% - 37%) at ages 80-84 years [96]. MCI is not necessarily
a pre-dementia condition, and some people with MCI may find that their cognition remains stable.
In a meta-analysis of 41 robust inception cohorts of people with MCI the annual conversion rate
from MCI to dementia was 6.7% (95% CI 4.6%-9.1%), with between 30%-50% of people developing
dementia with long term surveillance [97], suggesting that many people with MCI do not develop
dementia.
Indeed, in a study of 357 people aged over 75 years with MCI in general practice 42% found their
symptoms improved at three years [98]; other studies in different settings have reported that between
14% and 56% of people with MCI revert to normal [96]. The uncertainty about the disease course
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can cause ethical questions about the value of designating a clinical presentation as MCI as this will
inevitably raise concerns for the patient and their kin about the risk of developing dementia, perhaps
unnecessarily. The uncertain natural course of MCI is compounded by the apparent reduction
in the risk of conversion to dementia over time, with the risk of dementia being highest shortly
after identification of MCI, perhaps especially in the first two years [99], and reducing with time
[97]. Furthermore, compared to people with normal cognition at baseline, people with amnestic-
MCI who have improvement in their cognitive symptoms remain at higher risk of subsequently
developing dementia, though they are at lower risk than people with stable amnestic-MCI [99]. With
the exception of exercise twice-weekly as part of a holistic approach to management that includes
advance care planning and serial cognitive evaluation, there are no disease-modifying interventions
that are recommended unequivocally for people with MCI, though it is is advisable to avoid any
modifiable factors (such as medication) that may have an adverse impact on cognitive performance
[96]. In DSM–5 [2] MCI is referred to as Minor Neurocognitive Disorder, which is defined as:
• "A. Evidence of modest cognitive decline from a previous level of performance in one or more
cognitive domains (complex attention, executive function, learning and memory, language,
perceptual-motor, or social cognition) based on:
– Concern of the individual, a knowledgeable informant, or the clinician that there has been
a mild decline in cognitive function AND
– A modest impairment in cognitive performance, preferably documented by standardised
neuropsychological testing or, in its absence, another quantified clinical assessment.
• B. The cognitive deficits do not interfere with capacity for independence in everyday activities
(i.e., complex instrumental activities of daily living such as paying bills or managing medications
are preserved, but greater effort, compensatory strategies, or accommodation may be required).
• C. The cognitive deficits do not occur exclusively in the context of a delirium.
• D. The cognitive deficits are not better explained by another mental disorder (e.g., major depres-
sive disorder, schizophrenia)."
1.1.1.8 Complications
As dementia progresses, the specific features of the individual aetiologies often become less apparent
as the neuropathology becomes more generalised and there is more global cognitive impairment.
Advanced dementia is described in GDS 7 as: "All verbal abilities are lost ... Frequently there is no
speech at all only unintelligible utterances and rare emergence of seemingly forgotten words and
phrases. Incontinent of urine, requires assistance toileting and feeding. Basic psychomotor skills, e.g.,
ability to walk, are lost with the progression of this stage. The brain appears to no longer be able to
tell the body what to do. Generalized rigidity and developmental neurologic reflexes are frequently
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Table 1.4: Common symptoms in advanced dementia [102]
Symptom Cumulative incidence Mortality within six months
Eating problems 85% 39%
Febrile episode 53% 45%
Agitation 54% ‡
Dyspnoea § 48% ‡
Pneumonia 41% 47%
Aspiration 41% ‡
Pain § 39% ‡
Pressure ulcer † 39% ‡
§ ∏ five days per month † ∏ grade 2 ‡ not reported
Eating problems include weight loss, chewing problems, dysphagia,
refusal to eat, suspected dehydration, or persistent food refusal
Pneumonia defined as documentation by physician, nurse practitioner,
or physician assistant
Febrile episode, excluding pneumonia, defined as oral temperature
∏37.8°C; rectal ∏38.3°C; or axillary, ∏37.2°C
present." [79]. Table 1.4 shows that the most common clinical problems encountered in the later stages
of dementia are with eating, pyrexia, agitation, dyspnoea and chest infection [100]. Colonisation
with antimicrobial resistant organisms is also common, occurring in 48% of people with advanced
dementia, and may be due to liberal use of broad spectrum antimicrobials with relatively little
objective evidence of systemic infection [101]. Pain and agitation are also common symptoms, [102,
103], which are often managed with opiods, and anxiolytics respectively [103]. Opiods may also be
used to manage terminal dyspnoea [103]. Advance care planning, aiming to maximise comfort and
avoid unnecessary or potentially burdensome interventions, can help to improve the quality of care
in the late stages of dementia [100] and is important because 96% of health care proxies consider
comfort to be the principle goal for care at the end of life [102]. At the very end of life, delirium is also
a common problem for people with advanced cognitive impairment [104].
Dementia shortens life expectancy, even allowing for the effects of age and co-morbidity [51],
though some have hypothesised the secular trend that survival with dementia may be increasing [15].
Population based studies have reported that median survival after a diagnosis of dementia is between
3.3 years [105] and 4.4 years [106]. In contrast, a study based on primary care records of 22,529
people with dementia coded, and 112,645 people without dementia coded, reported that median
survival from recorded diagnosis was 6.7 years in those aged 60-69 years and 1.9 years in those aged
90 years and over [107]. The important distinction of the primary care based study is that cases were
those who were entered on the general practice record, which may be systematically under-recorded
[108], and this effect may be greatest in older people. Older age at symptom onset, male sex, higher
education, history of diabetes or depression symptoms, and greater cognitive decline have been




Delirium is a acute disturbance in attention and cognition, characterised by impaired consciousness,
fluctuating severity, and typically occurring in the context of an acute illness. The interrelation
between delirium and dementia is intricate. In a person who has MCI or dementia, superimposed
delirium results in an acute deterioration in their clinical status. Delirium is a syndrome and is not,
in itself, a diagnosis; it may be attributable to one or many aetiologies, commonly infection (e.g.
urinary tract, respiratory tract), medication effect (especially those with sedative or anti-cholinergic
action), trauma, metabolic disruption (e.g. electrolyte disturbance), or physiological abnormalities
(e.g. hypoxia), or occur peri-operatively, among other causes [110]. Delirium may be identified using
clinical tests such as the 3D-CAM [111], 4-AT [112] or OSLA [113].
Whether a person manifests delirium in an episode of acute illness is influenced by the back-
ground of the individual and characteristics of the acute illness episode. Prior factors influencing
tendency to delirium include previous episodes, age, and underlying cognitive impairment [114].
Characteristics of the acute episode include the number of acute parallel stresses, their nature or like-
lihood of causing delirium, and the severity of the illness(es) [115]. While the probability of delirium
is related to the prior susceptibility and the acute instigating factors of illness, it is a matter of ongoing
research whether these factors also influence the probability of long term cognitive impairment after
delirium [116, 117] independent of baseline cognition. However, it is clear that an episode of delirium
in an older aged adult increases the risk of future dementia, and it is possible this is not mediated
through classic dementia neuropathology [118, 119].
Identifying delirium superimposed on dementia (DSD) can be very difficult because there is
no agreed definition [120], but evaluating the extent to which motor function is compromised
may help to differentiate DSD from dementia [121]. Typically delirium develops rapidly, over hours
or days, and is associated with impaired attention and consciousness, whereas dementia without
delirium develops over months or years, and is not usually associated with inattention or obtundation.
Conversation in delirium is typically incoherent and disorganised, whereas in dementia while there
may be aphasia in severe stages the speech is usually ordered and has some logic, even if it is not
lucid. The crucial distinction for identifying DSD may be the report from relatives that the person is
behaving abnormally and out of character [110].
Delirium in a person who is apparently cognitively normal when well is especially complex
because it may herald incipient MCI or dementia, and a number of plausible mechanisms for this are
debated. Firstly, delirium may compromise cognitive reserve strategies that have previously masked
latent impairment, thus revealing undiagnosed dementia. Secondly, the triggering factors for an
episode of delirium may themselves be harmful to the brain and these may act alone (e.g. through
ischaemic, inflammatory, or apoptotic neural insults) or in synergism, to initiate or accelerate any
existing dementia neuropathology, resulting in neurodegeneration [110]. Thirdly, delirium may
itself mediate a directly deleterious impact on the brain regardless of the underlying aetiology [110].
Delirium may persist for an extended period, sometimes months or years following an acute insult
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and is associated with expedited cognitive decline following the acute episode: even if dementia does
not develop the person may not return to their baseline level of performance before the episode
of delirium, though factors that mediate this are an ongoing area of research [110]. In DSM–5 [2]
delirium is defined as:
• "A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention)
and awareness (reduced orientation to the environment).
• B. The disturbance develops over a short period of time (usually hours to a few days), represents
an acute change from baseline attention and awareness, and tends to fluctuate in severity during
the course of a day.
• C. An additional disturbance in cognition (e.g.memory deficit, disorientation, language, visu-
ospatial ability, or perception).
• D. The disturbances in Criteria A and C are not better explained by a pre-existing, established or
evolving neurocognitive disorder and do not occur in the context of a severely reduced level of
arousal such as coma.
• E. There is evidence from the history, physical examination or laboratory findings that the
disturbance is a direct physiological consequence of another medical condition, substance
intoxication or withdrawal (i.e. due to a drug of abuse or to a medication), or exposure to a toxin,
or is due to multiple etiologies."
Expert opinion has advised an inclusive approach to evaluating items (A) and (D) in DSM–5,
because of concerns that it might be impossible to formally evaluate inattention, and because
delirium is well recognised to cause impaired consciousness [122].
1.1.1.10 Treatment
Identifying a drug to modify the course of disease in dementia is a current focus of global research
efforts [123]. Even if a disease modifying therapy existed, arguably there would be greater benefit for
the population in investing in primary prevention, to reduce risk of dementia and improve cognitive
reserve [51, 124].
In the absence of a disease modifying therapy, the focus of treatment for people with dementia
should be a holistic care approach to the medical, social and psychological needs of the patient and
their relatives [51]. The diagnosis of a progressive incurable condition may be an opportunity to
consider future plans, including for future care at times of crises or in the terminal phase of life. Some
specific symptoms, such as cognition and neuropsychiatric symptoms may benefit from interven-
tions with drugs, but often a holistic approach thinking creatively about social approaches, problem
solving, promoting inclusivity and independence can be as helpful. For people with dementia, music
based stress reduction may improve depressive and behavioural symptoms [125], reminiscence
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therapy may help to improve quality of life and communication [126], and exercise programs may
support people with dementia to perform activities of daily living [127]. Group based cognitive stim-
ulation programs improve cognition in people with mild-moderate dementia [128]. For people who
are caring for those with dementia, mindfulness based stress reduction techniques may be helpful
[129] and telephone support may help to reduce depressive symptoms [130]. Recommendations on
treatment are limited by the lack of high quality primary research; even for interventions which seem
valid and may be commonly utilised in clinical practice, such as respite care [131], case management
[132], reducing antipsychotic prescribing [133] or thickening food to help with swallowing problems
[134].
Acetylcholine is a neurotransmitter with roles in the peripheral and central nervous system; a
deficit of cholinergic transmission is hypothesised to be part of the pathology in Alzheimer’s dis-
ease [135]. The deficit of acetylcholine in dementia can be partially ameliorated by inhibition of
the enzyme acetylcholinesterase which degrades the neurotransmitter in the synaptic cleft. Avail-
able cholinesterase inhibitors include donepezil (tablet or orodispersible tablet) [136], galantamine
(capsule) [137] and rivastigmine (patch, capsule or liquid) [138]. The three medicines have slightly
different pharmacological properties but all have the same end result [139] and have been shown to
improve cognitive symptoms in people with Alzheimer’s dementia and Lewy body dementia.
1.1.2 Diagnosis, diagnostic tests, and diagnostic accuracy
1.1.2.1 Diagnosis
One way to conceptualise diagnosis is that it is a label, or method of classification [140], which is
applied to a particular group of patients to help to understand the aetiology, prognosis and potential
treatment options of a particular clinical scenario. One definition of diagnosis is:
"the process of determining the health status and the factors responsible for it; [it] may be applied
to an individual, family, group, society. The term is applied both to the process of determination and to
its findings" [141].
A range of strategies are used by clinicians to help to formulate a diagnosis in any particular
clinical scenario [142]. Broadly, the diagnostic process can be understood as having three stages, each
with a range of options that may be used by the clinician. Firstly, initiating the diagnostic hypotheses
may result from the patient self labelling with a diagnosis or stating a symptom which is parsed
into a presenting complaint by the clinician. Alternatively the clinician may use pattern recognition
based on experience to generate a range of hypotheses or make a "spot diagnosis", such as acne,
where the refinement stage is skipped. A second stage in the diagnosis process refines the diagnosis by
eliciting further information and iteratively testing the hypotheses against the evidence. Approaches
at this second stage of the diagnostic process include stepwise refinement (e.g. of upper or lower
urinary tract infection), or estimating the probability of diseases, either implicitly using pattern
recognition or explicitly using a clinical prediction rule. The third stage of diagnosis, is to "define the
final diagnosis" [142], though this could also be worded define the management. At the third stage
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of diagnosis either the diagnosis is known and can be treated confidently, or further information
is required either by using further tests, monitoring the response to treatment, or observing the
scenario over time, when the symptoms may become more easily classified or spontaneously resolve.
This third stage of diagnosis has been described as implicitly comparing the probability of disease
against a treatment threshold, treatment is indicated when the probability of disease for a patient
exceeds the threshold, and a test threshold, if the probability of disease in a patient falls below the
threshold then further testing is not indicated [143]. An example:
A 75 year old man attends his GP surgery concerned that he is forgetting the names of relatives and
recently was unable to find his way home. He is concerned that he has dementia (hypothesis initiation
by self labelling). The clinician parses this into a hypothesis generating presenting complaint of
memory loss. The clinician elicits further detail to refine the diagnosis, establishing that there are no
other cognitive concerns and that that no other person is concerned. The patient and the clinician
weigh the probability of disease against the options for further testing or treatment and decide that
further information is needed before a final diagnosis can be reached. The probability of disease is
judged to not exceed the threshold for treatment or invasive testing at this stage and so it is agreed to
use a test of time and review in two months.
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Refiningstepwise refinement probability estimation
Defining
test threshold not reached
diagnosis excludedconsider other possibilities
treatment threshold exceeded treat
test threshold exceeded, but treatment threshold not met
further tests
monitoring response to treatment
observe
While the threshold for testing continues to be exceeded, defining the diagnosis iterates as the patient is observed, monitored in response to
treatment, or investigated further until the threshold treatment is exceeded.
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The three stage diagnostic process outlined above is typically executed rapidly and without
conscious thought by experienced clinicians, which can be described as being a type 1 process in the
dual model of cognition [144, 145]. The topic of the dual model of cognition is discussed further in
Section 1.1.3.
1.1.2.2 Diagnostic tests
As described in Section 1.1.2.1 in the broadest sense a clinical test could be any instrument that helps
a clinician and patient to refine the options that are available to management of a particular clinical
scenario, such as a test of time or a response to treatment. However, as more commonly understood
diagnostic tests are defined as:
"A test to diagnose whether or not a person has a disease or disorder. Not all biomedical (labora-
tory, imaging, genetic, other) tests have this aim. To protect individuals and groups from avoidable
adverse effects of diagnostic activities, it is essential to distinguish related but different aims, such as
diagnosing clinically overt disease; discovering occult disease (new process, recurrences); secondary
and tertiary prevention; determining the stage, characteristics, and activity of the disease; counselling;
or monitoring the clinical course and effects of therapies" [141].
The term diagnostic tests underestimates the role of tests in clinical medicine, because tests
are not synonymous with diagnosis. Some clinical tests, such as blood tests, imaging, or cellular
pathology are investigations. Investigations may have an important role in diagnosis to help refine the
probability of a particular disease, but they may also be used for other purposes in clinical practice,
such as: screening for disease, refining diagnosis within a category (e.g. at the molecular or genetic
level), guiding treatment and response to treatment, helping to determine prognosis, or providing
reassurance [146]. This thesis will not consider the use of tests for purposes other than diagnosis.
1.1.2.3 Diagnostic accuracy
The range of options for clinicians to reach a diagnosis is instructive as it highlights the broad range of
possible "tests" that could be used in practice. A test does not need to be a blood test, or a component
of the clinical evaluation, but could be a response to treatment or a change in the presentation
over time. Some have advocated that in the absence of indicators for immediate action such as
serious illness, the test of time is the most important diagnostic strategy in low prevalence settings
such as general practice [147]. As trivial symptoms without a significant disease aetiology resolve
spontaneously the prevalence of serious pathology in a given clinical profile increases, this has
the benefit of avoiding unnecessary actions in the majority of people who have a low probability
of disease. As the prevalence and spectrum of disease in a particular clinical profile changes, the
characteristics of test accuracy also vary.
For a single test, the test accuracy can be conveniently displayed in a two-by-two table. The
result of the test that is under investigation, termed the index test, for a particular target condition
is tabulated against the best available information about the presence of absence of that target
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disease, based on the reference standard [148]. Table 1.5 presents cross tabulated hypothetical data
on the presence of disease against the result of a test. Where there is discordance between the index
test and the reference standard the results of the index test are said to be false, and where there is
concordance they are said to be true, resulting in the terms true positives (TP), which is test positive
disease positive, and analogously false positives (FP), true negatives (TN) and false negatives (FN).
Table 1.5: Two by two table of test accuracy characteristics
Disease positive (n) Disease Negative (n) Total (n)
Test positive 84 (a) 11 (b) 95 (c)
Test negative 16 (d) 89 (e) 105 (f)
Total 100 (h) 100 (i) 200 (j)
a true positives; b false positives; d false negatives; e true negatives
c test positives; f test negatives; h disease positives; i disease negatives
j population; hj prevalence
in a strict epidemiological sense hj is not a prevalence but is more accurately a % of cases in a
sample; however prevalence is the recognised term in the diagnostic literature e.g. see [148]
Table 1.6 presents some measures that are used to assess accuracy of a single test and its per-
formance at a single threshold. Single tests can be judged on the basis of the paired test accuracy,
expressed as sensitivity and specificity, positive predictive value and negative predictive value, nega-
tive likelihood ratio (LRN) and positive likelihood ratio (LRP). In addition to the measures described
in the table, other measures include the Youden index [149, 150] which is derived from (sensitivity
+ specificity -1) and accuracy [151], which is described as the proportion correctly classified and
calculated as T P+T NT P+T N+F P+F N where TP, TN, FP and FN are respectively true positive, true negative,
false positive, false negative. The error rate, a weighted average of classification errors in people with
disease and those without the disease is given by [148]:
(1.2) error rate = (P (T ° |D+)£P (D+))+ (P (T +|D°)£P (D°))
For a test that gives results on a continuous scale, each of these measures is calculated for a single
threshold. In contrast, the area under ROC curve (AUROC) and diagnostic odds ratio (DOR) are
described in Section 1.1.2.6.
Figure 1.6 shows that for a hypothetical index test in a low prevalence setting (1%) when sensitivity
is low (1%), and specificity is high (99%), accuracy is high (98%); when sensitivity is high (99%), and
specificity is low (1%), accuracy is low (2%). Conversely in a high prevalence setting (80%) when
sensitivity is low (1%), and specificity is high (99%), accuracy is modestly low (21%); when sensitivity
is high (99%), and specificity is low (1%), accuracy is modestly high (79%).
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The figure plots the accuracy ( T P+T NT P+T N+F P+F N ) of a hypothetical index test and shows how accuracy, sensitivity and specificity vary with disease prevalence.
35
CHAPTER 1. INTRODUCTION
Table 1.6: Paired measures to assess test accuracy [148]
Measure Definition Notation §
Sensitivity Probability of an abnormal test in people with disease P(T+|D+)
Specificity Probability of a normal test in people without disease P(T-|D-)
PPV† Probability of disease given abnormal test P(D+|T+)
NPV ‡ Probability of non-disease § given normal test P(D-|T-)
LRP || Ratio of probability of abnormal test in diseased P (T+|D+)P (T+|D°
to abnormal tests in non-diseased
LRN ¶ Ratio of probability of normal test in diseased P (T°|D+)P (T°|D°
to normal tests in non-diseased
§ T+ test positive T- test negative D+ disease positive D- disease negative
†PPV positive predictive value ‡NPV negative predictive value
§the term non-disease is used because this only applies to one specific
disease and does not imply health
||LRP positive likelihood ratio ¶LRN negative likelihood ratio
Test accuracy is influenced by the prevalence of disease in the tested population, as well as the
threshold for determining disease. Sensitivity and specificity, and measures derived from them, are
often said to be independent of prevalence [152], and PPV and NPV are said to be dependent on
prevalence [152]. Sensitivity is derived from T PT P+F N and specificity from
T N
T N+F P . If D represents the
set of people that have disease and D0 the set of people who do not have disease7, then prevalence is
given by DD+D0 . Continuing with this notation, the denominators for sensitivity and specificity are
respectively D and D0 ; so that the ratio between D and D0 is not a component of the derivation of
these indices. In contrast PPV and NPV are respectively derived from T PT P+F P and
T N
T N+F N . Using the
same notation the denominator for PPV and NPV is respectively D+D0 and D0+D ; so that the ratio
between D and D0 has an impact on these measures.
Notwithstanding the mathematical independence of sensitivity and specificity from the ratio
of D and D0, these measures of accuracy still remain dependent on prevalence to the extent that
prevalence is a function of the threshold that is used to define disease. In different populations the
spectrum and prevalence of disease vary, which has an impact on the PPV and NPV, along with
sensitivity and specificity [148, 153, 154]. Test accuracy varies with prevalence but not in a consistent
pattern: sometimes the sensitivity will remain constant and the specificity will fall, other-times
the sensitivity will decrease and the specificity will increase [148]; other patterns may be observed.
Therefore measures of test accuracy are best understood as a function of the prevalence of disease
and the threshold for test positivity, with a trend for lower specificity to be associated with higher
disease prevalence [154] and lower sensitivity to be associated with lower disease prevalence [148].
7To facilitate interpretation of the denominators, which have + signs, D and D0 are used rather than D+ and D-.
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Figure 1.7: Distribution of test results between diseased and non-diseased














1.1.2.4 Thresholds in diagnostic testing
Clinical scenarios often encompass a broad range of possible presentations, manifesting in overlap
between health and disease. For any given test there are usually a range of potential results and there
is a spectrum of normal to abnormal. For example, the normal (non-diseased) range for many blood
tests is derived from the normal (Gaussian) distribution, implying by definition that the most extreme
5% of the normal population will have an abnormal result if the normal population is defined as the
middle 95%. Even for findings which may be considered to be dichotomous, such as the presence
or absence of a cardiovascular murmur on auscultation, intra and interobserver variability imply
that the abnormal range encompasses values or results that in some contexts might be judged as
being normal by some observers [153, 155]. Therefore, when assessing the accuracy of a single test,
particularly those with continuous results, it is often necessary to determine a threshold for normality,
with values outside of this range being considered abnormal. For example, the threshold on the mini
mental state examination [156], a brief test of cognitive function with scores from 0 (all wrong) to
30 (no errors; better cognition), is usually set at 24 with scores of 23 and below being an abnormal
result [157]. The threshold for abnormality has consequences for test accuracy, with more extreme
thresholds encompassing fewer people who are healthy and a more extreme set of people with
disease [150]. Figure 1.7 shows a hypothetical distribution of a set of results on the Mini Mental state
examination, if scores of 23 and below are taken to indicate abnormal then most of the abnormal
results are in people who have disease.
For measures which describe the accuracy at a single threshold, such as those described in table
1.6 it is important to consider the paired measures, rather than single items, because they are related
to one another and to the threshold for defining abnormal. Reconsider figure 1.7. If instead of 23
and below indicating abnormal the threshold were scores of 14 and below then only people with the
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most extreme test results would be identified which may be more likely to identify those with more
severe disease. Conversely the lower threshold of 14 instead of 23 would mean fewer people with
non-disease would be incorrectly identified as having a problem. The impact on the test accuracy
characteristics results in lower sensitivity, higher specificity; higher PPV, lower NPV. Conversely, if the
threshold were taken to be scores of 28 and below, then a larger number of people with non-disease
would have an abnormal test result, the impact on the test accuracy characteristics would be higher
sensitivity, lower specificity; lower PPV, higher NPV. The threshold at which a test is judged as being
abnormal depends on the clinical context, especially the setting (high or low prevalence) and purpose
of the test, whether the test being used to rule in, rule out, triage, or refine a set of people who may
have a particular condition [148]. The clinical consequences of test results also influence the desired
test characteristics, for instance when seeking to identify blood borne viruses in blood donated for
transfusions it would be important to use a test with very high sensitivity, because the consequences
of not identifying a blood borne virus could be grave, whereas when selecting people for aggressive
surgery or chemotherapy for cancer it would be important to minimise the number of false positive
diagnoses because of the significant harms of unnecessary treatment or diagnostic labelling.
1.1.2.5 Discrimination and calibration
In clinical practice it is common to combine single tests to form a model which can be used to aid
diagnosis or prognosis. For example, as described in Section 1.1.1.6, a model has been constructed to
predict the risk of future dementia. To judge the value of a model, it is important to evaluate explained
variation, discrimination, and calibration [158]. Explained variation can be quantified using the R2
statistic or Briar score, which are respectively logarithmic and quadratic scoring rules to quantify the
differences in observed and predicted outcomes [158].
Discrimination is a measure of the extent to which people with the target condition have higher
risk predictions than those without the target condition [158]. Discrimination can be quantified using
area under ROC curve (AUROC, Section 1.1.2.6), the discrimination slope (calculated as absolute
difference in average prediction for those with and without the target condition), or visualised with
box-plots or histograms [158]. For a binary outcome AUROC is equivalent [158] to the C statistic
[159]. For survival analysis with censored data, for example with prediction models, quantifying
discrimination with Uno’s C or Royston’s D may be less biased than AUROC. Uno’s C is a modified C
statistic that can be applied to censored data [160]. Royston’s D statistic is an alternative measure of
model discrimination which can be interpreted as "the log hazard ratio resulting from dichotomizing
a continuous prognostic index and fitting a Cox model with a single dummy variable to distinguish
the groups ... a difference of at least 0.1 may be needed to see an important difference in the survival
curves" [161].
Calibration is a measure of how well model-predicted probability of a target condition approxi-
mates the observed values. Calibration can be quantified using the Hosmer-Lemeshow goodness-of-
fit test [158] or by a plot of observed against predicted probabilities [158, 162]. When the intercept
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Figure 1.8: Example ROC














hypothetical diagnostic test non informative test
of the calibration plot is close to zero, a slope of 1 can be interpreted as indicating good calibration
[163].
1.1.2.6 Accuracy of tests over range of thresholds
For expressing the accuracy of a test over a range of thresholds a useful and commonly reported
measure is the area under ROC curve (AUROC) [164]. Figure 1.8 is an example ROC plot where the
a hypothetical test sensitivity is plotted against specificity, at six different thresholds. The plot of
sensitivity against specificity is in line with recommendations [150], but often the plot is sensitivity
against 1-specificity. A non-informative test is also plotted, which runs from (1,0) to (0,1), for this test
the distributions of test results in people with and without disease coincide [150]. The interpretation
of the AUROC is that it is the probability that for a randomly selected pair of diseased and non-
diseased people in the study the result of the diseased person would be more abnormal than the
result of the non-diseased person [165], and is equivalent to the Mann-Whitney-Wilcoxon test
statistic [166]. AUROC is given by
R1
0 Sp Se , that is the integral of specificity with respect to sensitivity.
An AUROC of 0.5 is uninformative and an AUROC of 1.0 is perfect, small changes in the AUROC may
be associated with clinically important changes in the diagnostic accuracy. In contrast, the DOR
is defined as the ratio of odds of positivity in subjects with disease relative to the odds in subjects
without disease:
(1.3)
P (T +|D+)£ (P (T ° |D°)
P (T +|D°)£P (T ° |D+)
The diagnostic odds ratio (DOR) can be used to express the accuracy of a test over a range of thresholds
[165], or as a measure of test accuracy at a single threshold.
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In clinical practice there can often be a preference to either identify disease correctly (TP, i.e.
sensitivity) or identify those who do not have disease (TN i.e. specificity) and the relative importance
of these two extremes depends on the role of the test and the setting. A disadvantage of both AUROC
and DOR is that as single measures of test accuracy it can be difficult to understand how a particular
result relates to the needs of the clinical scenario and whether the test is better at identifying people
with (high sensitivity) or without (high specificity) disease. When using the AUROC only certain
thresholds may be clinically appropriate so some investigators have advocated the use of partial
AUROC for clinically relevant thresholds only, but this approach has the disadvantage that values
just outside the interval are discarded [166]. The AUROC does not allow interpretation of the relative
clinical consequences of FP and FN and indeed the mis-classification costs vary along the curve
because they are dictated by its shape, which has been described as incoherent [166]. Prevalence
also varies along the ROC curve as the gradient changes, which can be problematic when using the
AUROC to compare tests [165].
Net benefit measures [167–169] are an alternative approach that summarise diagnostic perfor-
mance in a single measure at a clinically relevant threshold [165]. The weighted comparison net
benefit measure [169] weights differences in the sensitivity and specificity between two tests by the
disease prevalence and the relative clinical (mis-classification) costs8, which can be converted into a
net benefit of x TP cases per n patients [165]. The weighted comparison parameter is given by:
(1.4) W C = ±sensi t i vi t y + [( 1°pr evalence
pr evalence
)£ relative cost( F P
T P
)£±speci f i ci t y]
For example [165] consider two tests for the diagnosis of dementia AD8 sensitivity 0.91 specificity
0.91 [170] and IQCODE sensitivity 0.81 specificity 0.96 [171]. The difference in sensitivity is 0.1 and
the difference in specificity is -0.05. In a population with estimated disease prevalence 13% and a 30
fold higher weighting for TP compared to FP the WC is given by:
(1.5) W C = 0.1+ [ 0.87
0.13
£ (0.3)£°0.05]
Therefore WC = -0.0004; the negative value of the parameter indicates that test 2 (IQCODE) would
be marginally preferable to AD8, whereas a positive value would indicate that AD8 was preferable
to IQCODE. The weighted comparison can be framed as an increase in the TP per 100,000, if all the
benefit is for TPs, by calculating WC £ prevalence £ 100,000; for the worked example this means 5.2
fewer TP people per 100,000 people would be identified using AD8 compared to IQCODE (-4 £ 10 °4
£ 13% £ 100,000 = -5.2).
1.1.2.7 Accuracy of tests in clinical context
Some authors have questioned the value of calculating the diagnostic accuracy of a single test in




a clinician typically weighs a number of possible alternative diagnoses for a clinical scenario. In
contrast, in research the accuracy of tests is commonly evaluated with respect to a single diagnosis,
termed the target condition. Criteria for the target condition should be specified explicitly because
there is often more than one way to define the disease of interest, for instance a clinical syndrome, a
particular investigation result, or post mortem.
One approach to address the limitations of evaluating the accuracy of single tests is to use a
logistic regression equation, which can be shown to be equivalent to Bayes theorem [148], to analyse
the accuracy of the combination of several tests. Alternative approaches to the analysis of tests in
combination are outlined in Table 1.7 and include: simple tree building, classification and regression
tree software, logistic regression analysis, manipulated logistic regression, neural networks, latent
class analysis, Bayesian networks. Logistic regression is the most commonly used approach in the
literature but may appear to imply the test is symmetrical, that is equally good for ruling in or ruling
out disease, though this is rarely the case. Methods to overcome this limitation by transforming the
data before analysis have been described [148, 173].
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Table 1.7: Approaches to analysing combinations of tests [148]
Approach Advantages Drawbacks
Simple tree building Straightforward Impossible with many tests
Accounts for interactions Continuous tests must be categorised
More than two outcomes possible Excludes missing values
Thresholds can be chosen No measure of imprecision
Analysis not pre specified
Classification and regression Sequence can be manipulated Complex software needed
tree (CART) Interactions accounted for May need large sample
More than two outcomes possible Variable results
Can handle missing data
Logistic regression Continuous results stay continuous
Interactions accounted for
Usually only one outcome
Multiple imputation possible
Manipulated logistic regression Tests are entered in a specified order Variable results (subjective)
Can be more clinically relevant
Neural networks More than two outcomes possible Missing data problematic
Interactions and diagnostic asymmetry handled Difficult to interpret clinically
Latent class analysis Helpful when no reference standard Can be difficult to interpret
Number of variables limited
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1.1.2.8 Impact of tests on patient outcomes
Arguably, diagnosis is only useful or relevant to the extent that it addresses the patients questions
about their illness [174]. The most important questions relating to diagnosis might often be questions
about prognosis: what is likely to happen to the patient and what can be done to influence that [174,
175]. Determining outcomes of diagnostic processes that are relevant to patients and their kin may be
one approach to reduce over-diagnosis. Overdiagnosis is the term given to the phenomenon where
people undergoing medical evaluation are labelled as having pathology without evidence that the
identification or treatment of this results in improved outcomes. Beyond reducing overdiagnosis,
another advantage of the prognostic approach is that tests may be incorporated in modelling risk in
the context of patient outcomes on a spectrum, rather than a dichotomous expression of disease or
not-disease [175]. Finally, to the extent that prognosis (outcome) provides a more accurate classifica-
tion about the impact and harm-balanced merits of interventions than diagnosis (disease state) a
prognostic approach to clinical decision making may facilitate more individualised and stratified
healthcare [175].
Test accuracy studies are often cross sectional in nature [148] and do not have extended follow-up.
A disadvantage of the prognostic approach to clinical decision making and practice is the need to
understand the important outcomes that are meaningful to a range of patients and their kin, and the
requirement to follow people up for an extended period to ascertain these.
1.1.3 Clinical judgement
1.1.3.1 Reliability and observation
In clinical practice, many test results are subject to a degree of judgement. For instance, there is
reported to be inter-observer variability about the interpretation of an Magnetic Resonance Image
(MRI) of the brain in people with vascular dementia, that can be improved with the use of operational
definitions by experienced readers [176]. Variability in clinical judgement on the result of a test may
result in implicit, unmeasurable thresholds for tests, for instance the extent of micro-vascular infarcts
that are normal or pathological [148].
Kappa is a measure of reliability [177], which is often regarded as a measure of agreement [178]
for two or more observers of a categorical outcome, in contrast to weighted kappa and intraclass
correlation coefficient which may respectively be applied to ordinal and continuous outcomes. These
methods are less suitable for assessing diagnostic accuracy than the measures discussed in Section
1.1.2.3 because when evaluating diagnostic accuracy the reference standard is taken to represent
truth, whereas in evaluation of reliability and agreement multiple observers are typically regarded
as being equally likely to identify the true observation. To the extent that high observer variability
increases random error in the test result the test accuracy may be adversely affected, but tests with
high variability may still be useful for individual clinicians [179]. Observer bias may also influence
the scoring of test results, either from subjective prior knowledge of the person under evaluation
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which influences the implicit threshold, or from a clinician prejudging one test preferably to another
and (perhaps subconsciously) making more effort to obtain what they perceive as an accurate result
[148].
1.1.3.2 Diagnosis as categorisation
The diagnostic process can be scrutinised as a probabilistic, analytic process with a clear diagnostic
category as the intended outcome. However, in clinical practice decisions are typically dichotomous
[175], and reasoning is often non-analytic [180, 181], based on intuition which is derived from
recognition [180]. Clinical judgement, also known as instinct or gestalt [182], is the holistic judgement
about the diagnostic category. Understood in this framework, diagnosis is typically a system 1
cognitive process.
Table 1.8 compares the two processes that are described in the theory of the dual mode of
cognition. System 1 is prone to a range of biases, such as neglecting ambiguity, ignoring absent
evidence, overestimating low probabilities and using heuristics [181]. Interventions, especially guided
reflection, can help to modify clinician behaviour and reduce diagnostic error [183]. In contrast,
clinicians might also use a type 2 process in a restricted rule out to evaluate the probability of a
limited set of diagnoses that are rare but critical not to miss. Decisions about the management of a
Table 1.8: Type 1 and Type 2 cognitive processes [181]
System 1 System 2
Unconscious Conscious
Mostly emotional and involuntary Mostly voluntary and unemotional
Implicit Explicit
Low effort, high capacity, rapid High effort, low capacity, slow
clinical scenario are based on judgements about the trade-offs of different options weighed against
an implicit and perhaps subconscious threshold probability [143]. Decisions about treatment are
simply conceptualised as being based on whether the patient exceeds the threshold probability for
treatment (T), which is given by the ratio of the costs (C) and benefit (B) in the formula [184]
(1.6) T = C
B +C
In general practice, many treatments, especially for acute problems such as sore throat, are prescrip-
tion based and have relatively low cost and high benefit, so clinicians may have a low threshold
probability for treatment.
In contrast, where an intervention has tangible risks for patients, such as neurosurgery, or requires
long term treatment for chronic illness, such as anti-coagulation for atrial fibrillation, clinicians are
more likely to have a higher threshold probability for treatment compared to acute minor illness. In
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this situation, the risks of the investigation (i) directly influence the threshold for investigation (Tt ),
as determined by the formula [143]:
(1.7) Tt =
(P (F P )£C )+ i
(P (F P )£C )+ (P (T P )£B)
therefore the threshold probability for investigation rather than excluding the diagnosis based on
clinical features alone will fall as the risks of investigation fall and the accuracy of the test increases.
In contrast the threshold for treating rather than investigating, the test-treatment threshold
[Tt tr x ) is given by the formula [143]:
(1.8) Tt tr x =
(P (T N )£C )° i
(P (T N )£C )+ (P (F N )£B)
therefore the threshold for treating rather than investigating will tend to rise as the risks of investiga-
tion fall and the accuracy of the test increases.
If diagnosis represents a method of applied categorisation, it follows that clinicians will apply a
classification framework that is fit for purpose in their clinical setting. In general practice, it is often
difficult to place a person with a cluster of symptoms into a definite category, at least initially, and
it can be easier to identify the categories that they do not fit in to. In one study, over 50% of cases
in general practice could not be assigned to an definite initial diagnosis [142]. Consequently, GPs
may assign people to categories based on the intended action (observe, providing "safety net" advice
on the anticipated course of illness; investigate; treat; refer) rather than the specific diagnosis [142].
These categories reflect an implicit judgement based on the fit of the pattern of illness with illness
scripts [185] that have been developed through the integration of knowledge and experience [186].
1.1.3.3 Low incidence serious disease
Clinicians often use a variety of heuristics as part of their diagnostic reasoning [180]. The availability
heuristic is the concept that some diagnoses are more readily accessible to the cognitive processes of
the clinician, and therefore more likely to be selected, than others. Clinicians encounter common
conditions frequently, and so have many exemplars encompassing a diverse range of clinical pheno-
types with which to compare a new case with, whereas less commonly encountered conditions are
conceptualised using the textbook description which may be a poor fit for the patients presentation
[187]. Some rare conditions may be readily available to clinicians for consideration if the cognitive
representation is especially vivid such as if a condition has serious consequences, or is associated
with a particularly significant past encounter such as a complaint or death. Alternatively clinicians
may experience temporary increases in the cognitive availability of rare diagnosis if there is some
reason for the condition to be more in their mind, such as if they have recently received education.
In 2018 the average number of patients aged over 60 years that were registered with each GP
practice was 3,691 [188]. With a meta-analytic incidence of dementia in this age group of 17 per 1000
person years [14] each GP practice could expect to see approximately 64 new cases of dementia per
year, that is around 21 per GP in a three-GP practice. In contrast the average GP working 4 days a
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week has perhaps 6,300 consultations per year based on 35 contacts per day [189]. Therefore, in
general practice, dementia is a low incidence, serious disease. The serious consequences of dementia,
such as incontinence, immobility, and dependency in activities of daily living typically develop over
years, whereas meningitis, which is also a rare but serious condition, is rapidly fatal. The impact of
the varying time course is that while dementia is a serious condition, the stakes of not identifying it at
any one encounter are relatively low, in contrast to meningitis which has high stakes consequences
in the short term if missed and so is likely to be relatively cognitively available even though it is a
rare disease [190]. Consequently many clinicians are likely to experience relatively low cognitive
availability for their personal dementia exemplar: if the diagnosis of dementia is delayed by a week,
or even a month, the consequences for the doctor of the delayed diagnosis are relatively minimal.
Clinicians are likely to have particularly poor cognitive availability for dementia that is not due to
Alzheimer’s disease because the clinical exemplar probably includes memory loss [191, 192].
General practitioners can have important issues with dealing with low incidence serious disease
[193]. When evaluating a patient with symptoms that could represent serious illness, but where the
incidence in general practice is low, there is an inherent difficulty in identifying all the people who are
ill without also unnecessarily intervening and raising anxiety in the much larger number of people
whose symptoms, though similar, are attributable to a non-serious aetiology [193]. At a population
level it may cause more harm to investigate many people to identify the one person with disease [194].
GP’s clinical judgement can accurately identify people with serious illness [195], including cancer
[196]. However, in general practice there will often be uncertainty in managing people with symptoms
that indicate a non-zero risk of a serious pathology. GPs use a range of approaches to manage this
uncertainty to refine the diagnosis (Section 1.1.2.1), including interrogating their "gut feeling" about
a scenario, applying diagnostic algorithms explicitly or implicitly, arranging investigations and safety
netting [193]. Clinician gut feeling is a sense that something is wrong, which can be central to
diagnostic discrimination [193]. GPs may also consider their gut feeling when formulating a decision
about prognosis and treatment, even if there is currently no specific diagnostic label [189].
1.2 Scientific justification for the work
Very little empirical work has investigated the accuracy of tests for diagnosing dementia in general
practice. Even fewer studies have explored how accurate the judgement of general practitioners is
compared to arguably more objective measures such as brief cognitive tests. Because test accuracy
can vary between settings it is important to investigate the accuracy of tests in a general practice
setting, where the prevalence of dementia in people with cognitive symptoms can be anticipated
to be lower than in a group of people that have been referred to a specialist memory clinic. De-
mographic trends suggest that the workload for health systems associated with the diagnosis of
dementia will increase, and the political agenda appears to be inclining towards a desire to explore
an enhanced role for general practice in the diagnosis of cognitive disorders. Additional empirical
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research, based in general practice, to understand the accuracy of tests for the diagnosis of dementia
and the acceptability to patients of a GP based diagnosis is therefore important to inform future
policy developments.
1.3 Aims and objectives of the thesis
The aim of this thesis is to investigate approaches to diagnosing dementia syndrome in general
practice. The objectives are
• to determine the prevalence of dementia and mild cognitive impairment in a group of people
presenting with symptoms of dementia to their general practitioner
• to measure the accuracy of a range of tests for diagnosing dementia syndrome in symptomatic
people
• to identify if a combination of tests can have a high positive predictive value for identifying
people with dementia and normal cognition
• to investigate the acceptability to patients of GPs diagnosing dementia
.
Chapter Summary and thesis outline
This Chapter has presented an introduction to important topics for the thesis. Chapter 2 gives
the introduction, methods, results, and discussion of an empirical systematic review of the test
accuracy of general practitioners clinical judgement for the diagnosis of dementia. Chapter
3 presents details of the methods and Chapter 4 the results of an empirical diagnostic test
accuracy study investigating the accuracy of a range of tests for diagnosing dementia in general
practice. Chapter 5 presents the rationale, methods, results and discussion of an empirical
qualitative investigation to explore the acceptability to patients of GPs diagnosing dementia.
Chapter 6 reviews the empirical findings in the context of the existing literature, discusses the













his Chapter gives details of the systematic review of accuracy of clinical judgement of primary
care physicians for the diagnosis of dementia and cognitive impairment. Text from this
Chapter has been published as a Cochrane Systematic review protocol [197]. The results and
discussion were not published or submitted for review prior to submission of the thesis. Section one
outlines the objectives and Section two the background. Section three describes the method, detailing
the types of studies, participants, index test, target condition, reference standard, searches, selection
of studies, assessment of risk of bias, and analysis. Section four describes the results, including the
results of the search, a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram [198], the characteristics of the included studies and their methodological quality using
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [199], the findings relating to
diagnostic accuracy and heterogeneity, and the sensitivity analyses. Section five summarises the
main findings, discusses the strengths and limitations of the included studies and the review process,
relates the findings to the literature, and identifies conclusions. A PRISMA-DTA checklist is provided
in Appendix L.
2.1 Background
Details on dementia, diagnostic accuracy, and clinical judgement are provided in Chapter 1. Doctors
use a variety of processes to make a diagnosis and decision, including non-analytical reasoning
processes such as pattern recognition. Some people with dementia unfortunately have sufficiently
advanced disease at the time of presentation that no formal evaluation is required to make the
diagnosis of dementia syndrome and indeed GPs often report using their clinical judgement to make
a diagnosis of dementia, rather than a standard instrument [200, 201].
49
CHAPTER 2. SYSTEMATIC REVIEW
2.2 Objective of the systematic review
To determine the accuracy of general practitioners’ overall clinical judgement for diagnosing cognitive
impairment and dementia in people presenting to primary care.
2.3 Method of the systematic review
2.3.1 Type of study
Both cross-sectional studies and cohort studies were included in the review. Cross-sectional studies
are potentially at higher risk of incorporation bias than cohort studies and this was accounted for
when assessing studies for risk of bias. The risk of incorporation bias may be higher in cross sectional
studies than cohort studies because index tests and reference standards may be done by the same
examiner, or the results of one examination may be communicated to the patient who may in turn
communicate them to the other examiner. Conversely cross sectional studies are at lower risk of
bias due to participant flow causing partial verification of the reference standard. The approach of
excluding cross-sectional studies was judged to be too restrictive.
Case-control studies were excluded because they are at high risk of bias. Furthermore, by defini-
tion, any participants would have been recruited on the basis of disease state (dementia, cognitive
impairment or normal) which would typically prevent GPs from making a blinded clinical judgement
about the diagnosis.
2.3.2 Participants
Studies were only included if they recruited participants from primary care. Primary care was de-
fined as first-contact health care provided by a non-specialist clinician in a continuing-care office
setting. Studies were excluded if a consultation with a non-specialist occurred in hospital (including
outpatients or emergency departments) because this was judged as unlikely to represent primary
care in the sense that was relevant to the review objective.
Studies were included if GPs made a clinical judgement about the presence of cognitive im-
pairment or dementia. Studies were excluded if GPs were required to make a judgement about the
presence of cognitive impairment or dementia in all people attending primary care, regardless of
age as this was judged to be akin to screening. To avoid heterogeneity in studies by professional role,
included articles exclusively had GPs as the primary care provider, rather than other allied professions
(e.g. advanced nurse practitioners, physician assistant etc.), because the training requirements for
these different roles vary.
2.3.3 Index test
Clinical judgement was defined as being unaided by any additional test, investigation or inquiry
beyond that which is immediately available to the clinician [202–204]. The review investigated a
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single index test (clinical judgement) for two target conditions (cognitive impairment composite
or dementia) (see Section 2.3.4). In everyday practice a clinical judgement is formed by a GP after
an encounter with a patient, in which the GP typically accesses and reviews the medical record as
part of their consultation. In contrast, in diagnostic accuracy research in general practice there are
potentially three ways that clinical judgement may be defined.
Firstly, there may be a documented diagnosis of cognitive impairment or dementia in the medical
records, but this is likely to reflect the process of documentation rather than clinical judgement
(documented approach). In one study the number of patients registered as having dementia on GP
surgery records increased by 9% when diagnostic coding was systematically audited [108]. Docu-
mented diagnoses of dementia in the medical record may not reflect the clinical judgement of a GP
about the presence or absence of the target condition, and indeed the increase in the prevalence with
consistent coding suggests that documentation may be systematically under-coded in the electronic
medical record in routine practice.
Secondly, clinical judgement may be defined as an opinion based on knowledge of the patient
and review of the medical notes, but not relating to a specific encounter with the patient (retrospective
approach). However, this approach is likely to be affected by differences in consulting behaviour
of people with cognitive impairment or dementia compared to those without these problems. An
electronic record of a dementia diagnosis (which as indicated is likely to be systematically under-
recorded compared to actual diagnoses [108]) has been associated with an increase in primary
care attendances both around the time of recording on the electronic record [205] and in the five
years preceding this [206]; in contrast other investigators have reported that people with established
moderate-severe dementia have fewer consultations per year with a GP compared to those with no
or mild dementia [207]. Because cognitive status is associated with consultation behaviour it may
also be associated with the implicit (i.e. not formally recorded) knowledge that a GP has about an
individual when forming a retrospective clinical judgement.
Thirdly, clinical judgement in diagnostic accuracy research may be defined as the impression
formed by a clinician after consulting with a patient who has presented to a specific encounter
with the doctor (prospective approach). The patient may be consulting with symptoms suggestive of
possible dementia, but not necessarily, because it may be the consulting GP, or indeed a third party,
who raises the possibility of cognitive problems. This was considered as the definition of clinical
judgement that is most relevant to practice for this review. This definition of clinical judgement was
judged to be most applicable to clinical practice, being contemporaneous with a specific encounter,
and least likely to be subject to systematic bias in coding in the medical record.
Studies were included that used the third prospective definition. To avoid an empty review, studies
that used the second retrospective definition were also included so long as the GP’s determination
about cognitive status had taken place before any definitive diagnosis. Studies that used the docu-
mented approach were excluded as this was considered to not reflect clinical judgement.
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2.3.4 Target condition
There were two target conditions for the review: all-cause dementia, and cognitive impairment due
to dementia or Mild Cognitive Impairment (MCI) [3].
Experience in clinical general practice is that when there are concerns about impaired cognition
these are focused primarily on the possibility of dementia rather than MCI, but inevitably some
people who are evaluated for possible dementia will be diagnosed with MCI. The second target
condition includes both dementia and MCI because it would be unusual for a GP to diagnose MCI,
especially on the basis of clinical judgement alone, because neuropsychological evaluation is often
required. If clinical judgement was sensitive for any cognitive impairment then if the GP assessed the
person as being cognitively normal it would be likely that the person had neither dementia nor MCI.
Studies were excluded if they investigated the accuracy of clinical judgement for risk prediction
of future dementia. There was no restriction to a particular stage or clinical severity of dementia.
2.3.5 Reference Standard
2.3.5.1 Dementia
Studies were included if they used a definition from DSM-III-R, DSM-IV-TR, or ICD-10. Studies
were also included if they used Automated Geriatric Examination for Computer Assisted Taxonomy
(AGECAT) [208], Cambridge Mental Disorders of the Elderly Examination (CAMDEX) [209], CDR [73]
or structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia
and dementias of other aetiology according to ICD-10 and DSM-III-R (SIDAM) [210] because these
are well validated methods of applying the aforementioned diagnostic criteria. Studies were included
if they used expert specialist clinical judgement as the reference standard; a specialist was defined as
a clinician with particular expertise in diagnosing and managing dementia, practising in a hospital or
secondary care environment, with the professional status of geriatrician, psychiatrist or neurologist.
Studies were eligible for inclusion if they used longitudinal confirmation of the diagnosis of all-cause
dementia in primary care, because it was anticipated that in some studies a specialist assessment
would only be offered to some participants. Longitudinal confirmation of the diagnosis in primary
care was operationalised as case record review occurring at least three months after the index test
diagnosis of dementia where no other alternative diagnosis is identified. While recognising that many
people who could be correctly diagnosed as having dementia by unaided clinical judgement (true
positives) would have a fairly advanced stage of disease, stage of disease did not form part of the
target condition definition.
Although the target condition was all-cause dementia, studies that used an aetiological sub-type
definition were also eligible, these were: for Alzheimer disease the NINCDS-ADRDA criteria [62, 63];
for vascular dementia the NINDS-AIREN criteria [65]; for Lewy body dementia the Dementia with
Lewy Body Consortium criteria [70, 71]; and for frontotemporal dementia the consensus criteria [66].
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2.3.5.2 Cognitive impairment
Cognitive impairment was a composite target condition encompassing dementia (as defined above)
and MCI. Any recognised definition of MCI was eligible e.g. the original or revised criteria of Petersen
[93, 211], Winblad [94], or the NINCDS-ADRDA criteria [63]. Whilst acknowledging that causes of
cognitive impairment extend beyond dementia and MCI (e.g. head injury, delirium, and neoplasm,
Section 1.1.1.5) these were not part of the target condition for the review. Therefore, if (for example)
the index tests indicated cognitive impairment or dementia, and further evaluation demonstrated
that the clinical problem was neoplasm instead, the test would be false positive.
2.3.6 Searches
The search strategy was constructed in discussion and collaboration with Anna Noel-Storr, Informa-
tion Specialist for the Cochrane Dementia and Cognitive Improvement Group. The search strategy
and search report is provided in Appendix A.
The following electronic databases were searched by Anna Noel-Storr from inception to 29 April
2019: MEDLINE (OvidSP); Embase (OvidSP); Web of Science Core Collection, including the Science
Citation Index and the Conference Proceedings Citation Index (Thomson Reuters Web of Science);
PsycINFO (OvidSP), and LILACS (BIREME). Where appropriate controlled vocabulary was used, such
as MeSH terms (in MEDLINE) and EMTREE (in Embase) and other controlled vocabulary in other
databases. The reference lists of all included papers was also reviewed for additional studies. Search
filters designed to retrieve diagnostic test accuracy studies were not used because available filters
have not yet proved sensitive enough for systematic review searches [212]. No language restrictions
were applied to the electronic searches.
2.3.7 Selection of studies
Two investigators independently screened the retrieved citations at the title and abstract stage, using
Covidence software [213] to classify each citation as relevant, possibly relevant, or not relevant.
Conflicts in classification were resolved by discussion until consensus was reached. Full text articles
were obtained for all citations classified as either possibly relevant or relevant. Two investigators
independently reviewed the full text articles using Covidence and made a final judgement about the
relevance of the citation. All conflicts in classification were resolved by discussion. Articles that were
excluded at the full text stage were given a reason for exclusion using the following hierarchy:
1. Inappropriate participants: not primary care
2. Inappropriate reference standard
3. Inappropriate index standard
• Not GP
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• Not clinical judgement
4. Inappropriate target condition
5. Inappropriate study design (i.e. not a diagnostic test accuracy study e.g. a study reporting
qualitative data, descriptive epidemiology, randomised trial or survey)
Articles were classified under the highest order reason for exclusion, so that if a study was not set in
primary care then it was excluded at level one, whereas if it was set in primary care but did not use an
appropriate index test then it was excluded at level three. Only one reason was needed for a study to
be excluded. Authors of included studies were contacted by email when necessary to obtain paired
data on sensitivity and specificity if these were not clearly reported in the original article.
2.3.8 Assessment of risk of bias
Review Manager [214] was used to extract data to assess the risk of bias for each study, which was
appraised separately by two investigators using the QUADAS-2 checklist [199]. Any disagreements
were resolved by discussion.
2.3.9 Statistical analysis and data synthesis
Paired data on sensitivity and specificity were extracted from included studies separately by two
investigators into Review Manager. Discrepancies were resolved by discussion informed by further
review of the original manuscript until consensus was reached. Studies that did not report paired
sensitivity and specificity were described but not included in the meta-analysis. Data were used to
calculate the accuracy of the index test for diagnosing the two target conditions: cognitive impairment
(including both MCI and all-cause dementia), and all-cause dementia. Diagnostic accuracy was
calculated with 95% confidence intervals separately for each target condition, in all studies with
available data.
Meta-analyses was performed on pairs of sensitivity and specificity in Stata version 13 [215] using
metandi and xtmelogit. Since metandi does not allow analysis with fewer than four studies, and
xtmelogit does not produce output parameters for plotting a summary ROC curve, summary ROC
curves were generated using MetaDTA: Diagnostic Test Accuracy Meta-Analysis v1.45 [216]. The main
meta-analysis was done in the studies at lowest risk of bias (one or fewer QUADAS-2 domains at
high risk of bias). The bivariate random-effects model approach was used to estimate a summary
point for sensitivity and specificity, assuming this is appropriate to do, and the hierarchical SROC
(HSROC) model was used to estimate a summary ROC curve [150, 217–219]. The bivariate model and
the HSROC model are mathematically equivalent when no covariates are fitted but differ in their
parameterisation to (respectively) estimate an average sensitivity and specificity (bivariate approach)
and average ROC curve (HSROC approach) [150, 219]. Because the bivariate approach estimates a
single point along the HSROC curve it does not fully reflect the heterogeneity in the data and may
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be of limited value. In contrast using the HSROC approach to plot a summary ROC curve allows
investigators to observe where study points are plotted, and how close they lie in relation to the
summary curve, which allows a clear depiction of heterogeneity [150]. Different all-cause dementia
diagnostic criteria were analysed together. Meta-analyses by aetiological subtype of dementia was
not done, because it is unlikely that GPs would make an aetiological subtype diagnosis. The analysis
using the bivariate approach to estimate a summary point assumes that there is a constant threshold
for the diagnosis of the target condition according to clinical judgement across studies; Section 2.5.2
discusses this in detail.
2.3.10 Investigations of heterogeneity
Three sources of heterogeneity were designated in advance of the analyses as being important to
investigate: the definition used to define the reference standard (ICD-10, DSM-III-R or DSM-IV-TR);
whether the clinical judgement of the GP was based on a prospective opinion (having just seen the
patient) or a retrospective opinion (being asked to consider the case at some arbitrary date); and
whether the GP had access to use medical records when giving their opinion. A further investigation
of heterogeneity was defined when the characteristics of the included studies were known. The
post-hoc analysis investigated heterogeneity by risk of bias in the flow and timing QUADAS-2 domain
(high risk or not). Heterogeneity was initially investigated through visual examination of paired
diagnostic accuracy data in forest plots, and the ROC plot of the raw data. These components of
study design were extracted as covariates and added to the analytical model with likelihood ratio
tests being used to compare model fit [150].
The length of vocational training programme for GP participants were specifically not examined
as sources of heterogeneity because these were anticipated in advance to be poorly reported (or not
reported) in original studies. Furthermore, it is recommended to only consider possible sources of
heterogeneity which vary at the study level [220], which is unlikely to be the case for these domains.
Caution is advised when interpreting investigations of heterogeneity, especially exploratory
post-hoc analyses [220].
2.3.11 Sensitivity analyses
A pre-specified sensitivity analysis investigated how the estimates of diagnostic accuracy were
modified when including studies that were judged to be at high risk of bias in more than two
QUADAS-2 domains.
2.3.12 Assessment of reporting bias
Quantitative methods for exploring reporting bias are not well established for studies of DTA [220]
and so this was not examined.
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2.4 Results
2.4.1 Results of the search
Figure 2.1 shows that the search yielded 12,681 citations and 8,118 remained after de-duplication.
Review of the full text for 56 records led to 16 being included, referring to 10 studies, of which 9 were
included in the meta-analysis. One study [221] was included in the review but not in the meta-analysis
because it was not possible to obtain paired data on diagnostic accuracy either from the original
paper or after correspondence with the authors. The study is included for transparent reporting
because based on the study design paired diagnostic accuracy data should be available.
Of the 40 papers that were excluded at the full text review stage, nine were excluded because
they were not based in primary care. Instead, these papers were set in the community [9, 191, 222–
224], outpatients department [225–227] or hospital [228]. Seven papers were excluded because they
used an ineligible reference standard; instead of using a reference standard from the pre-specified
list (Section 2.3.5), the excluded papers used methods which would be at high risk of incorrectly
classifying the target condition. Of the seven papers excluded because of an ineligible reference
standard, four used cognitive tests as the reference standard, of which three [229–231] used the MMSE
[156] and one [232] used the Blessed Dementia Scale, [233] two [234, 235] did not have dementia as a
target condition and used a screening test for MCI which was not further detailed [234] or the World
Health Organisation Composite International Diagnostic Interview (CIDI) [235], and one aimed
to validate a new measure and cross-validated the new tool against other cognitive tests but not a
diagnosis [236].
One study, which was a letter, was excluded because it was not a diagnostic test accuracy study
[237].
Of the 23 papers that were excluded because they investigated an ineligible index test, two papers
were not investigating the accuracy of GPs [238, 239]. Of the remaining 21 papers which were excluded
because of an ineligible index test, five [192, 240–243] investigated the documentation of a diagnosis
in the medical record which was specified in advance as an ineligible index test (Section 2.3.3). Of the
remaining 16 papers that had an ineligible index test, eight papers [244–251] referring to one study
were excluded because GPs were asked to use the Dutch dementia guidelines to make a diagnosis
rather than their unaided clinical judgement, three papers [252–254] were excluded because GPs
were asked to use the MMSE [156], one study [255] used the ADMP1 scale [256], one study [257] used
the 6CIT [258], one study [259] used the CDR [75], one study [260] used a list of warning signs of
dementia from the Alzheimer’s Association, and one study [261] used the standardized physicians’
manual issued by the Ministry of Health, Labor and Welfare of Japan.
Two previous systematic reviews were identified [262, 263]. Table 2.1 compares the papers that
were included in the two previous reviews with the current review and indicates that there were four
studies that were included in all three reviews [221, 264–266]; two studies that were included only the
1ADMP is not an abbreviation
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56 full-text papers assessed for eligibility 40 papers excluded:
9 Not primary care [9, 191, 222–228]
7 Inappropriate reference standard
[229–232, 234–236]
Inappropriate index test
21 Not clinical judgement [192, 240–
255, 257, 259–261]
2 Not GP [238, 239]
1 Not diagnostic accuracy study
[237]16 papers included, referring to 10 studies
current review [267, 268]; four studies that were included in both the current review and Mitchell et
al., [269–273]; two studies that were included in both Mitchell et al., and Van den Dungen et al., but
not in the current review [192, 243]; and 12 studies that were only included by Mitchell et al., [191,
226, 227, 232, 247, 274–280].
Of the 14 studies that were included in previous reviews but not in the current review, 12 were
excluded from the current review because the index test did not meet the inclusion criteria (details in
Table 2.1), and two were excluded because the reference standard did not meet the inclusion criteria
[232, 276]. Of the 12 studies that were excluded from the current review because the index test did
not meet the inclusion criteria one study [247] required GPs to use the dutch dementia guidelines to
make a diagnosis of dementia and the other 11 studies defined clinical judgement as a documented
diagnosis of dementia in the medical record, neither of which met the criteria for clinical judgement
as defined in the current review.
Table 2.2 summarises the characteristics of included studies regarding sampling, index test,
57
CHAPTER 2. SYSTEMATIC REVIEW
reference standard, participant flow, target condition, definition, and access to medical records.
Table 2.3 provides a further overview of the participant selection, the characteristics of participants,
verification of the target condition, and the proportion classified by GP judgement and the reference
standard. The characteristics of Hawaii [221] are described but because there was no usable 2x2
data on diagnostic accuracy this study was not included in the meta analysis. Seven studies sam-
pled consecutive consulting patients or the entire registered GP list (Cambridge City, Mannheim,
Sydney, Zwolle, Hawaii, Antwerp, France) and three took a sample of patients from GP surgery lists
(Cambridge, Amsterdam, AgeCoDe). Four studies (Cambridge City, Cambridge, Amsterdam, Zwolle)
used a retrospective diagnosis, and six (Mannheim, Sydney, Hawaii, Antwerp, AgeCoDe, France)
used a prospective opinion. Six studies (Cambridge City, Cambridge, Mannheim, Amsterdam, Zwolle,
Antwerp) used CAMDEX as the reference standard, one used the Canberra interview for the Elderly
(Sydney) or the SIDAM (AgeCoDe) and two (Hawaii, France) used expert opinion. Five studies (Cam-
bridge City, Cambridge, Amsterdam, Hawaii, AgeCoDe) appeared to have complete verification of the
index test, with the reference standard being administered to all participants, but only two of these
(Cambridge and AgeCoDe) did not screen people in some way prior to the index test (see Table 2.2);
the other studies had some form of partial verification. All studies investigated dementia as a target
condition and four studies (Mannheim, Sydney, Zwolle, AgeCoDe) additionally investigated MCI as a
target condition. Five studies (Cambridge City, Cambridge, Mannheim, Amsterdam, Sydney) used
ICD-10 as the definition, two studies (Antwerp, AgeCoDe) used DSM-IV-TR and one study used each
of DSM-III-R (Zwolle), CDR (Hawaii), and NINCDS-ADRDA (France). Access to the medical records
was not available in two studies (Cambridge, Mannheim), was unclear in one (Cambridge City) and
was available in the remainder.
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Table 2.1: Comparison of included citations in systematic reviews
Citation Index Reference Mitchell Van den Dungen Current Study ID Why excluded
test standard 2011 [262] 2012 [263] review in review from this review §
Boise 2004 [274] Medical records CERAD † Yes No No - Index test
Borson 2006 [191] Medical records CERAD Yes No No - Index test
Boustani 2005 [275] Medical records CERAD Yes No No - Index test
Bowers 1990 [276] Prospective questionnaire MMSE ‡ Yes No No - Reference standard
Brayne 1990 [267] Retrospective rating CAMDEX|| No No Yes Cambridge -
Callahan 1995 [277] Medical records SPMSQ ¶ Yes No No - Reference standard; Index test
Chodosh 2004 [278] Medical records TDQ § Yes No No - Reference standard; Index test
Cooper 1992 [281] Prospective rating CAMDEX Yes Yes Yes Mannheim -
De Lepeleire 2004 [268] Prospective rating DSM-IV-TR No No Yes Antwerp -
Eefsting 1996 [265] Retrospective rating CAMDEX Yes Yes Yes Zwolle -
Ganguli 2004 [279] Medical records MMSE Yes No No - Reference standard; Index test
Iliffe 1990 [280] Medical records MMSE Yes No No - Reference standard; Index test
Jacinto 2009 [226] Medical records Expert consensus Yes No No - Reference standard; Index test
Kaduszkiewicz 2010 [269] Prospective rating MCI [94] Yes No Yes AgeCoDe -
Löppönen 2003 [192] Medical records DSM-IV-TR Yes Yes No - Index test
Mant 1988 [232] Doctors opinion MMSE Yes No No - Reference standard
O’Connor 1988 [270] Retrospective rating CAMDEX Yes No Yes Cambridge -
Ollafsdottir 2000 [243] Medical records DSM-III-R Yes Yes No - Index test
Pentzek 2009 [271] Prospective rating DSM-IV-TR Yes No Yes AgeCoDe -
Pond 1994 [266] Prospective rating DSM-III-R Yes Yes Yes Sydney -
Rondeau 2008 [272] Retrospective rating DSM-IV-TR Yes No Yes France -
Valcour [221] Prospective rating CDR Yes Yes Yes Hawaii -
Van Hout 2000 [247] Prospective, applying CAMDEX Yes No No - Index test
Dutch guidelines
Wilkins 2007 [227] Medical records CERAD Yes No No - Index test
Wind 1994 [273] Retrospective rating CAMDEX Yes No Yes Amsterdam -
§ Design aspect which did not meet criteria for current review † Consortium to Establish a Registry for Alzheimer’s Disease protocol (CERAD)[282]
‡ MMSE Mini Mental State Examination [156] ||CAMDEX Cambridge Mental Disorders of the Elderly Examination [209]
¶SPMSQ Short Portable Mental Status Questionnaire [283] §SPMSQ Telephone Dementia Questionnaire [284]
DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders (4th ed., Text Revision) MCI Mild Cognitive Impairment
DSM-III-R Diagnostic and Statistical Manual of Mental Disorders (3rd ed., Revised) CDR Clinical Dementia Rating scale
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Table 2.2: Characteristics of included studies
Citation Sampling Index Reference Flow Target Definition Notes
Country test standard condition available
Cambridge City [270] All people aged 75 years Retrospective CAMDEX § Timing not specified Dementia ICD-10 [5] † Unclear
UK and over from six Partial verification:
GP lists in Cambridge MMSE§ score <24: All
and 1 in 3 ‡ from score 24 or 25: 1 in 3‡
a 7th surgery
Cambridge [267] Randomly selected women Retrospective CAMDEX Timing not specified Dementia ICD-10 No
UK aged 70-74 years, and Verification complete
all women aged 75-79 years
from rural GP surgery list
Mannheim [281] Consulting patients over Prospective CAMDEX Timing not specified MCI ICD-10 No
Germany 65 years seen in 24 GP Partial verification: Dementia §§
surgeries over four weeks random sample stratified
by GP opinion
Amsterdam [273] Age stratified random Retrospective CAMDEX Timing not specified Dementia ICD-10 Yes
Netherlands sample from 30 GP Partial verification:
surgery lists MMSE score <22: all
score >22: random sample
Sydney [266] Consulting patients in a Prospective Canberra Timing not specified MCI ICD-10 Yes
Australia retirement complex seen Interview for Partial verification: Dementia §§
by GPs over four weeks the Elderly 50% random sample
Zwolle [265] All patients aged Retrospective CAMDEX Timing not specified MCI DSM-III-R Yes
Netherlands 65 years and over Partial verification: Dementia §§
on lists of eight GPs MMSE score <18: All
score 18-23 random 2 in 3
score >23 random 1 in 3
score >27 none
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Citation Sampling Index Reference Flow Target Definition Notes
Country test standard condition available
Hawaii [221] Consecutive patients aged Prospective Expert Timing not specified Dementia CDR Yes
USA 65 years or more Flow unclear
at one GP surgery
over six weeks
Antwerp [268] Consecutive patients aged Prospective CAMDEX Tests within one month Dementia DSM-IV-TR Yes
Belgium 65 years or more with Partial verification:
possible dementia were IADL ||score 4: all seen
sought score <4 none seen
AgeCoDe [269] Random sample of people Prospective SIDAM Reference test 1.5 years & MCI Winblad [94] Yes
Germany aged 75-89 years registered 3 years after index test Dementia DSM-IV-TR
with GP & postal invitation Complete verification
to participate
France [272] Consecutive patients in Prospective Expert Timing not specified Dementia NINCDS-ADRDA [63] Yes
France a trial to train GPs. Partial verification:
Only control patients 222 of 375 diagnosed
included. "dementia" by GP
38 of 711 diagnosed
"not dementia" by GP
125 of 311 diagnosed
"unsure" by GP
§ CAMDEX Cambridge Mental Disorders of the Elderly Examination † ICD-10 The International Classification of Diseases, Tenth Revision
‡ further detail not reported § MMSE Mini Mental State Examination (MMSE) CDR Clinical Dementia Rating scale (CDR)
||IADL Lawton instrumental activities of daily living scale §§ Same reference standard applies to both target conditions
Cambridge [267] included the minimal cases on CAMDEX in with mild cases. minimal dementia on CAMDEX approximates MCI
SIDAM structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias
of other aetiology according to ICD-10 and DSM-III-R UK United Kingdom USA United States of America
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Table 2.3: Comparison of diagnostic accuracy studies
Design aspect Mannheim Sydney Hawaii Antwerp AgeCoDe France Cambridge Zwolle Amsterdam Cambridge
[281] [266] [221] [268] [269] [267] 1990 [267] [265] [273] city [270]
Index Test ‡ P P P P P P B B B B
Participant selection
Series § C C C C R C R C R C
Symptomatic No No † No No No Yes No No No No
Characteristics of participants
Number (index test) 3721 200 303 1003 3242 1453 365 2536 475 444
Mean age (years) 76 83 75 75 80 81 - 73 § 75 -
% Female 70 86 63 63 66 71 100 - 62 -
% with dementia § 29 31 9 2 2 50 8 19 10 56
Verification with reference standard
Verified N 407 105 303 10 2294 385 365 375 475 444
Verified (%) § (11) (53) (100) (1) (70) (26) (100) (15) (100) (100)
GP judgement (%)
Not impaired 36 - 33 - 94 48 90 90 76 45
CIND 41 - - - - - 7 8 62 20
Dementia 23 27 33 - 6 26 3 2 50 18
Uncertain - - 33 - - 22 - - - 17
Diagnostic accuracy of GP judgement
Sensitivity (%) 91 42 - 100 51 73 34 39 52 58
Specificity (%) 76 89 - 100 96 58 94 99 94 78
§ C consecutive R random D dementia (see Table 2.2 for definitions)
Symptomatic: symptoms required for participation
% verified = number underwent reference testnumber underwent index test % with dementia =
number with dementia
number verified
† participants were not presenting with symptoms but GPs were asked to maximise the inclusion of people with suspected dementia
-: not reported § median ‡ P prospective B retrospective
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2.4.2 Funding of included studies
Cambridge City was funded by the Charles Wolfson Charitable Trust. Cambridge was funded by the
Medical Research Council and the Mental Health Foundation. Mannheim was funded by the Federal
Ministry of Science and Technology, Bonn. Amsterdam was funded by grants from The Netherlands
Health Research Promotion Programme and The Netherlands Foundation of Mental Health. Sydney
was funded by the National Health and Medical Research Council. Zwolle was funded by National
Fund for Mental Health, the Protestant Association for the Care of Chronic Patients, the Protestant
Foundation for the Care of Chronic Patients and the Foundation for Health Care Research. Hawaii
was funded by HMSA Foundation, Honolulu, Hawaii; and the John A. Hartford Center of Excellence
in Geriatric Medicine, University of Hawaii. Antwerp was funded by Pfizer. AgeCoDe was funded by
the German Federal Ministry of Education and Research. France was funded by Eisai and Pfizer.
2.4.3 Methodological quality of included studies
QUADAS-2 was used to judge the risk of bias in each study. Figure 2.2 shows that overall there was
low risk of bias in the included studies. Specifically most studies were at low risk of bias in the patient
selection domain, with the remainder being at unclear risk of bias 2; and this domain had concern
about applicability. All studies were at low risk of bias in the index test domain and most studies
had low concern about applicability. Most studies were at low risk of bias in the reference standard
domain and all had low concern about applicability, though two were at high risk of bias. Flow and
timing was the domain where there was most risk of bias, Section 2.5.2.1 discusses this in detail.
Figure 2.2: Summary of methodological quality in included studies
Figure 2.3 presents the summary risk of bias and applicability assessment for individual studies.
Four studies were at unclear risk of bias in the patient selection domain. AgeCoDe [269] required
potential participants to have had least one GP contact in the past 12 months and excluded people
who were housebound, which may have resulted in the systematic exclusion of people who lived
2QUADAS-2 categorises risk of bias as high risk, low risk, or unclear risk, and applicability as high concern, low concern,
or unclear concern
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alone or did not seek help, or with the most severe impairment. Similarly Antwerp [268] specifically
excluded people who lived in a residential home for the elderly (regardless of whether home visits
were needed) and Cambridge City [270] excluded people who lived in long stay hospitals, and also
those who were diagnosed as having "minimal dementia", which was not defined. France [272]
stated that consecutive patients were enrolled, but it was not clear that these patients were genuinely
consecutive because five patients per GP were recruited over two years, which appears low. There
were no concerns about the applicability of patient selection.
All studies were judged to be at low risk of bias in the index test domain. However, three studies
had unclear applicability of the index test. Amsterdam [273] and Zwolle [265] explained the reference
standard criteria (but not the diagnosis) to participating GPs before they made their judgement.
Antwerp [268] asked GPs to give their opinion after they had asked four questions on a four-item test
of instrumental activities of daily living [285], though did not specifically state the GPs had to use the
results of this instrument.
Two studies were judged to be at high risk of bias in the reference standard domain. Both Age-
CoDe [269] and Antwerp [268] were judged to be at high risk of bias in this domain because they
incorporated the index test into the reference standard. No studies were at unclear risk of bias in
the reference standard domain and there were no concerns about the applicability of the reference
standard.
Five studies were judged to be at high risk of bias in the flow and timing domain. AgeCoDe [269]
applied the reference standard at 1.5 years and 3 years after the index test assessment. Cambridge
City [270] did not provide any information on timing, but was at risk of partial verification because
the reference test CAMDEX was used to evaluate people who scored 23 or less on the MMSE, together
with sample of those who scored 24 or 25, but none of those who scored over 25. Zwolle [265] followed
a similar procedure, performing the reference standard on all participants scoring 17 or below on the
MMSE, together with a random 2/3 sample of those scoring 18-23, a random 1/3 sample of those
scoring between 24-27 and none of those scoring 28 and above. France [272] was also at high risk of
bias in this domain because of partial verification: 222 of 375 (59%) people diagnosed with dementia
by GP were seen by a specialist, in contrast 38 of of 711 (5%) people not diagnosed with dementia
by GP were seen by a specialist, and 125 of 311 (40%) people with an uncertain GP diagnosis were
seen by a specialist. Antwerp [268] was at high risk of bias in this domain because it appeared that
the reference standard was only done on 10 people of 1003 who were evaluated by a GP. Mannheim
[281] was at unclear risk of bias because there was partial verification but a stratified random sample
was taken for verification, containing equal numbers in each of the four categories of GP assigned
impairment. Similarly, Sydney [266] took a random sample for verification by the reference standard
and was at unclear risk of bias. Amsterdam [273] was at unclear risk of bias because although there
appeared to be full verification, this was derived from people who had been screened with the MMSE
prior to the index test, including a sample of those who scored up to 30 (see Table 2.2), and there was
no information on timing.
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Figure 2.3: QUADAS-2 summary for each study
Two studies, AgeCoDe [269] and Antwerp [268] were judged to be at high risk of bias in two
QUADAS-2 domains (reference standard, flow and timing).
65
CHAPTER 2. SYSTEMATIC REVIEW
2.4.4 Findings
2.4.4.1 Target condition: Dementia
Two studies reported the prevalence of dementia, Zwolle [265] reported a prevalence of 7% and
Cambridge City [270] reported a prevalence of 11%. In both cases the reported prevalence takes
account of weighting in the sampling for the reference test and so differs from the raw calculation of
T P+F N
T P+F N+F P+T N .
Figure 2.4: Forest plot of GPs clinical judgement for diagnosis of dementia
TP true positive FP false positive FN false negative TN true negative 95% CI 95% confidence interval
Figure 2.4 is a forest plot of the accuracy of clinical judgement of GPs for the diagnosis of dementia
in the nine studies that had paired data on sensitivity and specificity. Excluding Antwerp, which
reported a sensitivity and specificity of 100% but was also one of two studies that were at high risk of
bias in two QUADAS-2 domains, in individual studies sensitivity ranged from 34% (95% CI 18% to
54%) in Cambridge to 91% (95% CI 85% to 96%) in Mannheim, which was one of only two studies (the
other being France) that reported higher sensitivity than specificity. Specificity was generally higher
than sensitivity and ranged from 58% (95% CI 51% to 66%) in France to 99% (95% CI 97% to 100%) in
Zwolle.
Figure 2.5 is a summary plot of the accuracy of clinical judgement of GPs for the diagnosis of
dementia. Recall that as described in Section 2.3.9 and Section 2.3.11 the main analysis was restricted
to studies at lowest risk of bias, and therefore AgeCoDe [269] and Antwerp [268] were excluded
from the main meta-analysis. The individual study points are shown with the calculated prevalence
( TP + FNn ), together with an indication of whether the index test was prospective (blue square surround)
or retrospective (yellow circle surround), and are coloured to indicate the risk of bias in the flow
and timing domain (green low risk of bias, grey unclear risk of bias, red high risk of bias). The blue
single filled dot indicates the summary point estimate of diagnostic accuracy, and is displayed on a
summary ROC curve. The dashed bubble indicates the 95% confidence interval around the summary
point and the larger dotted bubble indicates the 95% prediction region. The 95% confidence interval
indicates the region where in 95 samples out of 100 the calculated 95% confidence interval will
contain the true mean value, based on the included data [286]. The 95% prediction region indicates
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Figure 2.5: Summary plot of GPs clinical judgement for diagnosis of dementia
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Clinical judgement for dementia: main analysis

































Colours of dots: indicate risk of bias in flow and timing domain, all are at unclear risk of bias in this domain
Surround indicates prospective retrospective ; decimals indicate prevalence of target condition
the area where the results of a future study could be expected to lie, based on the analysed data [286].
In the meta analysis for dementia as the target condition, the summary diagnostic accuracy of
clinical judgement of general practitioners was sensitivity 59% (95% CI 41% to 74%), specificity 89%
(95% CI 77% to 95%), diagnostic odds ratio (DOR) 11 (95% CI 6 to 22), positive likelihood ratio 5.3
(95% CI 2.7 to 10.7) and negative likelihood ratio 0.46 (95% CI 0.33 to 0.66). As shown in Figure 2.5 the
summary point is an average of the studies in the meta-analysis. The single studies with the most
comparable diagnostic accuracy to the summary point on either sensitivity or specificity had lower
values for the other measure: the single study with a sensitivity closest to the summary point (see
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Figure 2.4) was Cambridge City (sensitivity 58% specificity 78%) and the single study with a specificity
closest to the summary point was Sydney (specificity 89%, sensitivity 42%). Furthermore, only four
of the seven studies in the meta-analysis were included in the 95% confidence region displayed
on the summary ROC curve, with one lying just outside (Zwolle), and two lying further outside
(Mannheim, France). Therefore the summary point in isolation is over-simplistic as a representation




2.4.4.2 Target condition: Cognitive impairment
Figure 2.6: Forest plot of GPs clinical judgement for diagnosis of cognitive impairment
TP true positive FP false positive FN false negative TN true negative 95% CI 95% confidence interval
Figure 2.6 is a forest plot of the accuracy of clinical judgement of GPs for the diagnosis of cognitive
impairment in the four studies that had paired data on sensitivity and specificity. Excluding AgeCoDe,
which was at high risk of bias in two QUADAS-2 domains and reported sensitivity 97% (95% CI 93%
to 99%) specificity 94% (95% CI 93% to 95%), in individual studies sensitivity ranged from 58% (95%
CI 49% to 67%) in Amsterdam to 97% (95% CI 93% to 99%) in Mannheim, which was the only study
that reported higher sensitivity than specificity. Specificity ranged from 51% (95% CI 44% to 57%) in
Mannheim to 88% in both Amsterdam (95% CI 84% to 91%) and Zwolle (95% CI 84% to 92%).
Figure 2.7 is a summary plot of the accuracy of clinical judgement of GPs for the diagnosis of
cognitive impairment. The individual study points are shown with the calculated prevalence, together
with an indication of whether the index test was prospective (blue square surround) or retrospective
(yellow circle surround), and are coloured to indicate the risk of bias in the flow and timing domain
(green low risk of bias, grey unclear risk of bias, red high risk of bias). The blue single filled dot
indicates the summary point estimate of diagnostic accuracy, and is displayed on a summary ROC
curve. The dashed bubble indicates the 95% confidence interval around the summary point and the
larger dotted bubble indicates the 95% prediction region.
In the meta analysis for cognitive impairment (including dementia) as the target condition, the
summary diagnostic accuracy of clinical judgement of general practitioners was sensitivity 80% (95%
CI 45% to 95%), specificity 79% (95% CI 57% to 92%), DOR 15 (95% CI 8 to 29), positive likelihood
ratio 3.8 (95% CI 2.6 to 5.8) and negative likelihood ratio 0.25 (95% CI 0.09 to 0.72). No single study
had a comparable diagnostic accuracy to the summary point on either sensitivity or specificity.
Furthermore, the 95% confidence region was the same size as the 95% prediction region which
covered a large amount of ROC space. Therefore the summary point in isolation is over-simplistic as
a representation of the diagnostic accuracy of clinical judgement for dementia and does not reflect
the heterogeneity in the data.
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Figure 2.7: Summary plot of GPs clinical judgement for diagnosis of cognitive impairment
●













Clinical judgement for cognitive impairment: main analysis

























Colours of dots: indicate risk of bias in flow and timing domain, all are at unclear risk of bias in this domain




Methods for analysis are described in Section 2.3.10. Unfortunately due to technical limitations
described in Section 2.3.9 it is not possible to plot all of the data with two curves on a single ROC
space.
Definition Figure 2.8 shows the ROC plots for the studies by definition, with the studies that used
the ICD-10 definition on the right and studies that used either DSM-III-R or DSM-IV-TR on the
left. For both plots, especially the DSM plot there is significant uncertainty in the 95% confidence
interval and 95% prediction region; for the DSM plot this fills almost the entire ROC space. The
summary points are plotted but not reported in numbers because the uncertainty means these are a
poor representation of the data. There does not appear to be any strong visual evidence to support
the possibility of heterogeneity in sensitivity between ICD-10 and DSM definitions, because the
ICD-10 data cover such a large amount of ROC space for sensitivity. It is possible there may be some
heterogeneity in specificity by definition, with studies that used the ICD-10 or DSM-III-R definition
appearing to report a higher specificity, but this could be due to chance. The study that used the
DSM-IV-TR definition (France) had a higher sensitivity than the two studies that used a DSM-III-R
definition (Sydney and Zwolle) at a cost of lower specificity, but this finding could be due to chance.
Alternatively, the specificity in France could be an outlier, possibly related to the high risk of bias in
the flow and timing domain. The shape of the ROC curves is broadly comparable, i.e. concave, with
the slope gradient being steeper in the studies that used an ICD-10 definition than those that used a
DSM definition. In a meta-regression model using xtmelogit the model could not converge.
Index test Figure 2.9 shows the ROC plots for the studies by index test with the studies that used a
prospective clinical judgement on the right and a retrospective clinical judgement on the left. For both
plots, especially the prospective index test plot there is significant uncertainty in the 95% confidence
interval and 95% prediction region; for the prospective index test plot this fills the entire ROC
space. The summary points are plotted but not reported in numbers because the uncertainty means
these are a poor representation of the data. There does not appear to be any strong visual evidence
to support the possibility of heterogeneity in specificity between prospective and retrospective
judgement, but it is possible that a retrospective definition may be more specific than a prospective
definition. Similarly, there does not appear to be any strong visual evidence to support the possibility
of heterogeneity in sensitivity between prospective and retrospective judgement, but it is possible
that a prospective judgement has a higher sensitivity than a retrospective judgement, but this could
be due to chance. The shape of the ROC curves is broadly comparable, with the slope gradient
being steeper in the studies that used a prospective judgement than those that used a retrospective
judgement. In a meta-regression model using xtmelogit the model could not converge.
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Figure 2.8: Summary plot showing clinical judgement of GPs for diagnosis of dementia according to
ICD-10 (right) and DSM-III-R & DSM-IV-TR definition (left)
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Colours of dots: indicate risk of bias in flow and timing domain, all are at unclear risk of bias in this domain
Surround indicates prospective retrospective ; decimals indicate prevalence of target condition
in the left figure France - high risk in flow & timing - used DSM-IV-TR
Medical records Figure 2.10 shows the ROC plots for the studies by access to the medical records
with the studies that allowed access to the medical records on the right and those that did not
definitely allow access on the left. There is significant uncertainty in the 95% confidence interval and
95% prediction region; for the plot of studies with access to the medical records the 95% confidence
interval contains a large amount of ROC space but the prediction region contains almost the whole
plot, whereas for the plot with records either not available or uncertain the uncertainty extends over
the whole plot. The summary points are plotted but not reported in numbers because the uncertainty
means these are a poor representation of the data. It is plausible that studies that reported access to
the medical records was available have higher sensitivity than those where access was not available
or uncertain, however, there are two studies where access was available where sensitivity was low
(Sydney and Zwolle) so this finding could be due to chance, especially as one of the two studies
with higher sensitivity (France) was at high risk of bias in the flow and timing QUADAS-2 domain.
There does not appear to be any strong visual evidence to support the possibility of heterogeneity
in specificity by access to the medical records. The shape of the ROC curves is broadly comparable,
i.e. concave, with a similar gradient to the slopes. In a meta-regression model using xtmelogit the
model could not converge.
Flow and Timing Figure 2.11 shows the ROC plots for the studies by risk of bias in the QUADAS-2
flow and timing domain, with studies at low and unclear risk of bias on the right and studies at
72
2.4. RESULTS
Figure 2.9: Summary plot showing clinical judgement of GPs for diagnosis of dementia according to
prospective index test (right) and retrospective index test (left)
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The coloured dots indicate the risk of bias in the flow and timing QUADAS-2 domain
decimals indicate prevalence of target condition
high risk of bias on the left. There is significant uncertainty in the 95% confidence interval and 95%
prediction region especially for the left plot which encompasses the whole plot. For the plot on the
right side, compared to the 95% confidence interval in the main analysis, shown in Figure 2.5, there
is less uncertainty indicating that removing the studies at high risk of bias in the flow and timing
QUADAS-2 domain has reduced the uncertainty. However, the 95% prediction interval still contains a
large amount of ROC space. The summary points are plotted but not reported in numbers because
the uncertainty means these are a poor representation of the data. It is plausible that studies that
were at high risk of bias in the flow and timing domain had lower specificity than studies that were at
low or unclear risk of bias in this domain. However, this finding could also be due to chance, because
only one study was at low risk of bias in the flow and timing domain (Cambridge). The shape of the
ROC curves is broadly comparable, i.e. concave, with the gradient slope being steeper in the plot of
studies at low and unclear risk of bias. In a meta-regression model using xtmelogit the model could
not converge.
Cognitive impairment target condition There were three studies in the meta-analysis with cogni-
tive impairment as the target condition, which restricted the opportunity to explore heterogeneity.
For definition, two studies used the ICD-10 definition and one used the DSM-III-R definition. For
index test, two studies used a retrospective judgement and one used a prospective judgement. For
access to the medical records, all studies allowed access. For risk of bias in the flow and timing
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Figure 2.10: Summary plot showing clinical judgement of GPs for diagnosis of dementia by access to
medical records available (right) and not available or uncertain (left)
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The coloured dots indicate the risk of bias in the flow and timing QUADAS-2 domain
ICD-10 was the definition used for both studies on the left plot
decimals indicate prevalence of target condition
Figure 2.11: Summary plot showing clinical judgement of GPs for diagnosis of dementia by risk of
bias in QUADAS-2 flow and timing domain: low or unclear (right) and high (left)
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The coloured dots indicate the risk of bias in the flow and timing QUADAS-2 domain
decimals indicate prevalence of target condition
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QUADAS-2 domain all three studies were at unclear risk of bias.
Figure 2.12 plots the data for the target condition cognitive impairment. One study used a
prospective index test, and used the ICD-10 definition for the target condition (Mannheim); whereas
two studies used a retrospective index test, of which one used the ICD-10 definition for the target
condition (Amsterdam) and one used the DSM-III-R definition (Zwolle). Figure 2.12 shows that
there is no evidence of heterogeneity by definition for the cognitive impairment target condition,
because two studies that used different definitions (Zwolle, DSM-III-R; Amsterdam, ICD-10) had
similar sensitivity and specificity. However, one of the two studies (Mannheim) that used the ICD-10
definition had higher sensitivity and lower specificity than Zwolle so it is impossible to draw firm
conclusions. Because of the small number of studies there is a possibility of a type 2 error, i.e. that
there may be heterogeneity which is not shown. Figure 2.13 (right) shows that compared to the
analysis of all three studies including the one that used the DSM-III-R definition, in the analysis of
the two studies that used the ICD-10 definition the ROC curve is the same shape, fills a similar ROC
space, but has a wider 95% confidence and prediction interval (so wide that it fills the plot).
Figure 2.13 (left) shows a plot of studies that used retrospective judgement compared to the one
that used prospective judgement. There is a possibility that prospective clinical judgement is more
sensitive and less specific than retrospective clinical judgement but there is significant uncertainty
and no firm conclusions can be drawn. There were insufficient studies to perform meta-regression.
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Figure 2.12: Summary plot showing clinical judgement of GPs for diagnosis of cognitive impairment
target condition showing definition
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Amsterdam: ICD-10, retrospective; Mannheim: ICD-10, prospective, highest sensitivity; Zwolle: DSM-III-R, retrospective
decimals indicate prevalence of target condition
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Figure 2.13: Summary plot for clinical judgement for target condition cognitive impairment, showing
the summary curve for studies that used the ICD-10 definition (right) and retrospective judgement
(left)
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Amsterdam: ICD-10, retrospective; Mannheim: ICD-10, prospective, highest sensitivity; Zwolle: DSM-III-R, retrospective
The sensitivity analysis model: is the model with either just ICD-10 studies (right) or just retrospective judgement (left)
The original model: is the model with all three studies; the labelling ("sensitivity analysis") cannot be changed
decimals indicate prevalence of target condition
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2.4.4.4 Sensitivity analyses
Dementia target condition Figure 2.14 shows the summary ROC plot for the pre-specified sensi-
tivity analysis which included the two studies (AgeCoDe and Antwerp) that were judged to be at high
risk of bias in two QUADAS-2 domains. Compared to the main analysis there is greater uncertainty
and more heterogeneity in the data. One of the studies that was excluded from the main analysis
(Antwerp) is an outlier, with very high sensitivity and high specificity; the other study at high risk of
bias in two QUADAS-2 domains (AgeCoDe) had more comparable sensitivity and specificity to the
other eight studies. The summary estimate was sensitivity 65% (95% CI 44% to 80%) specificity 94%
(95% CI 82% to 98%). This compares to sensitivity 59% (95% CI 41% to 74%) specificity 89% (95% CI
77% to 95%) in the main analysis. Therefore when including the two studies that were judged to be at
high risk of bias in more than two QUADAS-2 domains the sensitivity was 6 percentage points higher
and the specificity was 5 percentage points higher; both were within the 95% CI for the main analysis.
However, the uncertainty in the estimates was increased substantially as shown by the wider 95%
confidence and prediction regions in the summary ROC plot and because of heterogeneity the point
estimates are not a good representation of the data.
Cognitive impairment target condition Figure 2.15 shows the summary ROC plot for the pre-
specified sensitivity analysis for the target condition cognitive impairment. Compared to the main
analysis there is greater uncertainty and more heterogeneity in the data. The study that was excluded
from the main analysis (AgeCoDe) is an outlier, with very low sensitivity compared to the other three
studies. The summary estimate was sensitivity 72% (95% CI 33% to 93%) specificity 79% (95% CI
57% to 91%). This compares to sensitivity 80% (95% CI 45% to 95%) specificity 79% (95% CI 57% to
92%) in the main analysis. Therefore when including the study that was judged to be at high risk of
bias in more than two QUADAS-2 domains the sensitivity was 8 percentage points lower and the
specificity was the same; both were within the 95% CI for the main analysis. However, the uncertainty
in the estimates was increased substantially as shown by the wider 95% confidence and prediction
regions in the summary ROC plot and because of heterogeneity the point estimates are not a good
representation of the data.
Re-coded target condition By re-coding the TN as TP it is possible to meta-analyse the accuracy
of GPs for the target condition normal, which is sensitivity 79% (95% CI 57% to 92%) specificity 80%
(95% CI 45% to 95%). 3
3If normal were the target condition instead of cognitive impairment then people who are true negative (Tar g et°
Test°) for cognitive impairment as the target condition become true positive (Tar g et+ Test+) for normal as the target
condition. For example: a score of <24 on the MMSE indicates cognitive impairment; a candidate (who is normal) scores 25.
For the target condition cognitive impairment they are Test° Tar g et° so they are a TN. For the target condition normal
they are Test+ Tar g et+ so they are a TP. By analogy, FN become FP, FP become FN, and TP become TN.
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Figure 2.14: Summary plot for sensitivity analysis of clinical judgement for target condition dementia
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Amsterdam: ICD-10, retrospective; Mannheim: ICD-10, prospective, highest sensitivity; Zwolle: DSM-III-R, retrospective
decimals indicate prevalence of target condition
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Figure 2.15: Summary plot for sensitivity analysis of clinical judgement for target condition cognitive
impairment
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Amsterdam: ICD-10, retrospective; Mannheim: ICD-10, prospective, highest sensitivity; Zwolle: DSM-III-R, retrospective
decimals indicate prevalence of target condition
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2.5 Discussion of the systematic review
2.5.1 Summary of main findings
Five electronic databases were searched for studies investigating the accuracy of clinical judgement of
general practitioners for the diagnosis of two target conditions, dementia, and cognitive impairment
including dementia. From 12,681 records retrieved, sixteen articles referring to 10 studies were
included in the review but one study did not report paired data on test accuracy. Overall the included
studies were judged to be at low risk of bias and to have low concern about applicability. However,
five of the seven studies included in the meta analysis were at high risk of bias in the flow and timing
QUADAS-2 domain and two were also at high risk of bias in the reference standard domain.
In the seven studies in the meta analysis for dementia as the target condition the test accuracy
ranged from sensitivity 34% (95% CI 18% to 54%) for Cambridge to 91% (95% CI 85% to 96%) for
Mannheim; and specificity ranged from 58% (95% CI 51% to 66%) for France to 99% (95% CI 97% to
100%) for Zwolle. In the three studies in the meta analysis for cognitive impairment as the target
condition the test accuracy ranged from sensitivity 58% (95% CI 49% to 67%) for Amsterdam to
97% (95% CI 93% to 99%) for Mannheim; and specificity ranged from 51% (95% CI 44% to 57%) for
Mannheim to 88% (95% CI 84% to 91%) for Amsterdam and 88% (95% CI 84% to 92%) for Zwolle.
Because of the wide 95% confidence intervals and prediction intervals there is significant uncertainty
in the findings and they should not be regarded as definitive.
There was heterogeneity in the data between studies, as illustrated in Figures 2.5 and 2.7. Di-
agnostic accuracy reviews often find greater heterogeneity in sensitivity than specificity because
primary diagnostic accuracy studies typically contain fewer people with disease than without disease
[220]. It was difficult to draw firm conclusions about heterogeneity but the data were compatible with
studies that used ICD-10, or applied retrospective judgement, having higher specificity compared to
studies with DSM definitions or using prospective judgement. For sensitivity there was no evidence of
heterogeneity by definition, studies that used a prospective index test may have had higher sensitivity
than studies that used a retrospective index test, and studies that allowed access to the medical
records may have had higher sensitivity than studies that did not or where this was unclear. Studies
at high risk of bias in the flow and timing domain appeared to have lower specificity and sensitivity
than studies at unclear or low risk of bias in this domain. However, all of these findings could have
been due to chance and there was significant uncertainty.
2.5.2 Strengths and limitations
2.5.2.1 Strengths and weaknesses of the included studies
One limitation of the included studies, which is inherent in the general practice setting, is the low
prevalence of the target condition, which consequently leads to higher uncertainty in the estimates of
diagnostic test accuracy and contributes to the heterogeneity between studies. The seven studies in
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the meta analysis incorporated a total of 445 people who were true positives and 249 false negatives
for the target condition dementia, totalling 694 people who were disease positive out of 2550, for a
prevalence of 27% (95% CI 26% to 29%). In contrast the average prevalence of dementia in the included
studies, calculated for each study as tr ueposi t i ves+ f al seneg ati vestot al was 21%, and ranged from 2% in
AgeCoDe and Antwerp to 47% in Cambridge City and 51% in France. Participant flow in studies, and
specifically incomplete verification of the target condition with the reference standard means that
calculated prevalence may not accurately reflect the true prevalence of the target condition. However,
only two studies reported a figure for prevalence that accounted for the design of participant flow:
Zwolle [265] reported a prevalence of 7% and Cambridge City [270] reported a prevalence of 11%. In
contrast prevalence of dementia in the community is reported to be around 6% [239, 287].
The strength of evidence in this review is restricted by limitations in the primary studies regarding
participant flow, and heterogeneity in the data. Only one study in the meta analysis [267] was judged
to be at low risk of bias in the flow and timing QUADAS-2 domain. This may in part reflect the
practical difficulties of investigating a disease in a low prevalence setting: large numbers of patients
require evaluation to identify the people with disease; evaluating large numbers of people with a
reference standard is resource intensive (i.e. expensive) and arguably burdensome for people who
are unlikely to have a cognitive disorder. Partial verification may have led to over optimistic estimates
of diagnostic accuracy in some studies. In contrast all studies were judged at low risk of bias in the
index test QUADAS-2 domain. However, despite this there was still considerable heterogeneity in
the data, which is probably inherent in the nature of the index test. Background literature relating
to clinical judgement is discussed in detail in Section 1.1.3 and Section 2.5.2.2 discusses the review
findings in context.
In contrast, the evidence in this review is supported by methodological strengths of the included
studies, such as participant sampling and the conduct of the index test and reference standard.
Five of the seven studies in the meta analysis were at judged at low risk of bias in the patient
selection QUADAS-2 domain and the remainder to be at unclear risk of bias; all studies reported that
participants were sampled either consecutively or randomly. All seven studies were at low risk of bias
in the reference standard QUADAS-2 domain.
The estimates of accuracy varied between studies but despite this there were consistent trends.
In general specificity was higher than sensitivity, specificity was relatively high (at least 0.78 in eight
studies), whereas sensitivity was modest (at best 0.91 in eight studies). The findings were robust to
a sensitivity analysis. Both prospective and retrospective clinical judgement generally had higher
specificity than sensitivity. These findings suggest that clinical judgement of GPs is generally better at
identifying healthy people as disease free than recognising disease in affected people. Section 2.5.4
and Figure 2.16 explore the implications of this for practice.
There was low concern about the applicability of studies to the review question. Only three
studies had unclear concern4 about the applicability of the index test but otherwise all studies were
4QUADAS-2 categorises risk of bias as high risk, low risk, or unclear risk, and applicability as high concern, low concern,
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of low concern in all QUADAS-2 applicability domains.
Overall the characteristics of studies, quantity, numbers of disease positive, and consistency
of the findings are supportive factors for the strength of evidence in the review. In contrast the
strength of evidence is diluted by the heterogeneity in the data. However, heterogeneity is present
in all diagnostic test accuracy reviews to some extent, and the nature of clinical judgement is that
it will tend to be more heterogeneous than a machine read test. Given the nature of the index test,
substantial heterogeneity in the data is likely to be unavoidable.
2.5.2.2 Strengths and weaknesses of the review process
The search was comprehensive and systematic. The search strategy was written in consultation with a
highly experienced systematic reviewer with substantial expertise in diagnostic test accuracy studies
investigating cognitive disorders and dementia. A number of databases were searched and the search
yielded more results that previous reviews, notwithstanding the later search date. All studies that
were identified by previous systematic reviews were identified by the current search strategy, though
not all were included in the review. The comprehensiveness of the search makes it unlikely that
the findings would be undermined by some unidentified study, but this cannot be fully excluded.
In particular unpublished studies are hard to identify, and methods to identify reporting bias in
diagnostic test accuracy reviews are not yet well established [220].
Studies were excluded that used a documented diagnosis of dementia in the medical record
as the index test. This meant that some studies that had been included by previous reviews were
not included in this review. Furthermore, it is not possible to infer the accuracy of documented
diagnosis in the GP medical record for the diagnosis of dementia from this review. However, this
exclusion means that the findings of this review are highly applicable to the review question which
is arguably more focused on clinical practice than previous reviews. Understanding the accuracy
of a documented diagnosis of dementia in the medical record would be helpful if (for instance)
investigators were seeking to ascertain people with dementia diagnosed by a GP in a database
of routinely collected data from primary care. Other investigators have reported inconsistency in
ascertaining cases of dementia from routinely collected data [288].
The process for including and excluding studies was robust, as was data extraction, being done
separately in duplicate by two reviewers and disagreements resolved by consensus. Authors of original
studies were contacted when necessary to obtain data on diagnostic accuracy, but this was not
available. The approach to the statistical analysis used standard techniques that are recommended
by the Cochrane diagnostic test accuracy review methods group. Recently reported approaches such
as imputation of data [289] were not used, but are less widely recognised and are not yet mentioned
in the Cochrane handbook [150, 220] .
An important limitation is the difficulty in understanding how the accuracy of clinical judgement
for the diagnosis of dementia or cognitive impairment is related to the stage of the condition. De-
or unclear concern
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mentia is a progressive disease, and it is possible that GPs do not make a diagnosis of dementia until
the condition has advanced to a stage where the diagnosis is relatively apparent, perhaps even to
a non-medical person. If GP clinical judgement is only accurate in advanced stages of the disease
then arguably it contributes little beyond the opinion of the patients family and friends. However,
attempting to analyse how the accuracy of clinical judgement varied over different stages of disease
would have led to small numbers in the analysis, and would have been hampered by reporting in
primary studies. The review did however include two target conditions: dementia, and cognitive im-
pairment including dementia. The cognitive impairment target condition includes a wider spectrum
of people including those with milder degrees of cognitive impairment was well as those with florid
dementia. There was no strong evidence of difference in the sensitivity and specificity of clinical
judgement for the two target conditions, with overlapping confidence intervals and the findings
limited by uncertainty, however when comparing Figure 2.5 and Figure 2.7 it is possible that the
sensitivity of clinical judgement for cognitive impairment may be higher than for dementia, without
loss of specificity.
An important aspect of the interpretation of the results is the threshold of clinical judgement for
the diagnosis of the target conditions. It is only sensible to estimate average sensitivity and specificity
at a common test threshold [220]. The philosophy in this review is that the common threshold for
the diagnosis of clinical judgement is the diagnostic label of dementia or cognitive impairment. A
clinician makes a clinical judgement about the presence of dementia (or indeed any diagnosis) when
they judge that the patient fits better, on balance, in that group of people than outside of the group,
especially with regards to prognosis and response to treatment [140, 175]. While different clinicians
may formulate differing conclusions about whether or not a condition is present in a particular
patient, their threshold for clinical judgement in decision making is likely to be a function of factors
such as the implications of the disease (regarding prognosis or treatment), their familiarity with the
patient, and the urgency of the decision. This review takes the stance that if a GP participating in
one study (for instance Antwerp) had instead been participating in a different study (for instance
Amsterdam) evaluating the same patient under the the same circumstances would lead to the same
decision about the target condition, because the threshold for the target condition in both studies
was consistently a diagnostic label of dementia. That is, that there is low intra-observer variability in
the classification of a person as having dementia. Unfortunately, there is very little evidence on the
intra-observer variability of the diagnosis of dementia in general practice. Available data indicate
good inter-observer agreement (kappa 0.63-0.90) for the categorisation of dementia | no dementia
[290–292] but these studies are based on specialists applying standardised criteria and no similar
studies investigating the reliability of clinical judgement of general practitioners could be identified.
However, the alternate view is that there is no common threshold for clinical judgement because it is
a subjective test. This view is considered less plausible because this position would mean that despite
identical circumstances, clinician and patient a different classification could be reached regarding
the target condition (due to varying test threshold), and (though the play of chance is acknowledged)
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this is considered unlikely. If correct, the view of no common index test threshold would imply that it
is not appropriate to perform bivariate meta-analysis of the data on clinical judgement. As discussed
in Section 1.1.3 many tests (perhaps all other than those which are read by a machine) are subject to
a degree of clinical judgement, user variability and implicit thresholds.
There were four differences between the methods as described in this Chapter and those in the
published protocol [197]. Firstly, studies were not restricted to people with cognitive symptoms
for because (a) this restriction was judged on reflection to be incompatible with the retrospective
definition of clinical judgement (which was included in the published protocol) and (b) this approach
would have been overly restrictive. Secondly, all abstracts were screened by two reviewers rather than
one. Thirdly, information on covariates was not extracted for stage of dementia, experience of GPs,
proportion of male and female doctors, or type of practice because these factors were found to be
poorly reported and judged on reflection to be of less relevance to the review question. Fourthly,
based on discussion with expert statistical advisers, the main analysis was in studies at lowest risk of
bias and a sensitivity analysis was done when studies at high risk of bias in two or more QUADAS-2
domains were included.
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Table 2.4: Diagnostic accuracy of clinical judgement for diagnosis of dementia in context
Test Number Total Threshold Prevalence Sensitivity Specificity Diagnostic
of studies participants for normal of dementia (95% CI) (95% CI) odds ratio
Mini-Cog [293] 4 Max = 4
[294] 142 ∑ 2 35% 1.00 (0.93 to 1.00) 0.40 (0.30 to 0.50) 1
[295] 423 ∑ 2 5% 1.00 (0.84 to 1.00) 0.85 (0.81 to 0.89) 1
[296] 383 ∑ 2 6% 0.76 (0.53 to 0.92) 0.73 (0.68 to 0.77) 9 (95% CI 3 to 30)
[297] 569 ∑ 3 90% 0.84 (0.81 to 0.87) 0.27 (0.16 to 0.41) 2 (95% CI 1 to 4)
26 item IQCODE [298] § 1 262 max = 5 7%
[171] 3.2 1.0 † 0.76 1
3.3 1.0 0.82 1
3.4 1.0 0.87 1
3.5 0.88 0.91 72 (95% CI 14 to 670)
3.6 0.81 0.96 99 (95% CI 21 to 593)
3.7 0.75 0.98 158 (95% CI 29 to 931)
AD8 [299] 1 309 max = 8 14%
[170] 3 0.91 (0.78 to 0.97) 0.91 (0.87 to 0.94) 100 (95% CI 32 to 406)
MMSE [156] ‡ 6 max = 30
[294] 360 24 21% 1.00 (0.95 to 1.0) 0.46 (0.40 to 0.52) 1
[300] 303 24 26% 0.81 (0.70 to 0.89) 0.65 (0.59 to 0.72) 8 (95% CI 4 to 16)
[301] 176 25 47% 0.80 (0.70 to 0.88) 0.76 (0.66 to 0.84) 13 (95% CI 6 to 28)
[302] 160 19 9% 0.80 (0.52 to 0.96) 0.85 (0.80 to 0.91) 25 (95% CI 6 to 145)
[303] 314 23 9% 0.68 (0.48 to 0.84) 0.92 (0.88 to 0.95) 24 (95% CI 9 to 67)
[266] 368 24 16% 0.37 (0.24 to 0.51) 0.95 (0.92 to 0.97) 11 (95% CI 5 to 24)
Clinical judgement
For dementia 7 2550 - 27% 0.59 (0.41 to 0.74) 0.89 (0.77 to 0.95) 11 (95% CI 6 to 22)
For cognitive impairment 3 1257 - 32% 0.80 (0.45 to 0.95) 0.79 (0.57 to 0.92) 15 (95% CI 8 to 29)
§IQCODE Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly. Typically the short 16 item version [304] is used in practice
† confidence intervals not available. ‡ MMSE Mini Mental State Examination
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2.5.3 Relation to literature
Table 2.4 presents the results in the context of the existing literature, based on findings of a series
of Cochrane reviews of diagnostic test accuracy that reported on the accuracy of brief cognitive
tests for the diagnosis of dementia in primary care. Comparisons between tests are difficult because
of variations in study design such as sampling, reference standard and especially participant flow.
Additionally different sensitivity and specificity combinations may result in the same diagnostic odds
ratio [220]. Furthermore, the summary estimates in this review do not reflect the heterogeneity in the
data. Comparisons between different studies requires great care because the comparisons are indirect
and are very susceptible to confounding by factors other than the test of interest. However, in general
in comparison to the tests that are outlined in Table 2.4 clinical judgement has lower sensitivity
but higher specificity. To some extent this is expected. Recall that specificity = T NT N+F P . As discussed
in the previous paragraph, GPs in studies that contributed to this review may have understood
their clinical judgement as equivalent to the diagnosis, with potentially important implications
for their patients and so they may have been erring on the side of minimising the number of false
positives, which would tend to lead to a higher specificity. From Figure 2.5 and Figure 2.7 it is plausible
that studies with higher sensitivity are also those with a higher prevalence of the target condition,
which may suggest that the implicit threshold for clinical judgement of dementia varies with the
prevalence of the target condition. However, it is difficult to draw any firm conclusions about because
of limitations in the data, for example in Figure 2.5 two studies with similar prevalence have very
different sensitivity (Sydney prevalence 25% sensitivity 42%; Mannheim prevalence 29% sensitivity
91%) that are both at unclear risk of bias in the flow and timing QUADAS-2 domain. In contrast,
many of the brief cognitive tests that are outlined in Table 2.4 have the purpose of improving the
identification of people with cognitive disorders and so would tend to minimise the number of false
negatives, optimising sensitivity.
None of the Cochrane systematic reviews of brief cognitive tests were able to perform meta
analysis, either because of insufficient studies or because of heterogeneity in the data, particularly
regarding varying test threshold. For the mini-cog in four studies the sensitivity for the diagnosis of
dementia varied between 76% to 100% and the specificity varied between 27% to 85%; the study at
the lowest risk of bias, at low risk on all QUADAS-2 domains, [296] reported a sensitivity of 76% and
specificity 73% for a DOR of 9. For the IQCODE only one study, which was at high risk of bias in all
domains, was identified in primary care, which used the long form (26 item) rather than the more
commonly used (and recommended [305]) 16 item version. At a threshold of 3.2 the IQCODE for
the diagnosis of dementia had sensitivity 100% and specificity 76% whereas at a threshold of 3.7 the
sensitivity was 75%, specificity 98% [171]. For the AD8 in one study in primary care, which was at
high risk of bias in the flow and timing QUADAS-2 domain and unclear risk of bias in the selection
and index test QUADAS-2 domains, the sensitivity and specificity were both 91% [170]. For the MMSE
in six studies in primary care the accuracy for the diagnosis of dementia ranged from sensitivity 37%
specificity 95% at a threshold of 24 [266] to sensitivity 100% specificity 46% at a threshold of 24 [294];
87
CHAPTER 2. SYSTEMATIC REVIEW
none of the studies were at high risk of bias in more than one QUADAS-2 domain.
Overall in the context of the existing literature the present findings suggest that clinical judgement
of GPs is comparable to brief cognitive tests for the diagnosis of dementia. Clinical judgement for the
diagnosis of dementia is a comparatively high specificity, moderate sensitivity test. The accuracy of
clinical judgement for the diagnosis of dementia DOR 11 (95% CI 6 to 22) is comparable to reported
figures for the accuracy of the MMSE at a threshold of 24, DOR 11 (95% CI 5 to 24), and the accuracy of
clinical judgement for the diagnosis of cognitive impairment DOR 15 (95% CI 8 to 29) is comparable
to reported figures for the accuracy of the MMSE at a threshold of 25, DOR 13 (95% CI 6 to 28).
Clinical pathway Clinical judgement, as described in Section 1.1.3 is a categorisation process
which is (as defined in Section 2.3.3) unaided by any additional test, investigation or inquiry beyond
that which is immediately available to the clinician. Arguably, clinical judgement, as detailed in
Section 1.1.3, is typically formulated without conscious direction. Clinicians will typically reach a
judgement about problems which they are presented with, however the problem arises: for instance
when performing chest auscultation a GP may observe an abnormal looking mole and decide the
patient requires referral for this, even if the patient did not know the mole was there. Similarly, a GP
may observe that a patient is having cognitive problems, for example being repetitive or vague in
their presentation of the clinical problem, even if the patient is not presenting about these things
directly. The extent to which the GP identifies these coincidental problems probably depends on
the extent to which the non-explicitly presented problems are consciously available to the GP (the
availability heuristic; Section 1.1.3.3)
The Author suggests that typically the presentation of cognitive problems is broadly speaking
one of the following scenarios:
1. Cognitive problems, noted by the patient or someone else, are the main reason for the en-
counter in a routine (planned) encounter;
2. Cognitive problems are not the main reason for the encounter but are opportunistically noted
by the clinician;
3. A crisis has occurred. This may be a physical crisis (such as chest infection) with associated
cognitive problems such as delirium, or a cognitive crisis such as getting lost, wandering,
leaving the stove on, or a driving accident.
It is likely that the prevalence of underlying cognitive problems is different in each scenario, for
example, cognitive problems may be more likely in scenarios 1 and 3 than in scenario 2, but this is a
question for future research. The findings of this review suggest that clinical judgement of dementia
and cognitive impairment is a comparatively high specificity moderate sensitivity test. Using clinical
judgement without any additional test, especially when the patient presents with subjective cognitive
problems, would be at risk of missing cases of dementia; this is discussed further in Paragraph Natural
frequencies for tests and judgement below. The role of clinical judgement in the clinical pathway
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depends partly on the clinical scenario. For example, in scenario 1 above, clinical judgement may
be an add-on test to other measures because it is likely that some form of objective testing will be
needed to help meet patients’ ideas about what they expect from an encounter which is focused on
cognition. In contrast, in scenario 2 and 3 clinical judgement is unavoidable (recall from Section
1.1.3.2 that clinical judgement is a system 1 cognitive process) and is indispensable in recognising the
possibility of underlying cognitive impairment: if the clinician does not recognise impairment as
being possible then no further tests will be done.
2.5.4 Conclusion and implications
One interpretation of these findings is that the clinical judgement of a GP is of limited practical value
because in a low prevalence setting there is a high probability that person without disease will be
labelled as disease free if people are sorted randomly into categories based on the prior probability
of disease (prevalence). Figure 2.16 shows that if disease state was allocated randomly based on
prevalence then in a group of 1000 people of whom 130 had dementia (see Figure 1.2), 77 additional
people would be given an incorrect diagnosis, of whom 60 would be additional false negatives (to
those mis-assigned by GP clinical judgement) and 17 would be additional false positives. Clinical
judgement could be expected to correctly identify 60 more people of the 130 with disease and 17 more
people of the 870 with no disease than categorisation based on prevalence alone. It should be noted
that these figures are calculated on the basis of the point estimates, which as emphasised previously
do not reflect the heterogeneity in the data, and which may be over-simplistic as a summary of the
diagnostic accuracy of clinical judgement.
Natural frequencies for tests and judgement Some investigators have argued that tests should
be used to support the identification of people with dementia [306], though this is debated [307].
Using a brief cognitive test that is completed by the patient (such as the MMSE at a threshold of
25) would result in 104 TPs (27 more than clinical judgement), but at the cost of 209 FPs (113 more
than clinical judgement); meaning that compared to clinical judgement alone, using the MMSE at
a threshold of 25 would result in four additional disease free people undergoing further workup or
being misdiagnosed for every one additional person with disease who was correctly identified ( 11327 ).
In contrast asking an informant to complete the IQCODE, at a threshold of 3.5, would result in 114
TPs and 78 FPs, resulting in two fewer diseased free people being identified for every 1 additional
person who was identified with dementia ( 37°18 ), compared to clinical judgement. Therefore if it
is a goal to identify people with dementia who are missed by their GP it may be preferable to use
informant measures rather than patient measures. It can be anticipated that this may cause some
difficulties for people who are socially isolated.
From a public heath perspective an important implication is that in a population of 1000 people
of whom 130 have dementia, a GP could be anticipated to classify 828 as not having dementia, and of
these 94% will not have dementia. In contrast, if people were randomly assigned to a diagnosis on
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77 TP 53 FN
870 no dementia
774 TN 96 FP
Based on prevalence only
1000 people
130 dementia
17 TP 113 FN
870 no dementia
757 TN 113 FP
Based on 13% prevalence of dementia ( 7655847 people had de-
mentia; Figure 2.4 see also Figure 1.2), clinical judgement
64% sensitivity 94% specificity. Prevalence only, e.g. 17 TP
based on 13% *130
TP true positive FN false negative TN true negative FP false
positive
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the basis of the disease prevalence then 870 people would be classified as free of dementia, of whom
87% would actually not have dementia; of the 130 people who were classed as having dementia only
17 would have the disease.
A question for health systems that deserves consideration is what is the threshold probability of
dementia at which specialist evaluation is warranted. In the United Kingdom GPs are encouraged to
refer for evaluation to exclude cancer if the probability of cancer exceeds 3% in an adult and 1% in a
child. Compared to cancer, dementia is also a serious condition with important implications.
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Implications for future studies An important unanswered question from this review is what is the
accuracy of GP clinical judgement for the diagnosis of dementia in people with symptoms compared
to those without. Most studies in this review did not distinguish between people attending their
GP with symptoms of dementia and those attending their GP for other reasons. This is especially
important because the prevalence of dementia in people attending their GP with symptoms can be
anticipated to be higher than the 13% calculated in this review, as well as also altering the spectrum
of disease in people who do have dementia (being more severe in people who are presenting with
symptoms). Overall the estimates of diagnostic accuracy in this review are likely an underestimate of
diagnostic accuracy in people with symptoms.
There are least two further important unanswered question from this review. Firstly, what is the
comparative accuracy of clinical judgement compared to brief cognitive tests [308] for diagnosing
dementia. Direct comparison of test accuracy in a single study is preferable to indirect comparisons
but requires additional methodological considerations to ensure robust study design. Secondly, what
is the evidence for heterogeneity in the aspects of study design that were investigated in this review?
To investigate heterogeneity in test accuracy further, future studies could attempt to apply more than
one definition, could elicit retrospective judgement in a randomly selected sample of people who
had already had prospective GP clinical judgement and who were intended to receive the reference
standard assessment (but had not yet), could blind some (randomly assigned) participating GPs to
using the medical records for the retrospective judgement and others to not, and could take steps to
attempt full verification of the reference standard and provide extended follow-up of the medical
records for those people who were not verified.
Dementia is an uncommon disease in general practice and it has been projected that most GPs
could expect one to two new cases each year, per physician [309]. If a GP thinks a patient has dementia
then there may be merit in using a brief cognitive test to measure objective cognitive impairment
because the probability of dementia based on GP clinical judgement alone is not high enough to
confirm dementia. It is also important to objectively quantify cognitive functioning in someone with
symptoms of dementia who is judged by their GP to be disease free, because the sensitivity of clinical
judgement is too low to definitively exclude cognitive problems.
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Chapter Summary
This Chapter has presented the methods and results for a review of diagnostic test accuracy of
GP clinical judgement for two target conditions: dementia and cognitive impairment. Clinical
judgement was defined as being unaided by any additional test, investigation or inquiry beyond
that which is immediately available to the clinician.
A search was conducted in five electronic databases by an information specialist without
language restrictions. The search yielded 12,681 citations, of which 8118 remained after de-
duplication and were independently screened by two reviewers. Full text records were reviewed
for 56 papers and of these 16 were included, referring to 10 studies of which 7 could be included
in the meta-analysis. Data extraction and quality appraisal was done in duplicate and disagree-
ments were resolved by discussion. Studies were classified by whether the GP judgement of
the target condition was prospective: done after seeing a patient, or retrospective: made in
hindsight by reflecting on their past encounters with the patient.
QUADAS-2 was used to appraise the quality of included studies, which were generally at
low risk of bias, with the exception of the flow and timing domain. For dementia as the target
condition the sensitivity of GP judgement ranged from 34% (95% CI 18% to 54%) for Cambridge
to 91% (95% CI 85% to 96%) for Mannheim; and specificity ranged from 58% (95% CI 51% to 66%)
for France to 99% (95% CI 97% to 100%) for Zwolle.
There was was substantial heterogeneity between studies. Uncertainty in the estimates














his Chapter details the methods for an empirical quantitative study to investigate the accuracy
of tests for diagnosing dementia in people presenting to GPs with cognitive symptoms. The
first Section defines the target conditions and the research questions. The second Section
describes the recruitment of participants, including exclusion criteria, the setting, context, sampling
and referral to the study. The third Section describes administrative arrangements including details
of how referrals to the study were processed, how research clinic appointments were arranged,
and other standard operating procedures. The fourth Section describes the test methods and data
collection for tests, including the rationale for index test selection, an overview of the tests in the
index battery, the specialist evaluation, and the collection of follow-up data after the research clinic.
The fifth Section provides details of the reference standard and describes how the medical record
extract was reviewed. The sixth Section describes data collection, including locations of research
clinics, and revisions to the case report form, and data management. The seventh Section describes
the statistical methods. The eighth Section reviews the methods and considers the risk of bias using
the QUADAS-2 tool.
3.1 Target conditions and research questions
3.1.1 Target condition definition
The two target conditions for evaluating diagnostic accuracy were dementia (of any aetiology) and
normal. Dementia was chosen as a target condition because tests with high accuracy for diagnosing
this condition would allow GPs to make a positive confirmatory diagnosis of dementia in people with
manifest impairment. If GPs were able to make a positive diagnosis of dementia this might avoid
referral to specialist services unless there were features which required expert input to manage, or
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there were other factors complicating the presentation such as young age, atypical symptoms, or
rapid onset and progression. Normal cognition was chosen as a target condition because tests with a
high accuracy for diagnosing this would allow GPs to identify people with no current impairment,
who could potentially be reassured. People who GPs could not make a positive diagnosis of either
dementia or normal cognition would likely require a individualised approach including options as
outlined in Section 1.1.2.1, such as test of time, further tests, or referral to specialist; these people
may have MCI, dementia or normal cognition.
These target conditions were chosen as being most relevant to general practice because general
practitioners are unlikely to have sufficient expertise to differentiate specific aetiologies and because
most patients with cognitive impairment in primary care will have a composite aetiology (Section
1.1.1.3). Dementia was defined according to ICD-10 criteria.
3.1.2 Quantitative research questions
The research questions for the quantitative study were:
• What is the accuracy of clinical judgement of general practitioners for diagnosing the target
conditions in people with cognitive symptoms?
• What is the accuracy of a range of tests for diagnosing the target conditions in people presenting
to general practice with cognitive symptoms?
• Which combinations of tests have the greatest net benefit to diagnose the target conditions?
3.2 Participants
Participants were people with symptoms of possible dementia, who were aged at least 70 years, and
had been referred by their GP surgery during the recruitment period. People who had already been
diagnosed with dementia were not eligible. In contrast, people who had been previously evaluated
for cognitive symptoms in the past were eligible so long as there was a persisting genuine concern
about the possibility of dementia. Symptoms of dementia are detailed in Section 1.1.1.4. The concern
about symptoms of dementia was permitted to be from the person themselves, their kin, a health
professional including their GP, or another person. There was no eligibility threshold for the extent of
concern about dementia, but people were required to have had symptoms for at least six months and
be able to attend with an informant, because these aspects of the history facilitated a robust reference
standard. People with symptoms that were progressing every week, or those with neurological
symptoms that were co-incident with the cognitive impairment were not eligible, because these were
considered to be clinical red flags for rare but important neurodegenerative disease such as prion
disorder. Table 3.1 shows the medical comorbidities that were exclusion criteria to avoid including
people with complicated presentations that were judged likely to require specialist evaluation in all
cases. People with very severe dementia, operationalised as inability to consent to participate, were
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excluded. People with very severe dementia were judged, in consultation with a lay advisory panel,
to find participating in research burdensome, and have difficulty in completing formal evaluations
of cognition. Transport was provided free of charge to participants on request, either with a taxi
or with a wheelchair adapted minibus. People were not excluded if they were resident in a nursing
home, older persons home, or supported housing, so long as they were fit enough to travel out to an
appointment. Translation services were offered to all participants and arranged on request, so that
inability to communicate in English did not exclude people.
Table 3.1: Medical comorbidities that were exclusion criteria






Severe hearing impairment †
§ including Parkinson’s disease
† operationalised as unable to use telephone
3.2.1 Setting
Participants were recruited from GP practices in the Bristol, North Somerset, and South Gloucester-
shire area (BNSSG) area. BNSSG is an diverse geographical area within approximately 15 miles of the
City of Bristol, that had a total population of 900,000 people across 82 general practices. Practices
in Bristol were predominantly in an urban catchment area, whereas those in South Gloucestershire
and Somerset included patients in suburban and semi-rural areas. Practices in the West of England
Clinical Research Network were invited to participate through direct contact, regular circulars and
networking events. All practices who expressed interest before the deadline were included in the
study but the practice start dates for recruitment were staggered for operational and logistical rea-
sons. Practices that were identified by the Clinical Research Network as having particular expertise
in recruiting to studies were selected to an early start date. Table 3.2 shows the details of recruiting
practices. The median list size of practices was 11,333 (interquartile range 8004 to 14,654) and list
size ranged from 4,224 (Stoke Bishop (L81622)) to 21,588 (Mendip Vale (L81086)). The practice with
the highest proportion of patients in the eligible age group out of the total list size was Clevedon
(L81102), in a relatively affluent town outside of Bristol, which had 1,383 of 7,229 patients eligible
(19%). The practice with the lowest proportion of patients in the eligible age group was Redfield
(L81061), in a relatively deprived inner city ward, with 524 of 8431 (6%) being eligible. Recruitment
began in March 2015 and is detailed further in Section 3.2.4.
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Table 3.2: Details of recruiting Practices [310]
Location§ List size List at Set up date Region ‡
(code †) least 70 years
Backwell (L81060) 13,500 2,378 December 2015 N.S
Bedminster (L81053) 8,004 1,160 February 2015 Bristol
Clevedon (L81102) 7,229 1,383 September 2016 N.S
Clevedon (L81040) 16,094 2,701 April 2015 N.S
Clifton (L81081) 12,965 1,042 March 2016 Bristol
Close Farm (L81050) 7,102 803 December 2015 S.G
Fishponds (L81087) 10,644 1,024 April 2015 S.G
Frampton Cotterell (L81014) 14,654 2,553 February 2016 S.G
Hanham (L81079) 21,327 3,343 February 2015 S.G
Henleaze (L81131) 9,120 1,501 October 2015 Bristol
Horfield (L81022) 15,474 1,133 March 2015 Bristol
Kingswood (L81063) 12,062 1,632 May 2015 S.G
Long Ashton (L81056) 6,900 939 May 2016 N.S
Mendip Vale (L81086) 21,588 3,486 April 2015 N.S
Portishead (L81004) 18,285 3,235 February 2016 N.S
Redfield (L81061) 8,431 524 February 2016 Bristol
Shirehampton (L81008) 11,333 1,228 March 2015 Bristol
Southmead (L81098) 7,423 951 December 2015 Bristol
Stoke Bishop (L81622) 4,224 366 April 2015 Bristol
Westbury on Trym (L81017) 9,772 1,375 March 2015 Bristol
Yate (L81047) 13,320 2,199 January 2016 S.G
Total 249,556 34,956
§ Location is given rather than practice name because practice names change with mergers
and change of doctors
† Practice code is a unique identifier held by NHS England
‡ N.S North Somerset S.G South Gloucestershire
3.2.2 Context
GP practices in the UK were funded through a complex set of arrangements typically including
an annually negotiated national contract, the Quality and Outcomes Framework, public health
programmes, and additional local or direct (i.e. national) enhanced services to support activity that
was particularly important to the government of the day, along with other NHS (National Health
Service) and non-NHS activities [311]. Total NHS funding received per patient was typically in the
order of £150 per patient per year [312]. Between April 2013 and April 2016 many GP practices (81%
at one point, [313]) participated in a direct enhanced service under which they received £0.37 per
patient on their list and a further payment based on the number of assessments the practice had
performed out of the national total, in return they were asked to "a) identify patients at clinical risk
of dementia; b) offer an assessment to detect for possible signs of dementia in those at risk; c) offer a
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referral for diagnosis where dementia is suspected; and, d) support the health and well-being of carers
for patients diagnosed with dementia." [314]. In addition, since July 2013 GP practices in Bristol,
but not South Gloucestershire or North Somerset, were able to participate in a separate programme
under which they were paid £500 to cover set up costs, plus £164 for each new diagnosis of dementia,
in return they were asked to [315]:
• "Adopt the shared care pathway including management of people stable on dementia medica-
tion.
• Undertake a diagnosis of uncomplicated dementia (Alzheimer’s Disease or Vascular Demen-
tia) within a Primary Care setting (using the agreed template) and provide appropriate post
diagnostic support and signposting information
• Carry out enhanced reviews of people with dementia and their family/carer (using the agreed
template) that delivers review of all medication including cholinesterase inhibitors, memantine
and anti- psychotic medication.
• Undertake investigations [as detailed] and investigate any abnormalities to exclude potentially
treatable causes
• Undertake a diagnosis of dementia and initiate medication in line with guidance
• Complete a plan for the patient that includes relevant information including where to go for
further support and signposting
• Note the diagnosis of dementia, if made in secondary care and record accordingly with relevant
read code.
• Review stable cases of people with dementia, currently seen in secondary care (payment £40 per
review)
• Review every person diagnosed with dementia at least once a year (6 monthly if on dementia
related medication, 3 monthly if on anti- psychotic medication), following the review template
provided
• Continue the prescribing of Cholinesterase Inhibitor or memantine
• Notify the Memory Nurse of any adverse drug reactions, deterioration in condition or any other
clinical concerns regarding the person’s health that can not be managed in Primary Care
• In order to qualify for payment the practice must complete the work detailed above. The memory
nurse for the locality will be able to provide support, advice and guidance. The memory nurse
will be able to carry out joint home visits with the GP/nurse. If the memory nurse carries out a
home visit on their own, the practice will not be eligible to claim payment.
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• Practices will receive a bonus payment of £200 if they achieve a 5% increase in the number of
people on the practice register with a diagnosis of dementia, in year, or if they achieve 65% of
expected diagnosis against expected prevalence."
The clinical commissioners were consulted about the programme of quantitative research, and
advised that GPs would still be able to participate in the funded work outlined above, as well as the
research study. The commissioner requested that all clinical decision making regarding diagnosis,
explanation to the patient, investigations, onward referral, and interventions be done by the GP
surgery rather than the research clinic; the research team concurred that this approach would be
appropriate. The potential impact of these programmes of funded activity on the setting is explored
in the Discussion.
3.2.3 Sampling
GPs were encouraged to refer a consecutive series of eligible patients with no need to perform any
form of prior testing. Table 3.3 shows details of barriers to referral that were identified and mitigated.
To encourage recruitment a computer prompt was used at the point of care to remind GPs about the
study. GP practices in BNSSG all used the EMIS1 Web [316] clinical records software, which stored
details of patients medications, investigations, documents, appointments and consultations elec-
tronically. EMIS Web allowed for the entry of both free text and coded data. Software in participating
GP practices was programmed so that when GPs entered a problem code regarding memory loss,
confusion, or cognitive decline, or synonyms for these things in the consultation page, a prompt
reminded them about the research study. Table 3.4 gives details of the full list of codes that triggered
the electronic point of care prompt. Some clinical problems (e.g. confusion) have more than one
code, so all variants were included in the list of trigger codes. To avoid GPs being prompted to refer
people who had already been diagnosed with dementia, codes for dementia were specifically not
included in the list of trigger codes.
The electronic prompt allowed the GP to directly open the study referral form. This was designed
to facilitate discussion with the patient and make the referral process easy. Alternatively the GP could
cancel the prompt and the reason for the prompt being cancelled was recorded. This process was
tested in five GP practices and the feedback from GPs was very positive; there was only one change
suggested which was to change the code that was used to record the use of the prompt.
3.2.4 Referral to the study
The referring GP checked eligibility, gained the consent of the symptomatic person to refer them to
the research study, and completed a referral form providing details on the patient and their contact
details. The referral form also asked who had concerns about cognitive symptoms (the patient, their
kin, the GP, another professional, someone else); the GP’s clinical judgement about the extent of
1EMIS originally stood for Egton Medical Information Systems, but EMIS is now the name of the company
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Table 3.3: Methods to mitigate potential barriers to recruitment
Barrier Mitigation
GP not remembering the study Computer prompt
GP unsure about eligibility criteria GPs encouraged to be inclusive,
study staff recheck and confirm eligibility
Difficulty contacting participant to Multiple call backs §
arrange appointment
Patient difficulty in accessing Offer transport, range of days
research clinic and times
Acute illness in participants Allow people to rearrange appointment
Participants forgetting appointment Reminder telephone call in week of
appointment
Uncertainty about participation Allow people time to think
and call back
§ at least four attempted calls per person at different times and days
cognitive problems (operationalised as normal, CIND (cognitive impairment, but not dementia),
dementia); the confidence of the GP in this opinion on a 10cm visual analogue scale; the rationale
of the GP in forming their clinical judgement. The referral form reminded the GP about the local
guidelines for investigating possible dementia, but the GP was not required to arrange any tests
exclusively for the research study. GPs were encouraged to try to continue with their routine clinical
practice and not let referral to the study influence their decisions; for instance GPs were not prevented
from referring people to the NHS memory service simultaneously or subsequently to the person
attending the research study.
3.3 Administrative arrangements
GPs were asked to send referrals to the research study team by secure nhs.net email, which is approved
for patient identifiable communication within the NHS. The nhs.net email account was reviewed
regularly to identify new referrals and issues relating to existing referrals. The study administration
team followed a standard operating procedure (SOP) to review the referral form and contact potential
participants. If there was any missing information on the referral form then the GP practice was sent
a template letter which identified and requested the missing information, and the referral was added
to a tracking sheet for follow-up. Missing data was followed up with at least three contacts to the
practice for all referrals, regardless of whether the person was subsequently recruited to the study.
If there were no contact details for the referred person then the practice was asked to supply these
urgently. When contact details were provided the referred person was contacted on at least three
occasions on at least two different parts of the day. If no contact had been made within a week of the
referral the GP practice was advised that it had not been possible to contact the person.
The study administration team were given a SOP and script for the initial conversation with the
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Table 3.4: Codes to trigger study prompt
Code Clinical term
2841 Confused
1B1A-2 Memory loss symptom
1B1A-3 Memory disturbance
1B1A1 Short term memory loss
2841-1 Confusion
28E Cognitive decline
28E0 Mild cognitive impairment
28E3 Cognitive impairment
311B Cognitive assessment
38C15 Initial memory assessment
3A-1 Memory assessment
E030-2 Toxic confusional state
E042 Chronic confusional state
E2A10 Mild memory disturbance





R009-1 [D] Senile confusion
the clinical term may have more than one code
person about the study. This confirmed the details of the referred person (name, date of birth, address)
and then confirmed their eligibility for the study. When the referred person had been confirmed to
be eligible for the study, details of the study were provided and the administration team discussed
details of options for appointments. Consent forms and patient information leaflets were sent to
participants prior to their attendance at the clinic. The administration team offered to book transport
or translation services for people, and provided the study email address and mobile phone details. A
time was agreed for a reminder telephone call three days before the appointment.
The initial conversation SOP also provided details on the action to take if the referred person
reported information that implied that they were not eligible for the study. The administration team
were instructed to only resolve someone as ineligible if the statement could be confirmed, with
consent, from a second party (e.g. the referral form, a spouse, or relative). For instance, if the person
claimed to have no problem with their memory this was was not taken at face value and the person
was only judged to be ineligible if this was verified by either the referral form or a second person.
If the person wanted more time to decide whether to take part then a follow up telephone call was
scheduled with the administrative team.
A set of SOP were provided in addition to the SOP for the initial telephone call. The SOP are
provided in full in the Appendices. Administrative SOP before the research clinic appointment
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are provided in Appendix B. These included how to deal with missing information in the referral
form, how to book a research clinic, template emails and correspondence for arranging transport
and communicating with GP surgeries, how to deal with issues regarding appointments, how to
address the matter of there being apparently no cognitive concerns, and how to handle a cancelled
appointment. SOP for use on the day of the research clinic are provided in Appendix C, these address
a checklist of matters to be done on the day, assessing capacity and taking consent; how to administer
the index tests; how to handle fire, safeguarding and serious adverse events; and how to deal with
participant withdrawal. SOP for after the research clinic appointment are provided in Appendix D,
these cover how to deal with requests for a copy of the notes taken at the research clinic and how to
scan the case report forms securely.
3.3.1 Ethical approval
The empirical research received a favourable ethical opinion from the National Research Ethics
Service Committee London - Bromley (reference 14/LO/2025) on 26 November 2014. An amendment,
which allowed for the qualitative interviews to take place, received a favourable opinion on 04 May
2015.
NHS Research and development approvals were granted by Avon Primary Care research Collab-
oration on behalf of Bristol, North Somerset, and South Gloucestershire Clinical Commissioning
groups. Staff employed by the West of England Clinical Research Network had honorary NHS con-
tracts and all other researchers (including the author and the specialists) accessing NHS data and
patients had a substantive contract directly with the NHS for a clinical role. The University of Bristol
was the Sponsor for the study and indemnified the empirical work.
3.4 Test methods
Each participant underwent a set of index tests (Section 3.4.1) and a specialist assessment (Section
3.4.2) on the same day, at the same appointment. Staff from the Clinical Research Network visited
each practice six months after the research clinic to take an extract of the medical records prior and
subsequent to the research clinic and this is described in Section 3.4.3.
At the research clinic two examiners undertook a separate blinded evaluation of each participant,
one who performed the index test battery, and one who performed the specialist assessment. The
examiners were not aware of any information about the participants other than that which was
elicited during the assessment. Neither examiner was aware of the referring GPs opinion on the
participants cognitive status, and furthermore the index test examiner was not aware of the details of
the clinical history (symptoms, duration, who had reported problems) because these were not elicited
in the encounter. Efforts were made to put participants at ease on their arrival at the research clinic.
Signs were displayed prominently at the research site to indicate where the clinic was happening,
and GP reception staff were briefed by the practice manager and by researchers. Participants were
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welcomed as soon as possible after their arrival by the research team, and taken to the rooms that
the research clinic was operating from. The researcher assessed the capacity of each participant
by asking them their reason for coming to the practice, and checking that they were willing to be
there. Once participants had been determined to have capacity they were offered the opportunity to
discuss the study, and then asked to sign a form to record their consent to participate. Participants
were randomly assigned to receive the index test battery first or the specialist assessment first, and
were offered refreshments in an interval between the two assessments.
Participants received a short debrief at the end of the research clinic where they were advised to
contact their GP in a few weeks to discuss the next steps but not informed of any diagnosis. There
were two reasons for this, firstly there were concerns that test results that would influence a diagnosis
would not be available at the research clinic due to delays in the clinical pathway or difficulties with
information governance. Indeed, tests were uniformly not available to the specialist at the research
clinic so that the specialist was blinded to investigation results, forcing them to make a decision on the
basis of their clinical judgement. Secondly it was agreed with the host clinical commissioning groups
that contractual requirements (Section 3.2.1) required the general practitioner to make and convey
the diagnosis, accounting for the clinical judgement of the specialist assessment and diagnostic tests.
If the research team identified any safeguarding concerns the participants were advised to discuss
these the same day with the referring GP practice.
3.4.1 Index tests
Tests for the index test assessment were identified after a review of the literature and a guide for
clinicians regarding tests that could be used in the evaluation of possible cognitive disorder [317].
Tests were selected for the index test battery on the basis of the following criteria:
1. Available to use for free – i.e. not copyright (therefore mini mental state examination [156]
excluded);
2. Previously evaluated in a primary care setting in at least one study;
3. Not been evaluated in primary care before but conceptually of interest (e.g. Sniffin’ sticks);
4. Good diagnostic accuracy, determined as Youden index [149] of greater than 0.75, or a sensitivity
or specificity of greater than 0.85 at the optimal reported threshold;
5. The diagnostic accuracy was weighed with the burden and time needed to complete the test,
with brief tests with high PPV being preferred.
Table 3.5 shows the tests that were selected for inclusion in the index assessment. A range of cognitive
domains were examined. Where possible, items were not repeated, e.g. the 6CIT and the GPCOG both
require the recall of a 5-item name and address, and to avoid burdening and potentially confusing
participants this item was done once and then scored separately for each test.
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Table 3.5: Tests in the index battery
Index test Items
Abbreviation §
Memory alteration test [318] 40 items
MAT Encoding; Immediate Recall; Orientation;
Semantic memory; Free and cued recall
Eurotest [319] 11 items
Knowledge; Calculation; Verbal fluency;
Delayed recall
Phototest [320] 14 items
Name pictured items; Verbal fluency;
Free and cued recall
Scenery Picture Memory Test [321] 23 items
SPMT Free recall of 23 items in a picture;
Cued recall of 3 items
Six Item Cognitive Impairment Test [258] 6 items
6CIT Orientation; Delayed recall
General Practitioner Assessment of Cognition [301] 5 items
GPCOG Orientation; Mark hands and time on clock;
Free recall; Informant section
Mini-Cog [293] 2 items
Clock draw and recall
Time and change (TAC) [322] 2 items
TAC Telling time on a printed clock;
Making change from coins
Timed up-and-go [323] 3 trials
TAC Stand, walk 3 meters, turn and sit down
Extra pyramidal signs scale [324] 7 items
EPSS Standardised evaluation for extra pyramidal signs
Sniffin’ sticks [325, 326] 12 items
Identify a smell in a standardised pen
from a choice of 4
Pfeffer FAQ [327] 10 items
FAQ Informant reported status of
instrumental ADLs †
Lawton IADL [328] 8 items
IADL Informant reported status of
instrumental ADLs †
Katz ADL [329] 6 items
ADL Informant reported status of
independence in ADLs †
AD8 [299] 8 items
Informant report of symptoms over last
"several years"
IQCODE ‡ short version [304] 15 items
Informant report of symptoms over last
10 years
§ Abbreviation, where appropriate
† ADLs Activities of daily living
‡ IQCODE Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly
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During the process of selecting tests for inclusion in the index battery, a review was published
[330] regarding the use of cognitive tests in primary care. Compared to the tests identified by that
group the index battery did not include the memory impairment screen (MIS) [331] or the abbreviated
mental test (AMT) [332]. The MIS had all rights reserved and was therefore not eligible for the index
battery, but the index battery did include indicators which reflect similar aspects of cognitive testing.
Under evaluation with MIS candidates are asked to read from a list of four words, then engaged in a
distractor activity, and then scored on free and cued recall; in comparison when under examination
by Phototest (which was available for use under a creative commons license, and included in the
index battery) participants are asked to identify six photos, perform a distractor task, and then scored
on free and cued recall. Of the 10 items in the AMT, six were included in the index battery, whereas
age, recognition of two people, year of First World War, and name of present monarch were not
included. Arguably these four items of the AMT which were not included in the index battery are less
discriminative in people with mild impairment (age, recognition), or are culturally determined (war,
monarch).
The Montreal Cognitive Assessment (MOCA [333]) was initially not included in the index battery
as it was originally designed to diagnose or identify MCI, had been advocated for use in secondary
care [317] and had not been investigated in primary care [334]. However, the protocol was revised
in light of subsequent policy changes in 2015 that encouraged GPs to diagnose dementia in typical
situations without referring to a specialist [335] using the MOCA as the preferred instrument. The
Memory alteration test (MAT) was replaced with the MOCA because it was judged that including
both the MOCA and the MAT would be overly burdensome for participants and have little added
value. The MOCA is a 22 item test that is scored out of 30 and evaluates visuospatial skills, naming,
memory, attention, language, abstraction, delayed recall and orientation.
Sniffin sticks had to be imported on special order and so were added at a later stage so as to avoid
delaying the start of recruitment while waiting for this single test.
All index test assessments were conducted by the same examiner, the author: a male medical
doctor who had obtained Membership of the Royal College of Physicians (UK) and who was complet-
ing post-graduate training in general practice. Excluding Sniffin Sticks, the order of the index tests in
the battery was randomly assigned for each participant so as to avoid the effect of order influencing
test accuracy, results of the randomisation process are provided in Appendix K. Each participant was
offered the chance to undertake every test in the battery, but the examiner was responsive to the
participants and if they appeared to be becoming tired or distressed then they were asked if they
wanted to rest or indeed skip a question. Index tests were conducted as instructed by the original
authors. The assessment was piloted to ensure it was not overly burdensome and took 25 minutes




Each specialist assessment was conducted by the same examiner: a female medical doctor who had
more than 20 years specialist expertise in the field of dementia. A standardised clinical evaluation
was done for each participant, lasting approximately an hour and comprising clinical history, the
Addenbrooke’s Cognitive Examination III (ACE3) [336], Brief Assessment Schedule Depression Cards
(BASDEC) [337] and the Bristol activities of daily living questionnaire (BADL) [338]. The specialist
did not have access to any investigation results. If the specialist judged that further investigations
and assessment were necessary to exclude a rare dementia aetiology the referring GP was advised to
consider referring the person to the NHS memory service. The specialist was asked to reach a clinical
judgement about the cognitive status of participants operationalised as normal, cognitive impair-
ment, or dementia, as well as the most likely aetiology of the dementia based on the information
available to them.
3.4.3 Follow-up
Staff from the West of England Clinical Research Network visited participating GP practices and
extracted a limited set of data from the EMIS Web medical record of consenting participants. The data
comprised consultation history, documents, and investigations, in the period six months before to six
months after the research clinic appointment. Consultation history was exported to word processing
software, electronically redacted, exported as a secure PDF, and emailed by secure nhs.net email to
University staff in a separate file for each participant. Documents and investigations that could not
be sent electronically were printed at the participating GP practice, labelled with the study identifier,
redacted of identifying information, transported to secure storage at the University of Bristol in a
locked folder, scanned onto secure University of Bristol servers, and then securely destroyed.
3.5 Reference standard
The original intention was that the reference standard would be a consensus diagnosis by three
independent consultants: a neurologist, a geriatrician, and an old age psychiatrist. Procedures were
developed so that the consultants would be able to remotely review the information from the research
clinic that had been gathered during the specialist assessment. An electronic case report form was
designed, piloted and refined to facilitate the data capture of the consensus review. Investigation
results, including laboratory tests and neuro-imaging, were to be reviewed by the consensus review
group.
Unfortunately, due to circumstances beyond the control of the investigators it was not possible
to complete the consensus review prior to writing the thesis. Therefore the reference standard was
based on the clinical opinion of the specialist clinician at the research clinic, who reached a decision
about the clinical diagnosis of dementia syndrome according to ICD-10 criteria or MCI according
to Peterson criteria [93]. The specialist clinician based their opinion on the information that was
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available to them at the clinic, as detailed in Section 3.4.2. The specialist at the research clinic was not
forced to make only one judgement about the level of impairment (normal, MCI, dementia), because
discriminating borderline cases (MCI or mild dementia; MCI or normal) is especially difficult and
the original plan had been that the specialist panel would adjudicate these cases with the benefit
of follow up information and test results. Therefore, for each participant, there were two possible
outcomes of the specialist evaluation at the research clinic with respect to the level of impairment:
1. The specialist assigned one and only one category. For these cases the process outlined in
Section 3.5.1 was followed.
2. The specialist assigned no category, or more than one category. These cases were reviewed
by a second independent specialist to allow a single impairment category to be assigned. The
review was of all information pertinent to the case, excepting index test data, as had been
originally planned, but this was done by a single specialist only rather than three. The specialist
formulated their best judgement on the basis of the available information and this was taken
as the reference standard.
3.5.1 Review of medical record extract
All available notes needed to be reviewed because the original intention was that these would be
reviewed by the specialist panel and there was the possibility that the notes review might yield
information that would contradict the specialist assessment. Therefore the intention of this process
was to establish if there any evidence in the extract of the medical records that would contradict
the impairment category assigned by the specialist evaluation, according to ICD-10 definition. The
extract of the medical records was reviewed by the investigator and discussed with advisers. The
following components were judged in advance to contradict the specialist opinion:
1. Alternative diagnosis assigned by a secondary care specialist, as an explanation for the symp-
toms,
2. Problem coded by a primary care specialist after the research clinic and adjudicated by two
research General Practitioners as explaining the symptoms,
3. Abnormal CT imaging incompatible with diagnosis (i.e. not reported as changes associated
with age, vascular damage, or typical processes associated with dementia). CT imaging findings
that were possibly incompatible with the diagnosis were discussed with a specialist.
An alternative diagnosis (item 1) was only taken as contradicting the specialist opinion if it was an
alternative disease process other than a dementia, e.g. cancer. A change to the impairment category,
whether downgrading (i.e. from MCI to normal, dementia to MCI, or indeed dementia to normal) or
upgrading (vice versa) was not accepted as contradicting the specialist opinion at the research clinic.
The reason for this is that typically the grading of cognitive impairment categories hinges critically
108
3.6. DATA COLLECTION AND MANAGEMENT
on the judgement regarding the extent to which a person with cognitive symptoms is experiencing
impairment in functioning in daily life. The view of the investigator, in discussion with advisers, was
that the specialist clinician had formulated their judgement about the level of impairment on the
basis of a detailed, systematic and structured evaluation, in the context of substantial experience and
expertise. In contrast in BNSSG at the time of the research the NHS provided a range of evaluations
for people with memory problems, including assessments by non-medical staff using the Mini-
Addenbrooke’s Cognitive Examination [339], assessments by GPs using a variety of brief cognitive
tests [340], and evaluations by specialist doctors and psychologists in old age psychiatry or neurology
clinics. Therefore there was substantial heterogeneity in the evaluation processes for people outside
of the research setting, and arguably the determinations on the category of cognitive impairment
were being made (in almost all cases) by a less expert person than at the research clinic.
The absence of items 1-3 when the medical records were reviewed was interpreted as indicating
that there was no evidence to contradict the opinion of the specialist evaluation at the research
clinic and therefore the specialist opinion at the research clinic was taken as the reference standard.
Therefore there was one reference standard, expert specialist assessment according to ICD-10 criteria,
based on two possible approaches:
1. Judgement by an expert based on the clinical assessment of a patient at a research clinic
2. For borderline cases, where it was not possible to reach a single determination about the
cognitive impairment category at the research clinic, a single expert reviewed the information
from the research clinic (excluding the index tests) together with the medical records extract
from six months before the research clinic to six months after the research clinic.
3.6 Data collection and management
3.6.1 Research clinic locations
Research clinics were held at one of three participating GP practices: Clevedon (L81040), Hanham
(L81079) or Shirehampton (L81008). Research clinic sites were chosen on the basis of accessibility to
patients in recruiting practices across the Clinical Research Network, in practices that had adequate
capacity of rooms for the clinic. Additionally a one-off research clinic was held at Frampton Cotterell
(L81014) because this study site only agreed to participate on the basis that a research clinic would
be held at that site. Figure 3.1 plots the location of the recruiting GP surgeries and the research clinic
locations.
3.6.2 Case report form
A case report form was used to collect and record the data for each participant. The case report form
was subject to four revisions because of changes to the set of index tests that were used during the
course of the study. The revisions are described in Appendix E.
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Figure 3.1: Map of recruiting sites and research clinics [341]
Legend    
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Recruiting sites: Clevedon (West), Shirehampton (Central), Hanham (East)
3.6.3 Data management
Study data were electronically entered and managed using REDCap (Research Electronic Data
Capture [342, 343]) hosted at the University of Bristol. REDCap is a secure, web-based software
platform designed to support data capture for research studies, providing 1) an intuitive interface
for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3)
automated export procedures for seamless data downloads to common statistical packages; and
4) procedures for data integration and interoperability with external sources. The electronic data
capture form was initially tested on a mock case report form and then refined. The revisions are
described in Appendix E.
Data were entered by four different data coders. Each coder was individually trained by the
investigator with the session covering how to use REDCap and how to enter data; coders were
encouraged to ask any questions and to ask the investigator how data should be handled on a case-
by-case basis if they were unsure. All coders completed a test case report form which was checked,
verified and discussed with the investigator before the coder entered real data. The number of cases
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entered by each coder was determined by the duration of time that they were able to be committed
and employed to enter study data. Table 3.6 shows that the number of cases entered by each coder
ranged from 19 to 108.
Data were exported from REDCap, imported to Stata version 13 [215] and then tabulated and
plotted to verify the quality of data entry. When data items were identified as missing or implausible
the original case report forms were reviewed and values checked and re-entered in the REDCap
database. To further quality assure the data entry process a 10% random sample of each case entered
by a coder was selected for duplicate data entry. RStudio [344] was used to randomly select 10% of
cases coded by each coder.
Table 3.6: Errors in coded cases, by coder
Coder Coded cases (n) Cases reviewed (n) Number of coded items Number of errors (%)
A 108 11 5423 5 (0.09%)
B 60 6 2958 1 (0.03%)
C 54 6 2886 7 (0.02%)
D 19 2 986 0 (0.00%)
Total 241 25 12,253 13 (0.11%)
For each of the cases that were selected for review, the original case report form was reviewed
against the REDCap entry, data were manually checked and when incorrect, corrected and enumer-
ated. The total case report form comprised 478 items (version 1), 479 items (version 2) and 493 items
(version 3). Table 3.6 shows the number of items coded and number of errors by each coder in the
10% random sample.
3.7 Statistical methods
3.7.1 Characteristics of participants
Data were exported from REDCap to Stata and cleaned. Details on recruitment were tabulated by
practice and list size. A summary was plotted by practice of people who were referred to the study by
GPs and who participated, or who were ineligible, declined to participate, or were uncontactable.
Characteristics of participants including age, sex, duration of symptoms, education, symptom pat-
tern, and ACE3 score were tabulated by cognitive status according to the reference standard. Known
characteristics of people who declined were tabulated against those who participated. Separate logis-
tic regression analyses were used with declined as the dependent variable and GP judgement, age (in
years), and female sex as the independent variables to test the hypothesis of no association between
these variables. Time from referral to appointment was described using median and interquartile
range, and logistic regression was used to test the hypothesis of no association between time to
appointment (in days) and dementia (as the dependent variable).
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Separate linear regression analyses were used with cognition in categories (normal, MCI, demen-
tia, other) as the independent variable and the dependent variables: age at clinic in years, total ACE3
score, ACE3 sub-domain scores (for attention, memory, fluency, language, and visuospatial domains)
to test the hypothesis of no association between these variables. Total ACE3 score was plotted using
box plots over the GP judgement, to illustrate the range of scores in each group, and compared to four
exemplar tests, MOCA, AD8, Minicog and IQCODE (which were chosen because Cochrane reviews
have been done on these tests). Standardised scores on each of the five ACE3 sub-domains were
plotted using box plots over the cognitive categories, to explore the profile of performance between
different groups and to illustrate the range of scores in each ACE3 sub-domain.
3.7.2 Characteristics of tests
The index tests were evaluated at the threshold indicated below, where •• indicates the threshold for
dementia:
Clinician or informant completed Physical tests Multi-domain tests Brief tests
GP judgement •• dementia EPSS ••>1 [345] Eurotest ••<21 [319] TAC ••<2 [322]
FAQ ••>2 [346] TUG ••>15 [255] MAT ••<28 [318] SPMT ••<10
ADL ••>1 [347] Sniffin Sticks ••<11 MOCA ••<26 [333] [321]
IADL ••<5 [347] [348] GPCOG § Phototest ••<27
AD8 ••>1 [349] 6CIT ••>7 [258] [320]
IQCODE ••>3.3 [350] Minicog ••<3
[293]
§ For GPCOG a two stage approach to scoring is used whereby scores >8 indicate normal and <5
indicate abnormal and scores 5-8 indicate GPCOGi needed, where scores <4 indicate abnormal [301].
All of the thresholds were pre-specified.
Characteristics of the index tests were tabulated by cognitive category according to the reference
standard, with mean test scores and test duration compared to normal (with 95% 95% confidence
intervals). Separate linear regression analyses with the number of tests that were declined by par-
ticipants as the dependent variable were used to test the null hypothesis of no association between
declined tests and the independent variables cognition (in categories: normal, MCI, dementia, other)
and physical frailty (using TUG). Because the number of people who declined tests was small, logistic
regression analyses with declined tests (none, ∏ 1) as the dependent variable and the independent
variables cognition and physical frailty were also used.
Duration of each index test was summarised and tabulated, and plotted using box plots. Linear
regression was used to explore the association between test duration as the dependent variable and
cognition in categories as the independent variable to test the null hypothesis of no association
between cognition and test duration. Some people may take much longer to complete tests than
others, and operationally in practice it is important to know what length of appointment is needed
for a person who is booked to take a test. Therefore average test duration was judged of less relevance
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to clinicians and patients than the 95th centile of duration (C95), the time that 95% of participants
completed the test within. On this basis the tests were classified as follows; short tests (<5 minutes -
or half of a typical GP consultation), medium tests (∏ 5 minutes but ∑ 10 minutes), and longer tests
(> 10 minutes).
3.7.3 Informant tests
Five tests which asked questions of the informant of the person with cognitive problems were
completed both as standalone index tests both by independent completion of a paper questionnaire
and then by interview (by the GP researcher). These five tests were Functional Activities Questionnaire
(FAQ [327]), Lawton instrumental activities of daily living scale (IADL [328]), Katz index of activities
of daily living (ADL [329]), Galvin AD8 Dementia Screening Interview (AD8 [299]), and Short Form of
the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE [304]). Weighted kappa
was used to judge agreement between the different approaches to completing these five index
tests. Weighted kappa was used to account for the fact that (for instance) a disagreement between
categories 0 and 1 is less than the disagreement between categories 0 and 12. Weighted kappa was
calculated for the whole instrument rather than individual items on the instrument because only
the instrument as a whole would be used for diagnostic accuracy. The summary diagnostic accuracy
of the informant measures was assessed using the DOR, and ROC curves were plotted to compare
the accuracy of measures when completed by independent completion against those completed by
interview.
3.7.4 Single test accuracy
For each of 17 index tests, scores were dichotomised at previously reported thresholds (Section 3.7.2),
so that the results were either test positive or negative. For GP clinical judgement the threshold for the
target condition dementia was a judgement of "dementia", whereas for the target condition normal
the threshold was a judgement of not normal, including people GPs judged as having dementia and
CIND (Section 3.2.4).
Measures of test accuracy are discussed in detail in Section 1.1.2.3. Accuracy (referred to hereafter
as classification accuracy for clarity), defined as T P+T NT P+T N+F P+F N is dependent on prevalence of the
disease. However, despite the association of classification accuracy with prevalence, when comparing
tests under constant prevalence, as in this empirical study, relative classification accuracy of tests is
of some relevance to patients and clinicians to the extent that it indicates the probability that a person
will be correctly classified when that single test is used for diagnosis. This is of some importance
clinically because in a low prevalence setting it is possible that a test could have perfect sensitivity but
low classification accuracy, with a large proportion of people mis-classified and potentially needing
unnecessary further testing. Classification accuracy was calculated for each index test.
Diagnostic accuracy of each single test was calculated using standard measures: sensitivity,
specificity, PPV, NPV, LRP, LRN and DOR. The number of TP, TN, FP, and FN was plotted using
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natural frequencies. Calibration and discrimination for the single tests were not considered, both
because it would be usual for single tests to be done in isolation in clinical practice and also because
when using each single test at the pre-specified threshold the test could take only two values (positive
or negative).
3.7.4.1 Decision curve analysis and net benefit
Decision curve analysis [167] was used to show the net benefit of each index test at varying threshold
probabilities. Net benefit is calculated as
(3.1) Net Benefit = (sensi t i vi t y £pr evalence)° [(1° speci f i ci t y)£pr evalence £w]
Where w is the odds at the threshold probability.
With an index test that takes values indicating the predicted probability of disease p̂, pt is the
threshold probability, and sensitivity and specificity at a given threshold are calculated by defining
test positive as p̂ > pt [351]. The threshold probability pt indicates the preferred management
approach for the clinician when dealing with a patient, a higher pt indicates a stronger preference
for avoiding unnecessary interventions. At a threshold probability of 80% (1:4 odds) the clinician is of
the opinion that treating a well person as having dementia is four times as bad as missing a case. At a
threshold probability of 10% (9:1 odds) the clinician is of the view that missing a case of dementia
is nine times as bad as intervening in someone who doesn’t have dementia [351]. Net benefit is
expressed in units of true positives, typically does not consider confidence intervals, and there is no
minimum specified difference in net benefit required to identify the optimal strategy [351]. Decision
curves are plotted with a treat all line which indicates the net benefit of treating everybody as disease
positive, and a treat none line which conversely indicates the net benefit of treating nobody.
Figure 3.2 shows an example decision curve for MMSE based on data from a systematic review
[157]. Curves are plotted for the net benefit of MMSE for the target condition dementia, at test
thresholds (referred to in this paragraph as "cut-points") of 17 (sensitivity 70.1% specificity 92.9%)
and 24 (sensitivity 100% specificity 45.9%) indicating normal; 77 of 360 in the data-set had dementia
(prevalence 21.39%). The treat none line and the treat all line are also plotted. The figure shows that
at threshold probabilities of up to 15% the MMSE at a cut-point of 24 has the greatest net benefit. In
contrast, the MMSE at a cut-point of 17 has greatest net benefit at threshold probabilities of 15% to
73%, and at threshold probabilities above 73% the treat none approach has the greatest net benefit.
Recall Equation 3.1. At a threshold probability of 30%, MMSE at a cut-point of 17 has a net benefit of





= 0.126024 º 0.13, meaning that there are 13 true positives for every 100 patients in the target
population. In contrast MMSE at a cut-point of 24 has a net-benefit of







= 0.0316371. º 0.03, meaning that there are 3 true positives for every 100 patients in the target
population.






















The curves plot the net benefit across a range of thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
Based on data from a systematic review [157]
In decision curve analysis harm can be quantified as the reciprocal of "the number of tests that
would be done to identify one true case, assuming the test is perfect" [351, 352]. All of the evaluated
index tests are relatively simple tests (mostly pen-and-paper), and are not invasive. However, there
may be harm from the time spent completing the test, and this is also the main determinant of the
test cost. Therefore harm for each test was derived from the number of tests per hour, based on the
median test duration:
(3.4) har m = 160
median test duration
Therefore harm is less when the test duration is less. To continue the example in Figure 3.2, MMSE is
said to take five minutes for someone with normal cognition and seven minutes for someone with
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dementia [157], so the harm can be calculated 2:
(3.5) harm for MMSE = 160
7
Therefore harm for MMSE = 0.117, which is the reciprocal of the number of people tested per hour.
Figure 3.2 shows that the harm adjusted net benefit curves for MMSE are parallel to the curves
without adjustment for harm, and are 0.117 TP lower at each threshold.
For informant completed tests and GP judgement the harm was zero because these tests would
not take any additional time in an additional consultation; GP judgement would be reached after the
end of an index consultation and an informant completed test could be given to the informant to
take away and return. Minicog was derived from items on GPCOG and so no time was available, so
time was estimated from the time taken to complete GPCOG.
Decision curves were plotted for each of the individual index tests, for both target conditions,
both with harm = 0 (naïve curves) and harm quantified as in Equation 3.5 (harm-adjusted curves).
Curves for the single tests were plotted on the same axis as the test in combination with GP judgement
(see Section 3.7.5.1) to facilitate interpretation, because it would be typical in clinical practice for
the index tests to be done in combination with GP judgement; the plots are provided in Appendix H.
A plot of naïve curves for each of the index tests combined with GP judgement, on a single axis, is
provided in Section 4.6, and a separate axis shows all harm-adjusted curves.
As detailed in Section 1.1.3.2, decisions about treatment are based on probabilities which are
derived from the ratio of the costs and benefits. At the present time, given the absence of a disease
modifying treatment, especially in an older adult with multi-morbidity, the threshold for diagnosis
of dementia may be relatively high, because false positives are arguably more harmful than false
negatives. In contrast the threshold probability for normal cognition in someone with cognitive
symptoms may be lower than the threshold probability for dementia, because interventions to aid
cognition and independence are arguably of benefit regardless of whether cognition is normal or
impaired. Therefore to facilitate interpretation, the plot of multiple index tests in Section 4.6 is shown
only for threshold probabilities above 80% for the target condition dementia and above 60% for the
target condition normal.
2in a sample of 240 people of whom 55% have dementia the median test time for MMSE would be seven minutes
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3.7.5 Index tests in combination
3.7.5.1 Two test combination: GP combined tests
The accuracy of each index test in combination with GP clinical judgement was evaluated (termed GP
combined tests). This approach was taken because in clinical practice GP clinical judgement would
likely be formulated before any other tests took place. Based on clinical experience and reports of GP
diagnosis of dementia in practice which indicated that up to four consultations were used to make
the diagnosis [340], it was judged probable that a GP would use an initial encounter to formulate a
clinical judgement about the cognition and then use subsequent encounters to conduct further tests
based on their clinical judgement.
Logistic regression equation Logistic regression analyses were used to evaluate the accuracy of
each index test in combination with GP clinical judgement (the GP combined tests) for the diagnosis
of the two target conditions: dementia or normal. The dependent variable was the target condition
(either dementia or normal, taking values: 0=target condition not present, 1=target condition present).
The independent variables were GP clinical judgement and one of the other index tests listed in
Section 3.7.2. GP clinical judgement was represented by the variable gpd and gpn respectively
indicating a GP judgement of dementia or normal, and taking values 0 (test negative) or 1 (test
positive). Similarly, for the other index tests the possible values were 0=test target condition not
present, 1=test target condition present. The logistic regression equation took the form (for example)
logistic dementia gpd moca. The predict command was used to predict the probability of the
target condition based on the results of the logistic regression equation in the estimation sample.
For each GP combined test, predicted probabilities took one of up to four categories of probability,
because there were up to four permutations of values for the independent variables in the logistic
regression equations (0|0; 0|1; 1|0; 1|1). The diagt command was used to calculate the diagnostic
accuracy. Diagt collapsed the categories of predicted probabilities of disease into two categories,
the highest predicted based on the logistic regression equation which defined test positives, and the
other categories.
Evaluation of GP combined tests Standard measures of diagnostic accuracy (sensitivity, specificity,
likelihood ratios, and predictive values) were calculated for the GP combined tests, together with
95% confidence intervals. As described in Section 3.7.4.1, decision curves were plotted for all tests,
both as single tests and as GP combined tests, for both target conditions, both with harm = 0 (naïve
curves) and harm quantified as in Equation 3.5 (harm-adjusted curves); these plots are provided in
Appendix H.
The discrimination of the GP combined tests compared to the single test was assessed using
visual inspections of ROC curves plotted using roccomp. Calibration for GP combined tests was
assessed by using pmcalplot to plot observed probabilities of dementia based on the reference
standard, against the predicted probabilities (based on paragraph logistic regression equation above).
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The individual plots of calibration and discrimination are provided in Appendix I. GP combined tests
were judged to have good discrimination if the AUROC was ∏ 0.75; calibration was assessed by visual
inspection [353].
From the GP combined tests that were judged to have good discrimination and calibration
four decision curves were plotted on the same axis, two patient-completed (t pA and t pB) and two
informant-completed (t iA and t iB) combined tests, selected on the basis of the highest LRP for
the GP combined test. LRP was used as the indicator of diagnostic accuracy because an aim of the
thesis was to identify if a combination of tests can have a high positive predictive value for identifying
people with dementia and LRP determines the the informative value of a positive test result [148].
Patient- or informant- completion was considered because in clinical practice it would be preferable
to have objective evidence of both impaired cognitive function and of concern from a knowledgeable
informant (see definitions in Section 1.1.1.1).
The analysis of tests using decision curves on the same axis was limited to four (t p A and t p B;t i A
and t i B 3) for each target condition because plotting all of the possible naïve curves (let alone the
harm-adjusted curves) would have resulted in 19 lines on the plot (17 index tests, treat all, treat
none) which was judged to be a barrier to interpretation. Comparison of naïve curves rather than
harm-adjusted curves was done because (a) the pen-and-paper nature of the tests meant that other
than time there was little or no harm from any test (b) harm adjusted curves have lower net benefit
than naïve curves, making comparisons between curves difficult because tests can have negative net
benefit and therefore not be displayed on the curve, especially at higher threshold probabilities.
3.7.5.2 Three test combination: GP 360 tests
As described, for a credible clinical diagnosis it would be preferable for a combined test to include
both informant- and patient- completed measures and therefore the accuracy of three combined
tests (GP judgement and a patient-completed test and an informant-completed test) for diagnosing
both target conditions was analysed. For each target condition, the four GP combined tests (t p A and
t p B; t i A and t i B) with the highest LRP were also evaluated as a combination of three tests (termed
GP 360 test, as in a 360°evaluation).
The results of the logistic regression equation for three tests in combination resulted in eight
categories: (+|+|+; +|+|-; +|-|+; -|+|+; -|-|+; +|-|-; -|+|-; -|-|-). For each GP 360 test discrimination and
calibration were assessed as previously. For the target condition dementia the GP 360 test was di-
chotomised at a 80% predicted probability of dementia, and for normal as the target condition
the four GP 360 tests were dichotomised at a 60% predicted probability of normal (Section 3.7.4.1).
Discrimination of both the dichotomised and eight-category GP 360 tests are presented on the same
axis in the Results Chapter. Calibration plots are presented in Appendix I. For both the dichotomised
tests, and the continuous probabilities from the logistic regression equation measures of diagnostic
3two patient-completed (t p A, t p B) and two informant-completed (t i A, t iB) GP combined tests, selected on the basis
of the highest LRP for the GP combined test
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accuracy were calculated using diagt, which as described in paragraph logistic regression equation
dichotomised the continuous probabilities so that the group with the highest predicted probability
was taken to indicate test positive. Sensitivity, specificity, likelihood ratios, and predictive values were
calculated, together with 95% confidence intervals. For each target condition four naïve decision
curves were plotted on the same axis for each of the four possible GP 360 tests (t p A|t i A, t p A|t i B,
t p B|t i A, t p B|t i B), both dichotomised and continuous. The predicted classification of people accord-
ing to each of the four GP 360 tests was tabulated using natural frequencies. For each target condition
the optimal GP 360 test was identified.
3.7.6 Sensitivity analysis
Sensitivity analyses are detailed in Sections below. Sensitivity analyses were not done to investigate
whether diagnostic accuracy for the single tests varied with age and sex because it would be typical
in clinical practice to combine the index tests with GP clinical judgement. Sensitivity analyses were
not done on GP 360 tests because it was judged this analysis would be under-powered. Sensitivity
analysis on the order effect of tests within the battery, and the order of index test assessment and
specialist evaluation, were not done because these factors were randomised. Sensitivity analyses
exploring the accuracy of individual tests at different thresholds were not done because of the risk of
chance findings due to multiple analyses.
3.7.6.1 Continuous test scores
In clinical practice clinicians typically categorise continuous test scores as either test positive or
negative (Section 1.1.2.4). However, this dichotomisation results in a loss of data and when combining
tests may attenuate the diagnostic accuracy. Diagnostic accuracy was calculated for the GP com-
bined tests when using the component patient-completed and informant-completed index tests as
continuous scores, for each target condition. The predicted probabilities of the target condition from
the logistic regression were used to calculate diagnostic accuracy, as described in paragraph logistic
regression equation above. The predicted probabilities were dichotomised at a threshold of 80% for
dementia and 60% for normal (see Section 3.7.4.1 for rationale for these thresholds), to facilitate
comparisons between the main analysis and the sensitivity analysis, with predicted probabilities
above this indicating test positive and probabilities below this indicating test negative for the target
condition. This was done because the diagt command dichotomises the test at the highest predicted
probability of the target condition, which would vary between the categorical and continuous index
tests, and thus artificially impact diagnostic accuracy.
3.7.6.2 Age and sex
Sensitivity analyses were also done to investigate whether diagnostic accuracy for the GP combined
tests varied with age and sex. Age was dichotomised as age < 80 years or age ∏ 80 years because there
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is evidence that predictors vary in performance in these groups [90]. Logistic regression was done
restricted to each group (Men | Women; Age < 80 years | Age ∏ 80 years) and used to generate predicted
probabilities of the target condition. The predicted probabilities were dichotomised at a threshold of
80% for dementia and 60% for normal. The diagt command could not be used to calculate diagnostic
accuracy because of small numbers in the analysis, and so the estat classification command
was used to generate the sensitivity and specificity directly from the results of the logistic regression
equation, and confidence intervals were then calculated by extracting the values of the regression
coefficients and classification table, calculating the test positive/negatives and the total tested, and
then using cii proportions to calculate the confidence interval for a proportion, for each of the 17
GP combined tests, for each target condition.
For heterogeneity by age and sex, the proportion in each group (Men | Women; Age < 80 years |
Age ∏ 80 years) with dementia, MCI and normal cognition was calculated, along with the mean age,
ACE3 score and school leaving age. Linear regression was used to investigate an association between
the independent variable (age | sex) and the dependent variables ACE3 score and school leaving age.
3.7.6.3 Combining tests
Further sensitivity analyses were done to explore the diagnostic accuracy when each of the 12 GP
combined patient-completed index tests were combined with each of the five informant completed
tests, for each target condition. The estat classification procedure described in the above
paragraph was used to calculate the diagnostic accuracy for each of the 60 combinations (12 £ 5) for
each target condition.
3.7.6.4 Geography
A final sensitivity analysis investigated heterogeneity in GP judgement by setting, with two groups
Bristol (which had the diagnosis scheme, see Section 3.2.2), and South Gloucestershire/North Somer-
set which did not. The proportion of people with dementia according to the reference standard was
also calculated for Bristol and South Gloucestershire/North Somerset.
3.7.7 Sample size
Standard tables [354] were used to calculate that a minimum sample size of 200 was needed for a
95% confidence interval lower bound of 80%, based on a specificity of 95%, based on prior studies
[255, 273] and a 75% proportion of people with dementia in a population of people with cognitive
complaints, based on data from Bristol memory clinic data prior to July 2013; this allowed evaluation
of between 30-45 diagnostic indicators, based on the five events per variable rule [355].
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3.8 Risk of bias
Figure 3.3 shows the appraisal of the risk of bias in the described work using the QUADAS-2 tool [199].
QUADAS-2 is a tool to judge the risk of bias in diagnostic test accuracy studies and comprises four
domains, each with signalling questions to assess the risk of bias. QUADAS-2 is summarised as:
1. Patient selection: Was a consecutive or random series of patients enrolled? Was a case control
design avoided? Did the study avoid inappropriate exclusions?
2. Index test: Were the index test results interpreted without knowledge of the results of the
reference standard? If a threshold was used, was it pre-specified?
3. Reference standard: Is the reference standard likely to correctly classify the target condition?
Were the reference standard results interpreted without knowledge of the results of the index
test?
4. Flow and timing: Was there an appropriate interval between index test(s) and reference stan-
dard? Did all patients receive a reference standard? Did all patients receive the same reference
standard? Were all patients included in the analysis?
The first three domains also consider concerns about applicability of the study to the review question,
which is less relevant for this assessment of risk of bias but is relevant to the applicability of the
findings to clinical practice.
Figure 3.3: Risk of bias in this study using the QUADAS-2 [199] tool
Overall in this study all four domains were judged to be at low risk of bias. Patient selection was
judged to be at low risk of bias because a consecutive sample of patients was enrolled (the impact of
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GP referral bias is discussed in Chapter 6), and a case control design and inappropriate exclusions
were avoided. The index test domain was judged to be at low risk of bias because the results were
interpreted independently of the reference standard, and pre-specified thresholds were used. The
reference standard was judged at low risk of bias because it was likely to correctly classify the target
condition and it was interpreted without knowledge of the index test. The flow and timing was
judged at low risk of bias because there was an appropriate interval between index test and reference
standard (done same day), ICD-10 and Peterson MCI definitions were used consistently and applied
by a specialist, and all patients were included in the analysis.
3.8.1 Differences to protocol
A study protocol was published [356]. The methods in this Chapter differ to the methods in the
published protocol in two aspects. Firstly, it was not possible to ascertain the diagnosis according to
different reference standards within the time limits of the thesis due to difficulties with the consensus
panel. Secondly, multiple imputation was not used in the analysis because the missing data were
judged to violate the missing at random assumption.
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Chapter Summary
This Chapter has presented the methods for the empirical quantitative investigation of diag-
nostic test accuracy. The target conditions for evaluating diagnostic accuracy were dementia of
any aetiology, and normal. Participants were people aged at least 70 years with symptoms of
dementia, who had been referred by their GP to a research study conducted in general practices.
Participants were recruited from 21 practices with a total population of 249,556, of whom 34,956
were aged at least 70 years.
Referring GPs were asked to provide their clinical judgement about the extent of cognitive
problems on a referral form which was sent to a secure nhs.net email account. Electronic
prompts were used at the point of care to facilitate referral of a consecutive series of patients.
Standard procedures were used by research staff to process referrals, contact potential partici-
pants, confirm eligibility, and arrange appointments and transport.
At the research clinic two examiners undertook a separate blinded examination on each
participant. All index test evaluations were conducted by one physician, and all reference test
evaluations were conducted by a second physician. The reference standard for dementia was
expert specialist assessment according to ICD-10 criteria and Peterson criteria [93] for MCI.
Medical records were reviewed for the period six months before and after the research clinic.
Characteristics of participants and tests were summarised using plots and regression analy-
ses. Accuracy of tests was investigated as single tests, in combination with GP judgement (GP
combined tests) and as a combination of GP judgement, informant-completed and patient-
completed tests (GP 360 tests). Performance of tests was evaluated using measures of discrimi-













his Chapter covers the results of the quantitative diagnostic accuracy study. Firstly details of
ascertainment and missing data are provided. Secondly, the characteristics of participants
are described, with respect to age, sex, and cognitive status. Thirdly the characteristics of
the index tests are described regarding how the scores and duration were associated with cognition.
Fourthly the target conditions are described, the prevalence of the target conditions reported, and
GP judgement cross tabulated against the reference standard. Fifthly the informant measures are
described, weighted kappa is reported for the informant completed and interview completed tests,
and ROC curves of the paired informant tests are plotted. In the sixth Section diagnostic accuracy
is reported for both target conditions, firstly classification accuracy is reported, then diagnostic
accuracy of single tests is provided, and the meta-analysis of GP judgement from Chapter 2 is
updated. The accuracy of index tests in combination with GP clinical judgement (GP combined tests)
is then reported for both target conditions. Next, the accuracy of GP clinical judgement, a patient
completed test, and an informant completed test is reported (GP 360 test). The optimal combination
of tests for each target condition is identified. In the seventh Section the sensitivity analyses are
reported.
4.1 Ascertainment and missing data
Table 4.1 shows the recruitment of participants by each practice, with details of the number of
people on each GP practice list in each of five age groups: 70-74 years; 75-79 years; 80-84 years; 85-89
years; 90+ years. Clevedon (L81102) had the highest overall proportion of people aged over 70 years
out of the total list size (19%), other practices with a high proportion of people aged over 70 years
were Portishead which had 18% eligible, and Backwell, Clevedon (L81040), Frampton Cotterell, and
Yate which all had 17% eligible. In contrast Redfield had only 6% eligible, Horfield 7%, Clifton 8%
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and Stoke Bishop 9%. The number of participants recruited per practice varied from two (Redfield)
to 31 (Westbury on Trym). Because sites had different set up dates (see Methods Table 3.2) naïve
comparisons of the recruitment figures for practices, such as the calculated proportion who were
recruited out of the total who were potentially eligible, are likely to be misleading. Table 4.1 also
shows the number of people who were predicted to be eligible based on the person years at risk. The
person years at risk estimate of eligible population accounts for duration of recruitment from each
practice but does not account for factors such as changes in practice list size during recruitment
due to practice mergers; and the impact of mergers and other practice business, such as change
in staffing or other contractual commitments, that may have led a recruiting practice to be fallow
(effectively non-recruiting) for a period.
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Table 4.1: Practice recruitment
Location (code)§ List size† by age group in years Predicted Predicted Recruited
70-74 75-79 80-84 85-89 90+ eligible ‡ eligible PYAR
Backwell (L81060) 925 568 473 286 126 65 88 20
Bedminster (L81053) 321 288 285 168 98 39 85 4
Clevedon (L81102) 420 338 266 180 179 50 29 7
Clevedon (L81040) 893 682 502 385 239 87 174 29
Clifton (L81081) 382 270 196 109 85 31 35 3
Close Farm (L81050) 314 204 164 82 39 21 30 11
Fishponds (L81087) 356 253 203 130 82 32 62 3
Frampton Cotterell (L81014) 823 710 534 321 165 76 89 9
Hanham (L81079) 1098 825 713 454 253 104 225 30
Henleaze (L81131) 390 341 307 267 196 59 90 4
Horfield (L81022) 437 262 199 137 98 35 73 5
Kingswood (L81063) 521 406 339 234 132 52 98 12
Long Ashton (L81056) 302 253 206 119 59 28 25 2
Mendip Vale (L81086) 1390 902 623 367 204 94 188 20
Portishead (L81004) 1193 821 585 394 242 96 112 9
Redfield (L81061) 191 138 87 63 45 16 19 2
Shirehampton (L81008) 419 318 237 159 95 38 80 6
Southmead (L81098) 296 230 205 132 88 32 41 5
Stoke Bishop (L81622) 140 97 75 34 20 10 18 4
Westbury on Trym (L81017) 434 309 254 215 163 50 103 31
Yate (L81047) 815 659 404 216 105 57 71 25
§ Location is given rather than practice name because practice names change with mergers
and change of doctors. Practice code is a unique identifier held by NHS England
† based on NHS England data for 2018 [188]
‡ based on age specific incidence per 1000 person years at risk [14], multiplied by list size.
The meta-analytic incidence of dementia per 1000 person years at risk by age group is:
9.3 (70-74 years), 17.3 (75-79 years), 32.0 (80-84 years), 57.0 (85-89 years), and 122.4 (90+years) [14]
PYAR Person years at risk
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As outlined in Methods Table 3.2 there were a total of 249,556 people on the combined GP practice
lists in April 2018 and of these 34,956 were aged at least 70 years and so were potentially eligible for
the study if they developed symptoms of dementia. The meta-analytic incidence of dementia per
1000 person years at risk by age group is: 9 (70-74 years), 17 (75-79 years), 32 (80-84 years), 57 (85-89
years), and 122 (90+years) [14] (Section 1.1.3.3). Applying these age specific incidence rates to the
study population described in Table 4.1 it follows that the potentially eligible population who might
be expected to develop symptoms based on person years at risk would be 1,735 people based on
person years at risk.
Figure 4.1 presents the STARDdem [357] participant flowchart. Of the 34,956 people aged over 70
years in the recruiting practices, 456 were referred, which is 26% (95% CI 24% to 28%) of the estimated
potentially eligible population. Of the 456 people who were referred 241 (53%; 95% CI 48% to 57%)
participated, 170 (37%; 95% CI 33% to 42%) were uncontactable or declined, and 45 (10%; 95% CI 7% to
13%) were ineligible. Figure 4.2 shows the distribution by practice of people consenting to participate,
who were referred but deemed ineligible, who were eligible but declined to participate, or who were
uncontactable. Of the 456 people who were referred, 53% (95% CI 48% to 58%) were contactable,
eligible, and consented to participate. Overall 34% (95% CI 30% to 39%) of referred people declined
to participate, ranging from 0% in Clifton and Stoke Bishop (95% CI 0% to 52%) to 60% (95% CI 26%
to 88%) in Henleaze. In contrast 10% (95% CI 7% to 13%) of referred people were ineligible; with a
number of practices referring 0% ineligible people: Henleaze (95% CI 0% to 31%), Clevedon (L81102)
(95% CI 0% to 26%), Fishponds and Redfield (95% CI 0% to 37%), Portishead (95% CI 0% to 23%), and
Yate (95% CI 0% to 10%). In contrast, of the 12 referrals from Bedminster 33% (95% CI 10% to 65%)
were of ineligible people. The sustained efforts to make contact with people were generally successful
and overall only 3% (95% CI 2% to 5%) were uncontactable.
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Figure 4.1: STARDdem flowchart





































Notes review § of 220 assigned at clinic
abnormal neuroimaging 7, none refuting diagno-
sis ¶
237 classified
Dementia † 131MCI ‡ 59Normal 47
Unclassifiable 3
two people had cognitive impairment that did
not meet Petersen [93] criteria (1 acquired trau-
matic brain injury 1 low mood); one person had
DSM–5 major neurocognitive disorder but not
ICD-10 dementia because they had frontal de-
mentia with no amnesia
§ one person, who was randomly assigned to the expert
assessment first (Section 3.4) had to withdraw part way
through the reference test as they were acutely ill
† Dementia according to ICD-10 definition
‡ MCI according to [93] § see Section 3.5
¶ One person met criteria for ICD-10 dementia and also had
features of normal pressure hydrocephalus. Expert review
endorsed a reference standard diagnosis of dementia.
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Figure 4.2: Referrals from practices
















































Declined Ineligible Consented Uncontactable
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4.2 Characteristics of participants
Table 4.2 summarises the characteristics of participants and shows that there were a total of 240
participants included in the analysis; as described in Figure 4.1 one person (a man) withdrew after
consenting due to acute illness. Also as described in Figure 4.1 three people could not be classified
on the ICD-10 reference standard, of these two people had cognitive impairment that did not meet
Petersen [93] criteria (1 acquired traumatic brain injury 1 low mood) and one person had DSM–5
major neurocognitive disorder but not ICD-10 dementia because they had frontal dementia with no
amnesia.
Table 4.3 shows the known characteristics for people who declined compared to people who
participated. There was weak evidence of an association between declining and a GP judgement
of CIND (odds ratio 1.2; 95% CI 0.55 to 2.41) or dementia (odds ratio 1.9; 95% CI 0.90 to 3.93). There
was some evidence for an association between declining and age (odds ratio per year 1.08; 95% CI
1.04 to 1.12), or female sex (odds ratio 1.88; 95% CI 1.21 to 2.92). For participants, the median time
between referral (the date of GP judgement) and the clinic appointment (reference standard) was 47
days (IQR 30 to 72 days), the longest interval was 177 days, approximately six months, which was
due to difficulties with attending earlier appointments. There was no association between time from
referral to appointment and dementia (odds ratio per day 1.0; 95% CI 0.99 to 1.01; p=0.254). All other
index tests other than GP judgement were done on the same day as the reference standard.
Of the 240 people in the analysis, there were 114 women and 126 men. Overall the median age of
participants at the research clinic was 80 years (interquartile range 75 years to 85 years). Compared
to people with normal cognition (mean age 76.5 years; s, standard deviation, 5.2 years) people with
MCI were a mean 2.9 years older (95% CI 0.8 years to 5.0 years) and people with dementia a mean 5.5
years older (95% CI 3.7 years to 7.3 years). The three people who could not be classified according
to the ICD-10 reference standard (other in Table 4.2) were a mean 3.7 years older than people with
normal cognition (95% CI -2.7 years to 10 years). School leaving age was available for 234 people who
reported a median leaving age of 15 years (interquartile range 15 years to 16 years). Age at retirement
was available for 207 people, who reported a median retirement age of 60 years (interquartile range
58 years to 65 years).
Duration of symptoms was available for 171 people, who reported a median 24 months symptoms
(interquartile range 12 to 36 months). The reported duration of symptoms was similar in people with
normal cognition, MCI, and dementia, and those classified other. Most (87%) participants reported a
gradual onset of symptoms, a similar proportion (88%) reported no fluctuation in their symptoms,
and the findings were similar regardless of cognition. In contrast, most (76%) participants reported
that their symptoms were progressive but this was reported more often by people with dementia
(84%, 95% CI 77% to 90%) than people who had MCI (69%, 95% CI 56% to 80%), or normal (62%, 95%
CI 46% to 75%) or other cognition (67%, 95% CI 9% to 99%).
Two people could not complete the ACE3 because English was not their first language, they had
both been offered an interpreter and declined. In both cases sufficient information was available
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Table 4.2: Characteristics of participants
Cognitive diagnosis §
Characteristic Dementia MCI Other Normal
n=131 n=59 n=3 n=47
Sex n (row %)
Male 67 (53) 34 (27) 2 (2) 23 (18)
Female 64 (56) 25 (22) 1 (1) 24 (21)
Age (years) Median (IQR)
At clinic 82 (77-87) 80 (75-83) 80 (79-82) 75 (72-80)
Left School 15 (15-16) 15 (15-16) 17 (15-18) 16 (15-16)
Retired 60 (58-65) 61 (59-67) 60 (56-60) 61 (58-65)
Symptom onset
Median (IQR) (months)
Time ago 24 (12-36) 18 (12-24) 24 (24-24) 21 (12-36)
Type, n (column %)
Gradual 110 (84) 54 (92) 2 (67) 43 (91)
Sudden 13 (10) 4 (7) 1 (33) 0 (-)
Uncertain 8 (6) 1 (2) 0 (-) 4 (9)
Symptom pattern n (column %)
Course
Progressive 110 (84) 41 (69) 2 (67) 29 (62)
Stepwise 2 (2) 0 (-) 0 (-) 0 (-)
Regressive 1 (1) 0 (-) 1 (33) 1 (2)
Static 5 (4) 7 (12) 0 (-) 9 (19)
Uncertain 13 (10) 11 (19) 0 (-) 8 (17)
Fluctuation
None 111 (85) 51 (86) 3 (100) 45 (96)
Within one day 12 (9) 5 (8) 0 (-) 1 (2)
Over several days 8 (6) 3 (5) 0 (-) 1 (2)
ACE3 † score Median (IQR)
Total (max 100) 69 (61-74) 82 (76-87) 90 (70-94) 93 (90-95)
Attention (max 18) 14 (11-16) 16 (15-17) 17 (15-18) 17 (16-18)
Memory (max 26) 13 (10-17) 19 (14-22) 22 (22-25) 23 (22-25)
Fluency (max 14) 7 (5-9) 9 (7-11) 10 (7-12) 11 (11-13)
Language (max 26) 22 (19-24) 24 (23-26) 25 (22-25) 26 (25-26)
Visuospatial (max 16) 12 (10-14) 14 (12-15) 16 (12-16) 16 (15-16)
GP opinion n (row %)
Normal 6 (18) 8 (24) 1 (3) 19 (56)
Cognitive impairment 51 (43) 40 (33) 2 (2) 27 (23)
Dementia 74 (86) 11 (13) 0 (-) 1 (1)
§ Dementia according to ICD-10 definition MCI according to Peterson definition
Other impairment: not normal but impairment not meeting formal criteria
Due to low mood in one case and traumatic brain injury in one case
† ACE3 Addenbrooke’s Cognitive Examination III
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Table 4.3: Comparison of people who participated and declined
Facet Participated Declined
Demographics
Male n (%) 126 (53) 47 (37)
Female n (%) 114 (47) 80 (63)
Median age (years) 80 83
IQR age (years) 75 to 84 79 to 88
GP judgement
Dementia % (95% CI) 36 (30 to 42) 48 (39 to 58)
CIND % (95% CI) 50 (44 to 56) 42 (33 to 51)
Normal % (95% CI) 14 (10 to 19) 10 (5 to 17)
IQR interquartile range
CIND cognitive impairment, but not dementia
from other parts of the assessment for a categorisation about cognition to be made (one had normal
cognition, one had dementia). For the 238 people who had an ACE3 score, the median was 75
(interquartile range 65 to 87). Compared to people with normal cognition (who scored a mean (s) 92
(5) points) people with MCI scored a mean 12 points less (95% CI 16 points less to 8 points less) on the
ACE3, and people with dementia scored a mean 26 points less (95% CI 29 points less to 22 points less).
Referring GPs judged that 34 people were normal, 86 had dementia, and 120 had cognitive
impairment, but not dementia (CIND); the one person who withdrew from the study due to acute
illness was judged by the referring GP to have CIND. People who GPs judged as having dementia
had a mean age 81.6 years (æ 5.7 years; 95% CI 80.4 years to 82.8 years) compared to people who they
judged as not having dementia (including people judged as normal and CIND) who had a mean age
79.5 years (æ 5.7 years; 95% CI 78.6 years to 80.5 years). People that GPs judged as having dementia
had a total ACE3 score IQR of 60 to 74, with a 90th centile of 81/100 and a highest score of 95/100.
Similarly, people that GPs judged as having CIND (cognitive impairment, but not dementia) had an
ACE3 score IQR 71 to 89. By way of comparison, in contrast to GP judgement, people who were test
positive on MOCA had an ACE3 score IQR of 65 to 85, people who were test positive on Minicog had
an ACE3 score IQR of 61 to 75, people who were IQCODE test positive had an ACE3 score IQR of 65 to
82, and people who were test positive on AD8 had an ACE3 score IQR of 65 to 83.
As shown in Table 4.4, in the attention sub domain of ACE3 (max score 18) people with normal
cognition scored a mean of 17 points, and people with dementia scored 4 points less (95% CI 3 points
less to 5 points less). In the memory sub domain (max score 26) people with normal cognition scored
a mean of 23, people with MCI scored 5 points less (95% CI 4 points less to 7 points less) and people
with dementia scored 10 points less (95% CI 9 points less to 11 points less). In the fluency sub domain
(max score 14) people with normal cognition scored a mean of 12, people with MCI scored 3 points
less (95% CI 2 points less to 4 points less) and people with dementia scored 5 points less (95% CI 4
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Figure 4.3: Scores on ACE3 by GP judgement

















The box plots the median (darker middle line) and the quartiles (box edges), the whiskers enclose the lower (Q1 -
1.5 × interquartile range) and upper (Q3 + 1.5 × interquartile range) adjacent values, and the dots mark the
outlying values.
points less to 6 points less). In the language sub domain (max score 26) people with normal cognition
scored a mean of 25 and people with dementia scored a mean 4 points less (95% CI 3 points less to
6 points less). In the visuospatial skills sub domain (max score 16) people with normal cognition
scored a mean of 15 points, people with MCI 2 points less (95% CI 1 point less to 3 points less), and
people with dementia 3 points less (95% CI 2 points less to 4 points less). Comparisons with the
other cognition group are available in Table 4.4 but are not discussed in the text because the small
numbers (n=3) result in a high degree of uncertainty in the estimates. Figure 4.4 summarises the
standardised scores on the ACE3 sub domains, to facilitate comparisons because of the different
maximum scores in different domains. In general people with dementia had lower scores in all
ACE3 sub domains than people with MCI who in turn had generally lower scores than people with
normal cognition. People with dementia had median standardised scores in memory that were
lower than (sequentially) those in visuospatial, fluency, language and attention. In contrast people
with MCI had median standardised scores in fluency that were lower than (sequentially) those in
visuospatial, attention, memory and language domains. In turn, people with normal cognition had
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Table 4.4: Mean difference in ACE3 sub domain scores, compared to normal cognition
Cognitive diagnosis §
Dementia MCI Other Normal
ACE3 domain n=131 n=59 n=3 n=47
Compared to normal (95% CI) † x̄ (s) ‡
Total -26 (-29 to -22) -12 (-16 to -8.0) -7.4 (-19 to 4.7) 92.0 (4.8)
Attention -3.9 (-4.7 to -3.0) -0.9 (-2.0 to 0.1) -0.3 (-3.4 to 2.8) 17.0 (1.2)
Memory -9.9 (-11 to -8.5) -5.3 (-7.0 to -3.7) -0.1 (-5.0 to 5.0) 23.1 (2.4)
Fluency -4.8 (-5.6 to -3.9) -2.7 (-3.7 to -1.7) -1.8 (-4.8 to 1.1) 11.5 (1.7)
Language -4.2 (-5.5 to -3.0) -1.3 (-2.7 to 0.1) -1.1 (-5.4 to 3.3) 25.0 (1.5)
Visuospatial -3.2 (-4.1 to -2.4) -1.8 (-2.7 to -0.8) -0.7 (-3.6 to 2.1) 15.4 (1.0)
§ Dementia according to ICD-10 definition MCI according to Peterson definition
Other impairment: not normal but impairment not meeting formal criteria
Due to low mood in one case, traumatic brain injury in one case,
and DSM–5 dementia not meeting criteria for ICD-10 dementia in one case
† ACE3 Addenbrooke’s Cognitive Examination III
‡ x̄ mean s standard deviation
median standardised scores in the attention domain that were lower than their scores in language,
fluency; and had highest standardised median scores in visuospatial and especially memory. People
classified as other had similar scores in ACE3 sub-domains as those with normal cognition; this group
had lowest standardised scores in the language domain, with serially higher standardised scores
in fluency, visuospatial skills, attention, and highest standardised scores in memory. Scores in the
language domain were most tightly clustered with the smallest IQR but with a number of outliers,
with a similar pattern (though not distribution) observed in people who were normal and those with




Figure 4.4: Standardised scores on ACE3 sub domains








The box plots the median (darker middle line) and the quartiles (box edges), the whiskers enclose the lower (Q1 -
1.5 × interquartile range) and upper (Q3 + 1.5 × interquartile range) adjacent values, and the dots mark the
outlying values.
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4.3 Characteristics of tests
Table 4.5 summarises the characteristics of the 12 patient completed index tests. Five tests were
completed by all participants, and Minicog was derived from GPCOG, but MAT (n=34), Sniffin sticks
(n=188), MOCA (Montreal Cognitive Assessment, n=206), 6CIT (Six Item Cognitive Impairment Test,
n=236), TUG (Timed up-and-go, n=236), and Phototest (n=238) were not completed by all partici-
pants. MOCA and MAT had incomplete completion by participants because after data collection
commenced Sniffin sticks were introduced and MOCA replaced MAT (see Section 3.4.1). Other
missing data in the index tests was fully attributable to participants declining to complete the tests.
Accounting for the changes to the case report form, 230 participants completed all of the index
tests, nine people declined one test, and one person declined two tests. There was no evidence of
association between cognition and the number of declined tests, with beta coefficients (Ø) for MCI
and dementia, compared to normal, of -0.03 (95% CI -0.11 to 0.06) and 0.02 (95% CI -0.06 to 0.10)
respectively, or between the number of declined tests and TUG as a indicator of physical ill health Ø
-0.01 (95% CI -0.04 to 0.03). Similarly in logistic regression analyses the odds ratio for MCI was 0.39
(95% CI 0.03 to 4.4) and for dementia the odds ratio was 1.3 (95% CI 0.25 to 6.3); whereas the odds
ratio for the TUG was 0.97 (95% CI 0.82 to 1.14).
As shown in Table 4.5 scores on index tests were lower in people with dementia than those with
MCI or normal cognition. For all index tests except one (MAT) there was evidence against the null
hypothesis of no difference in mean index test score compared to people with normal cognition,
for people with both dementia and MCI. People with dementia had lower mean scores on MAT
compared to normal, but there was no evidence against the null hypothesis of no difference in mean
MAT score for people with MCI compared to people with normal cognition.
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Table 4.5: Characteristics of tests
Cognitive diagnosis §
Index test † Dementia MCI Other Normal
n=131 n=59 n=3 n=47
Compared to normal x̄ (s) ‡
MAT n=34 [0-50] * •• <28 §
Test score (95% CI) -14 (-20 to -6.6) -7.0 (-15 to 1.2) 2.5 (-12 to 17) 39 (3.7)
Test duration (95% CI) 3.3 (1.6 to 5.1) 1.9 (-0.20 to 4.0) 0.25 (-3.4 to 3.9) 4.8 (0.50)
MOCA n=206 [0-30] * •• <26
Test score (95% CI) -8.7 (-10 to -7.2) -3.8 (-5.6 to -2.1) -4.5 (-11 to 1.6) 24 (2.7)
Test duration (95% CI) 2.6 (1.8 to 3.3) 1.3 (0.46 to 2.2) 2.1 (-0.92 to 5.2) 9.4 (1.4)
Eurotest n=240 [0-35] * •• <21
Test score (95% CI) -11 (-13 to -9.1) -4.4 (-6.6 to -2.2) -5.4 (-12 to 1.2) 27 (3.5)
Test duration (95% CI) 1.9 (1.5 to 2.4) 1.1 (0.52 to 1.6) 1.7 (0.0053 to 3.4) 5.6 (1.2)
Time & Change n=240 * •• <2
Pass (n, col %) 95 (73) 55 (93) 3 (100) 47 (100)
Test duration (95% CI) 0.56 (0.32 to 0.81) 0.27 (-0.02 to 0.56) 0.20 (-0.67 to 1.1) 1.5 (0.55)
Phototest n=238 [0-1] * •• <27
Test score (95% CI) -12 (-15 to -10) -6.2 (-8.9 to -3.5) -3.6 (-12 to 4.7) 37 (6.2)
Test duration (95% CI) 0.22 (0.0079 to 0.43) 0.25 (0.0048 to 0.48) 0.20 (-0.54 to 0.93) 2.8 (0.54)
SPMT n=240 [0-23] * •• <10
Test score (95% CI) -7.9 (-9.2 to -6.6) -3.9 (-5.4 to -2.4) -1.5 (-6.1 to 3.0) 15 (3.5)
Test duration (95% CI) 0.015 (-0.46 to 0.49) 0.0037 (-0.54 to 0.55) -0.23 (-1.9 to 1.4) 6.6 (1.2)
6CIT n=238 [0-28] + •• >7
Test score (95% CI) 9 .9 (8.1 to 12) 5.1 (2.9 to 7.2) 3.7 (-2.7 to 10) 2.6 (2.9)
Test duration (95% CI) 0.52 (0.30 to 0.75) 0.25 (-0.013 to 0.53) -0.063 (-0.89 to 0.76) 1.1 (0.64)
Minicog n=240 [0-5] * •• <3
Test score (95% CI) -2.6 (-3.0 to -2.1) -1.4 (-2.0 to -0.88) -0.80 (-2.4 to 0.82) 4.5 (0.8)
Duration not available as calculated
GPCOG n=240 [0-9] * •• §§
Test score (95% CI) -4.4 (-5.1 to -3.7) -2.4 (-3.2 to -1.5) -1.1 (-3.6 to 1.4) 8.1 (1.2)
Test duration (95% CI) 1.1 (0.80 to 1.5) 0.64 (0.26 to 1.0) 0.57 (-0.60 to 1.7) 1.8 (0.60)
TUG n=236 [0-1] + •• > 15
Test time, seconds (95% CI) 4.7 (2.6 to 6.8) 2.7 (0.3 to 5.1) 1.5 (-5.8 to 8.8) 8.8 (2.1)
Test duration (95% CI) 0.35 (-0.011 to 0.71) 0.16 (-0.25 to 0.58) -0.70 (-2.0 to 0.57) 2.4 (1.1)
EPSS n=240 [0-28] + •• > 1
Test score (95% CI) 3.3 (2.2 to 4.4) 2.1 (0.87 to 3.4) -0.34 (-4.2 to 3.5) 2.3 (1.8)
Test duration (95% CI) 0.18 (-0.048 to 0.41) -0.063 (-0.33 to 0.20) 0.021 (-0.78 to 0.83) 1.0 (0.53)
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Cognitive diagnosis §
Index test † Dementia MCI Other Normal
n=131 n=59 n=3 n=47
Compared to normal x̄ (s) ‡
Sniffin sticks n=188 [0-16] * •• < 11
Test score (95% CI) -2.2 (-3.1 to 1.3) -1.5 (-2.6 to -0.59) -1.4 (-4.8 to 2.0) 7.9 (2.6)
Test duration (95% CI) 0.42 (-0.053 to 0.89) 0.65 (0.11 to 1.2) 0.52 (-1.3 to 2.4) 4.0 (1.0)
§ Dementia according to ICD-10 definition MCI according to Peterson definition
Other impairment: not normal but impairment not meeting formal criteria, see Figure 4.1
† MAT Memory alteration test
MOCA Montreal Cognitive Assessment SPMT Scenery Picture Memory Test
6CIT Six Item Cognitive Impairment Test
GPCOG General Practitioner Assessment of Cognition (± i informant)
TUG Timed up-and-go EPSS Extra pyramidal signs scale ‡ x̄ mean s standard deviation
§[n-n] range of possible scores * higher scores indicate better cognition
+ lower scores indicate better cognition •• threshold for dementia
§§ for GPCOG a two stage approach to scoring is used whereby scores >8 indicate normal and <5 indicate
abnormal and scores 5-8 indicate GPCOGi needed, where scores <4 indicate abnormal
Duration for minicog not given because the score was calculated using items from the GPCOG
Figure 4.5 displays the duration of the index tests that were done by participants who were people
with cognitive symptoms (patients), times of the tests are also provided in Table 4.5. Mini-cog is
not included in the figure because the score was calculated using items from the GPCOG (General
Practitioner Assessment of Cognition). The MOCA had the longest median duration (11 minutes)
of the tests and the 6CIT (1 minute) had the shortest duration. Six tests took longer in people with
dementia than people with normal cognition, these were: MAT, MOCA, Eurotest, Phototest, 6CIT,
and GPCOG. In contrast four tests took longer in people with MCI than people with normal cognition:
MOCA, Eurotest, GPCOG, and Sniffin sticks.
As shown by the outliers in Figure 4.5, some participants took much longer to complete tests.
The tests were classified by 95th centile of duration (see Section 3.7), the short tests had duration
<5 minutes, medium tests ∏ 5 minutes but ∑ 10 minutes, and longer tests (> 10 minutes). The short
duration tests were: EPSS (C95 2 minutes), TAC (C95 3 minutes), Phototest (C95 4 minutes), 6CIT (C95
3 minutes), GPCOG (C95 4 minutes). The medium duration tests were: Eurotest (C95 10 minutes),
SPMT (C95 9 minutes), TUG (C95 5 minutes), Sniffin sticks (C95 6 minutes). The long duration tests
were: MAT (C95 11 minutes), MOCA (C95 15 minutes).
Characteristics of GP clinical judgement are not presented in either Table 4.5 or Figure 4.5 because




Figure 4.5: Duration of index tests, all cognition categories










The box plots the median (darker middle line) and the quartiles (box edges), the whiskers enclose the lower (Q1 -
1.5 × interquartile range) and upper (Q3 + 1.5 × interquartile range) adjacent values, and the dots mark the
outlying values. - indicates no evidence and § indicates evidence against the null hypothesis of no difference in





As described in Section 3.1.1 the two target conditions for evaluating diagnostic accuracy were
dementia and normal. When assessing the diagnostic accuracy of the index tests, whether as single
tests or in combination, the participants were classified as follows:
• Dementia as target condition
– Disease positive: 131 people with reference standard diagnosis of ICD-10 dementia and
one person with reference standard diagnosis of other on ICD-10 who had DSM–5 fron-
totemporal dementia but no objective memory impairment. Total 132 people.
– Disease negative: 47 people with reference standard diagnosis of ICD-10 normal, 59
people with reference standard diagnosis of Peterson MCI, and two people with reference
standard diagnosis of other on ICD-10 of whom one had an affective disorder and one
had acquired brain injury. Total 108 people.
• Normal as target condition
– Disease positive: 47 people with reference standard diagnosis of ICD-10 normal
– Disease negative: 131 people with reference standard diagnosis of ICD-10 dementia, 59
people with reference standard diagnosis of ICD-10 MCI, and three people with reference
standard diagnosis of other on ICD-10. Total 193 people.
4.4.1 Prevalence of target condition
With dementia as the target condition there were 132 disease positives, for a prevalence of 55% (95%
CI 48% to 61%). With normal as the target condition there were 47 target-condition positives, meaning
that 193 people had cognitive impairment, for a prevalence of 80% (95% CI 75% to 85%). Table 4.6 cross
tabulates the judgement of GPs against the cognitive category according to the reference standard.
Of the 34 people who GPs judged as having normal cognition, 19 (56%) were normal according to the
reference standard, 8 (24%) had MCI and 6 (25%) had dementia. In contrast, of the 86 people who
GPs judged as having dementia, 1 (1%) had normal cognition according to the reference standard, 11
(13%) had MCI and 74 (86%) had dementia.
4.5 Informant tests
Five informant measures were completed as standalone index tests: Functional Activities Question-
naire (FAQ [327]), Lawton instrumental activities of daily living scale (IADL [328]), Katz index of
activities of daily living (ADL [329]), Galvin AD8 Dementia Screening Interview (AD8 [299]), and
Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE [304]). The
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Table 4.6: GP judgement against target conditions
Reference standard
GP judgement Normal MCI Dementia Other
Normal 19 8 6 1
CIND 27 40 51 2
Dementia 1 11 74 0
MCI Mild Cognitive Impairment
CIND cognitive impairment, but not dementia
ICD-10 definition for Dementia and Peterson for MCI
five measures which were completed as standalone index tests were completed both by indepen-
dent completion of a paper questionnaire (first), and shortly afterwards (within 30 minutes) by GP
researcher interview.
Kappa Table 4.7 shows the results when weighted kappa was calculated for the whole instrument
for each of the five tests, both as continuous measures and as a categorical test at the published
threshold. For all tests, weighted kappa was∏ 89% when comparing informant completed tests to
those done by interview.
Diagnostic accuracy As indicated by the DOR provided in Table 4.7 and the AUROC shown in
Figure 4.6, the informant measures had similar accuracy for the diagnosis of dementia regardless of
whether the test was completed by the interviewer or the informant.
Analysis of diagnostic accuracy of informant measures Based on the high weighted kappa be-
tween informant and interviewer completed measures for all of the informant tests, and the compa-
rable diagnostic accuracy based on the odds ratio, the informant completed measures were used
in preference to calculate diagnostic accuracy for single tests and in combinations, because these
would be less burdensome for completion in clinical practice.
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Table 4.7: Characteristics of informant tests
Test Agreement Expected Agreement Kappa Standard Error z p>z
Continuous measures
ADL 96% 89% 0.6592 0.0433 15.2 <0.001
FAQ 91% 70% 0.7071 0.0407 17.4 <0.001
IADL 92% 67% 0.7673 0.0408 18.8 <0.001
AD8 89% 61% 0.7077 0.0435 16.3 <0.001
IQCODE 93% 68% 0.7727 0.0422 18.3 <0.001
Categorical measures at published threshold §
ADL 93% 76% 0.7202 0.0632 11.4 <0.001
FAQ 90% 72% 0.6402 0.0644 9.9 <0.001
IADL 91% 61% 0.7632 0.0645 11.8 <0.001
AD8 90% 72% 0.6287 0.0645 9.7 <0.001
IQCODE 91% 70% 0.7074 0.0666 10.6 <0.001
Diagnostic accuracy for dementia at published threshold §
Informant Odds 95% CI Interviewer Odds 95% CI
completed ratio completed ratio
ADL 7.8 2.4 to 25 ADL 7.2 2.8 to 19
FAQ 15 4.7 to 46 FAQ 13 4.0 to 40
IADL 5.0 2.5 to 10 IADL 4.0 2.1 to 7.6
AD8 8.2 3.5 to 19 AD8 12 4.7 to 31
IQCODE 18 6.6 to 52 IQCODE 13 5.2 to 31
§ based on following threshold indicating abnormal: ADL >1 [259]
FAQ dependent in >2 activities [327] IADL <5 [259] AD8 >1 [349] IQCODE > 3.3 [350]
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Figure 4.6: ROC curves for informant tests
The plots show the comparative AUROC for informant and interviewer completed tests: ADL, FAQ, IADL, AD8,
and IQCODE. Completed by int Interviewer (full lines) and inf informant (dashed lines). AUROC area under
ROC curve
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4.6 Diagnostic accuracy of tests
The evaluated index tests are listed in Chapter 3 Section 3.7. Test accuracy is numerically associated
with prevalence of disease, and in particular positive predictive values are positively correlated with
higher prevalence of disease in the study sample (Section 1.1.2.3). The impact of these considerations
is discussed in Chapter 6, for example Section 6.4.3 considers how test accuracy could vary with
prevalence. Chapter 6 also discusses important matters relating to comparisons between tests; for
example in particular Section 6.2.6 emphasises that the overlapping confidence intervals for single
and combined tests means that apparent differences in test accuracy could be chance findings,
especially given the multiple comparisons. Confidence intervals for accuracy are important because
based on point estimates the accuracy of test A may be lower than test B, but if test B has a narrower
confidence interval (indicating greater certainty) that is generally higher than test A, then this may
support the use of test B in preference to test A.
4.6.1 Classification accuracy
Table 4.8 shows the error rate (calculated as F P+F NT P+T N+F P+F N ) for each index test, with the classification
accuracy being calculated as 1-error rate. Accounting for variation in the denominator, the test that
correctly classified most people for dementia as the target condition was SPMT which correctly
classified 78% (186 people) (56 TN (true negative); 123 TP (true positive)) and incorrectly classified 54
people (30 FN (false negative); 24 FP (false positive)). In addition to SPMT, with dementia as the target
condition, six of the 17 index tests correctly classified at least 70% of participants: Eurotest correctly
classified 75% (87 TN, 93 TP), GPCOG correctly classified 75% (56 TN, 123 TP), 6CIT correctly classified
73% (75 TN, 99 TP), clinical judgement correctly classified 71% (96 TN, 74 TP) IQCODE correctly
classified 71% (38 TN, 125 TP), and Minicog correctly classified 71% (79 TN, 92 TP). In contrast,
with dementia as the target condition, the tests that incorrectly classified the highest proportion of
participants were Sniffin sticks 46% (0 FN, 86 FP) and TUG 46% (99 FN, 10 FP).
The test that correctly classified most people with normal as the target condition was GPCOG
which correctly classified 85% (204 people; 166 TN, 38 TP) and incorrectly classified 36 people (9 FN,
27 FP). In addition to GPCOG, with normal cognition as the target condition, four of the 17 index tests
correctly classified ∏ 80% of people: GP clinical judgement, MOCA, and IQCODE correctly classified
82% (respectively 178, 158 and 166 TN; 19, 11 and 24 TP), and AD8 correctly classified 80% (172 TN,
19 TP). In contrast, with normal as the target condition, the tests that incorrectly classified the highest
proportion of participants were FAQ 65% (0 FN, 155 FP), TUG and TAC 64% (respectively 1 and 0 FN,
151 and 153 FP).
4.6.2 Dementia as target condition: single tests
Table 4.10 shows the accuracy of single tests for diagnosing dementia and Figure 4.9 shows the
diagnostic accuracy of the different tests in natural frequencies; the true results (TP and TN) are
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Table 4.8: Error rate of single tests for diagnosing dementia and normal cognition
Error rate % (95% CI) for Target condition
Test Dementia Normal
EPSS 40 (34 to 46) 25 (19 to 31)
TAC 42 (35 to 48) 64 (57 to 70)
Phototest 32 (26 to 38) 45 (38 to 51)
6CIT 27 (21 to 33) 27 (22 to 33)
GPCOG 25 (20 to 31) 15 (11 to 20)
Minicog 29 (23 to 35) 32 (26 to 38)
Eurotest 25 (20 to 31) 35 (29 to 41)
SPMT 23 (17 to 28) 30 (24 to 36)
TUG 46 (40 to 53) 64 (58 to 71)
Sniffin sticks 46 (38 to 53) 21 (15 to 27)
MAT 32 (17 to 51) 38 (22 to 56)
MOCA 40 (33 to 47) 18 (13 to 24)
GP judgement 29 (23 to 35) 18 (13 to 23)
FAQ 42 (35 to 48) 65 (58 to 71)
ADL 43 (36 to 49) 64 (58 to 70)
IADL 40 (34 to 47) 55 (48 to 61)
AD8 33 (27 to 39) 20 (16 to 26)
IQCODE 29 (24 to 36) 18 (13 to 23)
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test
GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire
ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
plotted above the line of zero and the false results (FP and FN) are plotted below the line.
For dementia as the target condition, positive likelihood ratios for single tests ranged from 1 (95%
CI 1 to 1) for EPSS, MOCA, Sniffin sticks, and AD8 (which had an upper 95% CI of 2 rather than 1) to
10 (95% CI 3 to 30) for FAQ. Other single tests with a LRP of five or more 1 were GP judgement LRP 5
(95% CI 3 to 9), ADL LRP 6 (95% CI 2 to 14) and TAC LRP 7 (95% CI 3 to 20). Of these no test had an LRP
95% CI lower bound of more than 3, and confidence intervals overlapped, indicating no real evidence
of superiority for any one test.
In contrast, negative likelihood ratios for single tests ranged from 0 (95% CI incalculable) for
MOCA and Sniffin sticks to 0.85 for TUG (95% CI 0.76 to 0.95). Other single tests with an LRN of
less than 0.2 2 were GPCOG LRN 0.13 (95% CI 0.07 to 0.25), AD8 LRN 0.12 (95% CI 0.05 to 0.29), and
IQCODE LRN 0.12 (95% CI 0.05 to 0.27). Of these only GPCOG, AD8 and IQCODE had an LRN 95% CI
upper bound of less than 0.30, providing some support for using these three tests in preference to
1an LRP of 5 corresponds approximately to a 30% increase in probability of disease if test positive [358]
2an LRN of 0.20 corresponds approximately to a 30% reduction in the probability of disease if test negative [358]
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others for ruling out dementia; however the confidence intervals overlapped between these tests and
others indicating no real evidence for superiority of any one single test.
Chapter 2 described a systematic review of the accuracy of GP clinical judgement for the diagnosis
of dementia. Table 4.10, Figure 4.7 and Figure 4.8 show the updated meta-analysis of the accuracy
of GP clinical judgement for the diagnosis of dementia and cognitive impairment. The data from
Chapter 2 are included and updated with the new data. Overall the updated accuracy including the
new data is very similar to the findings of the systematic review.
The updated meta-analysis of the accuracy for GP judgement for the diagnosis of dementia was:
sensitivity 58% (95% CI 43% to 72%) specificity 89% (95% CI 79% to 95%) which is very similar to the
results in Chapter 2: sensitivity 59% (95% CI 41% to 74%) specificity 89% (95% CI 77% to 95%). In
contrast the updated meta-analysis of the accuracy for GP judgement for the diagnosis of cognitive
impairment was sensitivity 84% (95% CI 60% to 95%) specificity 73% (95% CI 50% to 88%), compared
to Chapter 2 sensitivity 80% (95% CI 45% to 95%) specificity 79% (95% CI 57% to 92%). Figure 4.7
and 4.8 show the summary ROC curves including the new data and indicate that for dementia as
the target condition the new findings lie very close to the summary point and near to the summary
ROC curve. In contrast, for the cognitive impairment target condition the new findings lie close to
the summary ROC curve but are much further from the summary point, with a lower specificity
and higher sensitivity. Chapter 6 discusses possible reasons for this, discusses the new findings
in the context of the systematic review in Chapter 2 in more depth, and considers the extent to
which the results can be attributed to differences in study methodology or chance. As described in
Chapter 2 there is substantial heterogeneity in the data and this prevents the ability to draw any firm
conclusions.
As described in Section 3.7.4.1, Decision curves for all of the single tests are provided in Appendix
H.
Table 4.9: Updated meta-analysis of GP judgement for diagnosis of dementia and cognitive impair-
ment
Analysis Studies Sensitivity (95% CI) Specificity (95% CI) DOR (95% CI)
Dementia as target condition
Chapter 2 7 59 (41 to 74) 89 (77 to 95) 11 (6 to 22)
New findings 1 56 (47 to 65) 89 (81 to 94) 10 (5 to 22)
Updated 8 58 (43 to 72) 89 (79 to 95) 11 (5 to 18)
Cognitive impairment as target condition
Chapter 2 3 80 (45 to 95) 79 (57 to 92) 15 (8 to 29)
New findings 1 92 (88 to 96) 40 (26 to 56) 8 (4 to 18)
Updated 4 84 (60 to 95) 73 (50 to 88) 14 (8 to 19)
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Figure 4.7: Updated summary plot of clinical judgement of GPs for diagnosis of dementia
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Colours of dots: indicate risk of bias in flow and timing domain; decimals indicate prevalence of target condition
new findings: the study at low risk of bias and prevalence 0.55 (55%)
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Figure 4.8: Updated summary plot of clinical judgement of GPs for diagnosis of cognitive impairment
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Colours of dots: indicate risk of bias in flow and timing domain; decimals indicate prevalence of target condition
new findings: the study at low risk of bias and prevalence 0.80 (80%)
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Table 4.10: Diagnostic accuracy of single tests for dementia
Test Sensitivity (95% CI) Specificity (95% CI) PPV § (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI)
Brief tests †
EPSS 85 (78 to 90) 30 (21 to 39) 60 (52 to 67) 62 (47 to 75) 1.2 (1.0 to 1.4) 0.51 (0.31 to 0.84) 2 (1 to 5)
TAC 27 (20 to 36) 96 (91 to 99) 90 (76 to 97) 52 (45 to 59) 7.4 (2.7 to 20) 0.76 (0.68 to 0.84) 10 (3 to 39)
Phototest 57 (48 to 66) 82 (74 to 89) 80 (70 to 87) 61 (53 to 69) 3.2 (2.1 to 5.0) 0.52 (0.42 to 0.65) 6 (3 to 12)
6CIT 76 (67 to 83) 70 (60 to 79) 76 (67 to 83) 70 (60 to 79) 2.5 (1.9 to 3.4) 0.35 (0.25 to 0.48) 7 (4 to 13)
GPCOG 93 (87 to 97) 52 (42 to 62) 70 (63 to 77) 86 (75 to 93) 1.9 (1.6 to 2.4) 0.13 (0.07 to 0.25) 15 (7 to 36)
Minicog 70 (61 to 77) 73 (64 to 81) 76 (67 to 83) 66 (57 to 75) 0.4 (0.3 to 0.5) 0.41 (0.31 to 0.55) 6 (3 to 11)
Medium duration tests
Eurotest 70 (62 to 78) 81 (72 to 88) 82 (73 to 88) 69 (60 to 77) 3.6 (2.4 to 5.4) 0.37 (0.28 to 0.48) 10 (5 to 19)
SPMT 77 (69 to 84) 78 (69 to 85) 81 (73 to 87) 74 (65 to 81) 3.5 (2.4 to 5.0) 0.29 (0.21 to 0.41) 12 (6 to 23)
TUG 23 (16 to 31) 91 (84 to 95) 74 (58 to 87) 50 (43 to 57) 2.4 (1.3 to 4.8) 0.85 (0.76 to 0.95) 3 (1 to 7)
Sniffin sticks 100 (96 to 100) 4 (1 to 11) 53 (46 to 61) 100 (40 to 100) 1.0 (1.0 to 1.1) 0 (. to .) . (1 to .)
Longer tests
MAT 63 (41 to 81) 80 (44 to 97) 88 (64 to 99) 47 (23 to 72) 3.1 (0.9 to 11) 0.47 (0.26 to 0.86) 7 (1 to 74)
MOCA 100 (97 to 100) 16 (10 to 25) 57 (49 to 64) 100 (79 to 100) 1.2 (1.1 to 1.3) 0 (. to .) . (5 to .)
Clinician and informant tests
GP judgement 56 (47 to 65) 89 (81 to 94) 86 (77 to 93) 62 (54 to 70) 5 (2.9 to 8.8) 0.49 (0.4 to 0.61) 10 (5 to 22)
FAQ 27 (19 to 35) 97 (92 to 99) 92 (79 to 98) 52 (45 to 59) 9.5 (3.0 to 30) 0.76 (0.68 to 0.84) 13 (4 to 66)
ADL 26 (19 to 34) 95 (90 to 98) 87 (73 to 96) 52 (44 to 59) 2.5 (1.6 to 4.1) 0.78 (0.7 to 0.87) 7 (3 to 24)
IADL 37 (29 to 46) 87 (79 to 93) 78 (66 to 87) 53 (45 to 61) 2.9 (1.7 to 4.9) 0.72 (0.62 to 0.84) 4 (2 to 8)
AD8 96 (91 to 99) 32 (24 to 42) 64 (56 to 70) 88 (73 to 96) 1.4 (1.2 to 1.6) 0.12 (0.05 to 0.29) 12 (4 to 41)
IQCODE 95 (90 to 98) 38 (28 to 48) 67 (60 to 74) 86 (73 to 95) 1.5 (1.3 to 1.8) 0.12 (0.05 to 0.27) 13 (5 to 39)
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
† see Section 3.7.2 for test thresholds
. indicates incalculable results
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The figure plots the diagnostic accuracy of the index tests using natural frequencies. Plots above the line are true results and those below the line are false results.
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4.6.3 Normal cognition as target condition: single tests
Table 4.11 shows the accuracy of single tests for diagnosing normal cognition and Figure 4.10 shows
the diagnostic accuracy of the different tests in natural frequencies; the true results (TP and TN) are
plotted above the line of zero and the false results (FP and FN) are plotted below the line.
For normal as the target condition, positive likelihood ratios for single tests ranged from 1 (95%
CI 1 to 1) for TAC, TUG, FAQ, ADL, and IADL (which had an upper 95% CI of 2 rather than 1) to 11
(95% CI 1 to 101) for Sniffin sticks. Other single tests with a LRP of five or more were GP judgement
LRP 5 (95% CI 3 to 9), IQCODE LRP 5 (95% CI 3 to 8) GPCOG LRP 6 (95% CI 4 to 8), and MOCA LRP
8 (95% CI 3 to 23). Of these only GPCOG had an LRP 95% CI lower bound of more than 3, providing
some support for using this test in preference to others for ruling in normal; however the confidence
intervals overlapped between this test and others indicating no real evidence for superiority of any
one single test.
In contrast, negative likelihood ratios for single tests ranged from 0 (95% CI incalculable) for TAC,
MAT, FAQ and ADL to LRN 0.93 for Sniffin sticks (95% CI 0.86 to 1.0). Other single tests with an LRN
of less than 0.20 were Phototest LRN 0.19 (95% CI 0.07 to 0.48), TUG LRN 0.11 (95% CI 0.01 to 0.75),
Minicog LRN 0.07 (95% CI 0.02 to 0.27), Eurotest LRN 0.07 (95% CI 0.02 to 0.29), SPMT LRN 0.07 (95%
CI 0.02 to 0.26), IADL LRN 0.07 (95% CI 0.01 to 0.47) and 6CIT LRN 0.06 (95% CI 0.02 to 0.25). Of these
tests only Eurotest, SPMT and 6CIT had an LRN 95% CI upper bound of less than 0.30, providing
some support for using these three tests in preference to others for ruling out normal; however
the confidence intervals overlapped between these tests and others indicating no real evidence for
superiority of any one single test.
152
Table 4.11: Diagnostic accuracy of single tests for normal cognition
Test Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI)
Brief tests †
EPSS 43 (28 to 58) 83 (77 to 88) 38 (25 to 53) 86 (80 to 90) 2.6 (1.6 to 4.1) 0.69 (0.53 to 0.89) 4 (2 to 8)
TAC 100 (92 to 100) 21 (15 to 27) 24 (18 to 30) 100 (91 to 100) 1.3 (1.2 to 1.4) 0 (. to .) . (3 to .)
Phototest 91 (79 to 98) 47 (40 to 54) 29 (22 to 37) 96 (89 to 99) 1.7 (1.5 to 2.0) 0.19 (0.07 to 0.48) 9 (3 to 37)
6CIT 96 (85 to 99) 67 (60 to 74) 41 (32 to 51) 98 (95 to 100) 2.9 (2.4 to 3.6) 0.06 (0.02 to 0.25) 45 (11 to 390)
GPCOG 81 (67 to 91) 86 (80 to 91) 58 (46 to 71) 95 (90 to 98) 5.8 (4.0 to 8.4) 0.22 (0.12 to 0.4) 26 (11 to 67)
Minicog 96 (85 to 99) 62 (54 to 69) 38 (29 to 47) 98 (94 to 100) 0.1 (0.0 to 0.3) 0.07 (0.02 to 0.27) 36 (9 to 313)
Medium duration tests
Eurotest 96 (85 to 99) 58 (51 to 65) 36 (27 to 45) 98 (94 to 100) 2.3 (1.9 to 2.7) 0.07 (0.02 to 0.29) 31 (8 to 269)
SPMT 96 (85 to 99) 64 (57 to 71) 39 (30 to 49) 98 (94 to 100) 2.7 (2.2 to 3.3) 0.07 (0.02 to 0.26) 40 (10 to 350)
TUG 98 (89 to 100) 20 (15 to 27) 23 (18 to 30) 97 (87 to 100) 1.2 (1.1 to 1.3) 0.11 (0.01 to 0.75) 12 (2 to 479)
Sniffin sticks 7 (2 to 20) 99 (96 to 100) 75 (19 to 99) 79 (73 to 85) 11 (1.1 to 101) 0.93 (0.86 to 1.02) 12 (1 to 609)
Longer tests
MAT 100 (40 to 100) 57 (37 to 75) 24 (7 to 50) 100 (80 to 100) 2.3 (1.5 to 3.5) 0 (. to .) . (1 to .)
MOCA 26 (14 to 41) 97 (93 to 99) 69 (41 to 89) 83 (77 to 88) 8.3 (3.1 to 23) 0.77 (0.64 to 0.92) 11 (3 to 42)
Clinician and informant tests
GP judgement 40 (26 to 56) 92 (88 to 96) 56 (38 to 73) 86 (81 to 91) 5.2 (2.9 to 9.5) 0.65 (0.51 to 0.82) 8 (3 to 19)
FAQ 100 (92 to 100) 20 (14 to 26) 23 (18 to 30) 100 (91 to 100) 1.2 (1.2 to 1.3) 0 (. to .) . (3 to .)
ADL 100 (92 to 100) 20 (15 to 27) 24 (18 to 30) 100 (91 to 100) 1.3 (1.1 to 1.5) 0 (. to .) . (3 to .)
IADL 98 (89 to 100) 32 (26 to 39) 26 (20 to 33) 98 (91 to 100) 1.4 (1.3 to 1.6) 0.07 (0.01 to 0.47) 22 (4 to 892)
AD8 40 (26 to 56) 89 (84 to 93) 48 (32 to 64) 86 (80 to 90) 3.7 (2.2 to 6.3) 0.67 (0.53 to 0.85) 6 (2 to 12)
IQCODE 53 (38 to 68) 89 (84 to 93) 55 (39 to 70) 89 (83 to 93) 5.0 (3.0 to 8.1) 0.52 (0.38 to 0.72) 9 (4 to 21)
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
† see Section 3.7.2 for test thresholds
. indicates incalculable results
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The figure plots the diagnostic accuracy of the index tests using natural frequencies. Plots above the line are true results and those below the line are false results.
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4.6. DIAGNOSTIC ACCURACY OF TESTS
4.6.4 Index tests in combination
4.6.4.1 Two test combination: GP combined tests
Tables 4.10 and 4.11 give full details of the diagnostic accuracy of GP judgement as a single test and
indicate that a GP judgement of dementia has LRP 5 (95% CI 3 to 9) LRN 0.49 (95% CI 0.40 to 0.61) and
GP judgement of normal has LRP 5 (95% CI 3 to 9) LRN 0.65 (95% CI 0.51 to 0.82). Table 4.12 and Table
4.13 give the accuracy of GP clinical judgement, in combination with each individual index test, for
the target condition of dementia and normal respectively.
With dementia as the target condition, the combined tests with the highest LRP were GP +
Eurotest which had an LRP of 16 (95% CI 5 to 49) and GP + ADL which had LRP 16 (95% CI 2 to 115).
Other GP combined tests with an LRP of ten or more were GP + SPMT LRP 13 (95% CI 5 to 35) and
GP + FAQ LRP 10 (95% CI 2 to 42). Of these only GP + Eurotest and GP + SPMT had an LRP 95% CI
lower bound of more than 3, providing some support for using these combined tests in preference to
others for ruling in dementia; however the confidence intervals overlapped between these tests and
others, indicating no real evidence for superiority of any one GP combined test. In contrast the GP
combined test with the lowest LRN was GP + MAT LRN 0.46 (95% CI 0.30 to 0.71) and no test had an
upper 95% CI of LRN that was less than 0.60, indicating relatively poor performance of GP combined
tests for ruling out dementia.
With normal as the target condition, the combined tests with the highest LRP were GP + AD8
which had an LRP of 45 (95% CI 6 to 341) and GP + IQCODE which had LRP 29 (95% CI 7 to 123). Other
GP combined tests with an LRP of ten or more were GP + 6CIT LRP 13 (95% CI 5 to 30), GP + GPCOG
LRP 11 (95% CI 4 to 30), and GP + Minicog LRP 12 (95% CI 5 to 29). Of these five tests, four had an
LRP 95% CI lower bound of more than 3 (GP + GPCOG did not), providing some support for using
these four GP combined tests in preference to others for ruling in normal; however the confidence
intervals overlapped between these tests and others indicating no real evidence for superiority of any
one GP combined test. In contrast the GP combined test with the lowest LRN was GP + SPMT LRN
0.62 (95% CI 0.49 to 0.79) and no test had an upper 95% CI of LRN that was less than 0.79, indicating
relatively poor performance of GP combined tests for ruling out normal.
For normal as the target condition it was not possible to analyse the combination of GP judgement
and MAT because of perfect prediction, MAT as a single test had 100% sensitivity for the diagnosis of
normal. MAT was completed by 34 people of whom 32 were judged by the referring GP to have some
form of impairment. In contrast, four of the 34 people who completed MAT were normal according
to the reference standard and 30 had some impairment (of whom 1 had other impairment). All four
of the people with normal cognition were judged by the referring GP to have CIND and were normal
on MAT.
Figure 4.11 shows naïve decision curves for all of the index tests, on a separate axis for each target
condition. The pair of curves plot the net benefit across all thresholds, along with the treat-all and
treat-none lines. This plot provides the reader with an overview of the shape of the curves across
threshold probabilities. The second larger pair of curves (Figure 4.12 and Figure 4.13) plot the net
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benefit at the thresholds that were judged as being clinically plausible, as described in Section 3.7.4.1.
For the target condition dementia Figure 4.12 indicates that at threshold probabilities of 80% to
90% the combinations GP judgement + SPMT, and GP judgement + Eurotest have the largest net
benefit. At threshold probabilities of ∏ 93% to 98% the combination test GP judgement + TAC has
largest net benefit and at threshold probabilities of more than 98% the treat none approach has
largest net benefit.
For the target condition normal Figure 4.13 indicates that at threshold probabilities of up to
81% the combination test GP judgement + IQCODE has largest net benefit, with GP judgement +
AD8 having similar but slightly lower net benefit. At threshold probabilities of ∏ 82% to 93% the
combination test GP judgement + MOCA has largest net benefit and at threshold probabilities of
more than 93% the treat none approach has largest net benefit.
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Table 4.12: Diagnostic accuracy of tests for target condition dementia, in combination with GP judgement
Test Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI) Probability ‡
Brief tests †
EPSS 44 (35 to 53) 91 (84 to 95) 85 (75 to 93) 57 (49 to 64) 5 (3 to 9) 0.62 (0.53 to 0.73) 8 (4 to 18) 0.89
TAC 17 (11 to 24) 100 (97 to 100) 100 (85 to 100) 50 (43 to 56) . (. to .) 0.83 (0.77 to 0.90) . (6 to .) 0.98
Phototest 37 (29 to 46) 94 (88 to 98) 89 (78 to 96) 55 (48 to 63) 7 (3 to 15) 0.66 (0.58 to 0.76) 10 (4 to 30) 0.92
6CIT 46 (37 to 55) 93 (86 to 97) 88 (78 to 95) 58 (50 to 66) 6 (3 to 12) 0.59 (0.50 to 0.69) 10 (5 to 27) 0.91
GPCOG 55 (46 to 64) 91 (84 to 95) 88 (79 to 94) 62 (54 to 70) 6 (3 to 11) 0.49 (0.40 to 0.60) 12 (6 to 28) 0.88
Minicog 42 (34 to 51) 94 (87 to 97) 89 (78 to 95) 57 (49 to 64) 7 (3 to 14) 0.62 (0.53 to 0.72) 11 (4 to 29) 0.92
Medium duration tests
Eurotest 44 (35 to 53) 97 (92 to 99) 95 (86 to 99) 59 (51 to 66) 16 (5 to 49) 0.58 (0.49 to 0.67) 27 (8 to 140) 0.94
SPMT 49 (40 to 58) 96 (91 to 99) 94 (86 to 98) 61 (53 to 68) 13 (5 to 35) 0.53 (0.44 to 0.63) 25 (9 to 99) 0.92
TUG 14 (9 to 21) 98 (93 to 100) 90 (68 to 99) 49 (42 to 56) 8 (2 to 32) 0.88 (0.81 to 0.94) 9 (2 to 78) 0.93
Sniffin sticks 51 (41 to 61) 88 (80 to 94) 83 (71 to 92) 61 (52 to 70) 4 (2 to 8) 0.55 (0.45 to 0.69) 8 (4 to 19) 0.83
Longer tests
MAT 54 (33 to 74) 100 (69 to 100) 100 (75 to 100) 48 (26 to 70) . (. to .) 0.46 (0.30 to 0.71) . (3 to .) 0.95
MOCA 55 (45 to 64) 87 (77 to 93) 84 (74 to 92) 59 (50 to 68) 4 (2 to 7) 0.52 (0.42 to 0.66) 8 (4 to 18) 0.84
Informant tests
FAQ 19 (13 to 27) 98 (93 to 100) 93 (76 to 99) 50 (43 to 57) 10 (2 to 42) 0.83 (0.76 to 0.90) 12 (3 to 110) 0.97
ADL 15 (9 to 22) 99 (95 to 100) 95 (75 to 100) 49 (42 to 56) 16 (2 to 115) 0.86 (0.80 to 0.93) 18 (3 to 761) 0.97
IADL 26 (19 to 34) 96 (91 to 99) 89 (75 to 97) 51 (44 to 59) 7 (3 to 19) 0.77 (0.69 to 0.86) 9 (3 to 36) 0.92
AD8 55 (46 to 63) 92 (85 to 96) 89 (80 to 95) 62 (54 to 70) 7 (3 to 12) 0.50 (0.41 to 0.60) 13 (6 to 32) 0.89
IQCODE 56 (47 to 64) 91 (84 to 96) 89 (80 to 95) 61 (53 to 69) 6 (3 to 12) 0.49 (0.40 to 0.60) 13 (6 to 31) 0.88
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
† see Section 3.7.2 for test thresholds
. indicates incalculable results
‡ predicted probability of dementia in test positive group, from logistic regression equation, see Methods Section 3.7.5.1
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Table 4.13: Diagnostic accuracy of tests for target condition normal cognition, in combination with GP judgement
Test Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI) Probability ‡
Brief tests †
EPSS 13 (5 to 26) 98 (96 to 100) 67 (30 to 93) 82 (77 to 87) 8 (2 to 32) 0.89 (0.79 to 0.99) 9 (2 to 59) 0.79
TAC 40 (26 to 56) 91 (85 to 95) 58 (39 to 75) 83 (77 to 89) 4 (2 to 8) 0.66 (0.52 to 0.83) 7 (3 to 16) 0.58
Phototest 39 (25 to 55) 95 (91 to 97) 64 (44 to 81) 87 (81 to 91) 8 (4 to 15) 0.64 (0.51 to 0.81) 12 (5 to 31) 0.64
6CIT 39 (25 to 55) 97 (93 to 99) 75 (53 to 90) 87 (82 to 91) 13 (5 to 30) 0.63 (0.50 to 0.79) 20 (7 to 65) 0.76
GPCOG 30 (17 to 45) 97 (94 to 99) 74 (49 to 91) 85 (80 to 89) 11 (4 to 30) 0.72 (0.60 to 0.87) 16 (5 to 59) 0.85
Minicog 38 (25 to 54) 97 (93 to 99) 75 (53 to 90) 87 (81 to 91) 12 (5 to 29) 0.64 (0.51 to 0.80) 19 (7 to 63) 0.76
Medium duration tests
Eurotest 40 (26 to 56) 95 (91 to 97) 66 (46 to 82) 87 (81 to 91) 8 (4 to 16) 0.63 (0.50 to 0.80) 12 (5 to 33) 0.64
SPMT 40 (26 to 56) 95 (91 to 98) 68 (48 to 84) 87 (81 to 91) 9 (4 to 18) 0.62 (0.49 to 0.79) 14 (5 to 38) 0.67
TUG 40 (26 to 56) 94 (89 to 97) 61 (42 to 78) 86 (81 to 91) 6 (3 to 12) 0.64 (0.50 to 0.81) 10 (4 to 25) 0.6
Sniffin sticks 2 (0 to 13) 100 (98 to 100) 100 (3 to 100) 79 (72 to 84) . (. to .) 0.98 (0.93 to 1.02) . (0 to .) 0.94
Longer tests
MAT . (. to .) . (. to .) . (. to .) . (. to .) . (. to .) . (. to .) . (. to .) .
MOCA 12 (4 to 25) 100 (98 to 100) 100 (48 to 100) 81 (75 to 86) . (. to .) 0.88 (0.79 to 0.98) . (5 to .) 0.93
Informant tests
FAQ 40 (26 to 56) 90 (85 to 94) 56 (38 to 73) 83 (77 to 89) 4 (2 to 8) 0.66 (0.52 to 0.84) 6 (3 to 15) 0.56
ADL 40 (26 to 56) 91 (85 to 95) 58 (39 to 75) 83 (77 to 89) 4 (2 to 8) 0.66 (0.52 to 0.83) 7 (3 to 16) 0.58
IADL 40 (26 to 56) 93 (89 to 96) 59 (41 to 76) 87 (81 to 91) 6 (3 to 11) 0.64 (0.50 to 0.81) 9 (4 to 23) 0.59
AD8 23 (12 to 38) 99 (97 to 100) 92 (62 to 100) 84 (79 to 89) 45 (6 to 341) 0.77 (0.66 to 0.90) 59 (8 to 2537) 0.78
IQCODE 31 (18 to 47) 99 (96 to 100) 88 (62 to 98) 86 (80 to 90) 29 (7 to 123) 0.70 (0.57 to 0.85) 42 (9 to 384) 0.8
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
† see Section 3.7.2 for test thresholds
. indicates incalculable results
‡ predicted probability of dementia in test positive group, from logistic regression equation, see Methods Section 3.7.5.1
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4.6. DIAGNOSTIC ACCURACY OF TESTS
Figure 4.11: Decision curves for all tests, for both target conditions, at all threshold probabilities
The plot provides the reader with an overview of the shape of the curves across threshold probabilities.












































The curves plot the net benefit across a range of thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
Calibration plots for each GP combined test, for each target condition, are provided in Appendix I.
The GP combined tests were all well calibrated. Discrimination using AUROC is shown in Table 4.14.
For dementia as the target condition the GP combined test with the largest AUROC was GP + SPMT
which had AUROC 0.83 (95% CI 0.79 to 0.88). GP + Eurotest, GP + GPCOG GP + 6CIT and GP + Minicog
also had AUROC of >0.8 for dementia, as GP combined tests. For normal as the target condition the
same five GP combined tests had AUROC >0.8, but the combined test with the largest AUROC was GP
+ GPCOG which had AUROC 0.89 (95% CI 0.83 to 0.94). Overlapping confidence limit the ability to
draw inference about the the superiority of one test over another regarding discrimination.
As described in Section 3.7.5.1 GP combined tests with AUROC <0.75 were not for considered
combination as a GP 360 combination of three tests. For dementia as the target condition two GP
combined tests had an AUROC of <0.75: Sniffin sticks AUROC 0.70 and MOCA AUROC. For normal as
the target condition five tests had a AUROC of <0.75: TAC 0.66, Sniffin sticks 0.69, FAQ 0.65, ADL 0.66,
and AD8 0.72. Overlapping confidence limit the ability to draw inference about the the superiority of
one test over another regarding discrimination.
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Figure 4.12: Decision curves for all tests, with dementia as the target condition, at threshold probabil-























The curves plot the net benefit across a range of thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
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Figure 4.13: Decision curves for all tests, with normal as the target condition, at threshold probabilities


























The curves plot the net benefit across a range of thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
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Table 4.14: Discrimination, using AUROC, of the GP combined tests
AUROC (95% CI) for Target condition
Test Dementia Normal
EPSS 0.77 (0.72 to 0.82) 0.76 (0.68 to 0.83)
TAC 0.77 (0.72 to 0.82) 0.66 (0.58 to 0.73)
Phototest 0.79 (0.74 to 0.85) 0.78 (0.71 to 0.84)
6CIT 0.81 (0.76 to 0.86) 0.87 (0.83 to 0.91)
GPCOG 0.82 (0.77 to 0.87) 0.89 (0.83 to 0.94)
Minicog 0.81 (0.75 to 0.86) 0.85 (0.80 to 0.90)
Eurotest 0.82 (0.78 to 0.87) 0.83 (0.78 to 0.88)
SPMT 0.83 (0.79 to 0.88) 0.85 (0.80 to 0.90)
TUG 0.75 (0.7 to 0.81) 0.72 (0.65 to 0.79)
Sniffin sticks 0.70 (0.64 to 0.76) 0.69 (0.60 to 0.77)
MAT 0.79 (0.65 to 0.92) . (. to .)
MOCA 0.71 (0.65 to 0.77) 0.74 (0.66 to 0.82)
FAQ 0.76 (0.71 to 0.81) 0.65 (0.58 to 0.73)
ADL 0.78 (0.72 to 0.83) 0.66 (0.58 to 0.73)
IADL 0.76 (0.70 to 0.81) 0.75 (0.69 to 0.82)
AD8 0.79 (0.74 to 0.84) 0.72 (0.64 to 0.8)
IQCODE 0.79 (0.74 to 0.84) 0.76 (0.68 to 0.84)
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test
GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire
ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
† see Section 4.3. GP+ MAT was not possible for normal as target condition
. indicates incalculable results
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4.6.4.2 Three test combination: GP 360 tests
Accounting for discrimination and calibration, the tests with the highest LRP were selected for each
target condition. For dementia as the target condition the two patient completed tests were t p A =
TAC and t p B = Eurotest, and the two informant completed tests were t i A = FAQ and t i B=ADL (Section
3.7.5.1)3). For normal as the target condition the two patient completed tests were t p A = 6CIT and
t p B = Minicog, and the two informant completed tests were t i A = IQCODE and IADL. Section 3.7.5.2
describes how the tests were combined and dichotomised.
Table 4.15 shows the tabulated classification of the GP 360 tests using natural frequencies in a
theoretical population. Based on the study sample, of 1000 people who have presented to a GP with
symptoms of dementia; based on the study sample 546 of the 1000 have dementia. Table 4.15 shows
the natural frequencies for both the continuous tests and the dichotomised tests (at a predicted
probability of 80% for dementia and 60% for normal, see Section 3.7.5.2). Table 4.16 shows the
diagnostic accuracy of the GP 360 tests for both target conditions. Based on the new findings GPs
would be expected to identify 358 people as having dementia, and of those 308 would have dementia,
46 would have MCI and 4 would have normal cognition. In contrast, GPs would be expected to
identify 141 people as being normal, and of these 79 would be normal, 33 would have MCI, 25 would
have dementia and 4 would have other cognition.
Table 4.15 shows that for the target condition dementia in the 358 people classified by the GP as
having dementia, the dichotomised test GP + Eurotest + FAQ would have 292 test positives of whom
275 would have dementia and 17 would have MCI. In contrast, using GP + TAC + FAQ, which from
Table 4.16 has the highest LRP, would identify 183 people as having dementia, of whom 175 would
have dementia and eight would have MCI. Using Table 4.16 and Table 4.15 together it can be seen
that while GP + TAC + FAQ has the highest LRP 17 (95% CI 4 to 69) for dementia, using GP + Eurotest +
FAQ which has LRP 14 (95% CI 5 to 36) identifies an additional 100 TP cases of dementia at a cost of 9
additional FP, all of whom have MCI.
Figure 4.14 shows that for the target condition dementia at threshold probabilities above 80% to
around 93%, the dichotomised GP 360 test with GP judgement, Eurotest, and FAQ has the largest net
benefit, whereas GP + TAC + FAQ has largest net benefit at thresholds between 93% and 97%.
Table 4.15 shows that for the target condition normal in the 141 people classified by the GP as
being normal the dichotomised test GP + 6CIT + IQCODE would have 65 test positives of whom 61
would be normal and four would have MCI. In contrast, using continuous GP + Minicog + IQCODE,
which from Table 4.16 has the highest LRP (1), would identify 61 people as being normal, of whom
all would be normal.
Figure 4.15 shows that for the target condition normal at threshold probabilities above 60% to
around 93%, the dichotomised GP 360 test with GP judgement, 6CIT, and IQCODE has the largest
net benefit. The continuous test GP + Minicog + IQCODE has largest net benefit of the continuous
3two patient-completed (t p A, t p B) and two informant-completed (t i A, t iB) GP combined tests, selected on the basis
of the highest LRP for the GP combined test; see Section 3.7.5.2
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tests, at thresholds up to 90%, but the curve is unstable (indicated by the upward slant at thresholds
of 63%).
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Table 4.15: Tabulated classification of combined index tests
Test § Normal † MCI† Dementia† Other Predicted probability of
dementia if test positive ‡
in 1000 people, of whom 546 have dementia, of 358 people classified by GP as having dementia
GP Dementia 4 46 308 0
Target condition: dementia Number of people who test positive §
Binary tests
GP + TAC + FAQ 0 8 175 0 1
GP + TAC + ADL 0 8 151 0 1
GP + Eurotest + FAQ 0 17 275 0 1
GP + Eurotest + ADL 0 25 293 0 1
Continuous probability tests
GP + TAC + FAQ 0 0 33 0 0.99
GP + TAC + ADL 0 0 33 0 1
GP + Eurotest + FAQ 0 4 100 0 0.98
GP + Eurotest + ADL 0 0 75 0 0.98
in 1000 people, of whom 454 are normal, of 141 people classified by GP as normal
GP Normal 79 33 25 4
Target condition: normal Number of people who test positive §
Binary tests
GP + 6CIT + IQCODE 61 4 0 0 1
GP + Minicog + IQCODE 78 9 9 4 1
GP + 6CIT + IADL 76 13 8 4 1
GP + Minicog + IADL 75 8 8 4 1
Continuous probability tests
GP + 6CIT + IQCODE 61 4 0 0 0.87
GP + Minicog + IQCODE 61 0 0 0 0.89
GP + 6CIT + IADL 76 13 8 4 0.76
GP + Minicog + IADL 75 8 8 4 0.78
§ TAC Time and change FAQ Functional Activities Questionnaire
ADL Katz index of activities of daily living
6CIT Six Item Cognitive Impairment Test
IQCODE Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly
IADL Lawton instrumental activities of daily living scale
† Reference standard diagnosis; Dementia ICD-10 Peterson MCI; see Figure 4.1
‡ predicted probability of dementia in test positive group, from logistic regression equation,
Methods Section 3.7.5.1 probability is 1 where tests are dichotomised
§indicating for example 183 (175+8) people test positive on GP + TAC + FAQ of the 358 identified by GP
as having dementia. The remainder (358-183 = 175) test negative on the GP 360 test and may be
normal, MCI or have dementia
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Table 4.16: Diagnostic accuracy of GP 360 tests for both target conditions
Test Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI)
Dementia as the target condition
Binary tests
GP + TAC + FAQ 32 (24 to 40) 98 (93 to 100) 95 (85 to 99) 54 (47 to 61) 17 (4 to 69) 0.69 (0.62 to 0.78) 25 (6 to 215)
GP + TAC + ADL 27 (20 to 36) 98 (93 to 100) 95 (82 to 99) 53 (46 to 60) 15 (4 to 60) 0.74 (0.66 to 0.82) 20 (5 to 175)
GP + Eurotest + FAQ 50 (41 to 59) 96 (91 to 99) 94 (86 to 98) 61 (53 to 69) 14 (5 to 36) 0.52 (0.44 to 0.62) 26 (9 to 102)
GP + Eurotest + ADL 53 (45 to 62) 94 (88 to 98) 92 (84 to 97) 63 (55 to 70) 10 (4 to 21) 0.49 (0.41 to 0.6) 20 (8 to 58)
Continuous probability tests
GP + TAC + FAQ 6 (3 to 12) 100 (97 to 100) 100 (63 to 100) 47 (40 to 53) . (. to .) 0.94 (0.9 to 0.98) . (2 to .)
GP + TAC + ADL 6 (3 to 12) 100 (97 to 100) 100 (63 to 100) 47 (40 to 53) . (. to .) 0.94 (0.9 to 0.98) . (2 to .)
GP + Eurotest + FAQ 18 (12 to 26) 99 (95 to 100) 96 (80 to 100) 50 (43 to 57) 20 (3 to 143) 0.83 (0.76 to 0.9) 24 (4 to 987)
GP + Eurotest + ADL 14 (8 to 21) 100 (97 to 100) 100 (81 to 100) 49 (42 to 56) . (. to .) 0.86 (0.81 to 0.92) . (4 to .)
Normal as the target condition
Binary tests
GP + 6CIT + IQCODE 32 (19 to 48) 99 (97 to 100) 93 (68 to 100) 86 (81 to 90) 59 (8 to 436) 0.69 (0.56 to 0.84) 86 (12 to 3648)
GP + Minicog + IQCODE 40 (26 to 56) 97 (94 to 99) 78 (56 to 93) 87 (82 to 91) 15 (6 to 38) 0.62 (0.49 to 0.78) 24 (8 to 88)
GP + 6CIT + IADL 39 (25 to 55) 97 (93 to 99) 75 (53 to 90) 87 (82 to 91) 13 (5 to 30) 0.63 (0.5 to 0.79) 20 (7 to 65)
GP + Minicog + IADL 38 (25 to 54) 97 (94 to 99) 78 (56 to 93) 87 (81 to 91) 15 (6 to 38) 0.63 (0.51 to 0.79) 23 (7 to 85)
Continuous probability tests
GP + 6CIT + IQCODE 32 (19 to 48) 99 (97 to 100) 93 (68 to 100) 86 (81 to 90) 59 (8 to 436) 0.69 (0.56 to 0.84) 86 (12 to 3648)
GP + Minicog + IQCODE 31 (18 to 47) 100 (98 to 100) 100 (77 to 100) 86 (80 to 90) . (. to .) 0.69 (0.57 to 0.84) . (21 to .)
GP + 6CIT + IADL 39 (25 to 55) 97 (93 to 99) 75 (53 to 90) 87 (82 to 91) 13 (5 to 30) 0.63 (0.5 to 0.79) 20 (7 to 65)
GP + Minicog + IADL 38 (25 to 54) 97 (94 to 99) 78 (56 to 93) 87 (81 to 91) 15 (6 to 38) 0.63 (0.51 to 0.79) 23 (7 to 85)
§ TAC Time and change 6CIT Six Item Cognitive Impairment Test GPCOG General Practitioner Assessment of Cognition
SPMT Scenery Picture Memory Test TUG Timed up-and-go MAT Memory alteration test
MOCA Montreal Cognitive Assessment FAQ Functional Activities Questionnaire ADL Katz index of activities of daily living
IADL Lawton instrumental activities of daily living scale
† see Section 3.7.2 for test thresholds
. indicates incalculable results
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Figure 4.14: Decision curves for the GP 360 tests, with dementia as the target tests condition, at
























































The curves plot the net benefit across a range of thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
Figure 4.15: Decision curves for the GP 360 tests, with normal as the target condition, at threshold












































The curves plot the net benefit across a range of thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
For the GP 360 test with Eurotest and FAQ, the regression coefficients in the logistic regression
equation were GP judgement 1.88, Eurotest 1.87, FAQ 1.65 and constant -1.33. From these it can be
deduced that if all tests indicate dementia then the score from the regression coefficients would be
4.07, the exponent of which is 58.5, for a probability of dementia of 98% (derived from odd s1+odd s ). Con-
versely if GP judgement indicates dementia but the other tests indicate no dementia the probability
of dementia is 63%.
For the GP 360 test with 6CIT and IQCODE, the regression coefficients in the logistic regression
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equation were GP judgement 1.64, 6CIT 3.40, IQCODE 1.55 , and a constant of -4.66. From these, it can
be deduced that if all tests indicate normal cognition then the score from the regression coefficients
would be 1.93, the exponent of which is 6.88, for a probability of normal of 87%. Conversely if GP
judgement indicates normal cognition but the other tests indicate impairment the probability of
normal cognition is 5%.
4.7 Sensitivity analyses
The method of the sensitivity analyses is described in Section 3.7.6. The full results are provided in
Appendix J. For technical reasons, detailed in Section 3.7.6 the results are not the same as reported in
Table 4.12 and Table 4.13. A sensitivity analysis of TAC using continuous scores could not be done
for normal as the target condition because of perfect prediction, similarly a sensitivity analysis of
AD8 for dementia as the target condition could not be done by sex because of perfect prediction.
Findings related to MAT are reported in the full results in the Appendix but are not discussed in the
text because of small numbers leading to significant uncertainty in the estimates.
4.7.1 Continuous test scores
For the target condition dementia, analysis of GP combined tests as continuous scores had similar
sensitivity compared to when they were analysed at the published threshold. Some tests had lower
sensitivity, and this was most marked for Sniffin Sticks, which had a sensitivity of 37% (95% CI 27%
to 47%) when analysed as a continuous test, compared to a sensitivity of 51% (95% CI 41% to 61%)
when analysed at the published threshold. In contrast Eurotest had a higher sensitivity of 61% (95%
CI 52% to 69%) when analysed as a continuous test, compared to 44% (95% CI 35% to 53%) when
analysed at the published threshold. Phototest also had a higher sensitivity of 47% (95% CI 38% to
55%) when analysed as a continuous test, compared to 37% (95% CI 29% to 46%) at the published
threshold. Other differences in sensitivity when tests were analysed as continuous tests were less
than 10 percentage points. Specificity of tests when analysed as continuous measures was similar to
when they were analysed at the published threshold, with all differences being ∑ 6 percentage points.
For the target condition normal there were no differences when GP combined tests were analysed
as continuous tests or at the published threshold. This finding was checked and confirmed.
4.7.2 Age
For the target condition dementia some GP combined tests had lower sensitivity in people aged
< 80 years than people aged ∏ 80 years. ADL had a sensitivity of 4% (95% CI 1% to 15%) in people
aged < 80 years compared to sensitivity 69% (95% CI 58% to 79%) in people aged ∏ 80 years. Six
other tests had a sensitivity in younger people that was more than 10 percentage points less than the
sensitivity in older people: FAQ, MOCA, TAC, SPMT, Phototest and Eurotest. In contrast, specificity
on GP combined tests was often higher in people aged < 80 years. ADL had a specificity of 99% (95%
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CI 92% to 100%) in people aged < 80 years, compared to 76% (95% CI 60% to 89%) in people aged ∏
80 years. Five other GP combined tests had a specificity in younger people that was more than 10
percentage points more than the specificity in older people: TAC, SPMT, FAQ, MOCA, and Phototest.
For normal as the target condition, some GP combined tests had higher sensitivity in people aged
< 80 years than people aged ∏ 80 years. Sniffin sticks had a sensitivity of 44% (95% CI 26% to 62%) in
people aged < 80 years compared to a sensitivity of 0% (0% to 37%) in people aged ∏ 80 years. Nine
other GP combined tests had a sensitivity in younger people that was more than 10 percentage points
more than the sensitivity in older people: TAC, Phototest, Eurotest, FAQ, ADL, IADL, MOCA, AD8,
and GPCOG. In contrast, specificity on GP combined tests was often slightly lower in people aged <
80 years. Eurotest had a specificity of 86% (95% CI 73% to 95%) in people aged < 80 years compared to
a specificity of 100% (95% CI 97% to 100%) in people aged ∏ 80 years. Five other GP combined tests
had a specificity in younger people that was more than 10 percentage points less than the specificity
in older people: IADL, ADL, FAQ, Sniffin sticks, and TAC.
Fewer people aged < 80 years than those aged ∏ 80 years had dementia: < 80 years 40% (95% CI
31% to 50%) ∏ 80 years 68% (95% CI 59% to 76%); but the proportion with MCI was similar: < 80 years
29% (95% CI 21% to 38%) ∏ 80 years 20% (95% CI 14% to 29%); normal cognition was more common in
younger people: < 80 years 29% (95% CI 21% to 38%) ∏ 80 years 10% (95% CI 6% to 17%). Mean ACE3
scores were 79 (æ 14) in people aged < 80 years and 71 (æ 14) in people ∏ 80 years, and mean school
leaving age was the same: 16 (æ 1) in people < 80 years and ∏ 80 years. There was weak evidence of an
association between age and school leaving age with a coefficient for being ∏ 80 years of -0.20 (95%
CI -0.55 to 0.15). In contrast there was some evidence of an association between total ACE3 score and
age with a coefficient for being ∏ 80 years of -7.4 (95% CI -10.9 to -3.8).
4.7.3 Sex
In general, for the target condition dementia GP combined tests were more sensitive in women than
men. For example, ADL had a sensitivity of 73% (60% to 80%) in women compared to 9% (95% CI 3%
to 18%) in men. Similarly, IQCODE had a sensitivity of 62% (95% CI 49% to 74%) in women, compared
to a sensitivity of 0% (95% CI 0% to 5%) in men. The GP combined tests with the smallest difference in
sensitivity between women and men were GPCOG which had a sensitivity of 63% (95% CI 50% to 74%)
in women compared to 49% (95% CI 36% to 61%) in men, and Eurotest which had a sensitivity of 52%
(95% CI 39% to 64%) in women compared to 37% (95% CI 25% to 49%) in men. In contrast, specificity
of GP combined tests was similar between men and women and differed by less than 10 percentage
points.
For the target condition normal, some GP combined tests had lower sensitivity in women com-
pared to men. For example, ADL had a sensitivity of 0% (95% CI 0% to 14%) in women compared
to 43% (95% CI 23% to 66%) in men. Six other GP combined tests had lower sensitivity in women
compared to men: TAC, SPMT, TUG, FAQ, IADL, Phototest, and 6CIT. Two GP combined tests were
more sensitive in women than men, MOCA had a sensitivity of 30% (95% CI 13% to 53%) in women
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compared to 10% (95% CI 1% to 32%) in men, and GPCOG had a sensitivity of 83% (95% CI 63% to 95%)
in women compared to 30% (95% CI 13% to 53%) in men. In contrast, specificity of GP combined tests
was similar between men and women and differed by less than 10 percentage points. The proportion
of men and women with each category of cognition was similar: dementia men 53% (95% CI 44%
to 62%) women 56% (95% CI 47% to 65%); MCI men 27% (95% CI 19% to 36%) women 22% (95% CI
15% to 31%); normal cognition men 18% (95% CI 12% to 26%) women 21% (95% CI 14% to 30%). The
average age in women (81 years æ 6 years) was similar to that in men (80 years æ 6 years). Mean ACE3
scores were 73 (æ 15) in women and 77 (æ 14) in men, and mean school leaving age was 15 (æ 1) in
women and 16 (æ 1) in men. There was weak evidence of an association between sex and school
leaving age or ACE3 score, the coefficients for being male were respectively 0.39 (95% CI 0.03 to 0.73)
and 3.2 (95% CI -0.46 to 6.9).
4.7.4 All combinations of GP combined tests
As described in Section 3.7.5.2 and reported in Section 4.6.4.2 for the target condition dementia, four
tests were selected for analysis as GP 360 tests on the basis of discrimination, calibration and decision
curve analysis:
1. GP + TAC + FAQ sensitivity 32% (95% CI 23% to 40%) specificity 98% (95% CI 93% to 100%)
2. GP + TAC + ADL sensitivity 27% (95% CI 20% to 36%) specificity 98% (95% CI 93% to 100%)
3. GP + Eurotest + FAQ sensitivity 50% (95% CI 41% to 59%) specificity 96% (95% CI 91% to 99%)
4. GP + Eurotest + ADL sensitivity 53% (95% CI 45% to 62%) specificity 94% (95% CI 88% to 98%)
Appendix J shows the full results for the analysis of all GP 360 tests. For the target condition dementia,
in comparison to the four tests which were selected for analysis, two tests had higher sensitivity at
the same specificity: GP + SPMT + FAQ had sensitivity 54% (95% CI 45% to 62%) specificity 96% (95%
CI 91% to 99%) and GP + SPMT + ADL had sensitivity 59% (95% CI 50% to 67%) specificity 96% (95% CI
91% to 99%).
For the target condition normal, four tests were selected for analysis as GP 360 tests on the basis
of discrimination, calibration and decision curve analysis:
1. GP + 6CIT + IQCODE sensitivity 32% (95% CI 19% to 48%) specificity 99% (95% CI 97% to 100%)
2. GP + Minicog + IQCODE sensitivity 40% (95% CI 26% to 56%) specificity 97% (95% CI 94% to
99%)
3. GP + 6CIT + IADL sensitivity 39% (95% CI 25% to 55%) specificity 97% (95% CI 93% to 99%)
4. GP + Minicog + IADL sensitivity 38% (95% CI 25% to 54%) specificity 97% (95% CI 94% to 99%)
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For the target condition normal, in comparison to the four tests which were selected for analysis, two
tests had higher sensitivity at the same specificity: GP + MOCA + AD8 had sensitivity 40% (95% CI 25%
to 56%) specificity 99% (95% CI 96% to 100%) and GP + MOCA + IQCODE had sensitivity 44% (95% CI
28% to 60%) specificity 99% (95% CI 95% to 100%).
4.7.5 Geography
Of participants from Bristol practices, 57% (95% CI 45% to 69%) had dementia according to the
reference standard, compared to 53% (95% CI 46% to 61%) of patients from South Gloucestershire
and North Somerset practices.
Diagnostic accuracy of GP judgement for dementia in South Gloucestershire and North Somerset
practices was LRP 4 (95% CI 2 to 7) LRN 0.49 (95% CI 0.38 to 0.63), compared to diagnostic accuracy of
LRP 15 (95% CI 2 to 103) LRN 0.49 (95% CI 0.35 to 0.69) in Bristol practices. In contrast the diagnostic
accuracy for normal in South Gloucestershire and North Somerset practices was LRP 6 (95% CI 3 to
12) LRN 0.60 (95% CI 0.45 to 0.80), compared to diagnostic accuracy of LRP 3 (95% CI 0.6 to 12) LRN




This Chapter has presented the results for the empirical quantitative investigation of diagnostic
test accuracy. From 21 participating GP surgeries with a total population of 34,956 aged over 70
years, 465 people were referred to a diagnostic test accuracy study, 241 were seen (comprising
126 men and 114 women) and 240 were evaluated. Of the 240 participants, 132 had dementia,
and 47 had normal cognition. The informant completed measures were similar whether they
were completed by the interviewer or informant.
For dementia as the target condition, GP judgement as a single test had a sensitivity of 56%
and a specificity of 89%; five tests had an LRP of more than 3 but none had a lower bound of the
95% CI of more than 3 (Eurotest LRP 4 (95% CI 2 to 5); GP judgement LRP 5 (95% CI 3 to 9); ADL
LRP 6 (95% CI 2 to 14); TAC LRP 7 (95% CI 3 to 20); FAQ LRP 10 (95% CI 3 to 30)). In contrast three
tests had an LRN of less than 0.20 but none had a upper bound of the 95% CI which was less
than 0.20 (GPCOG LRN 0.13 (95% CI 0.07 to 0.25); AD8 LRN 0.12 (95% CI 0.05 to 0.29); IQCODE
LRN 0.12 (95% CI 0.05 to 0.27)). Confidence intervals overlapped and prevented inference about
the superiority of any one test.
For the target condition dementia, at threshold probabilities of 80% to 93%, the tests with
the largest net benefit in combination with GP judgement were SPMT and Eurotest. For the
target condition normal at threshold probabilities of 60% to 81%, the tests with the largest net
benefit in combination with GP judgement were IQCODE and AD8.
For the target condition dementia at threshold probabilities of 80% to 93% GP + Eurotest +
FAQ largest net benefit, whereas GP + TAC + FAQ had largest net benefit at threshold probabilities
of 93% to 97%, and at threshold probabilities above 97% the treat-none approach had largest
net benefit. For the target condition normal at threshold probabilities of 60% to 93% GP + 6CIT
+ IQCODE had largest net benefit, whereas at threshold probabilities above 93% the treat-none
approach had largest net benefit.
In sensitivity analyses for the target condition dementia GP combined tests generally had
similar diagnostic accuracy to when they were analysed at published thresholds, but Phototest
and Eurotest had higher sensitivity when analysed as a continuous test. There was some evi-
dence that for the target condition dementia GP combined tests were more sensitive in women,
compared to men, and people aged 80 years or over, than those aged between 70 and 80 years.
When all GP 360 tests were analysed for both target conditions, two tests had higher sensitivity
at the same specificity than the tests which were selected in advance for analysis on the basis of
discrimination calibration and decision curve analysis of the GP combined tests; for the target
condition dementia these two GP 360 tests were SPMT and either FAQ or ADL; for the target










ACCEPTABILITY OF DIAGNOSIS OF DEMENTIA BY A GENERAL PRACTITIONER
T
his Chapter describes the qualitative aspects of the empirical research. The rationale and
research questions are outlined. The methods, including the participants, sampling, data
collection and management, and data analysis are described. A series of qualitative interviews
were done with people who had symptoms of dementia, who were asked if they wished to be
accompanied by a person of their choice, typically a family member. The results of the qualitative
research are also presented, together with an interpretation of the findings through the lens of a
theoretical model. In this Chapter, the term kin is used to refer to the person who was chosen to
accompany the person with symptoms of dementia because this person was not necessarily a carer,
indeed this term was intensely disliked by some participants, or a family member, or even their
"nearest and dearest". The word kin was judged to best capture the nature of the accompanying
parties in a succinct way, defined as:
“The group of persons who are related to one; one’s kindred, kinsfolk, or relatives,
collectively. ” [359]
5.1 Rationale and research questions
Just because a test is accurate does not necessarily mean that it is appropriate or acceptable to
be used in clinical practice; it is important to understand how the evidence about the accuracy of
diagnostic tests can be applied in practice. Therefore, this qualitative component of the empirical
research investigated how acceptable a general practice based diagnosis of dementia would be to
patients and their kin.
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5.1.1 Qualitative research questions
The aim of this study was to understand the acceptability, to people with cognitive symptoms and
their kind, of a GP diagnosing dementia without specialist input. The objective was to obtain a
range of views on how acceptable people with cognitive problems and their kind perceived the
suggestion of GPs making a diagnosis of dementia, rather than specialists such as geriatricians or old
age psychiatrists. The qualitative research questions was:
• How acceptable is it to patients and their kin for general practitioners to make a diagnosis of
dementia independent of specialist input?
It is proposed1 that components of a diagnostic pathway that are "acceptable" may be cate-
gorised under three headings. Firstly some details require consideration regardless of whether the
diagnostician is a GP or specialist, such as the number, frequency and geographic setting of contacts
in the evaluation process. Secondly other aspects, such as preferences for particular interpersonal or
consulting characteristics, are specific to individual clinicians and patients. Thirdly, some features are
hallmarks of an acceptable diagnostic process that define the circumstances under which one process
resembles another sufficiently well for it to be acceptable, and these were of particular interest to
explore.
5.2 Participants and Sampling
Participants were people with cognitive problems (patients) and their kin who were taking part in the
quantitative diagnostic test accuracy study.
Participants in the main quantitative study who the GP researcher judged as having sufficient
cognitive and physical reserves were purposively sampled for maximum variation in characteristics of
referring practice, age and sex, and invited to partake in the additional optional qualitative interview.
To ensure maximum variation in these sample characteristics, potential participants were invited
at each of the three research sites (see Section 3.3), with particular efforts to invite older people
who had sufficient reserves to take part. In addition to the three sampling characteristics in which
maximum variation was sought, particular efforts were made to recruit people who might offer a
novel or original opinion in the interviews, specifically those with mild sensory impairment, or of
non-Caucasian ethnic origin. Additionally, partly because of changes to GP surgeries during the
practices, including mergers of practices, and partly because of difficulties in recruiting people from
certain practices to the qualitative study, as recruitment progressed sampling for maximum variation
in practice evolved into maximum variation in the size of practice (smaller than, or bigger than,
average list size - approximately 11,900; see Table 3.2 for details).
The GP researcher selected and invited people to participate in the qualitative study when they
had completed the research clinic. To avoid bias in the quantitative study, the GP researcher knew
1by the author
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little about the participants, other than their sex, age and referring GP surgery. Specifically, the GP
researcher did not know the opinion that the specialist had reached about the degree of cognitive
impairment, but had completed a number of index tests with the participants and therefore had
some insight into the degree of cognitive difficulties that the person experienced. People who the
GP researcher judged as being in an advanced stage of frailty, either physically or cognitively, were
not invited to avoid the research process being overly burdensome. Limitations of human resource
regarding researchers meant that only people who attended a research clinic in the final six months
(9 November 2016 to 9 May 2017) of the quantitative study (which commenced on 19 April 2015)
were invited to take part in a qualitative interview.
Having identified a person as potentially suitable, the GP researcher invited people to the qualita-
tive study by explaining that it was an additional, optional study that would take place on a separate
day, at a time and place convenient to the participants. An information leaflet about the qualitative
study was discussed and willing participants signed a consent form indicating their agreement to be
contacted to arrange an interview at a later date.
5.2.1 Data collection and management
Semi-structured interviews with participants were done in their homes, at a convenient time. The
participant with cognitive problems was encouraged to have a second person present at the interview,
either the same person who had attended the research clinic with them, or another person. The
attendance of a second person at the interview was encouraged but was not a mandatory inclusion
criteria. Interviews were usually arranged a week or so in advance of the meeting, and participants re-
ceived a confirmation phone call on the day. The intention was to recruit between 15-25 participants.
However, recruitment continued until there were no new emerging themes in the analysis.
At the start of the interviews the consent form for interviews was discussed together with the
patient information leaflet. The patient information leaflet for the qualitative interviews had been
provided previously at the main research clinic but further copies were available at the interview if
required. An opportunity for questions was provided and willing participants indicated their informed
consent to participate in the interview on a signed consent form. Written consent to participate was
taken from both the patient and (if present) their kin; each party consented for themselves only and
not as a proxy for one another. As outlined in Section 3.4 all participants in the main quantitative
study were assessed as having capacity to consent to their own involvement, and this was also the
case in the qualitative interviews.
The interviews explored the range of views for both the patient and their kin. The interview
guide was drafted before any interviews were done, but was then refined in response to the process
of interviewing people. The original interview guide elicited experiences of receiving care at the
participants’ GP surgeries and memory difficulties; their ideas about who should take the lead for
diagnosing memory problems; their thoughts about a GP diagnosing dementia without getting a
specialist involved; their thoughts on a hypothetical process where a specially trained GP in a local
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area triaged referrals and held intermediate care clinics; their thoughts on the hypothetical role of a
specialist nurse compared to a specialist GP; their priorities when trying to establish the cause of
memory problems; their suggestions for improvements to services in future. Participants were then
asked about how their particular memory problems had first been identified and to talk through their
personal experience of being diagnosed.
The original intention was that participants would be invited to complete five of the index tests
that had been done at the main research clinic, so that they could provide feedback on the burden
that they experienced by completing the test. These tests were the Montreal cognitive assessment
[333], timed up and go [323], Eurotest [319], GPCOG [301], and IQCODE [304]. These tests were
prioritised for investigation because they cover a range of domains and, with the exception of
Eurotest, are commonly used in clinical practice. A description of these tests is provided in Section
3.4.1. Patient participants were to be invited to complete these tests, which were also included in the
main quantitative study.
The interview guide was iterated and refined in response to experience of doing the interviews,
in discussion with research supervisors. The interviewer was vigilant and responsive to the burden
that the participant appeared to be experiencing and modified the depth of exploratory questions as
appropriate to the circumstances. The section regarding the personal experience of being diagnosed
was dropped from the interview guide, as it emerged that this section contributed little information
that was relevant to the research question. It became apparent within the first few interviews that
the original intention to ask the person to complete five index tests from the research clinic in order
to assess the burden of the test would be overly burdensome for participants, due to the time taken
to repeat the tests, and also because participants had already the completed many cognitive tests
with the research team and NHS service; therefore this section was dropped completely after nine
interviews with a diverse group of people. The ethical approval for the qualitative interviews had
been obtained as an amendment (Amendments 4 May 2015 and 10 May 2016) to the main study
(IRAS id 143065, Favourable Opinion 26 Nov 2014, London - Bromley Research Ethics Committee,
REC reference 14/LO/2025) and specified that the interview would last up to 30 minutes. It became
clear that repeating the index tests at the qualitative interview would itself take more than the 30
minutes and this would reduce the opportunity to gain valuable insights into the the first qualitative
research question, which was prioritised for investigation. It was judged as being overly burdensome
to extend the interview so re-applying for a further amendment to allow a longer interview was
decided to be inappropriate.
In contrast, some additional areas were added to the interview guide in response to interviews. A
question was added to explore whether the need to typically drive to an appointment mitigated the
desire for the appointment to be especially close to home. Some people were interested in the idea
of trying to improve, or preserve, their cognition and so a question was added about the perceived
value of being given activities or advice on interventions that might improve cognition. Finally, the
discordant view that it was not a problem to wait for an appointment because cognitive problems
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typically progress slowly prompted the addition of a question to explore the extent to which this view
was shared. The original and final interview guides are provided in Appendix F. Notes were made
after each interview and are provided in Appendix G.
5.3 Characteristics of qualitative subsample
During the period of recruitment to the qualitative study research clinics were held at one of three
locations: Clevedon (L81040), Hanham (L81079) or Shirehampton (L81008). Table 5.1 shows the
number of people from each practice who were seen in the quantitative study during the period of
recruitment to the qualitative study. Of the 15 practices who referred people to the quantitative study
during recruitment to the qualitative study, participants from 11 different practices had a qualitative
interview, this included two practices with an average list size (9 participants), six practices with a
smaller than average list size (9 participants) and three practices with a bigger than average list size
(8 participants).
Table 5.2 presents an overview of the participants in the qualitative interviews, giving details of
the diagnosis according to the reference standard, ACE3 score, sex, age, participants in the interview,
whether specific tests were done and the perception of them explored, together with the study
identifier for use with quotations. Of a total 36 people who were invited to take part, 26 participated
in interviews that took place between three and seven months after the quantitative research clinic
appointment (median 5 months). Participants came from 11 different GP surgeries (including urban,
semi-rural and rural locations), were aged from 70 to 89 years, included 10 women and 16 men.
Participants had a range of cognitive diagnoses (6 normal, 11 mild cognitive impairment, 9 dementia)
and performance on Addenbrooke’s Cognitive Examination III (ACE3), a standardised cognitive test,
with participant scores ranging from 62 to 98 out of 100; higher scores indicate better cognitive
function, scores below 82 are often consistent with dementia. Participants were interviewed alone (6),
with a spouse (18), a friend (1), or a daughter (1). Of the 26 participants, 25 agreed to video recording
for least part of the interview and one interview was audio-recorded only.
Three interviews had factors which are potentially relevant when considering their quotations:
E30 and her husband were both nurses while they were working; S13 was a GP when working; and
R13 stated she had been diagnosed with a brain tumour.
5.4 Data analysis
5.4.1 Analytical approach
The data were managed and analysed using a framework approach [360, 361] which is an appropriate
methodology to use when research aims to generate recommendations within a limited time frame
about a specific policy issue [360]. Framework analysis is broadly speaking a thematic analysis or qual-
itative content analysis, and has no strict requirement for either an inductive or deductive approach,
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Table 5.1: Referrals to qualitative study from each practice
Location§ Number seen in ‡ Number recruited to Practice
(code †) quantitative clinic during qualitative study § list
qualitative recruitment size ¶
Backwell (L81060) 6 4 A
Bedminster (L81053) 0 - -
Clevedon (L81102) 7 2 S
Clevedon (L81040) 8 5 B
Clifton (L81081) 2 0 A
Close Farm (L81050) 4 3 S
Fishponds (L81087) 0 - -
Frampton Cotterell (L81014) 4 0 B
Hanham (L81079) 3 0 B
Henleaze (L81131) 3 1 S
Horfield (L81022) 1 0 B
Kingswood (L81063) 0 - -
Long Ashton (L81056) 1 0 S
Mendip Vale (L81086) 3 1 B
Portishead (L81004) 2 2 B
Redfield (L81061) 0 - -
Shirehampton (L81008) 0 - -
Southmead (L81098) 2 1 S
Stoke Bishop (L81622) 0 - -
Westbury on Trym (L81017) 8 2 S
Yate (L81047) 6 5 A
Total 60 26
§ Location is given rather than practice name because practice names
change with mergers and change of doctors
† Practice code is a unique identifier held by NHS England
‡ includes total number seen, not necessarily eligible
§ - indicates zero referrals; recruitment impossible
¶ A Average [list size 10,000-14,000] B Bigger than average [list size >14,000]
S Smaller than average [list size <10,000]
or rigid adherence to any particular epistemological, philosophical, or theoretical underpinning
[362]. Additional features of framework analysis that made it a suitable approach are that it is heavily
based in the accounts of people which it relates to, is systematic and repeatable, responsive to new
data, comprehensive, and allows for comparisons between data [360]. While framework analysis
cannot be used with heterogeneous data that cover a plethora of issues [362], this was not the case
in the empirical semi-structured interviews. Phenomenological approaches were considered to be
less appropriate than a comparative approach, and ethnographic methods, narrative analysis and
discourse analysis were rejected because of time constraints [363].
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Table 5.2: Characteristics of qualitative participants
Study identifier§ Diagnosis † ACE3 ‡ Sex Age Participants § Specific tests
C20 MCI 93 male 72 h+w done
C25 MCI 91 female 88 solo not done
E19 dementia 76 male 89 h+w planned, not done
E23 dementia 77 female 76 friend done
E25 dementia 72 male 73 h+w not done
E27 MCI 83 male 80 solo not done
E30 dementia 76 female 82 h+w not done
G18 normal 92 male 88 h+w not done
L3 MCI 90 male 76 h+w done
L7 dementia 73 male 80 h+w not done
M18 dementia 62 male 77 h+w done
M22 MCI 84 female 89 solo not done
M23 MCI 74 male 73 solo not done
M24 normal 92 male 71 h+w not done
M25 dementia 69 female 87 solo not done
N2 dementia 81 male 86 h+w not done
P5 MCI 79 male 74 h+w not done
R13 normal 95 female 72 h+w done
R14 normal 97 female 73 solo done
R15 MCI 89 male 84 h+w done
R22 MCI 87 female 77 h+w not done
S13 normal 90 male 72 h+w not done
S14 MCI 87 female 85 daughter not done
S15 dementia 81 male 85 h+w not done
Z9 normal 98 female 73 h+w done
Z11 MCI 79 male 79 h+w not done
Specific tests indicates whether views on five specific index tests were elicited
(see Section 5.2.1)
§ Study identifier is an anonymous identifier but is used consistently with
quotations in this thesis
† Diagnosis as assigned by the reference standard evaluation
‡ ACE3 Addenbrooke’s Cognitive Examination III
§ h+w husband and wife
5.4.2 Procedure for analysis
A combined inductive / deductive approach was taken, as is common with a Framework analysis
[362]. The following seven-step approach was taken to data analysis, as is recommended [362]:
Transcription, Familiarisation, Coding, Developing a framework, Applying the Framework, Charting
the data, Interpreting the data.
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5.4.2.1 Transcription
Transcription of the audio files was done verbatim by a professional approved service. Transcriptions
were of the whole interview and so included attributed contributions from both the patient and
(where relevant) their kin. Data were transferred to the professional transcribers using best practice
in approved data management. Transcriptions were imported into NVivo 11 qualitative data analysis
software [364] and verified against the original data files by listening to the original recordings; any
corrections to the professional transcription were clearly marked on the transcript. Contributions to
the interview from both the patient and their kin were transcribed and clearly attributed.
Data management Interviews were electronically recorded using a secure encrypted laptop. All
interviews were audio-recorded and when participants consented the interviews were also simulta-
neously electronically video recording using the same equipment. Data were moved from the secure
encrypted laptop that had been used to record the interview onto a secure encrypted University
network drive for storage of research data (and deleted from the laptop) immediately on return from
the interview to the university. Data were stored in compliance with relevant regulation and the
University of Bristol data management policy. All audio recordings were anonymised. All personally
identifiable data was stored separately to study data on secure University of Bristol servers.
5.4.2.2 Familiarisation with the interview
The full interviews were listened to and checked against the professional transcript. All interviews
had been conducted by the same GP researcher and so there was already a good familiarity with the
content. Ethnographic notes were also reviewed at the time of reviewing the interviews. If a video
was available this was also viewed whilst reading the transcript to help provide immersion in the
context of the transcribed material.
5.4.2.3 Coding
Transcripts were read line-by-line, and codes were applied to relevant parts of the transcript by the
GP researcher using NVivo. Codes were derived from the words that were used in the transcript and
so emerged from the data. Values and emotions about the acceptability were especially identified for
coding. Particular effort was made to identify and code data that expressed an opinion or stance that
was discordant with the majority. Impressionistic data on the reliability of the testimony were coded
because some participants had a greater degree of cognitive impairment than others. Only data that
were relevant to the issue of the research question on the acceptability of a GP diagnosis of dementia
were coded. A 20% selection of transcripts were double coded by a second coder, a supervisor with
significant experience in qualitative research, for quality assurance.
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5.4.2.4 Developing a working analytical framework
A set of codes was discussed and agreed between coders after five transcripts had been coded.
The codes emerged from the data and had not been specified rigidly in advance, although the GP
researcher acknowledged some general preconceived ideas about the topic. The initial codes were:
• GP diagnosis
• Trained non-specialist diagnosis
• Specialist diagnosis
• Accessibility
• Credibility and competency




These codes were developed and iterated into the the working analytical framework outlined in Table
5.3. Two sets of codes were used. Chart 1 (aspects of acceptability) contained coded data relating
to GP diagnosis and role, diagnosis by a dedicated, trained but non-specialist clinician, specialist
diagnosis, self care, and the extent to which communication was effective. Chart 2 (organisational
competence) contained coded data relating to accessibility, nurturing and handling uncertainty, and
continuity.
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Code Operationalised as Example data
data relating to
Chart 1: Aspects of acceptability
GP diagnosis and role GP role and capacity for “it starts with your GP and then he can refer you on ”[P5 informant]
making diagnosis
Diagnosis by dedicated, trained Dedicated non-consultant specialist “Well I suppose as long as somebody diagnoses the problem and gets it right
non specialist clinician making a diagnosis it doesn’t really matter who does it ”[R22 patient]
Specialist diagnosis Diagnosis by a specialist “Well, what’s a specialist? They’ve learnt that by um, over the years by um,
observing and being involved with them anyway. I mean some people are
better at it than others that’s life anyway ”[M22 patient]
Self-care Self management and empowerment “I can live with it now. I’ve learned - it seems that you learn little tricks
that you can play with your brain ”[M23 patient]
Effective communication Extent to which communication transmitted “at the moment I’m not upset I’m a bit tangled ”[M25 patient]
by participant reflected their intended
meaning
Chart 2: Organisational competence
Accessibility Waiting times, geographical distance “as long as one of us can drive to get you know to that specialist er
or speed of diagnosis treatment it’s not important however I do feel sorry for the people that
have to travel hundreds of miles, that’s a different thing altogether
isn’t it? ”[L7 informant]
Nurturing and Support during the process “ [my friend who is dealing with cancer] can call somebody anyway,
handling uncertainty of diagnostic evaluation and the nurturing and the care, and the comfort she is getting is
amazing...you keep feeling dropped. You know you’ve left the radar
and then you go and see somebody ”[E25 informant]
Continuity Organisational coherence e.g. “Well if they’re only seeing you the once, they probably wouldn’t be able
seeing same clinician, records to diagnose that, but if they saw you a few times, I think they
being available could ”[E30 patient]
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5.4.2.5 Applying the analytical framework
The codes outlined in Table 5.3 were used to code the data in all of the transcripts, including the five
transcripts which had already been coded.
5.4.2.6 Charting data into the framework matrix
Coded data from each transcript were charted into the framework matrix using the codes outlined in
Table 5.3. Data were charted separately (side-by-side) depending on whether data were attributable
to a patients or their kin. Short verbatim quotes were included in the chart and were identified by
coloured text.
Themes were detected from the printed spreadsheet charts and written onto sticky notes which
were then categorised in an iterative process onto sheets of paper. The themes were mapped into
a comprehensive but succinct classification, which was then reconsidered and refined against the
detected sticky notes and charts to best fit the data. The data were mapped into a classification which
was judged to reflect the elements that contribute to the acceptability of a diagnostic process, and








5.4.2.7 Interpreting the data
The literature was reviewed to identify a theoretical framework to help interpret the findings of the
qualitative framework analysis. The Health Belief Model (HBM) [365], Theory of Planned Behavior
(TPB) [366], Normalization Process Theory (NPT) [367], and The Theoretical framework of accept-
ability (TFA) [368] were identified as being potentially relevant. The HBM relates to the uptake of
health services and was originally formulated to describe the uptake of screening programs and
health promoting behaviours. The TPB posits a function to understand deliberate human behaviour
and asserts that this is a function of perceived behavioural control and the intention to perform the
behaviour (which is held to be related to attitudes towards the behaviour and subjective). NPT is
advocated as being applicable to help understand the process of implementing, embedding and
integrating an innovative practice. The TFA is a multi-construct theoretical framework derived from
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a systematic review which relates to “the extent to which the person delivering or receiving the
healthcare intervention consider it to be appropriate” [368]. Overall the TFA was chosen as being the
most appropriate model as this relates specifically to the acceptability of a healthcare intervention.
Based on a systematic review of 43 studies the authors of the TFA propose that acceptability
has seven facets: affective attitude, burden, ethicality, intervention coherence, opportunity costs,
perceived effectiveness, and self-efficacy. Affective attitude is [368] “how an individual feels about
the intervention”. Burden is [368] “the perceived amount of effort that is required to participate
in the intervention”. Ethicality is [368] “the extent to which the intervention has a good fit with
the individuals value system”. Intervention coherence is [368] “the extent to which the participant
understands the intervention and how it works”. Opportunity costs are [368] “the extent to which
benefits, profits or values must be given up to engage in the intervention”. Perceived effectiveness
is [368] “the extent to which the intervention is perceived as likely to achieve its purpose”. Self-
efficacy is [368] “the participants confidence that they can perform the behaviour(s) required to
participate in the intervention”. Section 5.6 describes how the TFA was related to the empirically
derived classification for the acceptability of diagnosis of dementia by a GP.
Charted data in the category of effective communication were not re-categorised, or mapped into
a classification, but were retained to facilitate understanding of the context of the statements that
participants made. Section 5.7 reflects on the challenges that were experienced when interviewing
people with cognitive problems, and the impact of this.
5.5 Results: Acceptability of GP diagnosis
A classification comprising seven aspects was judged to comprehensively reflect the data. As a
reminder, the research question was: How acceptable is it to patients and family members for general
practitioners to make a diagnosis of dementia independent of specialist input? The findings for each
of the seven aspects are presented below followed by a statement suggesting the implications of the









5.5. RESULTS: ACCEPTABILITY OF GP DIAGNOSIS
5.5.1 Emotional context
A number of people framed the process of being evaluated for dementia as an experience that was
associated with fear, perhaps even being the most frightening diagnosis that they could imagine: “the
big D” (R15 patient). People stated that courage was needed to access help “my step forwards have
been going to the doctor, getting the courage to go” (L3 patient). For some people there was a sense of
urgency to get the problem addressed, “I think they should be seen quickly” (E19 informant), which
was increased by the desire to halt or indeed reverse the cognitive decline, or help reassure “that
would give people a lot more reassurance” (M24 patient). Other people did not perceive the speed of
access to appointments as important, so long as symptoms were mild and not progressing rapidly
“I’m not sure about being seen quickly is any benefit because you’ve gradually lost your memory over
30 years ... if you can’t remember anything it would be different” (G18 patient).
Implications of findings: Some people with cognitive symptoms report fear, especially while in
a period of uncertainty about the diagnosis, and may benefit from a process which supports positive
emotional and psychological well-being.
5.5.2 System resources
A number of participants experienced fragmented care at their general practice, which some at-
tributed to changes in working patterns of doctors: “GPs [are] all part time these days” (C20 patient).
Some people reported a tendency for people with cognitive difficulties to withdraw from society “I’ve
lost the group situation” (Z11 patient), and some thought that a whole community approach might
help people feel integrated “I think with memory people have to be sympathetic. I think sympathy
has gone out of the window... having neighbourly relationship we learn from each other” (S13 patient).
There were a range of views on the extent to which care should be provided locally to home. For
people who were able to drive, some were happy to travel though the acceptable distance varied from
the local GP surgery, to the major city, or indeed hundreds of miles. For people who could not drive
themselves there were a variety of approaches for getting to appointments, namely public transport,
taxis, family, or community transport. Some people experienced difficulties with travel arrangement
as a structural barrier to care, for instance if “the buses don’t go where I want to be” (S14 patient), but
for others it was less of an issue: “travelling these days, [is] quite easy, you can go anywhere quite
quickly” (E19 informant).
Implications of findings: Some groups of people may require particular assistance, perhaps
offered through community or voluntary organisations, to ensure they experience equitable access
to diagnostic resources. Continuity may need to be intentionally designed to be understood at the
organisation or system level, for example with a consistent visual identity, to mitigate for discontinuity
at the level of the individual.
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5.5.3 Own resources
For some participants cognitive difficulties made the business of daily life challenging. Advice on
how to handle the day-to-day was reported to be as useful as the bio-medical and pharmacological
expertise of a consultant “I think the day-to-day thing of having somewhere to go to perhaps to spend
a day or do things and people will give things to do that will be helpful, I think that’s just as important
as a consultant to be perfectly honest” (E23 informant). Some people had developed strategies to aid
their memory, or were interested in whether changes to diet and lifestyle might improve memory.
There was a desire amongst some people to be able to do something for themselves. Other people
felt that “in fact I was overwhelmed with, with information” (E19).
Implications of findings: People undergoing diagnostic evaluation for cognitive disorders should
be offered resources to enable effective self care and management, delivered in a self-paced way.
5.5.4 Responsive assessment
A variety of accounts indicated that a diagnostic evaluation for dementia needed to be personalised
and consider whether any impairment was attributable to medication, sensory impairment, or stress
“I think there’s other reasons for not remembering other than something wrong with your brain” (S14
patient). Some people reported that they had not received an assessment that actually evaluated the
concerns and problems that they were experiencing “I do feel that a lot of his problems haven’t really
been addressed” (C20 informant). For other people, the initial assessment that had been done by the
GP was not sufficiently in depth or challenging to identify a problem “from where we were coming
from it seemed a little bit kind of light and he was feeling that he needed to perhaps that we needed
something more” (R15 informant). There were sensitivities around the language that was used in the
diagnostic process, with some people being irritated by the idea of needing a carer as this implied a
degree of severity that did not correspond to their current difficulties “we have in the last two or three
months become irritated by the concept that [wife] is my helper, my carer, I’m not in requirement of
a helper or a carer” (R15 patient).
Implications of findings: People with cognitive problems should be offered an opportunity to
express their personal concerns and supported to perceive their assessment as personalised to them.
5.5.5 Important condition
A range of people viewed dementia as an important and complex problem that required training to
be able to diagnose properly: “It’s a very serious thing to be told you’ve got dementia” (R22 patient).
For some interviewees, the job title of the person who was making the diagnosis was not important,
so long as they were trained, and competent “I could be persuaded that the right nurse with the right
training, the right background and the right understanding could be the mechanism in the general
area. If not for anything else other than to sift through them” (R13 patient). Indeed, some people
conceptualised diagnosis as “a list of questions which are arranged by experts probably and they
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can ask those sorts of questions and ... at the bottom you’ve got a total” (E27 patient). For others
there was a need for the person who was diagnosing to be trained to the same level as a specialist.
A number of people held the view that dementia was too serious and specialist to be diagnosed by
GPs. For some people the desire to access help was so great that they would be willing to travel long
distances, even abroad, to see a someone who might be able to help: “I mean NHS says to me, sorry
we can’t do any more for you, and – but there is this genius in United States for instance, I would
like to go there and see him” (M23 patient). Some interviews indicated that a diagnosis of dementia
by a non-specialist would be subject to challenge or suspicion on the part of the patient because
they would consider the GP to be “misguided” (C25 patient) if they diagnosed dementia, whereas if a
specialist made this diagnosis they would be “more [pause] prone to take notice of what was said
and what was diagnosed” (C25 patient). In contrast other people stated they “would accept it [the
opinion of a GP] not because I’d be glad to or that I feel I should but I. . . I don’t think I would quarrel
with him if that was his opinion” (M25 patient). Various accounts indicated that continuity with a
particular GP was perceived as being a necessary condition for a GP based diagnosis of dementia:
“Well if they’re only seeing you the once, they probably wouldn’t be able to diagnose that, but if they
saw you a few times, I think they could” (E30 patient).
Implications of findings: Accreditation, re-certification, and quality standards may help patients
to be assured of a high quality services underpinned by rigorous training.
5.5.6 Diagnostic process
There was a recognition that it was important to have an explanation for cognitive problems and
symptoms, but for some people the diagnostic process was not just about getting a diagnosis or label,
but was inseparably linked to a desire for practical advice, an indication of prognosis or what to
expect, and an offer of interventions “Because I want to know one way or the other, what it is, what’s
the diagnosis, what’s the outcome or non-outcome?” (Z9 patient). A range of people recognised that
there was, or could be, a hierarchical (or step-wise) process to getting diagnosis. Some accounts
indicated that the stepwise approach was frustrating and unhelpful “it’s been a very long drawn out
process and I don’t feel anybody’s on top of anything. We feel in the wilderness” (E25 informant)
whereas others accepted it “you’ve really got to wait to allow the authorities to sort it out” (G18
patient). A number of people either explicitly or implicitly recognised a series of trade-offs between
expertise, access, and continuity “if you’re insisting on going right up to the top, it’s stupid, because
probably you’ve got to wait an awful long time to get in to see them” (L3 patient). Some interviewees
stated that interpersonal factors were an important factor in the extent to which the diagnostic
process was considered as acceptable “he was very good actually ... There again if it was the err
someone in their 20 something I don’t think I would be quite happy about it because they wouldn’t
have the experience” (M22 patient).
Implications of findings: Diagnostic pathways should be designed so that they can provide not
just a diagnostic label, but also advice and interventions. The number of encounters and stages in
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the process of reaching a diagnosis should be kept to a minimum.
5.5.7 Opportunity costs
Some participants recognised that resources in the health system were limited, and were stretched
because of the demand for healthcare “I mean, we all know the NHS is overstretched and you don’t
want to overburden it but I think there is a role for a doctor with one in the area that has extra training,
different tools” (R13 patient). One view was that GPs did not have the capacity to take on additional
work, or would have to drop something else to be able take on the diagnosis of dementia: “I can’t
see them sort of fulfilling a leading role in it because he wouldn’t have the time, even if he had the
expertise” (Z11 patient). Some people took the view that if diagnosis was not of practical benefit to
patients then perhaps money should be invested in social care instead “If early diagnosis makes no
difference then there’s a case to be made for a little pot of money to help people get through the first
stages and more to put into social care” (R13 patient).
Implications of findings: Organisations should be resourced to provide a service that monitors
demand and is able to anticipate and plan changes in the capacity it is required to deliver.
5.6 Interpretation of results
As outlined in subsection 5.4.2.7 the TFA was chosen as the most appropriate theoretical lens through
which to view the empirical findings. The TFA defines acceptability as follows:
“A multi-faceted construct that reflects the extent to which people delivering or re-
ceiving a healthcare intervention consider it to be appropriate, based on anticipated or
experienced cognitive and emotional responses to the intervention ” [368]
Table 5.4 outlines how the TFA fits against the the empirically derived categories and describes
some possible implications of the findings. If the seven aspects of the TFA are accepted as reflecting
the acceptability of a diagnostic evaluation for dementia then to an extent, some of these apply
regardless of whether the diagnosis takes place in a generalist or specialist setting, and some are
particularly important in one or other setting. Based on the interview accounts, perceived effectiveness
and ethicality were judged to be particularly influential on the acceptability of a diagnosis by a GP.
The other components of the TFA were considered be important to consider regardless of where the
diagnosis took place and so less specifically relating to acceptability of a diagnosis in general practice.
Perceived effectiveness is "the extent to which the intervention is perceived as likely to achieve
its purpose"[368] and corresponds to the concept of responsive assessment, because people who
are undergoing evaluation for possible dementia reported that they wanted the process to account
for individual differences and the particular individual problems; an unresponsive assessment
may leave an unmet need [369]. Diagnostic evaluations by GPs could be responsive by explicitly
asking how people would like to be addressed and eliciting the scope of the concerns in an open,
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relatively unstructured, and patient focused encounter, which is typically within the expertise of a
GP. Conversely it would be harder for GP evaluations to be responsive by addressing the specific
concerns with a bespoke assessment that will evaluate the particular concerns that the patient has
noticed, because GPs have a limited range of clinical phenotypes (see Section 1.1.3.3) that they can
compare a new case against, and limited expertise in using a variety of cognitive tests. These factors
make it unlikely that an evaluation by a GP would be totally bespoke and nuanced to the individual
problems that were faced by the patient, whereas a specialist assessment might have the opportunity
(whether or not it is done in practice) to offered a fully tailored evaluation. One response to this issue
would be for a GP to focus initially on taking a clear history about the scope and form of the cognitive
problems and then to evaluate only those phenotypes that were within their experience, and refer the
others to a specialist. Alternatively, future technology could be used to target the testing of cognition
to problematic domains. The crucial point is that the diagnostic evaluation must be responsive to
the needs and the problems of the individual and be comprehensive and plausible.
Ethicality is "the extent to which the intervention has a good fit with the individuals value system"
[368] which maps to the important condition concept in the empirical classification because some
people with memory problems report that dementia is a serious condition and have a level of
expectation that they will be evaluated comprehensively by an expert. GPs in the United Kingdom
practice within a professional framework set by the General Medical Council, and this requires
doctors to [368] "recognise and work within the limits of your competence" [370]. An accreditation
and certification process, and evaluation of care provision against approved quality standards may
help GP providers of a diagnosis of dementia to meet their professional obligations and the public
expectations that were described in the interviews. Any service commissioned from GP providers
would need to incorporate the costs of training and accreditation.
Five of the seven components of the TFA were considered as being generally important to consider
regardless of whether diagnosis is made by a GP or a specialist, and therefore less specific as factors
that would determine the acceptability of a diagnosis made by a GP. However, they are still important
factors that determine the acceptability of a diagnostic evaluation, regardless of where that evaluation
takes place. The emotional context (TFA: affective attitude) that people with cognitive symptoms and
their kin perceived while experiencing cognitive symptoms and waiting for a diagnosis or explanation
was often one of fear and uncertainty. Acceptability of diagnostic interventions might be enhanced
by supporting positive emotional and psychological well-being for patients and kin, encouraging
autonomy and self-empowerment by providing information about timescales, appointments and
action to take at times of deterioration or crisis. System resources (TFA: burden) that could improve
acceptability of diagnostic interventions might be the identifying and mitigating barriers to care,
especially for groups who may require particular assistance, such as those without a car or with
low levels of (health) literacy. Additionally, intentionally designing continuity into the system (e.g.
with a consistent visual identity, or a named caseworker) might help to reduce the number of steps
or transitions in the diagnostic process. Providing self resources (TFA: Self efficacy) or strategies
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that could be used by people experiencing cognitive problems to manage their symptoms and
enhance their own autonomy and independence might also improve acceptability of diagnostic
evaluations, because accounts indicated that these are often desired. A particular finding of the
empirical work was that it is important for self care resources to be self paced; this finding fits
within a well established literature reporting varying levels of patient activation, "an individual’s
knowledge, skill, and confidence for managing their health and health care" [371]. Empirical accounts
indicated that the diagnostic process (TFA: intervention coherence) should address needs for advice
and interventions, not a just a diagnosis. Through this lens, diagnostic pathways may be viewed
as more acceptable when they are joined-up and structured, keeping encounters to a minimum
while remaining comprehensive in scope, and considered in the context of the findings about self
efficacy. Opportunity costs was an item in both the TFA and in the empirically derived classification,
and serves as a helpful reminder that pathways should be resourced not just to be able to meet the
current demand but also to monitor and respond to changes in the balance between demand and
capacity.
Disregarding the impact of the two other factors in the TFA (perceived effectiveness and ethicality)
then there is no clear reason why diagnosis of dementia in general practice would be any more or less
acceptable than a diagnosis in secondary care, given consistency of the five factors in the TFA that
are generally applicable to the acceptability of a diagnostic evaluation regardless of setting (affective
attitude, burden, self-efficacy, intervention coherence, opportunity costs).
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Table 5.4: Implications of qualitative findings
Aspect of acceptability Example Possible implications Aligns to
TFA §
Emotional context Some people with cognitive symptoms experience At initial encounter provide information about Affective
fear about getting worse while waiting for an explanation indicative events†, timescales, prognosis, attitude
for their problems and when to seek help
System resources Some report lacking continuity with a particular GP Engage with local community partners e.g. Burden
Accessible care and a cohesive community approach to voluntary organisations, in partnership with
dementia were also important local care networks
Self-resources Some people want information about self-care Provide evidence-based self-management Self-efficacy
for their symptoms; others are overwhelmed by mis- strategies that are accessible at the
timed information or coping with daily life time of need e.g. guided handbook or online
Responsive assessment One view was that the cognitive evaluation did not Perform evaluations that explicitly elicit and Perceived
address the patients specific problems. Some people assess the patient’s concerns using agreed effectiveness
found certain terms distressing. language.
Serious condition Some people were concerned about misdiagnosis. Evaluations should be done by trained, Ethicality
Evaluations were said to require trained staff, credible staff who have sufficient time to
with sufficient time (or serial assessments) perform a plausible assessment
to evaluate the cognitive problem(s) in detail
Diagnostic process Some people linked diagnosis to an explanation The diagnosis - or explanation of symptoms Intervention
about prognosis, interventions and practical advice. - should be provided with advice on the coherence
Some people wanted help to understand their progress next steps. Patients should have a consistent
in a system they perceived as hierarchical. single point of access for queries.
Opportunity costs Some people said that GPs had limited Any diagnostic pathway should be Opportunity
capacity to take on extra work. resourced. costs
§ TFA Theoretical framework of acceptability
† indicative events e.g. neuroimaging or first outpatient appointment
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5.7 Discussion of qualitative work
This chapter has attempted to answer the following research questions using semi-structured quali-
tative interviews of people with cognitive symptoms and their kin:
• How acceptable is it to patients and family members for general practitioners to make a
diagnosis of dementia independent of specialist input?
5.7.1 Summary of main findings
Acceptability 26 interviews were done with people with symptoms of dementia and (if they wished)
a third party (their kin). A range of views was elicited from a group of people who represented a
diverse mix of cognitive diagnoses, age and sex, and GP practice. A framework analysis indicated that
there are seven aspects which influence the extent to which it is acceptable for general practitioners
to make a diagnosis of dementia independent of specialist input. Interpreted through the lens of the
TFA the empirical work suggests that the extent to which such an innovation is acceptable will be
increased by a process that: takes account of the (often fearful and pressing) emotional context, is
accessible and cohesive, recognises the daily challenges that are experienced by those with cognitive
problems and the desire of some people to self-care, is responsive to the needs and the problems of
the individual, evaluates the problems with a comprehensive and plausible evaluation, holistically
relates the desires of diagnosis advice and intervention, and is properly costed and resourced.
5.7.2 Relation to literature
The current study identified that for some people the process of diagnosis occurs within an emotional
context of fear and a sense of time urgency. Previous reports have identified the emotional impact
that a diagnosis of dementia has on a person, including a loss of identity, anger, uncertainty, and
frustration [372]. Similarly the diagnostic process has previously been identified as being frightening
and disorganised [373]. Many respondents to the empirical interviews reported a lack of continuity
and that having a care service that was accessible and cohesive were important. Similarly, participants
in previous studies have reported fragmented routes to a diagnosis and a lack of support and follow-
up after the diagnosis [374].
The current study found that dementia was regarded as a serious condition, that sufficient time
and resources would be required to provide an acceptable diagnostic service, and that there would be
opportunity costs in having the service provided by GPs. Similarly, other investigators have reported
the view that some people would rather be told that they have cancer than dementia [375], that GPs
had reservations about making an incorrect diagnosis of dementia [340], and that a primary care led
dementia service would need to be appropriately resourced and sufficient time made available [340].
The finding that people link diagnosis to an explanation about prognosis, interventions and
practical advice has also been reported by other investigators [372–375]. Indeed, more generally a
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hypothesised model for a lay understanding of ill-health is that patients typically are seeking answers
to six questions [174]:
1. What has happened?
2. Why has it happened?
3. Why to me?
4. Why now?
5. What would happen if nothing was done about it?
6. What should I do about it, or whom should I consult for further help
Some discordant views should be specifically noted. For instance, some people stated that waiting
for a diagnosis was not important because cognitive symptoms typically developed slowly, and this
is not in keeping with the literature in general, or with the rest of the respondents. Similarly some
people viewed diagnosis as a tick-box exercise and stated that it could be done by anybody with the
appropriate tools, which again is somewhat discordant with the rest of the literature.
5.7.3 Strengths and limitations
A strength of the work is the diverse range of people that contributed to the interviews, and the
systematic and repeatable approach to the analysis using Framework. The interviews regarding
acceptability continued until there were no new emerging themes, and the findings of this aspect of
the work are cohesive with the TFA model of acceptability.
As described in Section 5.4.1 the Framework Method was chosen because it uses a systematic
approach and is particularly appropriate for the analysis of semi-structured interviews [362]. Three
key limitations of the Framework approach have been described [362]. Firstly, the risk that for those
with a quantitative research background there will be a risk of quantifying qualitative data. Secondly,
that it can be time-consuming and resource intensive, like all qualitative research methods. Thirdly,
that there is a training component to the use of the method in a multi-disciplinary team. Measures
were taken to mitigate the impact of these limitations on the research described here. Firstly, efforts
were made to avoid quantifying research findings, other than in the description of the participants.
Terms such as some, a number of, or a range of were used in the reporting of the findings to avoid
inappropriate quantification. Secondly, dedicated time was allocated to the qualitative research
during the investigations. Recruitment to the qualitative interviews started towards the end of the
quantitative investigations, when research clinics were occurring only once a week, rather than two
or three times a week and this supported an opportunity for reflexivity regarding the qualitative
investigations. Thirdly, the Author undertook two formal training courses on Qualitative methods and
Framework at the NatCen National Centre for Social Research, in addition to a three-day introductory
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course at the University of Bristol. Additionally, the Author had a dedicated qualitative advisor with
significant experience of conducting qualitative research, who supported coding and reflexivity.
Although a wide spectrum of people were invited to take part in interviews, it is arguably a
limitation that the people who were judged as being most frail were not invited, and the presented
classification may not adequately reflect the views of this group. Indeed, by definition, the range of
views is restricted to people who were willing to participate in research. To the extent that people who
take part in research are different from those who do not, the opinions expressed may not reflect the
views of the entire population. In particular, it is plausible that people who take part in research are
willing to accept new ideas and suggestions, and so they may have been more open to the idea of a GP
diagnosis of dementia that the general population. A second limitation relating to the range of views
that were obtained is that all of the participants were recruited from BNSSG and the findings are only
transferable to the extent that the views are applicable to people in other settings. It is plausible that
people in BNSSG may be more open to the idea of GP diagnosis of dementia than others because
of the GP dementia diagnosis service described in Section 3.2.2, which was restricted to practices
in Bristol. Of the 26 participants in the qualitative interviews, four were from practices in Bristol
and the remaining 22 were from practices which were not part of the GP diagnosis service. It is very
likely that the views expressed reflect range of experience in dementia diagnosis services across 10
different practices and three different clinical commissioning groups. Although the interviewees
were all participants in research, the interviews elicited a wide range of views, including some views
that only a specialist could diagnose dementia (Section 5.5.5), and the interpretation is a synthesis of
the views expressed using Framework. Section 5.7.4 explores the impact of conducting triadic rather
than dyadic interviews.
A further limitation is that there were difficulties in answering the research question addressing
burden of tests. These difficulties are outlined in Section 5.2.1.
5.7.4 Trustworthiness and reflections
The credibility [376] of the findings is particularly supported by prolonged engagement and persistent
observation. One interviewer conducted all of the interviews with people. The interviewees had
all been encountered previously at the quantitative research clinic, and the researcher had been
considering the setting and context of the research for a year before the interviews were done. The
researcher was immersed in the data through the process of doing the interviews and reviewing the
transcripts, audio and video recording, and coding. As the interview guide was refined during the
process of the interviews the most important issues for the research question were crystallised and
persistently observed. Data were triangulated by specifically seeking dis-confirming views, and by
adding new questions as interviews progressed to explore ideas that had been proposed by earlier
participants. Quality assurance was done by having 20% of transcripts double coded.
There are at some important reflections on the qualitative work. Firstly, the interviews and analy-
sis were conducted by a researcher who is also a GP. The investigator therefore undertook the studies
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with some pre-conceived ideas about what might be important to people seeking professional advice
about cognitive symptoms. In particular the researcher was of the opinion that the acceptability of a
diagnosis was a function of the credibility of the process that had led to that outcome and the person
conveying the diagnosis, and that credibility was related to factors such as a person’s job title (more
credible if made by a Professor), the built environment that the encounter took place in (more credi-
ble if polished and clean), the extent to which expectations were met, and the emotional response to
the encounter (underpinned by relational and interpersonal factors). Secondly, the process of doing
interviews with people with cognitive problems was challenging at times. Specifically, it became
clear over the process of the interviews that it was more difficult than anticipated to ask people who
had cognitive impairment to talk in relatively abstract terms about the pros and cons of different
approaches to diagnosing a significant condition that they (and their kin) were emotionally involved
with. Notwithstanding that qualitative research can take a critical realist stance which recognises
multiple different perspectives, or a post-modern approach which understands there as being no
objective truth, there are particular issues when interviewing people with cognitive impairment.
In interviews and encounters with people who were experiencing cognitive symptoms, or who
may have had sensory impairment, there was a risk that both the reception and transmission of
information may be partial or misleading, as those with cognitive impairment may not have been
able to communicate their full intended meaning, or they may have been distracted. Reflecting on
this process, the joint interview with both the patient and their kin may have provided a support to
the person with cognitive symptoms and helped to ensure that their views were as well articulated
as possible. As described in Section 5.4.2.6 the transcribed data were charted (side-by-side) using a
Framework chart separately for patient and informant respondents to indicate the person who had
contributed the view. Participants were offered the option of taking part in the qualitative interview
with their kin, but this was not mandatory. Alternative approaches to data collection would have been
to mandate either dyadic or triadic interviews, or to conduct focus groups. It is likely that mandating
either dyadic or triadic interviews would have led to a reduced range of views being obtained for
two reasons. Firstly, it is plausible that some patient participants would have declined to take part
if they had to take part alone, because of concerns from them or their (often protective) kin about
their wellbeing. Secondly, it is plausible that in triadic interviews the views of the respondents may
have been influenced by one another; arguably this is similar to the use of focus groups and so is a
strength because it supports the development of ideas of views and ideas as they are articulated and
people respond to the developing discussion. In contrast, it is very likely that many of the patient
respondents would have struggled to have participate fully in a focus group because some people
had difficulties maintaining focus in a triadic - or even dyadic - interview.
Participants had a range of cognitive engagement with the interviews. Some participants were
able to give clear answers to questions, answering questions clearly and recalling events well, in-
cluding on occasions specific details of the research clinic some months prior to the the qualitative
interview. Other people had difficulty staying focused on the interview, for example talking at a
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tangent to the question about a previous medical problem, or on the other hand giving a very de-
tailed and drawn out response to a relatively simple question. Some people denied that they had
any problem with their memory but then would repeatedly ask for questions to be restated, and not
obviously because of sensory impairment. Some people had quite advanced cognitive impairment
and struggled to given specific answers to clear focused questions, or to find the right words to convey
their intended meaning.
5.7.5 Conclusion and implications
Table 5.4 summaries some of the possible implications that emerged from the interrogation of the
classification in Section 5.5. The coherence between the TFA and the classification in Table 5.4
provides support to the empirical findings. If commissioners were to introduce any of the recom-
mendations in Table 5.4 to the health system then the TFA might provide an appropriate framework
to evaluate the impact on the acceptability of the diagnostic process.
One view is that the findings described in Section 5.5 are recycling conventional wisdom. Certainly
for people who are interested in the delivery of healthcare and in particular the care of people
with dementia (such as the Author) some of the findings resonate with accepted views on good
practice; indeed the pre-conceptions of the Author prior to conducting the interviews have already
been discussed in Section 5.7.4. Likewise, as discussed fully in Section 5.7.2 other investigators
have reported many similar findings previously, particularly with respect to the emotional context
surrounding evaluation for cognitive symptoms, reports of fragmented services, the perception that
dementia is a serious condition, and the desire for practical support not just a diagnosis. Some
of these findings, such as the need for coordinated care, that engages with the voluntary sector,
and provides responsive information and support at the point of diagnosis are so well accepted by
professionals that they are incorporated in national guidelines [377]. To the extent that the views of
the participants, who may or may not have read the guidelines (either is plausible), are consistent
with accepted wisdom the findings may simply reflect that people are describing an accepted view.
An alternative stance is that the consistency between the interviews and accepted wisdom supports
the findings.
The Author proposes in Section 5.1.1 that some of the components that define acceptability of a
diagnostic evaluation are important regardless of the setting in which that evaluation takes place
and arguably this view is supported by the consistency between interviewee opinions on diagnosis
(in general practice), and national guidelines on diagnosis (typically in specialist settings). Section
5.6 suggests that the most important components of acceptability of diagnosis in general practice
relate to the TFA domains perceived effectiveness and ethicality. Regarding ethicality while current
guidelines [377] advise on the need for staff training, they do not clearly recognise the need for
showing people undergoing evaluation that their care-providers have been specially trained, for
example with certificates or quality assurance plaques being displayed in consulting rooms and
on correspondence. With respect to perceived effectiveness, while recognising the need for person
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centred care, current guidelines [377] do not currently explicitly recognise the need for agreeing a
shared language (viz. kin) when discussing cognitive symptoms and the impact of these on the life of
the person undergoing evaluation.
Given the acknowledged emotional context of people undergoing evaluation for people cognitive
symptoms these findings may have relevance for delivery of diagnostic services in all settings. Clear
display of quality assurance processes may enhance confidence in the diagnostic service. Explicit
agreement of a shared language and request by staff to forgive any unintentional "mis-speaking" may
help to humanise encounters. Taken together these relatively simple measures may make a stressful
and unsettling process less distressing regardless of the setting.
For research Further research might apply the framework to a clinically commissioned pathway
to evaluate the extent to which that service was acceptable and met the needs of service users.
Additionally there might be merit in exploring the extent to which patient activation measures [371]
can be used to target the information given to people using the service and whether giving targeted
information results in a more acceptable service.
There is likely to be value in using other additional qualitative methodologies to better understand
the experiences of people who are being evaluated for cognitive symptoms. One approach would
be a discourse analysis of reports on internet forums and social media to identify novel insights,
especially from people who do not participate in focus groups, interviews or quantitative surveys.
A second approach would be an ethnographic investigation into the experience of people who
are undergoing evaluation for cognitive symptoms which would give valuable insights, especially
because for people with cognitive symptoms there may be difficulty in recall at a later date. Because
of the emotional context that was identified in this study and has been described previously, an
ethnographic investigation would arguably be especially valuable if it could recruit people shortly
after they presented to their GP with cognitive symptoms, so the investigators could capture some of
the experiences and views of people in the process of evaluation and set within the life context, rather
than simply collecting data from events such as clinic appointments.
For clinical practice The findings of this study would support a GP based diagnosis of dementia
for some people with cognitive symptoms, in some circumstances, provided that clinicians were
provided with adequate training, resources, and time and so long as the service fully addresses
the agendas of people seeking help: not just a diagnosis but also an explanation about why it has
happened, what can be done about it (including self care) and what will happen next [174].
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Chapter Summary
This Chapter has presented the rationale, methods, characteristics, data analysis, findings
and discussion of the qualitative investigations. The qualitative research question was how
acceptable is it to patients and family members for general practitioners to make a diagnosis of
dementia independent of specialist input. Participants were purposively sampled from the main
quantitative study for maximum variation in characteristics of referring practice, age and sex.
People who were judged to be in an advanced stage of frailty, either physically or cognitively,
were not invited. Interviews were arranged on a separate day to the research clinic.
The data were managed and analysed using a framework approach. A combined inductive/
deductive approach was taken using a seven step approach to data analysis: transcription,
familiarisation, coding, developing a framework, applying the framework, charting the data,
interpreting the data.
The data were mapped into a seven-item classification which was judged to reflect the ele-
ments that contribute to the acceptability of a diagnostic process. The findings were interpreted
through the theoretical lens of the Theoretical Framework of Acceptability. The seven aspects of
acceptability that were judged to comprehensively reflect the data were: the emotional context
of fear about symptoms getting worse, system resources that contributed to a sense of cohe-
siveness and continuity, the challenge of supporting people with their own resources but not
overwhelming them, the need for a responsive assessment that addressed the specific problems
that were reported, the importance of dementia as a serious condition and the need for training
and time for an assessment, the view of the diagnostic process as comprising more than just
diagnosis, and the recognition of opportunity costs such as GPs having limited capacity for extra
work.
The findings indicated that a GP based diagnosis of dementia would be acceptable in some
circumstances if there were sufficient resources, training, and quality assurance, and if the












his Chapter discusses the results of the current work. The main findings are summarised, of
the systematic review, the current diagnostic test accuracy study, and the qualitative work.
The risk of bias and strengths and limitations of the work are considered. The findings are
interpreted in the context of the literature and clinical practice. In the final Section the implications
for practice and research are considered.
6.1 Summary of main findings
6.1.1 Systematic review
The systematic review included 10 studies, of which seven could be included in the meta-analysis. The
seven studies in the meta-analysis included a total of 2550 people, of whom 694 (27%; 95% CI 26% to
29%) had dementia. The summary accuracy of GP judgement for the diagnosis of dementia was LRP
5.3 (95% CI 2.7 to 10.7) LRN 0.46 (95% CI 0.33 to 0.66). In individual studies sensitivity ranged from 34%
(95% CI 17% to 54%) for Cambridge to 91% (95% CI 85% to 96%) for Mannheim, and specificity ranged
from 58% (95% CI 51% to 66%) for France to 99% (95% CI 97% to 100%) for Zwolle. The summary
accuracy of GP judgement for the diagnosis of cognitive impairment (including dementia) was LRP
3.8 (95% CI 2.6 to 5.8) LRN 0.25 (95% CI 0.09 to 0.72). In individual studies sensitivity ranged from 58%
(95% CI 49% to 67%) for Amsterdam to 97% (95% CI 93% to 99%) for Mannheim, and specificity ranged
from 51% (95% CI 44% to 57%) for Mannheim to 88% in Amsterdam (95% CI 84% to 91%) and Zwolle
(95% CI 84% to 92%). Cognitive impairment was chosen as a target condition for the systematic review
because that was commonly used by original studies. For the re-coded target condition normal, the
diagnostic accuracy of GPs was sensitivity 79% (95% CI 57% to 92%) specificity 80% (95% CI 45% to
95%). The summary points are overly-simplistic summaries of the data because of the heterogeneity
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and the summary accuracy may be better reflected by the summary ROC curve in Chapter 2. The
most important limitations to the meta-analysis were the substantial heterogeneity in the data and
that five studies were at high risk of bias in the flow and timing domain, because of incomplete
verification of the target condition.
Investigation of heterogeneity was limited by non-convergence of meta-regression models. It
was difficult to draw firm conclusions about heterogeneity but the data were compatible with studies
that used ICD-10, or applied retrospective judgement, having higher specificity compared to studies
with DSM definitions or using prospective judgement. For sensitivity there was no evidence of
heterogeneity by definition, studies that used a prospective index test may have had higher sensitivity
than studies that used a retrospective index test, and studies that allowed access to the medical
records may have had higher sensitivity than studies that did not or where this was unclear. Studies
at high risk of bias in the flow and timing domain appeared to have lower specificity and sensitivity
than studies at unclear or low risk of bias in this domain. However, all of these findings could have
been due to chance and there was significant uncertainty.
There were five key implications of the systematic review. Firstly, GP judgement results in better
classification than random allocation to disease state based on prevalence alone. Secondly, many
identified studies were at risk of partial verification bias. Thirdly, none of the identified studies had
investigated accuracy of GP judgement in combination with a test. Fourthly, the accuracy of GP
judgement alone was insufficient to rule in dementia. Finally the accuracy of GP judgement for the
diagnosis of dementia in people with symptoms was reported by only one study, whereas the other
eight studies reported the diagnostic accuracy in unselected people presenting to their GP.
6.1.2 Diagnostic test accuracy study
From 21 participating GP surgeries with a total population of 34,956 aged over 70 years, 465 people
were referred to a test accuracy study, 241 were seen (126 men and 114 women) and 240 were
evaluated. Of the 240 people who were evaluated, 132 (55%; 95% CI 48% to 61%) had dementia and 47
(20%; 95% CI 15% to 25%) were normal. On the ACE3, people with dementia had lowest standardised
scores in the memory domain, compared to people with MCI who had lowest scores in fluency, and
people who were normal who had lowest standardised in the attention domain. Mean duration
of tests varied from one minute (EPSS) to nine minutes (MOCA). People with dementia had lower
mean index test scores, and a longer mean index test duration, than people with normal cognition.
Informant measures had similar diagnostic accuracy and discrimination, regardless of whether they
were completed by an interviewer or self-completed, and had high levels of agreement as assessed
with weighted kappa.
GP judgement as a single test had LRP 5 (95% CI 3 to 9) LRN 0.5 (95% CI 0.4 to 0.6) for the target
condition dementia and LRP 5 (95% CI 3 to 9) LRN 0.7 (95% CI 0.5 to 0.8) for the target condition
normal.
In combination with GP judgement, TAC and MAT both had LRP 1 for the target condition
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dementia (95% CI incalculable). The LRN for GP + TAC was 0.8 (95% CI 0.8 to 0.9), whereas it was
0.5 (95% CI 0.3 to 0.7) for GP + MAT. Confidence intervals overlapped preventing inference about
superiority of particular test combinations. At threshold probabilities of 80% to 90% the GP combined
tests with the highest net benefit were GP + SPMT, and GP + Eurotest. GP + SPMT had a LRP of 13
(95% CI 5 to 35) and GP + Eurotest had a LRP of 16 (95% CI 5 to 49). At threshold probabilities of 93% to
98% the combination GP + TAC had the largest net benefit. The treat-none approach had the largest
net benefit at threshold approaches of more than 98%.
In combination with GP judgement, Sniffin sticks and MOCA both had LRP 1 for the target
condition normal (95% CI incalculable). The LRN of GP + Sniffin sticks was 1 (95% CI 0.9 to 1), whereas
it was 0.9 (95% CI 0.8 to 1) for GP + MOCA. Confidence intervals overlapped preventing inference
about superiority of particular test combinations. At threshold probabilities of up to 81% the GP
combined test with the largest net benefit was GP + IQCODE, which had a LRP of 29 (95% CI 7 to 123).
At threshold probabilities of 82% to 93% the GP combined test GP + MOCA had the largest net benefit
but at threshold probabilities of more than 93% the treat-none approach had the largest net benefit.
For the target condition dementia, there was some evidence that tests had lower sensitivity when
they were used as continuous scores in GP combined tests compared to when they were analysed at
the published thresholds, whereas specificity was relatively similar. For the target condition normal
there was no evidence of a difference when tests were analysed as continuous scores or when
analysed at the published thresholds. For the target condition dementia there was some evidence
of heterogeneity in diagnostic accuracy by age, with GP combined tests frequently having lower
sensitivity in people aged < 80 years than those aged ∏ 80 years, whereas specificity was often higher
in younger people; there was also some evidence that GP combined tests were more sensitive in
women than in men without loss of specificity. For the target condition normal there was some
evidence that GP combined tests often had higher sensitivity in people aged < 80 years than those
aged ∏ 80 years whereas specificity was often slightly lower; there was some evidence that GP
combined tests had lower sensitivity in women compared to men.
6.1.3 Qualitative interviews
From the 241 participants in the quantitative study, 26 people were recruited to semi-structured
interviews to investigate the acceptability of GPs making a diagnosis of dementia independently
of specialist input. Interviews were done with 10 women and 16 men, aged 70 to 89 years, with
ACE3 scores of 62 to 98 out of 100, and of whom nine had dementia, 11 had MCI and six had
normal cognition. A framework analysis was used to map the data into a classification which was
interpreted through the lens of the Theoretical framework of acceptability (TFA) and judged to reflect
the elements that contribute to the acceptability of a diagnostic process.
Seven aspects of acceptability were identified: the emotional context of fear while waiting for a
diagnosis, the system resources that could lead to lack of cohesion and continuity, self-resources which
could support self-care, the need for a responsive assessment that addressed the specific problems
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that were faced by the patient, the importance of dementia as a serious condition that required
training and time to evaluate the problem(s) in detail, the importance of coherence in the diagnostic
process and need for information on prognosis and interventions, and challenges of addressing
opportunity costs such as GPs limited capacity to take on additional work.
The key findings of the qualitative interviews were that a diagnosis of dementia would be more
likely to be acceptable if it were quality assured, addressed the specific concerns that were raised by
the patient including their emotional needs, and provided an opportunity for interventions including
self-paced resources for self-care.
6.2 Risk of bias, strengths and limitations
6.2.1 Introduction
The strengths and weaknesses of the review process are discussed fully in Section 2.5 and the
qualitative interviews are discussed in Section 5.7.
The current study reported in Chapter 4 was judged at low risk of bias in all QUADAS-2 domains,
but nevertheless there are some strengths and limitations of the work, and it can be considered in light
of the existing literature. Additionally because the empirical test accuracy study was a comparative
accuracy study there are additional methodological considerations that are discussed in Section 6.2.6.
Table 6.1 compares the current study to the six (of ten) studies from Chapter 2 that used a prospective
GP judgement about dementia.
6.2.2 Patient selection
As shown in Table 6.1, of the six studies in Chapter 2 that used a prospective GP judgement as the
index test, only one recruited people who were concerned about symptoms of dementia. While the
current study had the fewest number of people undergoing the index test, it was also one of only
two studies with complete verification by the reference standard. In other studies the numbers that
were verified by the reference standard ranged from 10 (1%) to 2294 (70%), and based on the number
verified the current study is the fifth largest study of the seven.
The results can be generalised to people presenting to general practice with symptoms of possible
dementia to the extent that the referred sample reflects the range of people presenting to general
practice, but it is difficult to fully quantify this. Efforts were made to fully recruit a consecutive sample
of patients, by emphasising to GPs that people could (and should) be referred even if the GP thought
they were normal, or had cognitive impairment that was not sufficiently bad to be dementia, so
long as someone was concerned about dementia. Efforts were made to reduce barriers to referral,
such as having the research team confirm eligibility and consent patients, and utilising electronic
prompts at the point of care to remind busy clinicians about the study. The generalisability of the
findings in the current study is supported by the finding that GPs judged 40% of participants to have
cognitive impairment that was not dementia, 36% as having dementia and 14% of participants to
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be unimpaired, and so were not restricting referrals to people who they believed to be impaired.
In contrast, in the only other study of people with symptoms GPs judged 48% of the participants
as being normal (of the 5% of these who were seen by a specialist, 32% had dementia) and 26% as
having dementia. In the four other studies that reported data on the level of GP judged impairment
the proportion judged to have dementia ranged from 6% in AgeCoDe to 33% in Hawaii.
In the current study, participants had a mean age of 80 years, 47% of participants were women,
and 55% had dementia. In contrast, as shown in Table 6.1, the mean age in the six most comparable
existing studies was 75 years to 85 years, and the proportion of female participants ranged from 63%
to 84%. In the five existing most comparable studies that recruited people regardless of symptoms
the proportion with dementia ranged from 2% to 29% whereas in the one other study that recruited
only people with cognitive symptoms the proportion with dementia was 50%. Overall, the proportion
of people with dementia and the age of participants is comparable to existing studies.
A notable finding shown in Table 6.1 is the difference in the proportion of women participants
between the current study and the six other studies. Despite this, the proportion of men who had
dementia, 54% (95% CI 45% to 63%) was similar to the proportion of women who had dementia, 56%
(95% CI 47% to 65%). The apparently high proportion of men in the sample relative to other studies
could be a chance finding, however, the probability of this is low because the confidence interval for
the proportion of women in the current study (40% to 54%) does not overlap with any other study
(Mannheim: 68% to 71%; Sydney 80% to 87%; Hawaii 57% to 68%; Antwerp 60% to 66%; AgeCoDe
64% to 68%; France 69% to 73%). A second explanation is linked to improved survival of men between
study dates. The six comparable studies were all conducted before 2005, nearly 10 years prior to
recruitment for the current study, when life expectancy for men was shorter [378]: if men have died,
they cannot participate in research, so the smaller proportion of men in earlier studies could be due
to smaller denominator of surviving men. For the current study, data from NHS England indicates
that in the recruiting practices at the time of the study there were 15,517 men and 19,439 women
aged over 70 [310]. A third possible explanation relates to the sampling of participants. This study
was specifically recruiting people in whom there were concerns about dementia, and these may be
more likely to be noted in men. People living alone may be less likely to have symptoms of dementia
noted by a spouse; women are more likely to outlive their partners than men, and live alone more
often than men [379]. The higher proportion of men in this study may reflect concern amongst a
spouse or other relative about symptoms or behaviours that do not meet criteria for dementia or MCI
"the worried-spouse well". Against this, the proportion of men and women with MCI and normal
cognition was similar (see Section 4.7.3). A fourth possibility is that the higher proportion of men
in this study reflects concerns about cognition which do not reach formal definitions for MCI or
dementia. Published incidence rates for dementia are similar in men and women up to age 80 years
[17], and in this study the average age in women (81 years æ 6 years) was similar to that in men (80




Excluded participants An important limitation is that the findings of this study cannot be gen-
eralised to people who were excluded, as outlined in Section 3.2. In the judgement of the author,
none of these exclusions are inappropriate, as they reflect clinical practice. A further limitation is that
despite providing translation services the population were largely Caucasian native English speakers.
The extent to which heterogeneity may affect the diagnostic accuracy of tests is unknown, but it it is
plausible that there may be some differences in the diagnostic accuracy between different ethnic
groups, especially for informant completed items which on activities of daily living, which may be at
least partly culturally determined [380].
Key strengths relating to patient selection The patient selection in the current study closely re-
flects clinical practice in the United Kingdom, with efforts to avoid people being excluded on the
basis of language, transport, or appointment availability. The age of participants is comparable with
the existing studies in the literature. The proportion of people with dementia is comparable to the
existing literature and lower than the 75% figure from NHS memory clinics in Bristol (Section 3.7.7)
which reflects the broader inclusion criteria compared to the NHS clinic. Perhaps most importantly
participants were included with a range of GP opinions about the presence of cognitive impairment
in people who had presented with symptoms. Most previous studies detailed in Table 6.1 had not
considered the presence of cognitive symptoms, and this is a major strength of this study as it makes it
much more applicable to clinical practice than the situation where index tests, be they GP judgement
or cognitive tests, are done in people attending their GP regardless of symptoms.
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Table 6.1: Comparison of prospective diagnostic accuracy studies
Design aspect Mannheim Sydney Hawaii Antwerp AgeCoDe France Chapter 4
Participant selection
Series § C C C C R C C
Symptomatic No No † No No No Yes Yes
Characteristics of participants
Number (index test) 3721 433 303 1003 3242 1453 240
Mean age (years) 76 85 75 75 80 81 80
% Female 70 84 63 63 66 71 47
% with dementia § 29 25 9 2 2 50 55
Target condition & verification with reference standard
Target condition § D D D D D D D
Verified N 407 105 303 10 2294 385 240
Verified (%) § (11) (24) (100) (1) (70) (26) 100
GP judgement (%)
Not impaired 36 76 33 - 94 48 14
CIND 41 - - - - - 40
Dementia 23 19 33 - 6 26 36
Uncertain - 5 33 - - 22 -
Diagnostic accuracy of GP judgement for dementia
Sensitivity (%) 91 42 - 100 51 73 56
Specificity (%) 76 89 - 100 96 58 89
§ C consecutive R random D dementia (see Table 2.2 for definitions)
Symptomatic: symptoms required for participation
% verified = number underwent reference testnumber underwent index test % with dementia =
number with dementia
number verified
† participants were not presenting with symptoms but GPs were asked to





GP judgement It is possible that GPs are only making a diagnosis of dementia in people with the
most manifest impairment. A test which only identifies people with the most serious illness would
generally have low sensitivity and high specificity. GP judgement for dementia follows this pattern
with sensitivity 56% specificity 89%, but the sensitivity is comparable to some other single index
tests, such as Phototest which had sensitivity 57%, and MAT which had sensitivity 63% specificity
80%. As described in Chapter 1 Section 1.1.3.3, dementia is a rare condition in general practice, with
approximately 21 new cases per GP per year, out of perhaps 6,300 consultations per GP per year, and
the range of clinical exemplars available to GPs for pattern recognition is relatively low. Despite the
acknowledged benefits of a diagnosis of dementia, such as an explanation for symptoms and the
opportunity to plan, there is no disease modifying therapy and some clinicians may view the harm of
a diagnosis as outweighing the potential benefit [381].
However, as Figure 4.3 shows, people that GPs judged as having dementia had a total ACE3
score IQR of 60 to 74, with a 90th centile of 81/100 and a highest score of 95/100. This compares to
published ACE3 thresholds of <82 for dementia [382], and suggests that in this study a GP judgement
of dementia is not restricted only to people with severe impairment. Similarly, people that GPs judged
as having CIND (cognitive impairment, but not dementia) had an ACE3 score IQR 71 to 89, which
compares to the published ACE3 threshold for MCI of < 88 [382], and indicates that GPs are not being
overly liberal in their identification of CIND. The lower end of the IQR is similar for GP judgement
and four other exemplar tests (within five units)1, while the upper end is slightly lower (1 - 11 units);
this suggests that compared to the four exemplar tests (MOCA, Minicog, IQCODE and AD8) GPs are
identifying a similarly impaired group of people as test positive at the lower end of impairment, and
not identifying the less impaired people, this is reflected in the lower sensitivity for GP judgement
reported in Table 4.10 compared to the other tests.
The GP judgement about cognitive impairment was made by the referring clinician. Clinicians
were asked:
"Is your gut feeling that this person
• Has dementia
• Has cognitive impairment but not dementia
• Has normal cognition for age"
One limitation relating to conduct of the index test is that GPs were not asked to give a continuous
probability of dementia, because in a pilot version of the referral form the GPs unanimously expressed
concern about judging diagnosis as a probability. The consequence of categorising GP judgement
rather than using a continuous probability of dementia is that it is difficult to understand whether
there is heterogeneity in diagnostic accuracy of GP judgement by assessed probability of the target
1see Section 4.2
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condition. Intuitively one might expect greater diagnostic accuracy of GP judgement when they
report higher probabilities (approaching 100%) of the target condition.
Another aspect relating to conduct of the GP judgement index test is that it reflects the judgement
of the referring GP, rather than the person conducting the index tests. Referrals were received from
21 different GP practices, each of which had more than one clinician. Indeed based on NHS England
data which indicate an average 1754 patients per whole time equivalent GP in the BNSSG region [383]
there would be an estimated 142 whole time equivalent GPs for the total 249,556 patients in the 21
practices (Table 3.2), and nearly all GPs work less than whole time [383]. It is difficult to quantify the
number of different referring clinicians as mail-merged details on the referral forms are not reliable
because the form may be completed at a later date by an administrator or other clinician rather than
the GP making the judgement. However, the correct interpretation of the index test GP judgement in
this study is that it reflects an average measure of diagnostic accuracy for many different GPs working
in different settings.
A final aspect regarding the conduct of GP judgement as an index test is that it is difficult to
operationalise exactly what aspects of the encounter the referring GP was integrating to form their
opinion. Referring GPs were asked to:
Please write a few words about what you think led you to form your gut feeling
and responses typically comprised comments such as "face to face presentation". As described in
Section 3.3 study administrators were instructed to ask the practice to supply any missing data, but
were not asked to make subjective judgements about the quality of information supplied. A particular
limitation is that GPs were not asked explicitly whether they had or had not used any formal test to
inform their judgement, though they were explicitly instructed that this was not necessary. Based on
previous studies, GP judgement is likely to be formulated by rules of thumb [201] and is unlikely to
be based on formal tests [270].
Section 6.4 outlines some possible implications for future research to better understand the
thought process behind GP judgement for dementia. It is important to note that all of the above
limitations described for the work in this thesis would also apply to all of the published studies on GP
judgement for dementia diagnosis detailed in Table 6.1.
Non GP judgement index tests All index tests were conducted without knowledge of GP opinion
or the reference standard, and were analysed at at published thresholds. Therefore the accuracy of
the single index tests, the GP combined tests, and the GP 360 tests may be interpreted as reflecting
the accuracy in clinical practice when a GP consults with a patient and then arranges for a cognitive
test to be completed by a different clinician. It is conceivable that diagnostic accuracy of the patient-
completed index tests could vary depending on whether they are completed by the consulting GP
or a third party. On one hand, accuracy could be higher if completed by the consulting GP because
they would be able to see how the patient completes the test and intuitively use heuristics [201] to
adjust the score, e.g. for sensory impairment. On the other hand, this additional random variation
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may lead to increased heterogeneity in test performance and indeed overall lower accuracy than if
the test were completed in a standardised form by an independent clinician.
Key strengths relating to index tests The GP opinion and the other index tests were conducted
independently which makes the findings applicable to practice when the tests are done by separate
clinician to the consulting GP. GP judgement was made prospectively, at the time of presentation, in
people who were presenting with cognitive symptoms, and very few studies had investigated this
previously. GP judgement reflected an average of GP diagnostic accuracy about dementia, rather
than the accuracy of a single clinician. A wide range of index tests were evaluated using published
thresholds so that it is possible to compare the accuracy of these tests, which is a novel and particular
strength.
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6.2.4 Reference standard
As described in Chapter 3 Section 3.5, the original intention had been to have a consensus panel form
a reference standard diagnosis about each participant, based on a specialist assessment at a research
clinic, however this was not possible. In comparison with the six most similar studies outlined
in Table 6.1 most (Mannheim, Hawaii, Antwerp, France) used only a single specialist to evaluate
each person and apply the reference standard, whereas Sydney and AgeCoDe used a consensus
classification. Consensus classification is arguably most useful for borderline cases i.e. those on the
cusp of dementia | MCI and MCI | normal. In the present study, a second independent specialist was
used to adjudicate borderline cases and reached a diagnosis after having access to the full reference
standard evaluation at the research clinic, as well as the primary medical record six months either
side of the research clinic visit.
While all participants had a consistent reference standard applied, there was a divergence in
how the primary medical record was reviewed. As described in Figure 4.1 and Section 3.5 for the 220
people where a single classification could be reached according to the reference standard the primary
medical record was reviewed by the author for any diagnosis that would contradict the judgement of
the specialist at clinic. For 20 people where a single classification could not be reached the medical
record was reviewed by the second specialist who was adjudicating borderline cases. Given unlimited
time and resource it would be ideal for the reference standard assessment, including the primary
medical record extract, for all cases to be reviewed by a second specialist, as had been originally
planned, but despite best efforts this was not possible within the time constraints of the thesis. While
acknowledging the difference in process between the 220 people whose primary medical record was
reviewed by the author and the 20 people whose record was reviewed by the adjudicating specialist it
is judged that the probability of a different outcome regarding diagnostic classification is low.
Key strengths relating to reference standard With respect to QUADAS-2 quality appraisal it is
likely that the reference standard as applied will correctly classify the target condition according to
a recognised definition of dementia, which was determined without knowledge of the index tests,
and using an approach which could be repeated in a future study; therefore in line with published
anchoring statements to assess the risk of bias relating to the reference standard [384] it is at low risk
of bias. The reference standard was based on a detailed, standardised evaluation which included
clinical history, informant interview, and standardised cognitive testing, and was performed by
a single clinician with significant expertise in the diagnosis and treatment of cognitive disorders.
Adjudication was used for borderline cases and follow-up data from the primary care record were
reviewed six months after the research clinic to ensure there were not alternative diagnoses that
would explain the symptoms.
209
CHAPTER 6. DISCUSSION
6.2.5 Flow and timing
A particular challenge for diagnostic test accuracy studies in general practice is that it is is a low
prevalence setting for many conditions. This means that to identify one person with the target
condition, many people must be evaluated, which is potentially expensive. As shown in Table 6.1,
in the six most comparable previous studies of GP judgement for dementia described in Chapter 2,
only one verified the whole sample of people who underwent the index test (GP judgement) with the
reference standard (though diagnostic accuracy data was not available), and only one other verified
more than 26% of the sample (but 18 months after the GP formed their opinion). In comparison, in
the current test accuracy study everybody who was evaluated by the index tests and who consented
to participating in research also underwent the reference standard.
Figure 4.1 shows that of the 456 people who were referred to the clinic, 155 people (33%) declined
to take part. In contrast, in [272] 40% of people who were seen by their GP with suspected dementia
declined further assessment. Table 4.3 shows the known characteristics for people who declined
compared to people who participated. There may be a variety of reasons why people declined to
participate. Some reasons for declining are unlikely to impact the diagnostic accuracy of tests, such as
inability or lack of willingness to travel, a role as a carer, or being too busy. There was weak evidence
of an association between declining and a GP judgement of CIND and slightly stronger evidence
for an association between declining and age or female sex (Section 4.2). It is not clear why people
who are older or female would be less likely to take part, but this may reflect the greater frequency
with which older people, especially women, live alone [378]. As attending with an informant was
necessary, some of these people living alone may have been reluctant to ask an informant (perhaps
an adult son or daughter) to attend (who would perhaps be taking time off work or from other caring
responsibilities). If the proportion of people with dementia according to the reference standard, or
the spectrum of disease, was different in people who declined to those who participated then the
diagnostic accuracy of the tests might be affected, and it is possible that this could affect some tests
more than others. If people who declined were more impaired than those who participated then it
is likely that the diagnostic accuracy of most tests, especially GP judgement, would be better than
reported. The number of people declining should be considered in the context of the design, to make
it easy for GPs to refer they did not have to fully discuss the study or consent the patient, only obtain
consent to pass their contact details to the research team. Therefore some people may have been
given only very scant information about the study from their GP, and may have been reluctant to
agree to something over the telephone, especially as older adults are often victims of scams using the
telephone [385].
It is plausible that in some cases people with suspected dementia were not referred to the study,
based on the potentially eligible figure of 1735 shown in Figure 4.1 which is derived from the age
standardised incidence applied to the study population using person years at risk. Therefore it
remains a limitation that GPs would have formulated a judgement about the presence of the target
conditions in people who were not evaluated by the study team. To standardise the administration
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of the index tests in the current test accuracy study and ensure full verification with the reference
standard, it was necessary for GPs to refer people to the research study. The alternative, to have had
GPs complete the full range of index tests in their practices, would have been unfeasible. Section
6.2.2 describes the potential impact of this on the results and generalisability.
The median time between referral (the date of GP judgement) and the clinic appointment
(reference standard) was 47 days (IQR 30 to 72 days), the longest interval was 177 days, approximately
six months, which was due to difficulties with attending earlier appointments. Dementia is a slowly
progressive condition and it is unlikely that the condition would have progressed significantly in a
six-month period. However, it is possible that for borderline cases impairment became more manifest
over time, and that the diagnostic accuracy of GP judgement would be biased towards being lower
for people who were seen with a longer delay. Compared to the studies in Table 6.1, France, Sydney,
Antwerp, Hawaii and Mannheim did not specify the interval between GP judgement and the reference
standard, AgeCoDe had an interval of 1.5 years. All other index tests other than GP judgement were
done on the same day as the reference standard.
Key strengths relating to flow and timing All index tests, other than GP judgement were completed
on the same day as the reference standard. The interval between GP judgement and the reference
standard was relatively short, and unlikely to be associated with a significant progression in cognitive
impairment. GP judgement was fully verified against the reference standard for all consenting people
who were referred and there was weak evidence of selective participation by cognitive status.
6.2.6 Comparisons between tests
In addition to the items outlined in QUADAS-2 there are further methodological aspects that deserve
consideration, arising from the comparative test accuracy design.
Firstly, the intention was that all of the participants would receive all of the index tests. Other
than as described in Chapter 3 Section 3.6.2 tests were not done by participants because they were
declined. Therefore the selection of participants is unlikely to have led to bias in the comparison
between index tests.
Secondly, participants received multiple index tests which were (except GP judgement) conducted
by the same examiner. Therefore it was impossible to blind the examiner to the results of prior tests.
To mitigate this, as described in Section 3.4.1 and reported in Appendix K, the order of the index test
battery was randomised to minimise order effect. The order of Sniffin Sticks was not randomised,
for two reasons: firstly this test was only given to some of the participants because, as described in
Section 3.4.1 it was imported on special order; secondly it was judged that it would minimise the
cognitive burden on participants to do Sniffin sticks last because it was a test of smell rather than
cognitive functioning. All of the index tests were interpreted without knowledge of the reference
standard and at prespecified thresholds. Overall the conduct of the index tests is unlikely to have
introduced systematic bias in the comparison of tests, but the performance of Sniffin Sticks may have
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been different (either better or worse) if it had been done first; which would have been an alternative
approach.
Thirdly, all of the index tests were verified against the same reference standard and none were
incorporated in the reference standard. The reference standard is unlikely to have led to bias in
comparisons between tests.
Fourthly, all tests had the same interval between index test and reference standard (with the
exception of clinical judgement). Because dementia is a progressive disorder, it is plausible that over
time the clinical scenario may have been more obvious (either normal, or cognitive impairment)
with a greater interval between clinical judgement and reference standard. However, as reported
in Chapter 4 Section 4.2 there was no evidence of an association between time from referral and
cognitive status. Undergoing multiple index tests may have been burdensome for participants and
towards the end of the index battery people may have made errors due to cognitive fatigue, but
the randomisation of the index tests should mean that no one test is systematically advantaged
or disadvantaged in the comparison. Missing data was due to participants declining or change to
the case report form as described previously and is unlikely to have led to systematic bias. Overall
participant flow is unlikely to have led to bias in comparisons between tests
Fifthly, because of the uncertainty around the point estimates of each single test and combination
of tests (both GP combined and GP 360) it is entirely possible that apparent differences in test accuracy
are due to chance (type 1 error). This is especially important because confidence intervals provided
are not adjusted for multiple comparisons (i.e. they are 95% CI rather than a 99% CI or Bayesian-
derived credible interval) and in view of the multiple comparisons and combinations this may
underestimate the impact of chance findings falsely implying superior test accuracy. In particular, the
uncertainty in the estimates indicated by the confidence intervals mean that some tests which appear
at face value to have superior diagnostic accuracy than others may in fact have very little diagnostic
value. Consider Table 4.11, Sniffin sticks for the target condition normal has a point estimate of LRP
11 compared to MOCA LRP 8, but the 95% CI for Sniffin sticks is 1 to 101, indicating a high level of
uncertainty and including 1, whereas for MOCA the 95% CI is 3 to 23, indicating stronger evidence
that MOCA has some diagnostic value but (because of the overlapping 95% CIs) no real evidence to
support use of one test rather than another.
Finally, the power of the sample size to make comparisons between different candidate index
tests is low. While the sample size calculation was based on published tables [354], methodological
advances since the design of the empirical test accuracy study have shown that conditional depen-
dence between comparator index tests requires a larger sample size than would be calculated using
less robust approaches [386] and that the traditional 10 events per variable rule [355] is misleading
and should be revised because sample size calculation is context specific [387].
Key matters relating to comparisons of tests In summary, while randomisation of test order was
used to partially mitigate the effect of a single examiner conducting all of the candidate index tests,
the small sample size, overlapping confidence intervals, and multiple comparisons mean that there
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is no real evidence to support the hypothesis of any one test being clearly superior to others and the
results should be interpreted with caution. The uncertainty due to sample size is important for single





Heterogeneity is described in Chapter 4 Section 4.7, and summarised in Table 6.2.
Age There was some evidence that for the target condition dementia GP combined tests had higher
sensitivity and lower specificity in people aged ∏ 80 years than those aged < 80 years, with a reversed
pattern for the target condition normal. This pattern of heterogeneity could reflect increasing sensory
impairment with age. People with visual or hearing impairment, which may be not even be serious
enough to have been noted by the patient, kin, or clinician, would be more likely to give incorrect
answers to questions which utilise these faculties. For example, TAC asks the candidate to make
change with coins, and other tests require drawing, or recognition of objects, all of which would
be very difficult for visually impaired people regardless of cognitive ability. Similarly, tests which
utilise delayed recall of an item which has been registered aurally would be difficult for a person
with hearing impairment, regardless of cognitive functioning. The idea of tests being less specific
with age due to sensory impairment is supported by the tests which were particularly affected: TAC,
SPMT, MOCA and Phototest all require sensory skills. Other studies have reported influences on
diagnostic accuracy of GP judgement for dementia. A false positive GP diagnosis of dementia is
more likely with increasing age, impaired mobility or hearing, subjective memory impairment, or
GP diagnosed depression [271]. Furthermore, less familiarity with the patient was associated with a
higher probability of being rated as impaired in one study [201] but a better recognition of dementia
in another study [270].
Heterogeneity by age also particularly affected FAQ but this is an informant completed test, so is
not explained by increasing sensory impairment with age. However, this heterogeneity could reflect
difficulty doing activities independently which is due to physical limitations rather than cognitive
problems. Of the items on FAQ, at least three (shopping alone, travelling, working on a hobby) would
be made more difficult by physical impairments
Table 6.2: Summary of heterogeneity
Characteristic Sensitivity Specificity
Target condition dementia
Age ∏ 80 years § higher lower
Female §§ higher similar
Target condition normal
Age ∏ 80 years § lower higher
Female §§ lower similar
§ compared to people aged < 80 years
§§ compared to men
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Sex There was some evidence that for the target condition dementia tests had higher sensitivity
and similar specificity for female participants than male participants, with a reversed pattern for
the target condition normal. Other studies have found that GPs label men as having dementia more
often than women [265, 273]. For tests which measure change in the performance of activities of
daily living, this may reflect a tendency for some of these items (such as doing the laundry, or cooking
a meal) to be things which have traditionally been a "female role" in some households, and so the
loss of the skill is more remarkable (and therefore more readily noted) in a woman than a man. Other
possible explanations are that women had more severe cognitive impairment than men, but mean
ACE3 scores were similar. Another possible explanation is that women (who are in general more
likely to live alone) were more likely than men to attend with a grown-up child as an informant, who
scored them more critically than a spouse would have done, but this cannot be evaluated with the
available data. A final possibility is that despite similar ACE3 scores female participants were more
frail, because frailty is a significant predictor of dementia and frail women may have a higher risk of
developing incident dementia than men [388].
Setting As detailed in Section 3.2.2, referring GP surgeries were able to participate in the research
study, as well as a funded programme of activity to encourage the diagnosis of dementia in general
practice. There were two separate programmes of funded activity in general practice: first a scheme
to identify people with cognitive impairment that was available to all practices in England, including
referring practices (case finding); secondly a specific funded programme to improve the diagnosis
and management of dementia in general practice which was restricted to Bristol practices (diagnosis).
It is likely that the net effect of the programmes was to encourage uptake of the study by referring
GPs. On the other hand, it is possible that in the context of some of the GPs in Bristol referring
practices (it is important to note, not all GPs) having received additional training on dementia and
how to make a diagnosis some GPs may have been less likely to refer people to the study than would
normally be the case, because they perceived themselves as being sufficiently capable to manage
the situation themselves. It is difficult to quantify the effect of this, if there is any. Of the 240 people
who were evaluated in the research clinic, 68 were referred by Bristol practices, and 86 by each of
North Somerset and South Gloucestershire practices; compared to an total population aged 70 years
and over of 10304 in Bristol, 14122 in North Somerset and 10530 in South Gloucestershire. However,
differing start dates for practices to recruit (Table 3.2) makes it difficult to compare recruitment
between practices and areas. A further possible impact of the NHS programmes of activity is that
they contributed to the relatively high recruitment of men in this study in comparison to other
studies (which is discussed in Section 6.2.2), because 53% of people with diabetes are men [389] and
under the case-finding programme people with diabetes would have typically been asked about their
memory at their annual diabetes review.
The NHS diagnosis programme of activity, which was restricted to Bristol, may also have had an
impact on the diagnostic accuracy of GP judgement. It is important to note that typically training
on the diagnosis and management of dementia for the programme would have been given to some,
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rather than all, of the GPs in a practice. However, it is conceivable that diagnostic accuracy of GP
judgement could be improved by a training programme which aimed to enhance the skills of GPs.
Diagnostic accuracy of GP judgement for dementia in South Gloucestershire and North Somerset
practices was lower than in Bristol practices (Section 4.7.5). In contrast the diagnostic accuracy for
normal in South Gloucestershire and North Somerset practices was very slightly better than in Bristol
practices. At face value, this would support the idea that the additional training that Bristol GPs
received enhanced their diagnostic accuracy for a positive diagnosis of dementia but impaired their
accuracy for diagnosing normal. An alternative possibility is that Bristol GPs were being more selective
in only referring people who they thought had dementia, for confirmation of the diagnosis, to gain
payment under the NHS scheme; this is plausible but a similar proportion of people from Bristol
practices had dementia according to the reference standard compared to South Gloucestershire
and North Somerset practices (Section 4.7.5). A further possibility, especially given the overlapping
confidence intervals is that this is a chance finding, because changing behaviours and practice of GPs
regarding dementia is very difficult: other tailored educational packages for GPs did not improve case
identification of dementia even when there was reimbursement under the Quality and Outcomes
Framework (see Section 3.2.2) [390].
A limitation is that because the systematic review and the empirical work were done simultane-
ously rather than in sequence it was not possible to use the empirical work to address the area for
future work that were identified in 2.5.4.
6.3 Interpretation
6.3.1 GP judgement
The finding from Chapter 4 of this thesis is that a positive GP judgement of dementia is often correct:
PPV 86% LRP 5, whereas a positive GP judgement of normal is less often correct: PPV 56% LRP 5;
the difference in PPV with a constant LRP is partly attributable to the prevalence of dementia being
higher than the prevalence of normal. These results fit well with the findings of the systematic review
described in Chapter 2 which were that GP judgement for dementia had a PPV of 61% LRP 11 whereas
GP judgement for normal had a PPV of 26% LRP 2. This means that GP judgement is better at ruling
in dementia, than at ruling in normal.
Dementia can be a complex clinical presentation, with physical symptoms and signs which can
be challenging for the patient to process and explain, as well as affective, psychological, and cognitive
symptoms, and of course an important impact on on social and role functioning. As discussed in
Section 1.1.3.3 dementia is a low incidence condition in general practice, with potentially serious
consequences, and this is likely to lead to a higher treatment threshold than for a more trivial
condition like a sore throat, which is more frequently encountered. Figure 6.1 summarises the
sensitivity and specificity of GP judgement for different conditions and shows that the accuracy for a
diagnosis of dementia is comparable to other conditions, with a similar sensitivity and specificity
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to a GP judgement of depression. Compared to dementia, depression can also have a variety of
presentations, is also predominantly a mental health condition, but is more commonly encountered
than dementia. For the diagnosis of depression GP judgement had LRP for GP judgement of 4 and
LRN of 0.6. Pneumonia is an acute respiratory infection which is fairly common in general practice
and often treated successfully by a course of antibiotics, and so with a relatively low treatment
threshold (see Section 1.1.2.1) in general practice. For the target condition pneumonia as defined by
chest radiograph, the index test GP judgement, based on history and examination alone, has LRP
5 (95% CI 3 to 7) LRN 0.3 (95% CI 0.2 to 0.7) [391]. For acute coronary syndrome, GP judgement had
LRP 25 LRN 0.5 [392]. These findings indicate that GP judgement for dementia is comparable to the
Figure 6.1: Comparison of diagnostic accuracy of GP judgement for different target conditions
The Forest plot shows the sensitivity and specificity of GP judgement for different conditions, Depression [393]
Pneumonia [391] Acute Coronary Syndrome [392] TP true positive FP false positive FN false negative TN true negative
95% CI 95% confidence interval
accuracy of clinicians for other similar conditions, and suggest that GP judgement may be higher for
more frequently encountered (i.e. more common) conditions with a more typical clinical phenotype,
such as pneumonia, than for rarer conditions with a more varied presentation, such as dementia or
depression.
6.3.2 What do we mean by dementia?
As described in Section 1.1.2 diagnosis can be conceptualised as a method of classification that is fit
for purpose in the clinical setting, and therefore GP judgement may often use heuristics and system
one cognitive processes. In this study, there was a signal that specificity of GP combined tests is
higher in younger people than older people (Section 6.2.7) which could reflect increasing sensory
impairment with age; making a false positive GP diagnosis of dementia more likely with increasing
age, impaired mobility, GP diagnosed depression and subjective memory impairment [271] (see
Section 6.2.7).
One lens to interpreting these findings is that the GP diagnosis paradigm for dementia and
cognitive impairment is different to formal definitions, and that just as ICD-10 and DSM-IV-TR
definitions of dementia identify different groups of people (Section 1.1.1.1), it is possible that the GP
heuristic for dementia is selecting a group of people who are systematically different to those who
are identified as having dementia by formal definitions. In particular the GP heuristic of dementia in
the older adult may be an individual with forgetfulness who also has sensory impairment, limited
mobility, multi-morbidity, and needs additional assistance performing activities of daily life. In the
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possible relationship between GP judgement and ICD-10 dementia (see also Section 4.4.1 Table 4.6)
some people with ICD-10 dementia are in the set of people with GP CIND, others are in the set with
GP dementia and still others are not identified by the GP as being impaired.
If diagnosis is conceptualised as a classification procedure (Section 1.1.2) with importance for
patient outcomes [175] and models of illness [174] (Section 1.1.2.8), then it may be that the GP
paradigm of dementia as described above better serves the needs of patients in that setting regarding
appropriate goals of care, support, and advance care planning than more formal definitions. An
important limitation of this GP paradigm of dementia is that it is a less clearly defined disease for
research, with a less certain disease course and for which the benefit of interventions is uncertain.
Further research using qualitative methods such as ethnography could explore further what
factors influence a GP heuristic of dementia and cognitive impairment (see also Section 6.4.1). When
the GP heuristic is better understood, quantitative methods could then explore whether the GP
paradigm is more valuable as a prognostic definition of disease [175] in a primary care population
than more formal definition of dementia.
6.3.3 Use of tests in practice
This thesis has demonstrated that a combination of tests including GP judgement can have high
diagnostic accuracy for the target conditions dementia and normal in a group of people who are
presenting with cognitive symptoms. How might these findings be applied? Often clinical practice
guidelines are used to inform clinical practice. A review of guidelines relating to BCAs (brief cognitive
assessments) for the diagnosis of dementia found four relevant guidelines, two in Canada, one in
Australia and one in the United Kingdom [308]. The United Kingdom guidelines did not recommend
any specific BCA but did indicate that at the initial assessment a history should be taken, including
from an informant if possible, and then appropriate investigations should be done along with
cognitive testing [377]. Of the tests in the GP 360 tests that were identified in this thesis, FAQ, 6CIT
and IQCODE are all listed in the United Kingdom guideline, but Eurotest is not [377]. Instead, the
United Kingdom guidelines include the six-item screener (which asks year, month, day, and a three
item recall) [394], Test your memory [395], Mini-cog; and two tests which are described in Section
3.4.1: Memory impairment screen [331] and 10-point cognitive screener [332]. Test your memory
is scored out of 50 and is designed to be self-completed by the patient, it tests a range of domains
including memory, orientation, verbal fluency, abstraction, visual coordination, recall, and clock-
draw; it is advised that the a person completing the test is supervised by a clinician. However, there
are many validated BCA and as illustrated in the review of clinical guidelines, there is very little
consensus about what test should be used: the Australian guidelines recommend ten further tests,
with no overlap with the United Kingdom guideline [308].
If there is little consensus from guidelines about what test to use in practice, then there is also
little consensus amongst clinicians. In a survey of 52 GPs, who indicated doing a mean four cognitive
assessments per month (range 0.24 - 30) the most commonly used tests were the MMSE and GPCOG,
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other tests that were used included clock draw, Minicog, ACE3, IQCODE and MOCA [308]. Factors
that were reported to influence test choice included: time (35%), local factors (21%), familiarity (19%),
patient factors (10%), other (9%), guidelines (6%) and cost (1%) [308]. Regarding time, 74% indicated
that an acceptable test time if a GP were doing the test was less than five minutes whereas if a non-GP
clinician were doing the test it would be acceptable to spend longer completing the test [308].
One problem for applying the findings of the thesis in practice is that health professionals
struggle to understand commonly used measures of test accuracy [396]. Similarly, systematic reviews
of test accuracy can also be reported to be difficult to understand, in part due to problems with
background knowledge, but also due to problems with layout and presentation [397]. In both cases,
the use of natural frequencies was helpful in improving understanding [396, 397]. A further problem
for both clinicians and policy makers to date has been that very few studies have made direct
comparisons between BCA and evaluated their accuracy in a clinical setting that is applicable to
general practitioners: that is, people presenting with symptoms to their GP [308]. Therefore, the
ability to compare accuracy between BCA, and GP combined BCA in a symptomatic general practice
population is a major strength and novel finding of the thesis.
Even with a perfect test, it might still be difficult to make a diagnosis of dementia in general prac-
tice. Barriers to diagnosis of dementia by GPs have been reported to fit within four main categories:
organisational, clinician-related, patient-related, and societal [398]. Organisation factors included
(among other things) time constraints and doubts about using BCA to diagnose dementia rather
than to highlight important symptoms that required a specialist opinion, especially in the context
of performance being subject to cultural or language factors [398]. Other potential barriers to the
diagnosis of dementia have been identified as being lack of support, stigma, diagnostic uncertainty,
and disclosing the diagnosis [399]. Because of resource constraints people with severe symptoms
have been reported to be prioritised over people with more mild problems [398]. On the other hand,
continuity has been reported to facilitate a GP recognising cognitive problems [398]. Concerns about
resources and lack of specialist expertise for GPs to diagnose and manage dementia well have been
reported for many years [400, 401], and GPs have been reported to frame dementia care as a specialist
activity [400]. Despite this, the priorities of patients and their kin are to get a prompt diagnosis, in
an emotionally safe setting, in a personalised way [402], and patients report that they are generally
satisfied with either primary or secondary care approaches to diagnosis [340]. General practice
based approaches to diagnosis have been used effectively in the United Kingdom [340, 403] and
Canada [404], and follow-up of people with dementia can be done as effectively by general practice
as by specialist [405]. However, regrettably, a well designed intervention to improve practice was not
effective in improving documentation or increasing case identification, and it may be that rather
than training up GPs, practices need to be provided with additional trained human resource [390] to
facilitate the diagnosis and management of dementia in general practice; in England this could be





This thesis has made an important contribution to the literature. The especially novel findings are the
data on the proportion of people presenting with cognitive symptoms who have dementia MCI and
normal cognition, and the comparative accuracy of a range of index tests including GP judgement for
diagnosing two target conditions. A further novel contribution has been the distinction of two target
conditions, normal and dementia, rather than just one (dementia). The thesis has not considered
cost effectiveness, specific dementia aetiologies, or evaluated the combinations of tests prospectively.
An important limitation is that the sample size limits the conclusions that can be reached about the
comparative accuracy of tests.
One future priority for research should be to determine the the proportion of people who have
a rare or atypical dementia out of those with cognitive symptoms, and the clinical features which
are markers for this. This is because these people would need specialist evaluation in any diagnostic
pathway and knowing the proportion of people aged over 70 years who would require specialist
evaluation is an important part of designing a diagnostic pathway.
A second area for future research is in people who are judged by their GP to have CIND. MCI was
not a target condition, but half of participants with cognitive symptoms were classified by referring
GPs as having CIND. Future research should explore what contributes to GPs making a diagnosis of
CIND rather than normal or dementia, perhaps using qualitative or ethnographic techniques.
Thirdly, it would be useful to identify the most discriminative tests to distinguish dementia and
normal from MCI in people who are judged by a GP as being cognitively impaired but not having
dementia. Because of the difficulty in distinguishing borderline cases, this group of people is likely
to require more detailed testing than can be done with a BCA, such as the ACE3 and perhaps also
bio-markers [407]. Electronic approaches to cognitive evaluation [408] may be especially informative
for people in this group. Finally, Chapter 5 describes a brief research agenda for further approaches
to investigate the experience and views of people being evaluated for cognitive symptoms.
These three further investigations should inform subsequent research to approach the design of
a diagnostic pathway through the lens of guidance to develop complex interventions [409, 410]. It
is likely to be valuable to consider the pathway in the context of a proposed theoretical framework
to determine whether a trial is necessary [411] and consider whether randomisation should be
at the level of the individual or in clusters (e.g. practices, primary care networks, or even Clinical
Commissioning Groups). Evaluating all of the combinations of GP combined and GP 360 tests in a
prospective diagnostic trial incorporating cost effectiveness, and powered to determine heterogeneity
by aetiology, is likely to require a very large sample size and therefore be very expensive. However,
given the workload associated with dementia diagnosis in the western world it may be still be cost-
effective for health services. An alternative approach would be to use the three proposed initial
investigations, together with the qualitative research agenda and the integrated development of
220
6.4. IMPLICATIONS
a complex intervention to select a number of (perhaps four) candidate GP combined and GP 360
tests that could be evaluated in a large number of people. Possible outcomes for a future trial could
include numbers diagnosed, cost, and time to diagnosis.
6.4.2 For practice
Based on the qualitative results in Chapter 5, when a GP encounters a patient who has consulted
about possible dementia the GP should aim to focus the initial consultation on identifying the
patients specific concerns, quantify the impact on daily life, determine safety (e.g. from the stove
or driving) and ask about red flags for rare or atypical illness. At the end of the initial encounter
the GP should aim to make an initial determination as to whether the person has dementia, or is
normal. People with rare or atypical presentations may need referral to a specialist who could provide
a bespoke assessment to address the problems they are facing, rather than a more generic evaluation
for the relatively limited range of clinical exemplars that are known to the GP.
Regarding the diagnostic process, based on the quantitative results and the qualitative interviews,
the initial clinical judgement from the GP should guide further tests to ensure that the tests evaluate
the symptoms that are reported by the patient. Based on the qualitative findings, these could be
conducted by a trained health worker such as a health care assistant. Based on the qualitative findings,
the second encounter could also offer advice about lifestyle measures to promote cognition, and
identifying any carers who might also need support. Further evaluation with formal measures of
mood, and investigations to exclude metabolic, endocrine or neoplastic disorders should also be
considered, as part of good practice and in line with guidelines [377]. The patient should then be
reviewed by a GP together with the results of tests.
A multidisciplinary approach is likely to be cheaper than a fully GP delivered model, but there
are three additional advantages that based on Chapter 5 would help to improve the acceptability of
diagnosis of dementia in general practice. Firstly, having formal cognitive testing done by an allied
professional would allow the GP time to explore the specific concerns of the patient and their family
and meet their needs. Secondly, within appropriate boundaries both professionals could provide
advice on interventions; the allied professional could advise on self care, and the GP could advise
on appropriate medication as the cost effectiveness of this has evolved due to lower acquisition
costs [412]. Thirdly a multi-disciplinary approach could facilitate the integration of community
services to providing holistic and integrated care for people with dementia and their kin after a
diagnosis and would fit within the framework of the NHS Long Term plan [413]. Finally the multi-
disciplinary approach could be readily quality assured by having regular certificated training for
the allied professional (perhaps relating to testing and self care) and the GP (perhaps relating to
prescribing). A limitation of the work for practice is that prescribed pharmacological interventions
for dementia are specifically licensed in the United Kingdom only for Alzheimer’s disease, rather than
all-cause dementia. Drugs are recommended for off-license use in Dementia with Lewy Bodies and
Frontotemporal dementia by the National Institute of Clinical Excellence [377].
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6.4.3 Accuracy as prevalence varies
A positive GP judgement for dementia is sufficiently accurate that if FAQ and Eurotest indicate no
dementia (as in the GP 360 test described in Section 4.6.4.2), the probability of dementia is still 63%;
though the uncertainty in this prediction limits the conclusions that can be reached at this stage.
Conversely, if a GP thinks a patient is normal and the 6CIT and FAQ indicate that cognition is not
normal, the probability of normal cognition is only 5%. Because, as described in 1.1.2.3 predictive
values are dependent on prevalence the high prevalence of dementia in this study inflates the PPV. If
the prevalence was lower, such as 30% of people having dementia [414] then the diagnostic accuracy
of GP + Eurotest + FAQ would be LRP 14 LRN 0.5 PPV 85% (95% CI 69% to 94%) i.e. the PPV would be
lower than reported in the thesis. The prevalence of normal cognition was not reported in [414] but
if it were 30% instead of 19% as in the thesis then the diagnostic accuracy of GP + 6CIT + IQCODE





To return to the aims and objectives of the thesis: The aim of this thesis was to investigate approaches
to diagnosing dementia syndrome in general practice. The objectives have been addressed:
• In a group of people presenting with symptoms of dementia to their general practitioner, the
prevalence of dementia was 131240 , and the prevalence of MCI was
59
240 .
• The accuracy of a range of tests, including GP judgement, for diagnosing dementia syndrome
in symptomatic people was investigated. LRP of single tests ranged from 1 (many tests) to 10
(FAQ).
• Combination of tests with good discrimination, calibration, and high LRP for identifying people
with dementia and normal cognition were identified. GP judgement + Eurotest + FAQ had
the largest net benefit for diagnosing dementia and GP + 6CIT + IQCODE had the largest net
benefit for confirming normal cognition. Uncertainty in the estimates and small sample size
restricted the ability to draw any firm conclusions about comparative test accuracy especially
for the combinations of tests.
• Based on interviews with patients and their kin it was judged that it would be acceptable
for GPs to diagnose dementia if clinicians were adequately trained and resourced, and if the
service fully addressed the needs of the patient for information and interventions, not just a
diagnosis.
Diagnosis of dementia is possible in primary care. Implementing this is likely to be a challenge,
and may require additional human resources, not just training of existing staff.
“Men must endure
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Search Report 








Searches by:    AN-S 
First assess by:     
Search results sent:   
 
Results:    TOTAL:  April 2016: 10154 // April 2019:  




Source Version/Platform/url Date of Search Filter applied as 
overall limiter 
Records retrieved 
1. MEDLINE In-process 
and other non-indexed 
citations and MEDLINE 
1946-present 




     
2. EMBASE 
1974-2016 April 25 




     
3. PSYCINFO 
1806-April week 3 2016 




     
4. Web of Science Core 
Collection 




     




     
TOTAL before de-duplication 10154 
2527 










Search strategy Hits retrieved 
1. MEDLINE In-process and other non-
indexed citations and MEDLINE 1946-present 
(Ovid SP) 
 
1. exp "sensitivity and specificity"/  
2. "reproducibility of results"/  
3. diagnos*.ti.  
4. di.fs.  
5. sensitivit*.ab.  
6. specificit*.ab.  
7. (ROC or "receiver operat*").ab.  
8. Area under curve/  
9. ("Area under curve" or AUC).ab.  
10. sROC.ab.  
11. accura*.ti,ab.  
12. (likelihood adj3 (ratio* or function*)).ab.  
13. ((true or false) adj3 (positive* or negative*)).ab.  
Apr 2016: 4493 
Apr 2019: 927 
14. ((positive* or negative* or false or true) adj3 rate*).ti,ab. 
15. or/1-14  
16. exp Dementia/  
17. Delirium, Dementia, Amnestic, Cognitive Disorders/ 
18. dement*.mp.  
19. alzheimer*.mp.  
20. (lewy* adj2 bod*).mp.  
21. (chronic adj2 cerebrovascular).mp.  
22. ("organic brain disease" or "organic brain syndrome").mp. 
23. ("normal pressure hydrocephalus" and "shunt*").mp. 
24. "benign senescent forgetfulness".mp.  
25. (cerebr* adj2 deteriorat*).mp.  
26. (cerebral* adj2 insufficient*).mp.  
27. (pick* adj2 disease).mp.  
28. (creutzfeldt or jcd or cjd).mp.  
29. huntington*.mp.  
30. binswanger*.mp.  
31. korsako*.mp.  
32. "cognit* impair*".mp.  
33. exp *Cognition Disorders/  
34. MCI.ti,ab.  
35. ACMI.ti,ab.  
36. ARCD.ti,ab.  
37. SMC.ti,ab.  
38. CIND.ti,ab.  
39. BSF.ti,ab.  
40. AAMI.ti,ab.  
41. MD.ti,ab.  
42. LCD.ti,ab.  
43. QD.ti,ab.  
44. AACD.ti,ab.  
45. MNCD.ti,ab.  
46. MCD.ti,ab.  
47. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.  
48. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or 
impair* or los* or deteriorat* or degenerat* or complain* or 
disturb* or disorder*)).ti,ab.  
49. "preclinical AD".mp.  
50. "pre-clinical AD".mp.  
51. ("preclinical alzheimer*" or "pre-clinical alzheimer*").mp. 
52. (aMCI or MCIa).ti,ab.  
53. ("CDR 0.5" or "clinical dementia rating scale 0.5").ti,ab. 
54. ("GDS 3" or "stage 3 GDS").ti,ab.  
55. ("global deterioration scale" and "stage 3").mp.  
56. "Benign senescent forgetfulness".ti,ab.  
57. "mild neurocognit* disorder*".ti,ab.  
58. (prodrom* adj2 dement*).ti,ab.  
59. (episodic* adj2 memory).mp.  
60. ("preclinical dementia" or "pre-clinical dementia").mp. 
61. or/16-60  
62. Family Practice/ or Ambulatory Care/  
63. Physicians, Family/ or Physicians, Primary Care/  
64. Primary Health Care/  
65. "family practice".ti,ab.  
66. "general practi*".ti,ab.  
67. *General Practice/  
68. "family practices".ti,ab.  
69. "family practitioner*".ti,ab.  
70. "general practitioner*".ti,ab.  
71. "primary care".ti,ab.  
72. Physician Assistants/  
73. "physician assistant*".ti,ab.  
74. Nurse Practitioners/  
75. "nurse practitioner*".ti,ab.  
76. or/62-75  
77. 61 and 76  
78. 15 and 77  
79. "clinical judgement*".ti,ab.  
80. "practitioner* judgement*".ti,ab.  
81. ((clinician* or GP* or physician* or doctor*) adj3 (intuit* or 
recognis* or detect* or diagnos*)).ti,ab.  
82. "gut feeling*".ti,ab.  
83. gestalt.ti,ab.  
84. "GP judgement*".ti,ab.  
85. ((clinician* or GP* or physician* or doctor*) adj3 
accura*).ti,ab.  
86. *Practice Patterns, Physicians'/  
87. or/79-86  
88. 61 and 87  
89. 78 or 88  
 
2. EMBASE 
1974-2016 April 25 (Ovid SP) 
1. *diagnostic accuracy/  
2. reproducibility/  
3. diagnos*.ti.  
4. sensitivit*.ab.  
5. specificit*.ab.  
6. (ROC or "receiver operat*").ab.  
7. area under the curve/  
8. ("Area under curve" or AUC).ab.  
9. sROC.ab.  
10. accura*.ti,ab.  
11. (likelihood adj3 (ratio* or function*)).ab.  
12. ((true or false) adj3 (positive* or negative*)).ab.  
13. ((positive* or negative* or false or true) adj3 rate*).ti,ab. 
14. "sensitivity and specificity"/  
15. or/1-14  
16. exp dementia/  
17. dement*.ti,ab.  
18. alzheimer*.ti,ab.  
19. (lewy* adj2 bod*).ti,ab.  
20. (chronic adj2 cerebrovascular).ti,ab.  
21. ("organic brain disease" or "organic brain syndrome").ti,ab. 
22. ("normal pressure hydrocephalus" and "shunt*").ti,ab. 
23. "benign senescent forgetfulness".ti,ab.  
24. (cerebr* adj2 deteriorat*).ti,ab.  
25. (cerebral* adj2 insufficient*).ti,ab.  
26. (pick* adj2 disease).ti,ab.  
27. (creutzfeldt or jcd or cid).ti,ab.  
28. "cognit* impair*".ti,ab.  
29. huntington*.ti,ab.  
30. binswanger*.ti,ab.  
31. korsako*.ti,ab.  
32. MCI.ti,ab.  
33. ACMI.ti,ab.  
34. ARCD.ti,ab.  
35. SMC.ti,ab.  
36. CIND.ti,ab.  
37. BSF.ti,ab.  
38. AAMI.ti,ab.  
39. LCD.ti,ab.  
40. QD.ti,ab.  
41. AACD.ti,ab.  
42. MNCD.ti,ab.  
43. MCD.ti,ab.  
44. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.  
45. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or 
impair* or los* or deteriorat* or degenerat* or complain* or 
disturb* or disorder*)).ti,ab.  
46. "preclinical AD".ti,ab.  
47. "pre-clinical AD".ti,ab.  
48. ("preclinical alzheimer*" or "pre-clinical alzheimer*").ti,ab.
  
Apr 2016: 2730 
Apr 2019: 1010 
49. (aMCI or MCIa).ti,ab.  
50. ("CDR 0.5" or "clinical dementia rating scale 0.5").ti,ab. 
51. ("GDS 3" or "stage 3 GDS").ti,ab.  
52. ("global deterioration scale" and "stage 3").ti,ab.  
53. "Benign senescent forgetfulness".ti,ab.  
54. "mild neurocognit* disorder*".ti,ab.  
55. (prodrom* adj2 dement*).ti,ab.  
56. (episodic* adj2 memory).ti,ab.  
57. ("preclinical dementia" or "pre-clinical dementia").ti,ab. 
58. or/16-57  
59. general practice/  
60. ambulatory care/  
61. primary medical care/  
62. "family practice".ti,ab.  
63. "general practi*".ti,ab.  
64. "family practice*".ti,ab.  
65. "family practitioner*".ti,ab.  
66. "general practitioner*".ti,ab.  
67. "primary care".ti,ab.  
68. physician assistant/  
69. "physician assistant*".ti,ab.  
70. nurse practitioner/  
71. "nurse practitioner*".ti,ab.  
72. or/59-71  
73. 15 and 58 and 72  
74. "clinical judgement*".ti,ab.  
75. "practitioner* judgement*".ti,ab.  
76. ((clinician* or GP* or physician* or doctor*) adj3 (intuit* or 
recognis* or detect* or diagnos*)).ti,ab.  
77. "gut feeling*".ti,ab.  
78. gestalt.ti,ab.  
79. "GP judgement*".ti,ab.  
80. ((clinician* or GP* or physician* or doctor*) adj3 
accura*).ti,ab.  
81. or/74-80  
82. 58 and 81  
83. 73 or 82  
 
3. PSYCINFO 
1806-April week 3 2016 (Ovid SP) 
1. diagnos*.ti.  
2. sensitivit*.ab.  
3. specificit*.ab.  
4. (ROC or "receiver operat*").ab.  
5. area under the curve/  
6. sROC.ab.  
7. accura*.ti,ab.  
8. (likelihood adj3 (ratio* or function*)).ab.  
9. ((true or false) adj3 (positive* or negative*)).ab.  
10. ((positive* or negative* or false or true) adj3 rate*).ti,ab. 
11. "sensitivity and specificity"/  
12. exp Test Reliability/ or exp Diagnosis/ or exp Medical 
Diagnosis/  
13. or/1-12  
14. exp DEMENTIA/  
15. dement*.ti,ab.  
16. alzheimer*.ti,ab.  
17. (lewy* adj2 bod*).ti,ab.  
18. (chronic adj2 cerebrovascular).ti,ab.  
19. ("organic brain disease" or "organic brain syndrome").ti,ab. 
20. ("normal pressure hydrocephalus" and "shunt*").ti,ab. 
21. "benign senescent forgetfulness".ti,ab.  
22. (cerebr* adj2 deteriorat*).ti,ab.  
23. (cerebral* adj2 insufficient*).ti,ab.  
24. (pick* adj2 disease).ti,ab.  
25. (creutzfeldt or jcd or cid).ti,ab.  
26. huntington*.ti,ab.  
27. binswanger*.ti,ab.  
Apr 2016: 1970 
Apr 2019: 367 
28. korsako*.ti,ab.  
29. "cognit* impair*".ti,ab.  
30. MCI.ti,ab.  
31. ACMI.ti,ab.  
32. ARCD.ti,ab.  
33. SMC.ti,ab.  
34. CIND.ti,ab.  
35. BSF.ti,ab.  
36. AAMI.ti,ab.  
37. MD.ti,ab.  
38. LCD.ti,ab.  
39. QD.ti,ab.  
40. AACD.ti,ab.  
41. MNCD.ti,ab.  
42. MCD.ti,ab.  
43. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.  
44. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or 
impair* or los* or deteriorat* or degenerat* or complain* or 
disturb* or disorder*)).ti,ab.  
45. "preclinical AD".ti,ab.  
46. "pre-clinical AD".ti,ab.  
47. ("preclinical alzheimer*" or "pre-clinical alzheimer*").ti,ab. 
48. (aMCI or MCIa).ti,ab.  
49. ("CDR 0.5" or "clinical dementia rating scale 0.5").ti,ab. 
50. ("GDS 3" or "stage 3 GDS").ti,ab.  
51. ("global deterioration scale" and "stage 3").ti,ab.  
52. "Benign senescent forgetfulness".ti,ab.  
53. "mild neurocognit* disorder*".ti,ab.  
54. (prodrom* adj2 dement*).ti,ab.  
55. (episodic* adj2 memory).ti,ab.  
56. ("preclinical dementia" or "pre-clinical dementia").ti,ab. 
57. or/14-56  
58. exp Family Physicians/ or exp Primary Health Care/  
59. exp General Practitioners/ or exp Clinical Practice/  
60. "family practice".ti,ab.  
61. "general practi*".ti,ab.  
62. "family practices".ti,ab.  
63. "family practitioner*".ti,ab.  
64. "general practitioner*".ti,ab.  
65. "primary care".ti,ab.  
66. "physician assistant*".ti,ab.  
67. "nurse practitioner*".ti,ab.  
68. or/58-67  
69. 13 and 57 and 68  
70. "clinical judgement*".ti,ab.  
71. "practitioner* judgement*".ti,ab.  
72. ((clinician* or GP* or physician* or doctor*) adj3 (intuit* or 
recognis* or detect* or diagnos*)).ti,ab.  
73. "gut feeling*".ti,ab.  
74. gestalt.ti,ab.  
75. "GP judgement*".ti,ab.  
76. ((clinician* or GP* or physician* or doctor*) adj3 
accura*).ti,ab.  
77. or/70-76  
78. 57 and 77  
79. 69 or 78  
 
4. Web of Science core collection TOPIC: (dement* OR alzheimer* OR "lewy bod*" OR DLB OR 
"vascular cognitive impairment*" OR FTD OF FTLD OR 
"cerebrovascular insufficienc*" OR "mild cognitive impairment" 
OR MCI) AND TOPIC: ("primary care" OR "general practi*" OR GP 
OR "doctor* surgery" OR "family practi*" OR "ambulatory care") 
AND TOPIC: (diagnosis OR sensitiv* OR specificit* OR ROC OR 
"receiver operat*" OR "Area under curve" or AUC OR sROC OR 
accura* OR "follow*-up" OR "positive predictive value*" OR 
"negative predictive value*" OR longitudinal OR longitudinally) 
Apr 2016: 928 
Apr 2019: 210 
AND TOPIC: (((GP OR practitioner* OR clinician*) AND 
(judgement* OR assessment* OR diagnosis)) OR "gut feeling*" 
OR gestalt) 
Timespan: All years. 
Search language=Auto 
6. LILACS (BIREME) dementia OR demencia OR demência OR alzheimer OR 
alzheimers OR alzheimer's OR cognition OR "mild cognitive 
impairment" [Words] and "primary care" OR "general practice" 
OR "atención primaria" OR "Práctica general" OR "Prática geral" 
[Words] 
Apr 2016: 33 
Apr 2019: 13 
TOTAL before de-duplication Apr 2016: 10154 
Apr 2019: 2527 
TOTAL after de-dupe and first-assess Apr 2016: 7060 
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Thank you for your reply regarding this patient. We are sorry but 
you still haven’t quite addressed the missing areas fully. It is 
very important for the research that we know your clinical opinion 
about the diagnosis, how confident you were, and what led you to 
form your judgement because this enables us to analyse how good GPs 
judgements are compared to tests, which is a key part of this work.  
Regarding confidence about the we need to know this on a scale from 
0 – 100, so if you cant get the word file to work, or can’t print, 
scan and email it to us, you could just say a percentage confidence. 
Bristol and South Gloucestershire CCGs, patient groups and our main 
funder the Wellcome Trust recognise this as an important aspect of 
our work – and we are grateful your help. 
We also noticed that there was a discrepancy between your clinical 
opinion in your original referral letter and your reply to our 
earlier email about missing information. Please could you confirm 
what your opinion was when you referred the patient? 
With best wishes, and thank you for your help, 
TIMeLi Memory Study timelimemorystudy@nhs.net  
b) Is your gut feeling that this 
person 
Has dementia  
 
 Has cognitive impairment but not dementia 
 
 Has normal cognition for age 
 






No idea (guess)                                                                      Certain                                        
x 
 
d) Please write a few words about what you think led you to form your gut feeling 
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MISSING	INFORMATION	LETTER	2	
NAME:	 	 	 	 	 	 	 NHS:		 	 	 	 	 	 	 DOB:		 	 	 	 	 	



















b) Is your gut feeling that this 
person 
Has dementia  
 
 Has cognitive impairment but not dementia 
 
 Has normal cognition for age 
 





No idea (guess)                                                  Certain                                        
x 
d) Please write a few words about what you think led you to form your gut 
feeling 
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STANDARD	OPERATING	PROCEDURE		
FAQS	REGARDING	ELIGIBILITY	AND	APPOINTMENTS	
1. Participant has been prepped for clinic and has study ID assigned and pack 
made but now can’t come at all or has declined so will not be participating. 
Example: Y6 was booked to come on 1 June 2013 but now doesn’t want to take part. 
Principle: Study IDs and packs should be uniquely linked to participants or potential 
participants.  
Solution: The next person to be prepped for clinic from surgery Y should be assigned the 
next sequential ID e.g. Y7 if this is not assigned. Pack Y6 should be securely discarded as it 
will contain patient identifiable information on it. Stata code referring to the random order of 
the tests should not be altered and should allow for the (now non-participating) Y6. 
Participant Y6 should have an ineligible or declined letter sent in accordance with the SOP. 
2. Participant had been prepped for clinic and had study ID assigned and pack 
made but had to change appointment. 
Example: Y3 was booked to come on 1 June 2013 but is now coming on 1 September 2013. 
Principle: Study IDs and packs should be uniquely linked to participants or potential 
participants.  
Solution: It is fine to use the previously prepared pack and study ID for this unique 
participant. Send the letter to GP surgery to confirm still appropriate to attend: 
Dear Doctor, 
Thank you very much for referring XXX to the Timeli memory study. They were supposed to 
attend our clinic on XXX but unfortunately they were unable to attend because they were 
unwell. We would normally arrange a new appointment for participants who failed to attend 
but we are not sure whether this is still appropriate given this episode.   
Could you please let us know whether you think it is still reasonable for us to see them via 
return email within the next few days. If we do not hear from you, we will assume it is still 
reasonable to see them. Thank you very much for your help. Best Wishes YOUR NAME 
3. Who to email if main contact away 
Example: Surgery G have an out-of-office to say they are not in this week. 
Principle: Communication with surgeries should be prompt and contemporary. Risks of data 
breach should be minimised. 
Solution:  Phone the surgery and let them know there is an email waiting for the person who 
is away and that due to data protection we would prefer not to send it to someone else - can 
they open it as a delegated mailbox? If this isn’t possible then ask the surgery to email you 
from the email address that they would like you to email.  
4. Informant has already been 
Example: Mr Jones came along with participant Y3 and now is planning to come with 
participant W2. 
Principle: Confidentiality should be preserved. 
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Solution:  It is acceptable for the same informant to come along with a different informant. 
Get permission from the new participant (W2 in example) to talk to the participant and 
emphasise the importance of confidentiality at the clinic. Alert Sam Creavin to the situation 
before clinic and on the case report forms so that confidentiality can be emphasised on the 
day as well. 
5. Changed mind about informant 
Example: Fictional participant GG had decided that he couldn’t find a suitable informant 
and a letter sent to the surgery to say he was ineligible but he has now found someone to 
come with him. 
Principle: Participation should be offered if appropriate. 
Solution: A new referral is NOT required but the GP should be updated. Get verbal 
permission from GG to write to the GP and inform them of this change and that he is now 
eligible. Use following wording, using wording based on email for cancelled appointment 
below: 
Dear Doctor, 
Thank you very much for referring XXX to the Timeli memory study. You had referred them 
but XXX was unable to find an informant and was therefore not suitable. However, XX has 
now found an informant to come along and given us verbal permission to inform you of this 
change in circumstances. We have arranged a new appointment but we are not sure whether 
this is still appropriate.   
Could you please let us know whether you think it is still reasonable for us to see them via 
return email within the next few days. If we do not hear from you, we will assume it is still 
reasonable to see them. Thank you very much for your help. Best Wishes YOUR NAME 
6. How long to wait between referral and attendance at clinic 
Example: Fictional participant HH had been referred on 1 April 2015 but was unable to 
attend clinic until 1 July 2015. 
Principle: Participation should be offered if appropriate. 
Solution: Appointments at clinic can continue to be offered up to six months from the 
original referral. A new referral is NOT required but the GP should be updated. Get verbal 
permission from GG to write to the GP and inform them of this change and that he is now 
eligible. Use following wording, using wording based on email for cancelled appointment 
below: 
Dear Doctor, 
Thank you very much for referring XXX to the Timeli memory study. They were supposed to 
attend our clinic on XXX but unfortunately they have been unable to attend appointments 
until now. Their appointment is booked for XXX but we are not sure whether this is still 
appropriate given the time interval.   
Could you please let us know whether you think it is still reasonable for us to see them via 
return email within the next few days. If we do not hear from you, we will assume it is still 
reasonable to see them. Thank you very much for your help. Best Wishes YOUR NAME 
7. Re-referral 
Example: Fictional participant JJ had been referred on 1 April 2015 but declined to take part 
and a declined letter was sent to the GP. Now JJ has been re-referred as he has changed his 
mind and would like to take part. 
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Principle: Participation should be offered if appropriate. 
Solution: It is fine to offer participation to JJ if he would like to take part. Both the original 
referral date and the new referral date should be kept on the Spread sheet that is used to track 
the interval between referral dates, appointments and letters back to surgeries. 
8. Prior memory clinic appointment 
Example: Fictional participant QQ had been seen in a memory clinic 10 years ago but not 
diagnosed with dementia.  
Principle: Participation should be offered if appropriate. 
Solution: Attendance at a memory clinic in the past is not an exclusion criterion for the study. 
However, people who have already been given a diagnosis of dementia are not suitable. 
People who have been seen at a memory clinic in the past are suitable, and it does not matter 
when they were seen. We do need to be careful about being used as a second opinion service: 
if appointment at memory clinic was within the last six months then advise that participation 
will probably be OK but need to confirm. 
9. Spouse or relative has already been as a patient. 
Example: Fictional participant BB  had been seen at TIMeli with his daughter. Now BB’s 
wife would like to come along with the same daughter. 
Principle: Participation should be offered if appropriate. Confidentiality should be preserved. 
Solution: See FAQ 4. The spouse should be offered participation but confidentiality should 
be emphasised to the informant – the daughter in the example. Eligibility should be checked 
carefully.  
APPENDIX B. ADMINISTRATIVE SOP
A standard letter was sent out to people to confirm the details of their appointment, together
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CONFIRMATION	OF	APPOINTMENT	DETAILS	
Your	appointment	with	the	timeli	memory	study	is	on	
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Hi XXXX,  
 
Thanks for sending this referral back to me so quickly. Dr. XXXX 
said in his referral letter that noone (neither him, the patient 
or  a relative) is concerned about possible dementia. It is a 
core inclusion criteria that someone (one of the three mentioned 
above) is concerned about possible dementia.  
 
Please could you clarify with Dr XXXX and ask him to re-refer the 
patient if appropriate..  
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a. Dear XXX Please find attached a letter for the 












a. Dear XXX Please find attached a letter for the 
attention of Dr XXX regarding XXX. A further letter 
will follow in due course with a clinical opinion. 
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Thank you so much for your email. Actually we don’t need to be 
emailed a copy of the blood results or tests - we will request 
access to these as and when it is necessary but don’t need to be 
sent them unless asked. 
 
Hope this makes sense, no reply needed.  
 













Dear XXX Please find attached a letter for the 
attention of Dr XXX regarding a clinical opinion for 
XXX.  
Due to feedback from the NHS memory service we have 
changed the format of our clinical opinion letter 
slightly and all future letters will be sent in this 
format. 
Thanks for your help with the study. 
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a. Dear XXX Please find attached a letter for the 
attention of Dr XXX regarding a clinical opinion for 








Thanks for your referral re XXX.. Please can you arrange for this 
referral to be resent to timelimemorystudy@nhs.net so that we can 
process it.  
Please note referrals containing patient identifiable information 
must be sent to and from an nhs.net account i.e. not this Bristol 
account 
Once we have this in the nhs.net account we can process from 
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Date:		 	 	 	 	 	
Pickup:		 	 	 	 	 	
From:		 	 	 	 	 	
Going	to:		 	 	 	 	 	
Arrive	time:	 	 	 	 	 	
Pick	up	time:		 	 	 	 	 	
Number	of	people	travelling:		 	 	 	 	 	
Mobility	issues?	i.e.	need	wheelchair?	 	
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a. Dear Doctor, 
b. Thank you very much for referring XXX to the Timeli 
memory study. They were supposed to attend our clinic on 
XXX but unfortunately they were unable to attend because 
they were unwell. We would normally arrange a new 
appointment for participants who failed to attend but we 
are not sure whether this is still appropriate given this 
episode.  Could you please let us know whether you think 
it is still reasonable for us to see them via return 
email within the next few days. If we do not hear from 
you, we will assume it is still reasonable to see them. 














his appendix includes the SOP that were used on the day of the research clinic. A SOP was
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A standard procedure was used for performing the index tests, in addition to following the
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TIMeLi memory diagnosis study Fire and DNA SOP Version 2 
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TIMeLi memory diagnosis study Safeguarding concerns SOP Version 2 















SOP FOR ISSUES AFTER RESEARCH CLINIC
T
his appendix includes the SOP that were used after the research clinic. A SOP was available
to in the event that a participant requested a copy of their notes. Sometimes this was done
if they were attending the NHS memory clinic.
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CASE REPORT FORM AND REDCAP VERSIONS
T
his appendix describes the revisions to the case report form and the REDCap data capture
instrument referred to in Chapter 3 Section 3.6.3.
The case report form had the following revisions:
1. Revision 1 [n=35] used from 17-04-2015
2. Revision 2 [n=15] used from 16-10-2015 Added order of assessments boxes on front page (index
test assessment first or reference test assessment first); added study site box on front page;
removed MAT; added MOCA
3. Revision 3 [n=191] used from 31-05-2016 Added Sniffin sticks test
The REDCap data collection instrument had the following revisions:
1. Revision 1 15-01-2016 12:07 Removed "don’t know" options from the informant section, as
these were not available on the case report form and had been included in error
2. Revision 2 02-06-2016 09:40 Added additional new coder
3. Revision 3 27-03-2017 08:24 Added additional new coders and made coder notes required field
on each page
4. Revision 4 03-07-2017 18:09 Added item for Eurotest recall errors, which had been erroneously
been missed in previous iterations. All cases were re-coded to enter this item
5. Revision 5 01-08-2017 09:42 Added additional GP surgeries, on referral form 1
6. Revision 6 01-08-2017 09:44 Added additional GP surgeries, on referral form 2
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APPENDIX E. CASE REPORT FORM AND REDCAP VERSIONS
The code in RStudio to randomly select a 10% sample of cases coded by each coder for duplicate
data entry was:
>sample(c(list)), size = number
Where list refers to the list of study ids for each coder and number refers to the number of cases











GUIDES FOR QUALITATIVE INTERVIEWS
T
his appendix includes the guide for the qualitative interviews. The original version, and
the final version, with all changes, is included. The intermediate versions are not available,
because the guide was iteratively refined between interviews some of which took place on the
same day.
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Original topic guide for qualitative interviews with patients and families  
 
1. Can you tell me a bit about your GP Practice and what your recent experience been 
of dealing with them?  
2. What are you expecting for today?  
Thinking now about memory problems in general 
3. Can you tell me about when your memory last let you down?  
4. When someone is worried about their memory who do you think should take the 
lead in diagnosing memory problems? 
5. What do you think about a GP making a diagnosis of dementia for a patient without 
getting a specialist involved?  
6. Some people have suggested the idea of a specialist GP for a local area who would 
take referrals from other GPs and act as a triage service, what do you think of that 
idea? 
a. Any further thoughts about how that might work? 
b. What about having a specialist nurse instead of a GP? 
7. What matters most to you when trying to find out what is causing memory 
problems?  
8. How do you think we could make things better for people in the future?  
Thinking now about your experience of dealing with your GP about memory issues 
[removed after first few interviews due to interview perception of low relevance of 
answers to research question and therefore unnecessary burden] 
9. What was your initial experience 
10. How was the topic of memory trouble first raised?  
11. How well did you know your GP before you spoke to them about this issue? 
12. Did you talk to anyone else about possible difficulties with the memory? 
a. Friends and family 
b. Carers 
c. Hospital staff 
d. Nurses  
 
● Participants’ experience of talking to their GP about concerns about possible 
dementia 
● Contrast between being diagnosed by GP compared to memory nurse or hospital  
● Benefits of some GPs being able to make a confident diagnosis of dementia in some 
people 
● Disadvantages and barriers to GPs diagnosing dementia 
● Potential solutions to perceived barriers 
Stop video [if videoing]  
Do 
1. MoCA [removed after first five interviews, other tests removed after first 2-3  
interviews due to excessive burden] 
2. Eurotest  




At the end of each test ask: 
[to patient]  
1. How did you feel when I was asking you those questions?  
2. What did you notice about that test? 
3. What do you think [carer] thought about that test? 
 
[To carer] 
4. How did you feel when I was asking you those questions?  
5. What did you notice about that test? 
 
[to both] 
6. [to both] Does it seem like a good test for diagnosing memory problems?  
 
Explain, “I’m just going to make some brief notes about my thoughts while you were 
doing that test and then we will do the next one”.  
 
Final topic guide for qualitative interviews with patients and families  
 
1. Can you tell me a bit about your GP Practice and what your recent experience been 
of dealing with them?  
 
Thinking now about memory problems in general 
2. Can you tell me about when your memory last let you down?  
3. When someone is worried about their memory who do you think should take the 
lead in diagnosing memory problems? 
4. What do you think about a GP making a diagnosis of dementia for a patient without 
getting a specialist involved?  
5. Some people have suggested the idea of a specialist GP for a local area who would 
take referrals from other GPs and act as a triage service, what do you think of that 
idea? 
a. Any further thoughts about how that might work? 
b. What about having a specialist nurse instead of a GP? 
c. Some people say this wouldn’t make any real difference as if you have to 
get in the car you have to travel anyway, what do you think?  [for 
interviews from 14-6-17] 
6. What matters most to you when trying to find out what is causing memory 
problems?  
7. How do you think we could make things better for people in the future?  
8. Some people have suggested having “brain exercises” to try to help, what do you 
think about that? [for interviews from 14-6-17] 
9. Some people have said that it doesn’t matter if you have to wait a bit, as the 
memory has declined over months - year and so it shouldn’t be a rushed process to 
try to sort it all out. What do you think?  [for interviews from 14-6-17] 
 
● Participants’ experience of talking to their GP about concerns about possible 
dementia 
● Contrast between being diagnosed by GP compared to memory nurse or hospital  
● Benefits of some GPs being able to make a confident diagnosis of dementia in some 
people 
● Disadvantages and barriers to GPs diagnosing dementia 















his appendix includes the ethnographic notes from the qualitative interviews.
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2017 24-02-2017. 
In a fairly affluent suburb. House set approximately 5 minutes drive from the surgery or around 
30-45 minutes walk for me. I guess middle - upper middleclass. In almost an entirely residential 
setting. Sun was shining, lovely day outside.  
Arrived 10 minutes late as had some problems setting up computer before I left. Had tried to 
call to confirm time with them on the day but no answer, so wasn’t sure they would be there. 
Had just been speaking to my wife on the telephone about a hospital appointment for her. His 
wife was leaving to go out to “buy a newspaper” as I arrived. I introduced myself, she 
remembered me from main clinic, and I went inside. Inside the house was comfortable and 
clean. Pictures on the wall that he had painted in younger life. Decoration tired but very 
presentable. We sat in the dining room [there was also a flight of stairs up, a small kitchen and a 
sitting room downstairs with a sofa and a couple of seats]. The wooden table in the dining had 
space for six and a big picture window that let the light in well, though not into our eyes.  
Shook patient’s hand and got kit set up. I quickly realised I had forgotten to print the interview 
topic guide, so tried to access it through 4g to no avail. I went down to the surgery in X and 
printed it off there. On my return they were both at home. 
We started the interview and they sat on one side of the table and me on the end. They wanted 
me to talk to the daughter as well, which I did at the end, as it seemed this was important to 
them, but I said I wouldn’t be able to do any recording of what she said as she wouldn’t be able 
to sign a consent form [she is in the states]. She told me that mum and dad had been to the GP 
before she visited in October following concerns from mum, and that the main concern seemed 
to be around the delays, it took a long time to have a scan [i perceived this was a key milestone 
for them] and then a long time to get the results.  
Interviews progressed fairly steadily; I think he could have gone on for a short while longer but 
not much more. I wouldn’t have wanted to do many more tests with him, maybe just TUG.  
Left around 13.15  
2017 22-93-2017.  
In a relatively deprived small town outside of the main city. Bungalows at approximately five 
minutes from the surgery or 10 minutes from the centre of town. A rainy wet drizzly day. 
Probably lower middleclass.  
Arrived on time I went inside to see them both. they recognised me from the main clinic. Inside 
the house was relatively clean and tidy but somewhat smaller than the previous interview and 
certainly more tired and in terms of decoration. We both sat in the front room his wife joined us 
and it was a little warm inside as there was a hot radiator on wall.  
We made small talk about the weather and started the interviews. Having changed the order of 
the topic guide I was able to talk first about the views and experiences of the practice followed 
by reflections on being diagnosed with dementia by GP. They were keen to share their 
experiences of GP's at the practice and my overriding sense was that transport was a key limiting 
factor for them they would struggle to get into the centre of town it would involve two buses 
and they were keen to see people close to home.  They had a good relationship with a particular 
GP and would be happy for that person that they trusted to effectively tell them what to do. 
They haven't seen anyone them other than the team at the practice and the timeli team. After I 
turned off the recorder at the end he was telling me about how laptops and mobile phones have 
now been banned from airlines which is a very recent topic in the news yesterday . 
Left after around one hour 
2017 22-03-2017. 
Second interview of the day. In an affluent suburb in the outer main part of the city, the 
weather had improved and although it was still raining and drizzly at times there were 
intermittent periods of sun. I should think middle - upper middleclass. I arrived in plenty of time 
despite it being the second interview and was able to wait outside in the car for 15 minutes 
before going in 15 minutes early.  
The house was very large and set back from the road in a quiet spot with lovely birds outside 
which were a very pleasant to hear their bird song. The patient greeted me from the window 
when I rang on the doorbell as he was helping his wife to get dressed as she had recently had a 
hip operation. He showed me in and we sat down in the main living area with them on two 
armchairs and me on the sofa. They were happy for me to video them and we started the 
interview following the new topic guide.  
They shared their experiences of dealing with a GP at the practice but my overriding sense here 
was that they were usually seeking to get the expert opinion of a specialist. In particular they 
had concerns that a nurse might not have sufficient training to deal with what they perceived as 
being a particularly difficult problem with the “mind” rather than a physical or medical issue. 
The wife shared concerns that she felt that there was something wrong but the cause for this 
had not yet been identified as he's been discharged from the memory service with a diagnosis of 
no dementia. They showed me a letter which had been provided to him from the memory service 
which was signed off by a senior nurse. It was not clear that he’d been assessed by a memory 
consultant and it looked as if the diagnosis of no dementia had been made in the context of him 
scoring higher on the Ace3 the second time he did it compared to the first time that he did it. As 
they both identified, this may have been due to a learning effect. The wife was concerned as 
she noticed particular issues with sequencing and thought that he would be likely to get a recipe 
wrong. They were both pleasant to talk to and I noticed that both the wife and the patient 
failed to complete the consent form correctly. The wife wants to have a go at doing one of the 
money questions and I allowed her to do this: I did not have the correct change for the money 
question neither had I for the first interview of today but was able to make up a similar question 
which tested the principle that I had wanted to examine. The patient was not keen to actually 
do the tests himself and so we talked through them and what it would mean to do them and how 
effective they were perceived as being as tests of the memory and brain functioning. 
No additional information of relevance are important was provided after the tape recorder was 
turned off. I did not notice any signs of distress or discomfort when doing the specific tests 
which were provided i.e. MoCA and eurotest 
I left after around 45 minutes  
2017 28-03-2017. 
First interview of the day, had been a sunny day with intermittent episodes of rain. Bungalow 
situated off the main road up a set of fairly steep steps on a small row of similar properties. In 
an economically middling area I should think. Perhaps lower - middle middleclass. Beautiful view 
of the [relatively calm] sea.  
Patient greeted me at the door and showed me inside, where her husband was also waiting. 
House was well decorated and maintained, clean tidy and comfortable. They both sat on the 
sofa facing out to the sea and I sat on the floor facing towards them.  
My main reflection on this interview was the extent to which the patient [lady] dominated the 
conversation while her partner sat relatively quietly to her side. Her main concern was about 
finding out what was going on and wanting an explanation for symptoms that she had noticed 
and perceived were abnormal. She was less concerned about who she saw - though she liked 
seeing a particular doctor at her own surgery - and more concerned about knowing what was 
causing her symptoms, even if nothing could be done about them. She mentioned on a couple of 
occasions that her memory wasn’t a particular concern for her.  
She seemed to cope well with the interview and probably could have gone on longer but I 
perceived I had the information that I needed.  
No additional information of relevance are important was provided after the tape recorder was 
turned off. I did not notice any signs of distress or discomfort when doing the specific tests 
which were provided i.e. MoCA and eurotest. My overriding sense was that there was no real 
difference in how these tests were perceived and that they would be happy to have had 
whatever test was most useful and helpful. 
I left after around 45 minutes  
2017 28-03-2017.  
Second interview of the day. Had been a pleasant drive from X to X along the coast road. Arrived 
at the house in a residential area in town. Small garage outside that I was able to park outside. 
In a relatively economically depressed area for the town, I would think. Perhaps lower - middle 
middleclass. Patient was at home by herself as her friend had not yet arrived. Inside I set up and 
after 10 minutes or so asked if it might be worth phoning her friend to check she was coming. 
The friend arrived a few minutes after this as she had in fact just been pulling up outside.  
I sat on the floor and they sat on chairs next to one another. She seemed to be doing fine with 
the interview but I noticed at around 20 minutes that she seemed to start to tire. The main issue 
that they both seemed to be expressing here was that they didn’t feel she [the patient] was too 
impaired at the moment, so it was fine to be managed by a GP. There seemed to be a sense that 
seeing a specialist would imply a more serious or advanced problem and that might not come in 
the future.  
No additional information of relevance are important was provided after the tape recorder was 
turned off. I did not notice any signs of distress or discomfort when doing the specific tests 
which were provided i.e. MoCA and eurotest. They commented that MoCA seemed to test a 
wider variety of domains than eurotest [though of course they may not have appreciated that in 
fact a large number of cognitive skills are tested with eurotest, even though it is relatively brief 
and appears simple]. 
I left after around 50 minutes.  
2017 04-04-2017.  
First interview of the day, four in total. Arrived in plenty of time, a very beautiful day outside. A 
detached house in a suburb, in a relatively affluent part of the [fairly middling] town I should 
think. So middle middleclass overall. She opened the door and let me in, she was at home by 
herself as she lives at home. Inside the house was notably clean and tidy, everything was put 
away and very clean. I took up her invitation to have a glass of water. I asked about recording 
the interview, which she was happy to do, and about videoing, which she was less happy to do, 
so we quickly agreed that we would not video.  
I set up the kit and we made some small talk about the pleasant weather, her move from X some 
years ago and her desire to finish at around 30 minutes as she was going out to Lunch. At one 
point I asked her to repeat what she said as she had a noisy clock that chimed. This did not seem 
to be a problem. I sat on a sofa near to her and then moved next to her at the end to show her 
the tests. At her request we did not do the MoCA or Eurotest but I just asked her about the 
questions. She seemed to find the Eurotest and MoCa of similar difficulty and neither of them 
was particularly burdensome for her. I think she would have been able to have been interviewed 
for longer if necessary or time was available, but I think we covered everything that we needed 
to do. No additional information of relevance was provided after the tape was switched off.  At 
the end we made some small talk about her plans to go out and eat at a local canteen.  
2017 04-04-2017.  
Second interview of the day, four in total, a short drive from interview #1 of the day. I arrived 
and the husband let me in. I sat on the floor opposite them. House in an economically more 
constrained part of town than interview #1 of the day, but still middle middleclass overall. 
Inside the house was clean and tidy and they were both able to take part in the interview and 
were happy to be videoed. I declined the offer of tea / coffee.  
They wanted to hear the outcome of the main clinic appointment as they still hadn’t heard, I 
apologised that I wasn’t able to tell them as I didn’t have the information to hand, and that I 
could confirm that the information had been emailed back to the surgery 2 months ago. They 
were happy to take this up with the practice. Before the consent forms were signed and 
therefore before the tape was switched on she spent some time talking about how she had had a 
series of MRI scans for a ongoing problem at the base of her skull that was not yet fully 
evaluated or determined. This did not seem to be causing her particular distress and I was rather 
struck by the calm way that she talked about it; she said that her view was that if it was 
something serious or worrying then things would have moved along more quickly so it was likely 
to be nothing to worry about.  I had no sense that either of the tests was especially burdensome 
or troublesome.  
After the tape was switched off we had a conversation about how the tests hadn’t really seemed 
to capture her problems and that whatever was shown up she remained sure that something was 
wrong, even if an explanation hadn’t been found. I said that the problem was that for most GPs 
they might not refer her as she would be normal on the tests, my approach might have been to 
refer her as she was so intelligent it was likely that specialist input would be needed in any 
event.  
2017 04-04-2017.  
Third interview of the day in probably the most affluent part of town so far. The gardener was 
outside and the husband then came out to greet me. The house had a beautiful garden out the 
back. I went inside, everything was clean and well decorated, though perhaps a little tired. I 
took up the offer of a cup of tea. A range of wildlife DVDs on the side cabinet. Probably middle - 
upper middleclass. Wife seemed a bit apprehensive at first but definitely warmed up.  
They talked to me about their experiences of the memory clinic and the appointments, and that 
it seemed to take an age to have and get the results of the CT scan. They were both interested 
to look over the memory tests together but I had no sense that either of the tests was especially 
burdensome or troublesome.  
We went on a little longer than I had anticipated as they [especially he] seemed to go off track, 
at times, from the questions that I asked, and I didn’t want to interrupt them too quickly.  
Nothing of relevance was said after the tape was switched off.  
2017 04-04-2017.  
Last interview of the day in a similarly affluent suburb and in an outskirts residential location. 
Probably middle - upper middleclass. I parked outside on the road and walked up the drive. 
There was a big dog inside which I found a bit scary, but they quickly put it inside a room and 
locked it there. We sat in the conservatory with a view of the sunny garden. They sat in chairs 
next to each other, which we had to move around a bit. There had been some confusion / 
muddle with the time of the interview as he had thought I had said 11.30 though I had definitely 
said - and written down - 1330. I had offered the opportunity to reschedule or rearrange or 
cancel but they were both happy to continue. I arrived on time.  
I declined the offer of refreshments as I had had plenty.  
They asked about the outcome of the main clinic visit as they had not yet had the letter. I 
apologised for this delay and said I was fairly sure that the letter would have gone back to the 
surgery but that I would check as soon as I got back to base, and that if the surgery said they 
still did not have the letter by the end of week then to let me know as it may have gone to their 
junk email.  
I thought the interview was about the right length and any longer might have been difficult. I 
noticed that he seemed to struggle more with the Eurotest than with the MoCA but neither 
seemed especially burdensome. They did not seem to perceive that the Eurotest on its own 
would be sufficient to make a diagnosis of dementia. The dog was barking a little bit during the 
test but was locked away and this was not especially distracting.  
After the tape was switched off we spoke briefly about how there had been an episode with 
nhs.net mail a few months ago - I couldn’t remember the precise date - when the system had 
melted down and around 4000 emails were received by users in a single day.  
2017 03-05-2017.  
First interview of two today in a lower-middle >middle-middle class part of town. Small 
bungalows and residential location. I went on my bicycle as the car was in the garage. I arrived 
five minutes early and was just sorting out my bike when a middle aged woman arrived; I asked 
if she was the daughter but she was in fact the cleaner. I went in with her. Inside the house was 
quite disorganised but tidy and clean. There was a large amount of stuff spread out in most of 
the rooms with the exception of the front room which is where we sat to do the interview. On 
my way in the patient was talking to the cleaner and remarking on how she had forgotten that 
the cleaner was coming, again. She offered me a glass of water and I took her up on the offer. 
The cleaners mobile phone rang a few times during the interview, though she was in the kitchen 
it was still possible for me to hear her talking and answering the phone, but this was not 
especially distracting and I don’t think the patient could hear it.  
We sat in the front room which was clean tidy and well kept. There was a large picture of a 
house on the facing wall that the lady sat in and I asked about this: it emerged that it was her 
former house in Saltford - quite a large [10 bedrooms she said] house that she had formerly run 
as a hotel with her daughter. I was interviewing her by herself. As we made a start in the 
interview she seemed to forget something she had said earlier on and to be struggling with some 
of the questions more than I had anticipated. I made sure to focus on the key areas that I 
wanted to get her views on. She did not seem to think she had any problem with her memory 
and so I chose not to ask her about when her memory last let her down and about her originally 
consulting her GP about her memory, as I did not want to cause her distress, especially as she 
was on her own. [I note, on return to the university, that the impression at her main clinic 
appointment was normal]. She was very clear that if there was a problem with her memory at all 
she would want to see a top specialist and would be happy to pay for this if necessary to go to 
London. After the tape was switched off she told me a bit more about her former house. As I 
went out the door she remarked that she had thought my bicycle had a light on it, I explained 
that it did but it was not visible as it folded up.  
 2017 03-05-2017.  
Second interview of two today, I cycled between the interviews on my bicycle as the car was in 
the garage. Relatively small but modern house in a fairly deprived part of town, probably lower-
middle to working social class. I arrived 30 minutes early but they were happy to start sooner 
than we had planned. I folded the bicycle up and went in, the patient opened the door to me as 
his wife was upstairs. They were both happy to take part and bought me a glass of water to 
drink. I sat on the floor in front of them.  
The house was clean and tidy but not large or spacious. There were a number of photos in the 
house of their grandchildren and I remarked on one of X which he told me he had taken himself. 
We got on with the interview. I got the impression that the wife was more verbose and 
dominating in the conversation but I tried to encourage him to speak and share his views as well.  
Unfortunately the video recording did not work. I tried - and failed - to connect via the internet 
using 3G on my phone but it was no good. At the end we spoke briefly about the garden and 
range of bird feeders that they had outside.  
 2017 09-05-2017.  
Only one interview today, but the end of the day after a research clinic. In a beautiful period [? 
Victorian] house on a quiet road near the edge of town, though not in an especially wealthy 
looking area. I would say middle middle class. There was a large, handsome, dog outside but 
they kindly kept it there without me having to say that I’m quite scared! We went it and got 
straight on with the interview, they had been outside in the garden as it was a beautiful day. 
Weather was absolutely splendid.  
I sat on the floor in front of them in the sitting room and they both participated. It was 
interesting to hear their views about getting access to a specialist. The wife seemed to 
repeatedly emphasise the sense of being dropped or abandoned to get on with it and seemed to 
value having someone that she could talk to and access easily. But expertise also seemed to be 
perceived as being very important too.  
They closed the encounter by emphasising that they would be happy to be contacted again in 
the future. 
 2017 19-05-2017.  
A beautiful sunny day. I was wearing shorts it was so hot. First interview of the day in a small 
bungalow in a town outside of the main city. He greeted me at the door, wearing clothes that 
looked as if he has been painting. Inside the house looked as though it was being redecorated, 
but was comfortable and homely. There was a large open plan living area with a small garden 
out the back. Lots of painting from the middle east on the walls, including one which he said he 
had painted himself.  He said a number of times that his financial situation was “not good”. My 
sense was that this was probably a lower-middle class house though as he referred to getting 
some money from rental income, but also that he needed his daughter to support him financially 
at times.  
I sat opposite him, there were just the two of us there as his daughter was not available. He told 
me about his time as a X of X.  
At the end, after the microphone was turned off, he told me about an X restaurant in X and 
showed me the picture in a book that he had copied the wall painting from.  
 2017 19-05-2017.  
Second interview of the day, I drove straight between the two. This was with a X X, and I knew 
he was a XX which was one of the reasons for asking him to take part in interviews. I arrived and 
he greeted me at the door. There were two fairly old, “unfashionable” cars on the drive. There 
was a large garden outside. He remembered that I was a GP: mostly participants have not 
remembered this though they may recall having seen me at the main clinic. He wanted to show 
me a series of photographs from X, which seemed important for him to do and so I let him do 
this. We had not signed the consent forms yet. He showed me X and told me about how X. There 
was a large photo album which we looked through together while he talked about this for about 
10 minutes. We then signed the consent forms and made a start, his wife was happy to take part 
as well.  
This interview was interesting because it struck me that he was keen to return to talking about X 
and it was a delicate balance to try to move him back to answering the questions that I had for 
him. He was keen to talk and I tried to make space to get his wife’s view as well.  
At the end his wife offered me some coffee, but I was not able to stay as I had to collect my 
daughter from preschool, so she gave me some poppadoms to take away.  
 2017 13-06-2017.  
First interview of the day, four in total. It had been a someone hectic morning having got up 
before 6am to do data analysis prior to a meeting with supervisors, driven to that meeting and 
then back to X to get the stuff for the interviews. A very beautiful day. A semi rural area but a 
small bungalow that looked like it might have been part of a housing association at one point. 
The lady greeted me at the door and showed me inside, she was at home by herself and lived 
alone. She seemed to be managing OK thought things were not spotless inside for example the 
carpet was a little dirty in places and there were some old bits of paper around. Though she 
described herself as having gone to a private school she told me afterwards that her father was a 
tenant farmer on a council farm. Certainly on the basis of the home as it was presented at the 
time I visited I would describe her situation as working class.  
She spoke about her farming background and how she was a country girl. She told me that she 
had lifelong problems with her hearing but this did not seem a particular problem during the 
encounter. I deliberately kept the interview fairly brief as I did not want to overburden her and 
was especially mindful of this as she was home by herself and struck me as fairly frail physically, 
regardless of her cognitive state.  
 2017 13-06-2017 
Second interview of four today. In a modern detached house on a modern estate. The daughter 
was present for our encounter. I would describe as middle-middle class. She told me she had 
been X for her main job since her thirties.  
Inside the house was very clean and tidy and well maintained. They offered me some water 
which I was happy to have as by this point I was quite thirsty. There was a small conservatory 
outside with a view onto the well maintained garden with water feature.  
The interview progressed fairly well. Of note she lip read.  
At the end I explained I might send out a postcard to all participants at some point in the future 
to invite them to a public meeting to share the results of TIMeLI with them, though this may not 
be for a few months or even a year or so.  
 2017 13-06-2017.  
Third interview of four today. The timetable was progressing well and to time, and my journeys 
between sites were not burdensome as I had planned well geographically. Things seemed to be 
going OK and I was not feeling hassled or stressed.  
I arrived and it was slightly difficult to find the house as it was on a lane that broke in the 
middle with a no through road due to it being so narrow; it was possible though to locate the 
house without a great deal of difficulty.  
A modest size bungalow that was clean and tidy inside and decorated in a modern fashion. All on 
one level as I think the patient’s wife has some mobility issues [there was a frame inside to help 
her get around]. A well maintained garden outside and a clear interest in plants. I would 
describe as lower-middle middle class.  
The conversation progressed well and we established I felt a good rapport. At the end he asked 
about what the next steps were and I explained that he should contact his own GP surgery to 
check that they had received our correspondence from the main clinic and they would then be 
able to progress things as needed from there. This seemed to cover things.  
At the end I explained I might send out a postcard to all participants at some point in the future 
to invite them to a public meeting to share the results of TIMeLI with them, though this may not 
be for a few months or even a year or so.  
 2017 13-06-2017.  
Last interview of four today. He greeted me outside the front door, there were some very old 
but elegant classic cars parked on the drive outside. A fairly large house in a suburb, but not 
flashy or grand. Inside well decorated though tired and with some clutter around. The back 
garden looked reasonably well maintained. I would say middle middle class.There was a variety 
of calligraphy in the home that he had done himself.   
His wife joined us for the encounter. The challenge here was that he didn’t seem to have any 
insight at all that he had a memory problem. The interview seemed to progress well.  
Afterwards, outside, the wife rushed out to X This seemed to be acceptable to the wife and we 
parted on a positive note.  
At the end I explained I might send out a postcard to all participants at some point in the future 
to invite them to a public meeting to share the results of TIMeLI with them, though this may not 
be for a few months or even a year or so.  
 2017 14-06-2017.  
First interview of two today. I had a fairly hectic morning having dropped my daughter at 
childcare and then tried to rush to be in the office for an early morning phone call. The house 
was further away than I anticipated and sat nav had directed me down a wrong road but I 
arrived unflustered. I walked up to the gate as it was difficult to park outside, and he greeted 
me at the gate. A beautiful sunny day. It was a modest bungalow in a small rural conurbation 
just outside the main town. Inside relatively well maintained and clean and tidy. I would 
describe as lower-middle class. 
I thought there were two interesting things about this interview. Firstly he made the point that 
if he had to get in the car anyway to see a doctor it didn’t really matter how far he had to go so 
seeing a GP or nurse locally wasn’t really adding anything to him going to X to see a specialist. 
Though he could see some merit in this if the appointment wait was less, and wouldn’t in 
principle have a problem with seeing a nurse for a diagnosis, providing they were appropriately 
trained, it sounded as if travelling to X instead of for example X was not really a priority for him. 
He mentioned his practice is now merged and he implied he may have to travel to X on occasions 
to see his GP, though whether this has had any impact on his views about the acceptability of 
travelling for healthcare or whether he has always found it acceptable to travel where needed 
was not clear and I did not especially want to explore this in great detail as it was not the main 
focus of the interview. Additionally the waiting time to see someone was not regarded as being 
especially important. 
The other point of note was that he related the memory to his recent X problem. He said that he 
had been given exercises for his X and it would be nice to have something to do to try to prevent 
the decline of his memory perhaps some brain exercises or something like that.  
At the end I explained I might send out a postcard to all participants at some point in the future 
to invite them to a public meeting to share the results of TIMeLI with them, though this may not 
be for a few months or even a year or so.  
 2017 14-06-2017.  
Second interview of two today. He was waiting outside his house when I arrived and greeted me, 
I parked on the drive. He was home alone as his wife was out for the day. The house was a little 
dated in decoration but was fair sized. I would describe as lower-middle class.  
I took the opportunity to follow up on some of the ideas that the previous interview of the day 
had raised. To what extent was it important to see someone quickly, to see a consultant, was 
there any value in seeing someone close to home, and were “brain exercises” perceived as 
useful. I have modified my interview topic guide as a result. The interview seemed to progress 
well. We closed by him telling me that he was planning to spend the afternoon in the garden 
doing some work and trimming a hedge.  
At the end I explained I might send out a postcard to all participants at some point in the future 
to invite them to a public meeting to share the results of TIMeLI with them, though this may not 
be for a few months or even a year or so.  
 2017 21-06-2017 
Only one interview today: and a very hot day at that. Traffic in X in the hot weather was not 
good and I arrived about 20 minutes late, but I had called on the way and they were fine when I 
arrived. I bungalow in a semi-rural suburb I would describe as middle middle class. They both 
greeted me at the door. Inside things were very clean and tidy and smartly / contemporarily 
decorated. We made some small talk about the weather as I didn’t want them to be nervous and 
I had a slight sense they might be. His wife joined us for the interview and bought me a glass of 
water as she had one.  
I sat on the floor in front of them and they sat on the sofa together.  
An interesting thing from this interview was that he seemed to think there was something 
particular about the mind that made it difficult to diagnose as a GP. I recalled this as being 
something that has come up before so I tried to explore it a bit further. We also explored the 
idea and consequences of travelling further to see a more expert specialist, or whether it didn’t 
really matter how far a distance was travelled because they had a car anyway. Though his wife 
recognised that the situation may change if it was more difficult for them to drive in the future.  
At the end we spoke about the next steps and I outlined that the GP would take things forward. 
They showed me a letter from the memory service and I explained that we could send on some 
of our information to them if he requested me to do that because we took his data protection 
very seriously. I explained I would wait to hear from him, mentioned the possibility of further 
contact with a postcard to explain the results in the future, and wished the best.  
2017 28-07-2017.  
Only one interview today. I arrived on time and went in. She lived in a large modern retirement 
complex of warden monitored flats in a small town outside of the main city. Inside the flat was 
small but well maintained and clean and tidy with modern fittings. There was quite a lot of stuff 
in a small space. An entrance hall, open plan kitchen – sitting area, bathroom and bedroom.  
She couldn’t get her head around how she had ending up taking part in the study. My impression 
as the interview went on was that she was modestly impaired cognitively and so I tried to keep 
the interview as short as possible. It was interesting though some things that she was able to 
remember.  
2017 01-08-2017.  
First of four interviews todays. I arrived on time. A reasonably large house on a hill in the older 
part of the town with a large vegetable patch at the front and a large garden at the back. We 
conducted the interview in the new modern wood framed conservatory with beautiful views 
across the estuary. I would say definitely middle middle-class. His wife bought us coffee and 
biscuits which I was pleased to have and we all sat down together. He was a bit tearful as we 
started the interview, my impression was that this was because he was concerned about the 
impact that his symptoms had on his wife.  
He spoke well and I did not need to ask his wife much. He had the letter that we had sent to his 
surgery printed out and in his file, which he showed to me. He was keen to know what could be 
done to try to prevent his memory getting worse and he shared the activities that he did with 
me, such as trying to stay active, going the gym and for walks. He told how he was used to being 
in a leading role and found it difficult when in situations he perceived he was no longer able to 
do that, for example following a map when leading people on a walk.  
He liked the idea of having exercises that might help so that he could retain some degree of 
control over things.  
2017 01-08-2017.  
Second of four interviews today I drove from nearby and arrived in time having grabbed a bite to 
eat on the way. Outside was a Tesla. They lived in a large bungalow in the middle of a very rural 
area down a lane with only a few houses on it. Difficult to gauge the socioeconomic 
circumstances as the house itself did not seem especially large or prosperous to the extent that 
the car would. He greeted me at the door and showed me inside. We sat at a small table in the 
living room and all spoke together.  
2017 01-08-2017.  
Third of four interviews. A small house in the centre of X, the house was organised and tidy. 
Three of us spoke together, me, the husband and the patient. She seemed to have at least 
modest impairment and would answer in short answers and seemed to struggle to answer the 
more abstract questions. They had moved to the area from elsewhere, in the recent past. Their 
current house was in a less affluent part of the town. A fire alarm was ticking for most of the 
interview. Husband wanted to talk and said more at length. She had a bit of a cold and a cough.  
2017 01-08-2017.  
Last interview of the day. A house in a hamlet down a country lane, approximately a mile from 
the main town. There was a garage, but no car parked outside. Fields out the back of the house. 
I saw her with her husband. The house was tidy and well organised, and clean. Would appear to 
be middle class regarding socioeconomic status but feels a bit isolated from the main town. She 
seemed to speak clearly and articulately in response to the questions. Could articulate reasons 
for things. We sat at a small table in the kitchen and spoke together, but generally she was able 
to answer questions without needing input from her husband. The extent to which people talk in 
the community about health issues was important to them both.  













his appendix provides the naïve and harm adjusted decision curves for each of the individual
index tests, for both of the target conditions, that are referred to in Section 3.7.4.1 and Section
4.6.4.
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APPENDIX H. DECISION CURVE ANALYSIS
Figure H.1: Naïve and harm adjusted decision curves, with dementia as the target condition on the






























































































































The curves plot the net benefit across all thresholds, along with the treat-all and treat-none lines.



































































































































The curves plot the net benefit across all thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
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The curves plot the net benefit across all thresholds, along with the treat-all and treat-none lines.





































































































































The curves plot the net benefit across all thresholds, along with the treat-all and treat-none lines.
Curves are smoothed, as recommended to minimise unstable results [168]
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The curves plot the net benefit across all thresholds, along with the treat-all and treat-none lines.












































































































The curves plot the net benefit across all thresholds, along with the treat-all and treat-none lines.














his appendix provides the ROC curves and calibration plots for each of the individual index
tests, and GP combined tests, for both of the target conditions, that are referred to in Section
3.7.4.1 and Section 4.6.4. Plots for MAT are not provided because as described in Section 4.6.4
the small numbers who completed this test made the analyses unstable. For dementia as the target
condition it was not possible to use roccomp to plot both the single test and the GP combined test on
the same axis for index tests Sniffin sticks and MOCA, due to perfect sensitivity in the single test. The
same applied for normal and TAC, FAQ and ADL. For these tests where it was not possible to plot
both single tests and GP combined tests using roccomp separate ROC plots were made for the single
test and GP combined test using roctab.
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APPENDIX I. DISCRIMINATION AND CALIBRATION
Figure I.1: ROC curves and calibration plots for the individual index tests and GP combined tests,




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































gtf GP + TAC + FAQ
The following calibration plots and ROC plots are for the GP 360 tests





















































































































































gci GP + 6CIT + IQCODE
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his appendix gives tables of the sensitivity analyses for the quantitative study.
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Table J.1: Sensitivity analysis: continuous tests combined with GP judgement, target condition dementia
Test Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI) Probability ‡
Tests as continuous scores, dichotomised at a predicted probability of dementia ∏ 80%
EPSS 39 (31 to 48) 92 (85 to 96) 85 (74 to 93) 55 (48 to 63) 5 (2 to 9) 0.66 (0.57 to 0.77) 7 (3 to 17) 0.99
TAC 67 (58 to 75) 85 (77 to 91) 85 (76 to 91) 68 (59 to 75) 5 (3 to 7) 0.39 (0.3 to 0.5) 12 (6 to 23) 1
Phototest 47 (38 to 55) 93 (86 to 97) 88 (78 to 95) 59 (51 to 66) 6 (3 to 12) 0.58 (0.49 to 0.68) 11 (5 to 28) 0.99
6CIT 47 (39 to 56) 90 (82 to 95) 85 (75 to 92) 58 (50 to 66) 5 (3 to 8) 0.59 (0.49 to 0.7) 8 (4 to 18) 0.99
GPCOG 52 (43 to 61) 94 (87 to 97) 91 (82 to 96) 62 (54 to 69) 8 (4 to 17) 0.51 (0.42 to 0.61) 16 (7 to 43) 0.98
Minicog 42 (34 to 51) 94 (87 to 97) 89 (78 to 95) 57 (49 to 64) 7 (3 to 14) 0.62 (0.53 to 0.72) 11 (4 to 29) 0.96
Eurotest 61 (52 to 69) 97 (92 to 99) 96 (90 to 99) 67 (59 to 74) 22 (7 to 67) 0.41 (0.33 to 0.5) 54 (16 to 275) 1
SPMT 56 (47 to 65) 94 (88 to 98) 93 (84 to 97) 64 (56 to 71) 10 (5 to 22) 0.47 (0.38 to 0.57) 22 (9 to 64) 0.98
TUG 51 (42 to 60) 91 (84 to 95) 87 (77 to 93) 61 (53 to 68) 5 (3 to 10) 0.54 (0.45 to 0.65) 10 (5 to 24) 1
Sniffin sticks 37 (27 to 47) 92 (85 to 97) 84 (69 to 93) 57 (49 to 65) 5 (2 to 10) 0.69 (0.58 to 0.81) 7 (3 to 19) 0.95
MAT 67 (45 to 84) 90 (55 to 100) 94 (71 to 100) 53 (28 to 77) 7 (1 to 44) 0.37 (0.2 to 0.68) 18 (2 to 837) 0.99
MOCA 56 (46 to 65) 92 (85 to 96) 88 (78 to 95) 65 (57 to 73) 7 (3 to 14) 0.48 (0.39 to 0.6) 14 (6 to 36) 1
FAQ 55 (46 to 63) 94 (88 to 98) 92 (84 to 97) 63 (55 to 70) 10 (4 to 22) 0.48 (0.4 to 0.58) 20 (8 to 60) 1
ADL 61 (52 to 69) 89 (81 to 94) 87 (78 to 93) 65 (57 to 73) 5 (3 to 9) 0.44 (0.36 to 0.55) 12 (6 to 27) 1
IADL 48 (40 to 57) 94 (88 to 98) 91 (82 to 97) 60 (52 to 67) 9 (4 to 19) 0.55 (0.46 to 0.65) 16 (6 to 47) 0.96
AD8 49 (40 to 58) 95 (90 to 98) 93 (84 to 98) 61 (53 to 68) 11 (4 to 25) 0.53 (0.45 to 0.63) 20 (7 to 66) 0.96
IQCODE 53 (44 to 61) 95 (89 to 98) 93 (85 to 98) 61 (52 to 68) 11 (4 to 25) 0.5 (0.41 to 0.6) 21 (8 to 70) 0.98
Tests using published thresholds, dichotomised at a predicted probability of dementia ∏ 80%
EPSS 44 (35 to 53) 91 (84 to 95) 85 (75 to 93) 57 (49 to 64) 5 (3 to 9) 0.62 (0.53 to 0.73) 8 (4 to 18) 0.99
TAC 67 (58 to 75) 85 (77 to 91) 85 (76 to 91) 68 (59 to 75) 5 (3 to 7) 0.39 (0.3 to 0.5) 12 (6 to 23) 1
Phototest 37 (29 to 46) 94 (88 to 98) 89 (78 to 96) 55 (48 to 63) 7 (3 to 15) 0.66 (0.58 to 0.76) 10 (4 to 30) 0.99
6CIT 46 (37 to 55) 93 (86 to 97) 88 (78 to 95) 58 (50 to 66) 6 (3 to 12) 0.59 (0.5 to 0.69) 10 (5 to 27) 0.99
GPCOG 55 (46 to 64) 91 (84 to 95) 88 (79 to 94) 62 (54 to 70) 6 (3 to 11) 0.49 (0.4 to 0.6) 12 (6 to 28) 0.98
Minicog 42 (34 to 51) 94 (87 to 97) 89 (78 to 95) 57 (49 to 64) 7 (3 to 14) 0.62 (0.53 to 0.72) 11 (4 to 29) 0.96
Eurotest 44 (35 to 53) 97 (92 to 99) 95 (86 to 99) 59 (51 to 66) 16 (5 to 49) 0.58 (0.49 to 0.67) 27 (8 to 140) 1
SPMT 49 (40 to 58) 96 (91 to 99) 94 (86 to 98) 61 (53 to 68) 13 (5 to 35) 0.53 (0.44 to 0.63) 25 (9 to 99) 0.98
TUG 57 (48 to 66) 89 (81 to 94) 86 (77 to 92) 64 (55 to 71) 5 (3 to 9) 0.48 (0.39 to 0.6) 11 (5 to 23) 1
Sniffin sticks 51 (41 to 61) 88 (80 to 94) 83 (71 to 92) 61 (52 to 70) 4 (2 to 8) 0.55 (0.45 to 0.69) 8 (4 to 19) 0.95
MAT 63 (41 to 81) 90 (55 to 100) 94 (70 to 100) 50 (26 to 74) 6 (1 to 41) 0.42 (0.24 to 0.73) 15 (2 to 700) 0.99
MOCA 55 (45 to 64) 87 (77 to 93) 84 (74 to 92) 59 (50 to 68) 4 (2 to 7) 0.52 (0.42 to 0.66) 8 (4 to 18) 1
FAQ 64 (55 to 72) 88 (80 to 93) 87 (78 to 93) 66 (58 to 74) 5 (3 to 9) 0.41 (0.33 to 0.52) 13 (6 to 27) 1
ADL 56 (48 to 65) 89 (81 to 94) 86 (77 to 93) 63 (55 to 70) 5 (3 to 9) 0.49 (0.4 to 0.6) 10 (5 to 23) 1
IADL 56 (47 to 65) 89 (81 to 94) 86 (77 to 93) 62 (54 to 70) 5 (3 to 9) 0.49 (0.4 to 0.61) 10 (5 to 22) 0.96
AD8 55 (46 to 63) 92 (85 to 96) 89 (80 to 95) 62 (54 to 70) 7 (3 to 12) 0.5 (0.41 to 0.6) 13 (6 to 32) 0.96
IQCODE 56 (47 to 64) 91 (84 to 96) 89 (80 to 95) 61 (53 to 69) 6 (3 to 12) 0.49 (0.4 to 0.6) 13 (6 to 31) 0.98
‡ predicted probability of dementia in test positive group
see Glossary for abbreviations of tests
336
Table J.2: Sensitivity analysis: continuous tests combined with GP judgement, target condition normal
Test Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LRP (95% CI) LRN (95% CI) DOR (95% CI) Probability ‡
Tests as continuous scores, dichotomised at a predicted probability of normal ∏ 60%
EPSS 32 (19 to 47) 97 (93 to 99) 71 (48 to 89) 85 (80 to 90) 10 (4 to 25) 0.7 (0.58 to 0.86) 15 (5 to 49) 0.78
Phototest 35 (21 to 50) 97 (93 to 99) 73 (50 to 89) 86 (81 to 90) 11 (5 to 27) 0.67 (0.54 to 0.83) 17 (6 to 55) 0.95
6CIT 50 (35 to 65) 94 (90 to 97) 68 (49 to 83) 89 (84 to 93) 9 (5 to 17) 0.53 (0.4 to 0.71) 16 (7 to 42) 0.88
GPCOG 30 (17 to 45) 98 (95 to 99) 78 (52 to 94) 85 (80 to 90) 14 (5 to 42) 0.72 (0.59 to 0.86) 20 (6 to 87) 0.89
Minicog 36 (23 to 51) 97 (93 to 99) 74 (52 to 90) 86 (81 to 90) 12 (5 to 28) 0.66 (0.53 to 0.82) 18 (6 to 58) 0.85
Eurotest 38 (25 to 54) 96 (92 to 98) 69 (48 to 86) 86 (81 to 91) 9 (4 to 20) 0.64 (0.51 to 0.81) 14 (5 to 41) 0.96
SPMT 30 (17 to 45) 96 (93 to 99) 67 (43 to 85) 85 (79 to 89) 8 (4 to 19) 0.73 (0.6 to 0.88) 11 (4 to 35) 0.95
TUG 26 (14 to 40) 96 (92 to 98) 60 (36 to 81) 84 (78 to 88) 6 (3 to 14) 0.78 (0.66 to 0.92) 8 (3 to 23) 0.84
Sniffin sticks 32 (18 to 48) 99 (95 to 100) 87 (60 to 98) 84 (77 to 89) 23 (5 to 99) 0.69 (0.56 to 0.85) 34 (7 to 315) 0.86
MAT 25 (1 to 81) 96 (82 to 100) 50 (1 to 99) 90 (73 to 98) 7 (1 to 91) 0.78 (0.44 to 1.38) 9 (0 to 731) 0.69
MOCA 49 (33 to 65) 96 (91 to 98) 75 (55 to 89) 88 (82 to 92) 11 (5 to 25) 0.53 (0.4 to 0.72) 21 (7 to 65) 0.98
FAQ 28 (16 to 43) 98 (95 to 99) 76 (50 to 93) 85 (79 to 89) 13 (5 to 39) 0.74 (0.62 to 0.88) 18 (5 to 79) 0.75
ADL 36 (23 to 51) 94 (90 to 97) 61 (41 to 78) 86 (80 to 90) 6 (3 to 13) 0.68 (0.54 to 0.84) 9 (4 to 24) 0.61
IADL 34 (21 to 49) 97 (93 to 99) 73 (50 to 89) 86 (80 to 90) 11 (5 to 26) 0.68 (0.55 to 0.84) 16 (5 to 53) 0.74
AD8 23 (12 to 38) 98 (96 to 100) 79 (49 to 95) 84 (79 to 89) 15 (4 to 52) 0.78 (0.66 to 0.91) 19 (5 to 111) 0.83
IQCODE 38 (24 to 53) 98 (95 to 99) 81 (58 to 95) 87 (81 to 91) 18 (6 to 50) 0.64 (0.51 to 0.8) 28 (8 to 118) 0.96
Tests using published thresholds, dichotomised at a predicted probability of normal ∏ 60%
EPSS 32 (19 to 47) 97 (93 to 99) 71 (48 to 89) 85 (80 to 90) 10 (4 to 25) 0.7 (0.58 to 0.86) 15 (5 to 49) 0.78
Phototest 35 (21 to 50) 97 (93 to 99) 73 (50 to 89) 86 (81 to 90) 11 (5 to 27) 0.67 (0.54 to 0.83) 17 (6 to 55) 0.95
6CIT 50 (35 to 65) 94 (90 to 97) 68 (49 to 83) 89 (84 to 93) 9 (5 to 17) 0.53 (0.4 to 0.71) 16 (7 to 42) 0.88
GPCOG 30 (17 to 45) 98 (95 to 99) 78 (52 to 94) 85 (80 to 90) 14 (5 to 42) 0.72 (0.59 to 0.86) 20 (6 to 87) 0.89
Minicog 36 (23 to 51) 97 (93 to 99) 74 (52 to 90) 86 (81 to 90) 12 (5 to 28) 0.66 (0.53 to 0.82) 18 (6 to 58) 0.85
Eurotest 38 (25 to 54) 96 (92 to 98) 69 (48 to 86) 86 (81 to 91) 9 (4 to 20) 0.64 (0.51 to 0.81) 14 (5 to 41) 0.96
SPMT 30 (17 to 45) 96 (93 to 99) 67 (43 to 85) 85 (79 to 89) 8 (4 to 19) 0.73 (0.6 to 0.88) 11 (4 to 35) 0.95
TUG 26 (14 to 40) 96 (92 to 98) 60 (36 to 81) 84 (78 to 88) 6 (3 to 14) 0.78 (0.66 to 0.92) 8 (3 to 23) 0.84
Sniffin sticks 32 (18 to 48) 99 (95 to 100) 87 (60 to 98) 84 (77 to 89) 23 (5 to 99) 0.69 (0.56 to 0.85) 34 (7 to 315) 0.86
MAT 25 (1 to 81) 96 (82 to 100) 50 (1 to 99) 90 (73 to 98) 7 (1 to 91) 0.78 (0.44 to 1.38) 9 (0 to 731) 0.69
MOCA 49 (33 to 65) 96 (91 to 98) 75 (55 to 89) 88 (82 to 92) 11 (5 to 25) 0.53 (0.4 to 0.72) 21 (7 to 65) 0.98
FAQ 28 (16 to 43) 98 (95 to 99) 76 (50 to 93) 85 (79 to 89) 13 (5 to 39) 0.74 (0.62 to 0.88) 18 (5 to 79) 0.75
ADL 36 (23 to 51) 94 (90 to 97) 61 (41 to 78) 86 (80 to 90) 6 (3 to 13) 0.68 (0.54 to 0.84) 9 (4 to 24) 0.61
IADL 34 (21 to 49) 97 (93 to 99) 73 (50 to 89) 86 (80 to 90) 11 (5 to 26) 0.68 (0.55 to 0.84) 16 (5 to 53) 0.74
AD8 23 (12 to 38) 98 (96 to 100) 79 (49 to 95) 84 (79 to 89) 15 (4 to 52) 0.78 (0.66 to 0.91) 19 (5 to 111) 0.83
IQCODE 38 (24 to 53) 98 (95 to 99) 81 (58 to 95) 87 (81 to 91) 18 (6 to 50) 0.64 (0.51 to 0.8) 28 (8 to 118) 0.96
‡ predicted probability of normal in test positive group
see Glossary for abbreviations of tests
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Table J.3: Sensitivity analysis: age, tests combined with GP judgement, target condition dementia
Test Sensitivity Sensitivity lb Sensitivity ub Specificity Specificity lb Specificity ub ‡
EPSS all 44 35 53 91 84 95
age80 =0 32 19 47 94 86 98
age80 =1 51 40 62 84 69 94
TAC all 67 58 75 85 77 91
age80 =0 15 6 28 100 95 100
age80 =1 68 57 78 79 63 90
Phototest all 37 29 46 94 88 98
age80 =0 38 25 54 96 88 99
age80 =1 57 46 68 84 68 94
6CIT all 46 37 55 93 86 97
age80 =0 43 28 58 96 88 99
age80 =1 48 37 59 87 72 96
GPCOG all 55 46 64 91 84 95
age80 =0 53 38 68 94 86 98
age80 =1 56 45 67 84 69 94
Minicog all 42 34 51 94 87 97
age80 =0 38 25 54 96 88 99
age80 =1 45 34 56 89 75 97
Eurotest all 44 35 53 97 92 99
age80 =0 34 21 49 97 90 100
age80 =1 49 38 60 97 86 100
SPMT all 49 40 58 96 91 99
age80 =0 47 32 62 97 90 100
age80 =1 80 70 88 76 60 89
TUG all 57 48 66 89 81 94
age80 =0 50 35 65 94 86 98
age80 =1 57 46 68 84 69 94
Sniffin Sticks all 51 41 61 88 80 94
age80 =0 55 38 71 91 81 97
age80 =1 48 35 62 82 63 94
MAT all 63 41 81 90 55 100
age80 =0 0 0 71 100 48 100
age80 =1 74 49 91 60 15 95
MOCA all 55 45 64 87 77 93
age80 =0 0 0 8 100 93 100
age80 =1 53 40 65 84 66 95
FAQ all 64 55 72 88 80 93
age80 =0 13 5 26 99 92 100
age80 =1 66 55 76 82 66 92
ADL all 56 48 65 89 81 94
age80 =0 4 1 15 99 92 100
age80 =1 69 58 79 76 60 89
IADL all 56 47 65 89 81 94
age80 =0 55 40 70 91 82 97
age80 =1 56 45 67 84 69 94
AD8 all 55 46 63 92 85 96
age80 =0 55 40 70 94 86 98
age80 =1 54 43 65 87 72 96
IQCODE all 56 47 64 91 84 96
age80 =0 55 40 70 94 85 98
age80 =1 56 45 67 85 69 95
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Table J.4: Sensitivity analysis: sex, tests combined with GP judgement, target condition dementia
Test Sensitivity Sensitivity lb Sensitivity ub Specificity Specificity lb Specificity ub ‡
EPSS all 44 35 53 91 84 95
Female 63 50 74 94 83 99
Male 43 31 55 86 75 94
TAC all 67 58 75 85 77 91
Female 72 59 82 92 81 98
Male 18 9 29 100 94 100
Phototest all 37 29 46 94 88 98
Female 63 50 75 94 83 99
Male 37 25 49 93 83 98
6CIT all 46 37 55 93 86 97
Female 63 50 74 94 83 99
Male 39 27 51 89 78 96
GPCOG all 55 46 64 91 84 95
Female 63 50 74 96 86 100
Male 49 36 61 86 75 94
Minicod all 42 34 51 94 87 97
Female 53 40 66 98 89 100
Male 32 22 45 90 79 96
Eurotest all 44 35 53 97 92 99
Female 52 39 64 98 89 100
Male 37 25 49 97 88 100
SPMT all 49 40 58 96 91 99
Female 63 50 74 94 83 99
Male 44 32 57 97 88 100
TUG all 57 48 66 89 81 94
Female 64 51 76 94 83 99
Male 10 4 20 98 91 100
Sniffin Sticks all 51 41 61 88 80 94
Female 57 41 72 95 83 99
Male 0 0 7 100 92 100
MAT all 63 41 81 90 55 100
Female 0 0 71 100 40 100
Male 50 19 81 83 36 100
MOCA all 55 45 64 87 77 93
Female 60 45 74 92 79 98
Male 0 0 6 100 92 100
FAQ all 64 55 72 88 80 93
Female 67 54 78 92 81 98
Male 13 6 24 97 88 100
ADL all 56 48 65 89 81 94
Female 73 60 83 92 81 98
Male 9 3 18 98 91 100
IADL all 56 47 65 89 81 94
Female 63 50 74 94 83 99
Male 24 14 35 97 88 100
IQCODE all 56 47 64 91 84 96
Female 62 49 74 100 92 100
Male 0 0 5 100 94 100
see Glossary for abbreviations of tests
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Table J.5: Sensitivity analysis: age, tests combined with GP judgement, target condition normal
Test Sensitivity Sensitivity lb Sensitivity ub Specificity Specificity lb Specificity ub ‡
EPSS all 13 5 26 98 96 100
age80 =0 12 3 27 98 92 100
age80 =1 15 2 45 99 95 100
TAC all 0 0 8 100 98 100
age80 =0 41 25 59 87 77 94
age80 =1 0 0 25 100 96 100
Phototest all 39 25 55 95 91 97
age80 =0 41 25 59 93 85 97
age80 =1 0 0 26 100 97 100
6CIT all 39 25 55 97 93 99
age80 =0 42 25 61 96 90 99
age80 =1 31 9 61 97 92 99
GPCOG all 30 17 45 97 94 99
age80 =0 35 20 54 96 90 99
age80 =1 15 2 45 98 94 100
Minicog all 38 25 54 97 93 99
age80 =0 41 25 59 96 90 99
age80 =1 31 9 61 97 92 99
Eurotest all 40 26 56 95 91 97
age80 =0 41 25 59 86 73 95
age80 =1 0 0 25 100 97 100
SPMT all 40 26 56 95 91 98
age80 =0 41 25 59 93 85 97
age80 =1 38 14 68 97 92 99
TUG all 40 26 56 94 89 97
age80 =0 41 25 59 89 80 95
age80 =1 38 14 68 96 89 99
Sniffin sticks all 7 2 20 99 96 100
age80 =0 44 26 62 88 78 95
age80 =1 0 0 37 100 95 100
MAT all 0 0 60 100 72 100
age80 =0 0 0 84 100 40 100
age80 =1 0 0 84 100 59 100
MOCA all 12 4 25 100 98 100
age80 =0 34 19 53 96 89 99
age80 =1 0 0 28 100 96 100
FAQ all 0 0 8 100 98 100
age80 =0 41 25 59 88 78 94
age80 =1 0 0 25 100 96 100
ADL all 0 0 8 100 98 100
age80 =0 41 25 59 88 78 94
age80 =1 0 0 25 100 95 100
IADL all 0 0 8 100 98 100
age80 =0 41 25 59 88 78 95
age80 =1 0 0 25 100 97 100
AD8 all 23 12 38 99 97 100
age80 =0 29 15 47 99 93 100
age80 =1 8 0 36 100 97 100
IQCODE all 31 18 47 99 96 100
age80 =0 33 18 52 98 91 100
age80 =1 25 5 57 100 97 100
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Table J.6: Sensitivity analysis: sex, tests combined with GP judgement, target condition normal
Test Sensitivity Sensitivity lb Sensitivity ub Specificity Specificity lb Specificity ub ‡
EPSS all 13 5 26 98 96 100
Female 17 5 37 98 92 100
Male 9 1 28 99 95 100
TAC all 0 0 8 100 98 100
Female 0 0 14 100 95 100
Male 43 23 66 93 84 97
Phototest all 39 25 55 95 91 97
Female 0 0 15 100 96 100
Male 39 20 61 97 92 99
6CIT all 39 25 55 97 93 99
Female 33 16 55 96 89 99
Male 45 24 68 98 93 100
GPCOG all 30 17 45 97 94 99
Female 83 63 95 90 82 95
Male 30 13 53 97 92 99
Minicog all 38 25 54 97 93 99
Female 33 16 55 97 91 99
Male 43 23 66 97 92 99
Eurotest all 40 26 56 95 91 97
Female 38 19 59 94 88 98
Male 43 23 66 90 79 97
SPMT all 40 26 56 95 91 98
Female 0 0 14 100 96 100
Male 43 23 66 98 93 100
TUG all 40 26 56 94 89 97
Female 0 0 14 100 96 100
Male 43 23 66 93 85 97
Sniffin sticks all 7 2 20 99 96 100
Female 0 0 17 100 94 100
Male 0 0 18 100 96 100
MAT all 0 0 60 100 72 100
Female 0 0 98 100 48 100
Male 0 0 71 100 54 100
MOCA all 12 4 25 100 98 100
Female 30 13 53 99 93 100
Male 10 1 32 100 96 100
FAQ all 0 0 8 100 98 100
Female 0 0 14 100 95 100
Male 43 23 66 93 85 97
ADL all 0 0 8 100 98 100
Female 0 0 14 100 95 100
Male 43 23 66 93 85 97
IADL all 0 0 8 100 98 100
Female 0 0 14 100 94 100
Male 43 23 66 95 89 98
AD8 all 23 12 38 99 97 100
Female 25 10 47 100 96 100
Male 22 7 44 99 95 100
IQCODE all 31 18 47 99 96 100
Female 35 16 57 98 92 100
Male 27 11 50 100 96 100
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Table J.7: Diagnostic accuracy of all GP 360 tests for target condition dementia
Test Sensitivity Sensitivity lb Sensitivity ub Specificity Specificity lb Specificity ub ‡
mat+faq 0 0 31 100 69 100
mat+adl 0 0 34 100 69 100
mat+iadl 0 0 34 100 69 100
tac+faq 32 24 40 98 93 100
tac+adl 27 20 36 98 93 100
euro+ad8 42 34 51 98 93 100
euro+iqcode 44 35 52 98 93 100
spmt+ad8 48 39 57 98 93 100
spmt+iqcode 49 40 58 98 93 100
sniffin+faq 11 6 19 98 92 100
euro+iadl 44 35 53 97 92 99
sniffin+iadl 21 14 31 97 90 99
photo+ad8 37 28 46 96 91 99
photo+iqcode 38 29 47 96 90 99
euro+faq 50 41 59 96 91 99
spmt+faq 54 45 62 96 91 99
spmt+adl 59 50 67 96 91 99
spmt+iadl 49 40 58 96 91 99
tug+faq 28 21 37 96 91 99
moca+iadl 23 16 32 95 88 99
tac+iadl 37 29 46 94 88 98
photo+faq 45 36 54 94 88 98
cit+ad8 44 36 53 94 88 98
cit+iqcode 45 37 54 94 87 98
minicog+faq 51 42 60 94 87 97
minicog+ad8 41 32 50 94 88 98
minicog+iq e 42 33 51 94 87 98
euro+adl 53 45 62 94 88 98
epss+ad8 42 34 51 93 86 97
photo+adl 44 35 53 93 87 97
photo+iadl 44 35 52 93 87 97
cit+iadl 46 37 55 93 86 97
gpcog+ad8 54 45 62 93 86 97
minicog+adl 55 46 64 93 86 97
epss+iqcode 44 35 52 92 85 96
cit+faq 56 47 64 92 85 96
cit+adl 58 49 66 92 85 96
gpcog+iqcode 55 46 64 92 85 96
minicog+iadl 48 39 57 92 85 96
tug+ad8 55 46 64 92 85 96
epss+adl 44 36 53 91 84 95
epss+iadl 45 37 54 91 84 95
gpcog+iadl 55 46 64 91 84 95
tug+iqcode 57 48 65 91 84 96
sniffin+ad8 49 39 59 91 82 96
epss+faq 54 45 62 90 83 95
tac+ad8 67 58 75 90 83 95
gpcog+faq 62 53 70 90 83 95
sniffin+iq e 51 40 61 90 81 96
mat+ad8 63 41 81 90 55 100
moca+ad8 53 43 62 90 82 96
tac+iqcode 66 57 74 89 81 94
gpcog+adl 66 58 74 89 81 94
tug+iadl 57 48 66 89 81 94
moca+iqcode 54 44 64 89 80 95
tug+adl 62 53 70 88 80 93
sniffin+adl 52 41 62 88 80 94
moca+faq 55 45 64 87 77 93
moca+adl 55 45 65 87 77 93
mat+iqcode 71 49 87 71 29 96
see Glossary for abbreviations of tests
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Table J.8: Diagnostic accuracy of all GP 360 tests for target condition normal
Test Sensitivity Sensitivity lb Sensitivity ub Specificity Specificity lb Specificity ub ‡
tac+faq 0 0 8 100 97 100
tac+adl 0 0 8 100 97 100
tac+iadl 0 0 8 100 98 100
mat+faq 0 0 60 100 69 100
mat+adl 0 0 60 100 66 100
mat+iadl 0 0 60 100 66 100
mat+ad8 0 0 60 100 66 100
mat+iqcode 0 0 60 100 69 100
moca+faq 0 0 9 100 97 100
tac+ad8 23 12 38 99 96 100
tac+iqcode 31 18 47 99 95 100
photo+ad8 24 13 39 99 97 100
photo+iqcode 32 19 48 99 96 100
cit+iqcode 32 19 48 99 97 100
euro+ad8 23 12 38 99 97 100
euro+iqcode 31 18 47 99 96 100
spmt+ad8 23 12 38 99 97 100
spmt+iqcode 31 18 47 99 96 100
tug+ad8 23 12 38 99 97 100
tug+iqcode 31 18 47 99 96 100
sniffin+faq 7 2 20 99 96 100
sniffin+adl 7 2 20 99 95 100
sniffin+iadl 5 1 17 99 96 100
sniffin+ad8 29 16 46 99 95 100
sniffin+iq e 31 17 48 99 96 100
moca+ad8 40 25 56 99 96 100
moca+iqcode 44 28 60 99 95 100
epss+faq 13 5 26 98 94 100
epss+adl 13 5 26 98 94 100
epss+iadl 13 5 26 98 96 100
epss+ad8 30 17 45 98 95 99
gpcog+iadl 30 17 45 98 95 99
gpcog+iqcode 31 18 47 98 95 99
moca+iadl 26 14 41 98 95 100
epss+iqcode 40 26 56 97 94 99
cit+adl 39 25 55 97 92 99
cit+iadl 39 25 55 97 93 99
cit+ad8 39 25 55 97 93 99
gpcog+faq 30 17 45 97 93 99
gpcog+adl 30 17 45 97 93 99
gpcog+ad8 30 17 45 97 94 99
minicog+adl 38 25 54 97 93 99
minicog+iadl 38 25 54 97 94 99
minicog+ad8 38 25 54 97 93 99
minicog+iq e 40 26 56 97 94 99
moca+adl 26 14 41 97 92 99
photo+iadl 39 25 55 96 92 98
cit+faq 39 25 55 96 92 99
minicog+faq 38 25 54 96 92 99
spmt+iadl 40 26 56 96 92 98
euro+iadl 40 26 56 95 91 98
spmt+adl 40 26 56 95 90 98
photo+faq 39 25 55 94 88 97
photo+adl 39 25 55 94 89 97
euro+faq 40 26 56 94 88 97
euro+adl 40 26 56 94 89 97
spmt+faq 40 26 56 94 89 97
tug+iadl 40 26 56 94 90 97
tug+faq 40 26 56 92 87 96
tug+adl 40 26 56 92 87 96












INDEX TEST POSITION IN THE BATTERY
T
his appendix provides tabulated figures of the position of each index test in the index test
battery.
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Table K.1: Test order in index test battery
Number (%) of tests in each test order position
Test order position MAT or MOCA Eurotest TAC Phototest SPMT 6CIT GPCOG EPSS TUG Sniffin Sticks
First 36 (15) 16 (7) 33 (14) 22 (9) 25 (10) 30 (13) 30 (13) 30 (13) 18 (8) ()
Second 24 (10) 21 (9) 26 (11) 24 (10) 31 (13) 25 (10) 35 (15) 36 (15) 18 (8) 0 (0)
Third 21 (9) 29 (12) 30 (13) 37 (16) 26 (11) 19 (8) 26 (11) 26 (11) 26 (11) 0 (0)
Fourth 30 (13) 27 (11) 21 (9) 34 (14) 23 (10) 32 (13) 17 (7) 21 (9) 34 (14) 0 (0)
Fifth 24 (10) 27 (11) 31 (13) 22 (9) 29 (12) 32 (13) 27 (11) 24 (10) 23 (10) 0 (0)
Sixth 26 (11) 26 (11) 24 (10) 28 (12) 32 (13) 23 (10) 28 (12) 22 (9) 29 (12) 0 (0)
Seventh 30 (13) 30 (13) 27 (11) 19 (8) 21 (9) 29 (12) 25 (10) 31 (13) 27 (11) 0 (0)
Eighth 24 (10) 27 (11) 33 (14) 30 (13) 30 (13) 22 (9) 18 (8) 20 (8) 35 (15) 0 (0)
Ninth 24 (10) 36 (15) 15 (6) 22 (9) 22 (9) 28 (12) 33 (14) 29 (12) 29 (12) 0 (0)
Tenth 0 (-) 0 (-) 0 (-) 0 (-) 0 (-) 0 (-) 0 (-) 0 (-) 0 (-) 189 (100)
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